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Vaccine hesitancy has grown in recent decades [1-4], leading to the clustering of vaccine refusal 
and associated outbreaks of vaccine preventable diseases (VPDs) [5-11]. Vaccination rates of 
pregnant women in particular are suboptimal [12]. 
This dissertation contains three manuscripts discussing research performed as part of an NIH-
funded large randomized controlled trial of a comprehensive prenatal intervention to increase 
uptake of maternal and infant vaccines (referred to as P3+) and its add-on study sponsored by 
Walgreen Co to increase knowledge and uptake of cocooning vaccines among close friends and 
family of participating P3+ pregnant women.   
As part of the P3+ provider-level intervention package, we performed a systematic review to 
update and succinctly summarize the scientific evidence assessing possible causal associations of 
adverse events following immunization (AEFI), with refined causality conclusions intended for 
health care providers. Although for 12 of the 47 AEFI studied a causal relationship was established 
with at least one vaccine currently routinely recommended to the general population in the United 
States, most of these were rare or mild, and no causal relationship was established for the other 35 
AEFI studied.  
As part of the P3+ patient-level intervention package, we developed an application called 
MomsTalkShots for smartphones, tablets and computers that delivers patient-tailored education 
materials to pregnant women and collects survey data to monitor vaccine knowledge, attitudes and 
beliefs. As part of the add-on study, the MomsTalkShots app encouraged P3+ pregnant women to 
iii 
refer their close friends and family to the app. Baseline survey data showed suboptimal maternal 
vaccine knowledge and intentions among P3+ pregnant women, especially among first-time 
pregnant women. In addition, pregnant women who valued vaccination and perceived their social 
network to value vaccination were more likely to refer their close friends and family to the app.  
This research demonstrates the opportunity for individually-tailored vaccine education of pregnant 
women and their social networks to increase vaccine confidence and informed decision making at 
this stage of life.  
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Immunization is one of the most effective ways to prevent infectious diseases and their associated 
morbidity and mortality [13]. Vaccine coverage among children in the United States remains high 
[14]. However, vaccine hesitancy has emerged in recent decades as a threat to this high coverage 
[1-4], leading to the clustering of vaccine refusal and associated outbreaks of vaccine preventable 
diseases (VPDs) [5-11].  
Most people in the U.S., including parents who are vaccine hesitant, rely on health care providers 
as their most frequently used and credible source for vaccine information [15-17]. To be confident 
in answering increasingly wide-ranging patient questions about vaccine safety, clinicians desire 
vaccine safety information which is evidence-based, objective, and provides clear guidance [18-
23]. In particular, the first pregnancy is seen as a “teachable moment” – a key opportunity for 
clinicians to provide accurate information about both maternal and infant vaccinations to new 
parents – since one’s vaccine attitudes and beliefs are often forming at this point as they are 
considering vaccines for themselves during pregnancy and considering vaccination of their child 
[24].  
Both the Advisory Committee on Immunization Practices (ACIP) and the American College of 
Obstetricians and Gynecologists (ACOG) recommend that pregnant women are vaccinated against 
influenza and pertussis during pregnancy to best protect themselves and their infants [25-28]. 
Pregnant women are at increased risk of influenza morbidity and mortality [29-37]. Infants have 
the highest risk of complication, hospitalization and death from influenza and pertussis [38, 39], 
and are too young to complete the primary three dose series of pertussis vaccine or receive their 
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first influenza vaccine until six months of age [28, 40]. However, vaccination rates of pregnant 
women are suboptimal: 49% and 54% of pregnant women were vaccinated against influenza and 
pertussis during the 2017-18 season, respectively [12]. Additional strategies are needed to 
optimally protect infants against these diseases.  
Most infants with pertussis were infected either by a parent or a relative in close contact with the 
infant [41-45]. The cocoon vaccination strategy entails vaccinating as many of the close contacts 
of the incoming newborn as possible, thereby lowering the risk of disease transmission and 
forming a protective “cocoon” around the infant. In tandem with maternal vaccination, cocooning 
is a method of further lowering the risk of potentially deadly pertussis and influenza infections in 
young infants [46-48].  
Factors associated with higher rates of cocooning in the U.S. include high perceived benefits of 
vaccine, high perceived susceptibility to disease, and low perceived barriers to vaccination [49]. 
One potential intervention to influence perceived benefits of vaccine and susceptibility to disease 
is education. Another potential intervention that may be able to reduce perceived barriers to 
vaccination is the distribution of financial incentives.  
As part of an NIH-funded large randomized controlled trial of a prenatal intervention to increase 
uptake of maternal and infant vaccines (referred to as P3+), we developed a patient-level 
application (called MomsTalkShots) for smartphones, tablets and computers that delivers patient-
tailored education materials to pregnant women and collects patient-level survey data to monitor 
changes in their vaccine knowledge, attitudes and beliefs over time. As part of an add-on study 
sponsored by Walgreen Co., the MomsTalkShots app encouraged P3+ pregnant women to refer 
their close friends and family to the app so they could receive the patient-tailored education 
materials as well as a small financial incentive for receiving cocooning vaccinations at Walgreens.  
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This thesis includes three distinct manuscripts to be submitted for publication in scientific journals: 
a systematic review of vaccine safety; a thorough examination of the baseline vaccine intentions, 
knowledge, attitudes and beliefs of the pregnant women enrolled in P3+; and an analysis of the 
factors associated with these women referring their close friends and family to the MomsTalkShots 
app.  
4 
Research Questions and Hypotheses 
 
The three distinct manuscripts included in this thesis are: a systematic review of a broad range of 
vaccine safety issues; a thorough examination of the baseline vaccine intentions, knowledge, 
attitudes and beliefs of the pregnant women enrolled in P3+; and an analysis of the factors 
associated with these women referring their close friends and family to the MomsTalkShots app. 
The primary and secondary research questions for each of these manuscripts is detailed below 
along with testable hypotheses and analysis plans when appropriate. 
 
Manuscript 1: Systematic Literature Review of U.S. Vaccine Safety 
Primary Research Question: Which adverse events following immunization (AEFI) have been 
shown to be caused by vaccines routinely administered to the general population in the United 
States based on the current evidence, and which have not?   
Analysis Plan: systematic literature review.  
Secondary Research Question: For those AEFI that are confirmed to be caused by vaccines, what 
is the risk attributable to vaccination? 
Analysis Plan: systematic literature review.  
 
Manuscript 2: Characterizing pregnant women’s vaccine attitudes and beliefs  
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Primary Research Question: What are the baseline vaccine intentions, attitudes, beliefs, norms, 
and levels of trust among recently pregnant women in GA and CO? 
Analysis Plan: univariate analysis.  
Secondary Research Question 1: Do these intentions, attitudes, beliefs, norms, and levels of trust 
differ by state, ethnicity, education, and having prior children? 
H10: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust do not 
differ by state, ethnicity, education, or having prior children. 
H1A: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust do differ 
by state, ethnicity, education, or having prior children. 
Analysis Plan: stratified analysis using Pearson’s chi-squared test for independence.  
Secondary Research Question 2: Which attitudes, beliefs, norms, and levels of trust affect vaccine 
intentions? 
H10: Pregnant women’s vaccine attitudes, beliefs, norms, and levels of trust do not affect their 
vaccine intentions. 
H1A: Pregnant women’s vaccine attitudes, beliefs, norms, and levels of trust do affect their vaccine 
intentions. 
Analysis Plan: simple logistic regressions with dichotomous indicators for vaccine intentions as 
dependent variables and dichotomous or categorical indicators for attitudes, beliefs, norms, trust 
and number of specific vaccine safety concerns as independent variables.  
Secondary Research Question 3: Which demographics, attitudes, beliefs, norms, and levels of trust 
are the best predictors of vaccine intentions? 
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H10: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust do 
not affect their vaccine intentions. 
H1A: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust do 
affect their vaccine intentions. 
Analysis Plan: best-fit multiple logistic regression models created by backwards selection to 
include only those variables with statistical significance (P<0.05) in both the simple and multiple 
models. Dichotomous indicators for vaccine intentions used as dependent variables, and 
dichotomous or categorical indicators for demographics and vaccine attitudes, beliefs, norms, 
trust and number of specific vaccine safety concerns as independent variables.  
Secondary Research Question 4: How many groups of pregnant women with distinct patterns of 
vaccine intentions, attitudes, beliefs, norms, and levels of trust can be identified, and how are they 
characterized?  
H10: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust are best 
characterized by one homogenous group. 
H1A: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust are best 
characterized by multiple homogenous groups. 
Analysis Plan: latent class analysis (using categorical indicators for vaccine intentions, attitudes, 
beliefs, norms, and trust) performed sequentially, increasing one group at a time, until the new 
model does not fit the data better than the last based on the Lo-Mendell-Rubin likelihood ratio 
test.  
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Manuscript 3: Factors associated with referring close contacts to an app with individually-
tailored vaccine information 
Primary Research Question: Which demographics and vaccine intentions, attitudes, beliefs, norms, 
and levels of trust are associated with higher likelihood of a pregnant woman referring friends and 
family to an educational app about vaccines? 
H10: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust 
are not associated with likelihood of referring contacts to app. 
H1A: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust 
are associated with likelihood of referring contacts to app. 
Analysis Plan: simple logistic regressions with a dichotomous indicator for referring contacts to 
app as the dependent variable and dichotomous or categorical indicators for demographics and 
vaccine intentions, attitudes, beliefs, norms, trust and number of specific vaccine safety concerns 
as independent variables. 
Secondary Research Question 1: How many contacts were referred per pregnant woman, and of 
each type of relationship to the referring pregnant woman? 
Analysis Plan: univariate analysis.  
Secondary Research Question 2: Which types of contacts based on relationship to the referring 
pregnant woman are more likely to enroll in such an app upon invitation to do so? 
H10: Contacts who enroll in app do not differ from contacts who do not enroll in app based on 
relationship to the referring pregnant woman. 
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H1A: Contacts who enroll in app do differ from contacts who do not enroll in app based on 
relationship to the referring pregnant woman. 




Background and Significance 
 
The Importance of Vaccines 
 
Immunization is one of the most effective ways to prevent infectious diseases and their associated 
morbidity and mortality [13]. High vaccine coverage has succeeded in controlling or eliminating 
many vaccine-preventable diseases (VPDs) from the United States. The effectiveness of 
vaccinations is particularly evident when examining the morbidity and mortality from VPDs in the 
eras prior to vaccine introduction compared to the present day. The percent reduction in estimated 
annual average number of VPD cases comparing the pre-vaccine era to the 21st century has been 
calculated as 100% for diphtheria, 99.9% for measles, 95.9% for mumps, 92.2% for pertussis, 
100% for poliomyelitis, 99.9% for rubella, 100% for smallpox, 92.9% for tetanus, 87% for 
hepatitis A, 80.1% for acute hepatitis B, >99.8% for Hib, 34.1% for invasive pneumococcal 
disease, and 85% for varicella. Similarly, the percent reduction in estimated annual average 
number of deaths from VPDs has been calculated as 100% for diphtheria, 100% for measles, 100% 
for mumps, 99.3% for pertussis, 100% for poliomyelitis, 100% for rubella, 100% for smallpox, 
99.2% for tetanus, 86.9% for hepatitis A, 80.2% for acute hepatitis B, >99.5% for Hib, 25.4% for 
invasive pneumococcal disease, and 81.9% for varicella [50].  
High vaccine coverage is crucial to preventing the spread of VPDs, especially as populations 
become denser and average frequency and distance of travel increase. This is because if enough 
people in a population are immune to an infectious disease, transmission of the disease is 
interrupted, and the disease can be eliminated from the population. This concept is commonly 
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known as “community protection”, “community immunity” or “herd immunity”. Each VPD has 
its own threshold for vaccine coverage required to interrupt transmission, depending primarily on 
the effectiveness of the vaccine and the contagiousness of the disease. For example, a highly 
contagious disease such as measles requires vaccine coverage of over 90% to have a chance at 
interruption of transmission, whereas less contagious diseases such as diphtheria and polio may 
only require 80-85% vaccine coverage [51, 52]. The safest way to ensure “community protection” 
from VPDs is to obtain the highest vaccine coverage possible. However, it is not enough to have 
high vaccine coverage on a national or state level; to be most effective, vaccine coverage also must 
be consistently high on a community level. Geographic clustering of unvaccinated and under-
vaccinated persons interferes with interruption of disease transmission from otherwise high 
vaccine coverage [53-55], and has led to sustained outbreaks of VPDs such as pertussis and 
measles [56-59].   
Vaccines have made an immense positive impact on the health of the world population and stand 
as one of the greatest achievements of biomedical science and public health to date [50]. 
Maintaining high coverage is essential to preventing VPDs [51, 52]. However, the importance of 
vaccination to individual and population health is not recognized by everyone, as evidenced by the 




What is Vaccine Hesitancy? 
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Vaccine hesitancy has been defined in several ways. The Strategic Advisory Group of Experts 
(SAGE) on Immunization of the World Health Organization (WHO) defined vaccine hesitancy as 
a “delay in acceptance or refusal of vaccines despite availability of vaccinations services. Vaccine 
hesitancy is complex and context specific, varying across time, place, and vaccines. It is influenced 
by factors such as complacency, convenience, and confidence” [60]. Salmon et al. defined vaccine 
hesitancy as “concerns about the decision to vaccinate oneself or one’s children” [24]. Larson et 
al. described the utility of the term “vaccine hesitancy” as “de-polarizing earlier attention to ‘pro’- 
versus ‘anti’-vaccination individuals and groups”, and defined vaccine-hesitant individuals as “a 
heterogeneous group in the middle of a continuum ranging from total acceptors to complete 
refusers” [61]. Edwards et al. expanded upon this idea, stating: “vaccine-hesitant individuals may 
accept all vaccines but remain concerned about them, they may refuse or delay some vaccines but 
accept others, or they may refuse all vaccines” [62].  
 
Measuring Vaccine Hesitancy and Refusal 
 
Several tools to measure vaccine hesitancy have been developed and validated within the last 
decade, including most prominently the Vaccine Hesitancy Scale (VHS) created by SAGE [63-
66] and the Parent Attitudes about Childhood Vaccines (PACV) scale developed by Opel et al. 
[67-71], among others [72-74]. However, these tools have so far only been used in isolated 
instances among non-representative study populations. To accurately assess changes in vaccine 
hesitancy in the U.S. over time, a nationally representative, serial cross-sectional survey using a 
validated measurement tool like those described above is needed [24]. 
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Fluctuations in vaccine refusal in the U.S. over time is much easier to quantify than vaccine 
hesitancy due to the presence of mandatory vaccination requirements for school entry, as rates of 
exemptions from these requirements are recorded in each state.  
From 1991 to 2004, the mean state-level rate of nonmedical exemptions in the U.S. increased from 
0.98 to 1.48%. This was primarily due to an increase from 0.99 to 2.54% for states that allowed 
exemptions for philosophical or personal beliefs, as states that allowed only religious exemptions 
remained at approximately 1% during this period [6]. The rate of increase in nonmedical 
exemptions continued to increase between 2005 and 2013 before stabilizing in 2015-2016 [5, 7]. 
Exemptions for philosophical beliefs has risen since 2009 in 12 of the 18 states in which they are 
offered [75, 76]. A 2014 systematic review including 42 studies also concluded that exemption 
rates are rising, and that high rates of exemptions tend to occur in clusters [77]. Clustering of 
nonmedical vaccine exemptions has been shown to be associated with increased outbreaks of 
pertussis and measles [56-59].  
Occasional changes in state laws can dramatically impact rates of nonmedical exemptions by 
making them easier or more difficult to obtain [78-81]. Easier exemption procedures have been 
shown to increase rates of exemptions, in turn increasing individual and community disease risk. 
Although most parents who obtained exemptions questioned the safety of vaccines, some did so 
simply out of convenience [77].  
Nonmedical exemption rates capture the percentage of parents who refuse at least one vaccine 
required by state law for school entry; however, it does not distinguish between those who refuse 
one vaccine and those who refuse many vaccines. Only approximately 3% of U.S. parents refuse 
all vaccines, although this likely varies substantially geographically [62, 82, 83]. 
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The Origins of Vaccine Hesitancy and Refusal 
 
Vaccine hesitancy and refusal is as old as vaccines themselves. Perhaps even older; before the 
invention of vaccination, proponents of variolation (purposely infecting patients with smallpox 
material in such a way to cause a milder form of the disease than the dangerous natural infection 
typically did) faced resistance from critics who feared the benefits of the practice did not outweigh 
the harm it caused [84]. The first vaccine, which induced the even milder cowpox disease to its 
recipient in order to confer immunity against smallpox, became widespread in the United Kingdom 
in the early 1800s, was simultaneously met with great enthusiasm from some and great fear from 
others [85]. For example, Reverend Edmund Massey went as far as to call vaccines “diabolical 
operations” in his 1772 sermon entitled “The Dangerous and Sinful Practice of Inoculation”, in 
which he also denounced vaccines as an attempt to bypass the punishments handed down by God 
for mankind’s sins [86].   
Despite early opposition, vaccination was such a revelation that the U.K. government enacted the 
Vaccination Act of 1840 to provide free vaccines to the poor and the Vaccination Act of 1853 to 
require vaccination for all infants within the first three months of life, holding parents liable to a 
fine or imprisonment if the law was disobeyed. The Vaccination Act of 1867 then extended the 
age range for required vaccination to 14 years and added further penalties for noncompliance [85, 
87]. However, once vaccination was made compulsory by law, resistance grew even further, 
centered around the laws’ infringements of personal freedom. Founding of the Anti-Vaccination 
League and the Anti-Compulsory Vaccination League occurred immediately after the 1853 and 
1867 laws, respectively. Violent riots took place. Anti-vaccination messages grew, primarily in 
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the form of books and journals. As public pressure mounted, the English government finally passed 
a new Vaccination Act in 1898 to allow parents to obtain an exemption from penalties for non-
compliance [85, 88-90].  
As vaccination and mandatory vaccination laws spread to other countries in Europe and North 
America, so did the anti-vaccination movement [85, 91, 92]. The first U.S. state law mandating 
smallpox vaccination was passed in Massachusetts in 1809, and similar legislation soon spread to 
other states as well [93-95]. As more states passed and enforced mandatory vaccination laws, 
opposition rose and court battles over these laws became commonplace with some states even 
repealing their previously enacted laws [92, 93, 95]. The Anti-Vaccination Society of America 
was founded in 1879 [85, 92]. In 1905, the legality of mandatory vaccine laws was ruled upon in 
the U.S. Supreme Court in the case Jacobson v. Massachusetts, and the right of states to pass and 
enforce such laws was upheld [93]. 
 
The Modern Reemergence of the Anti-Vaccination Movement 
 
Over a century after the beginnings of the anti-vaccination movement in the U.S., skepticism and 
fear of vaccines resurfaced dramatically in the public eye. In 1998, Andrew Wakefield, a 
gastroenterologist at the Royal Free Hospital in England, published a case series in the medical 
journal The Lancet. In this article he described 12 children with pervasive developmental disorder 
associated with gastrointestinal symptoms, 8 of whom had behavioral issues temporally associated 
with MMR vaccination via retrospective accounts by their parents or physicians [96]. Despite 
study authors acknowledging that this did not prove an association between the vaccine and autism, 
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the lead author went far beyond the paper’s conclusions in a press release and ongoing interactions 
with the media [97, 98]. Public concern on the topic grew quickly. In 2010, Dr. Wakefield’s license 
to practice medicine in the UK was revoked by the British General Medical Council and his study 
was retracted by The Lancet as evidence of serious professional misconduct mounted. Among 
other infractions, Wakefield was found to have ordered unnecessary invasive procedures on 
children without approval of the hospital ethics committee and received undeclared financial 
considerations from the Legal Aid Board, a group pursuing multiparty legal action for allegedly 
vaccine-damaged children [99-104]. In addition, he had applied for patents for vaccines to rival 
MMR vaccine. It was also revealed that, for most of the children in the original study, their 
symptoms either started well before or long after MMR vaccination. Despite the complete 
refutation of Wakefield’s fraudulent findings by the scientific community, concern about autism 
and vaccines still exists among some parents; nationally representative data from 2010 indicate 
that about 30% of parents still have this concern [2]. 
As strong epidemiological evidence mounted that MMR vaccine was not associated with autism 
[105-118], some autism interest groups shifted their hypothesis from MMR vaccine to the belief 
that thimerosal, an ethylmercury-containing preservative that was present in some vaccines at the 
time, was causing autism in children. This theory was based upon observed similarities in some 
features of ASD and mercury poisoning [119]. As part of the Food and Drug Administration (FDA) 
Modernization Act of 1997, the FDA had conducted an analysis on exposure to mercury in 
children, leading them to examine the risk of thimerosal in vaccines. The FDA risk assessment 
determined that, when applying the methylmercury standard to ethylmercury (thimerosal), the 
vaccine thimerosal exposure was above EPA but not FDA or ATSDR guidelines [120]. 
Considerable uncertainty remained as the differences between ethyl and meth mercury were not 
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known and the guidelines were based on chronic rather than bolus exposure such as vaccines. Long 
term follow-up of children to evaluate the risk of mild neurologic effects from ethylmercury had 
not been conducted at that time. Because of the uncertainty in the risk assessment, as a 
precautionary measure thimerosal was removed as a preservative from most vaccines administered 
to children (small amounts of thimerosal are still present in multi-dose vials of influenza vaccine). 
The plausibility of this suspected association was later refuted by neurologists, and several large 
studies have documented that thimerosal was not associated with an increased risk of ASD [121].  
 
Causes of Vaccine Hesitancy 
 
A number of factors contribute to vaccine hesitancy. Vaccines are the victims of their own success; 
the more effective and widespread vaccines are, the less prominent VPDs are, and the less the 
general population is familiar with these VPDs. Most vaccines are given to healthy people to 
prevent disease instead of to sick people to treat disease like most medicine, thus the positive 
outcome of vaccinating (absence of disease) is less tangible than the reduction of existing 
symptoms from medication. Most healthy people (especially young children) get vaccinated at 
multiple timepoints throughout life, thus adverse health outcomes will coincidentally occur after 
vaccinations occasionally simply by chance. By human nature many people are susceptible to the 
logical fallacy “post hoc ergo propter hoc” (after this, therefore because of this), sometimes even 
if the scientific and medical community concludes otherwise [24]. Heuristics that impact risk 
perception, including a preference for errors of omission over errors of commission, lead some to 
miscalculate the risk of not vaccinating as less than vaccinating [122]. Trust is low in government 
agencies and the pharmaceutical industry, who mandate and manufacture vaccines, respectively 
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[16, 123, 124]. Other factors such as needle aversion and the rapid spread of misinformation via 
the internet may also contribute [10, 24]. To better understand how all these and other factors 
combine and interact to comprise vaccine hesitancy, data on vaccine intentions, attitudes and 




Surveys of Vaccine Intentions, Knowledge, Attitudes and Beliefs 
 
Childhood and Adolescent Vaccines 
 
There have been numerous individual surveys assessing attitudes and beliefs parents regarding 
childhood vaccines conducted since the turn of the century in the U.S. [2, 10, 15, 82, 125-138] and 
Canada [139-142] which show that although most parents believe vaccines to be important, safe 
and effective, concerns are very prevalent. A 1999 nationally representative telephone survey 
found that about 25% of parents of children under 6 years old believed their child’s immune system 
could be weakened by too many vaccines and 23% believed that children get more immunizations 
than are good for them [125]. A 2009 nationally representative online survey found that 54% of 
parents were concerned about serious adverse effects of vaccines and 25% thought some vaccines 
cause autism in healthy children [133]. National data from the 2010 HealthStyles Panel found that 
77% of parents reported having at least one concern about vaccines. Some of these reported 
concerns were relatively minor such as pain (38%) or fever (32%), but other concerns were much 
more serious, such as too many vaccines given at once (36%) or during the first two years of life 
(34%), autism (30%), unsafe ingredients (26%), and inadequate safety testing (17%) [2]. 
Nationally representative data on the prevalence of vaccine attitudes and beliefs are not available 
in the published literature since these 2010 HealthStyles data. 
Many of the most recent surveys assessing vaccine attitudes and beliefs focus specifically on HPV 
vaccine, either from the viewpoint of parents [131, 143-161], young adults [162-171], or both 
[172]. These surveys illustrate the importance of a strong provider recommendation [143-145, 147, 
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151, 155, 159, 167] and parental vaccine knowledge/education [151, 152, 155] in increasing HPV 
vaccine uptake.  
Numerous recent surveys have also demonstrated substantial differences in vaccine knowledge, 
attitudes and beliefs by gender, education, socioeconomic status, residence, ethnicity and race 
[133, 151, 159, 163, 166, 173-193]. For example, Hispanics and blacks are less likely to have heard 
of HPV and HPV vaccine than whites [163, 173]. Blacks are also less likely to vaccinate against 
HPV [177, 184, 187, 188] or to report trust in the flu vaccine [178, 192]. Although Hispanics are 
more likely to be concerned about series adverse effects of vaccines than whites, they are also 
more likely to follow their doctor’s recommendation and vaccinate [133, 151, 185].  
The vast majority of parents [16, 123, 129] cite health care providers as their most trusted source 
of vaccine information. In contrast, much lower levels of trust are reported in government and its 
associated agencies as well as in the pharmaceutical industry among those who express vaccine 




Recent surveys assessing attitudes and beliefs of pregnant women in the U.S. [49, 194-207] and 
Canada [22, 208-210] highlight the existing gaps in vaccine knowledge, attitudes, beliefs and 
intentions. Among 325 pregnant women in GA during the 2012-2013 season who had not yet 
received maternal vaccinations, most believed flu (75%) and whooping cough (81%) would be 
serious during pregnancy, and even more believed flu (87%) and whooping cough (92%) would 
be serious to their infants; however, less than half intended to receive maternal flu (34%) and Tdap 
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(44%) vaccines, perhaps partly due to low perceptions of safety of the vaccines during pregnancy 
(46%) [196].  
Most parents primarily seek out vaccine information during and immediately after their first 
pregnancy [211-214]. In one study, about two-thirds of first-time pregnant women in their second 
trimester had not yet received information about childhood vaccines directly from their 
obstetrician/gynecologist (OB/GYN) or midwife, despite expressing interest in the topic [207]. 
This highlights the first pregnancy as a “teachable moment” – a key opportunity to provide 
accurate information about both maternal and childhood vaccinations – since one’s vaccine 
attitudes and beliefs are being formed at this point as they are after making vaccine decisions for 
themselves and their infant [24]. The vast majority of pregnant women [22, 195, 198, 200, 202, 
204, 208] also cite health care providers as their most trusted source of vaccine information, 
indicating that obstetricians and midwives are in a unique position to provide vaccine information 
to soon-to-be mothers and their partners who have not yet made firm vaccine decisions for 
themselves and their children.  
 
Identifying Homogeneous Groups of Parents Based on Their Vaccine Intentions, Knowledge, 
Attitudes and Beliefs 
 
Historically, vaccine attitudes were often looked at by researchers and medical professionals as 
dichotomous: either one was completely supportive of vaccines or one was “anti-vaccine” [215]. 
However, as more data on vaccine attitudes and beliefs was collected and examined, vaccine 
hesitancy began to be understood as a spectrum with more than just two contrasting viewpoints 
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[82, 134]. Gellin et al. analyzed data from a 1999 national telephone survey, of which three main 
(yet overlapping) subgroups of parents were identified: those who rated immunization as 
“extremely important” (87%), those who considered government or school requirements as the 
principal motivation for immunization (8%), and those who would choose to opt out of at least one 
immunization for their child (14%) [125]. Gust et al. performed a K-means clusters technique on 
data from 2002 HealthStyles and ConsumerStyles surveys and identified five homogeneous groups 
of parents: Immunization Advocates (33.0%), Go Along to Get Alongs (26.4%), Health Advocates 
(24.8%), Fencesitters (13.2%), and Worrieds (2.6%) [134]. Benin et al. used grounded theory to 
analyze qualitative data from open-ended interviews of 33 postpartum mothers in 2002-2003, and 
identified two main groups, each with two subgroups: Vaccinators (subgroups: accepters and 
vaccine-hesitant) and NonVaccinators (subgroups: late vaccinators and rejecters) [216]. Downs et 
al. used a mental models approach to analyze qualitative data from open-ended interviews of 30 
parents recruited from three cities providing diversity in race, background, and vaccination 
attitudes, and identified two main vaccine decision making types: health oriented (trusting 
anecdotal information more than statistical) and risk oriented (trusting statistical information more 
than anecdotal). Smith et al. analyzed data of over 11,000 parents of young children from the 2009 
National Immunization Survey (NIS) and categorized parents as neither delaying nor refusing 
vaccines (60%), only delaying one or more vaccines (26%), only refusing one or more vaccines 
(8%), and both delaying and refusing vaccines (6%) [217]. Leask et al. used a literature review to 
identify five distinct parental groups as part of a framework for health professionals: the 
“unquestioning acceptor” (30–40%), the “cautious acceptor” (25–35%), the “hesitant” (20–30%), 
the “late or selective vaccinator” (2–27%), and the “refuser” of all vaccines (<2%) [83]. Weiss et 
al. performed a latent class analysis (LCA) on 14 5-point Likert scale belief statements from 189 
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questionnaires completed by Swiss mothers living in the Aargau region and identified three latent 





Providers Need Better and More Accessible Vaccine Safety Information 
 
Most patients and parents, including parents who are vaccine hesitant, rely on health care providers 
as their most frequently used and credible source for vaccine information [15-17]. Providers need 
information on a broad range of vaccine safety issues to be confident in answering patient 
questions about vaccine safety as those questions become more specific, complex and wide-
ranging. Clinicians desire vaccine safety information which is evidence-based, objective, and 
provides clear guidance on whether or not vaccines cause specific adverse event following 
immunization (AEFI), and the risk for AEFI that caused by vaccines [18-23]. 
Websites that include reliable sources of vaccine safety information for providers include the 
Centers for Disease Control and Prevention (CDC) [219, 220], the American Academy of 
Pediatrics, the Food and Drug Administration, and the Immunization Action Coalition [221]. 
However, much of the information available is not based on systematic comprehensive reviews 
and lacks clear statements on causality. The most comprehensive source of vaccine safety 
information available to date is the independent 2012 report by the Institute of Medicine (IOM), 
now called the National Academy of Medicine (NAM), entitled Adverse Effects of Vaccines: 
Evidence and Causality, [222] which builds on previous vaccine safety reports from the IOM [113, 
114, 223-225]. These extraordinarily comprehensive reviews were conducted at the request of the 
Department of Health and Human Services (HHS) and its agencies, for the primary purpose of 
updating the National Vaccine Injury Compensation Program [226]. Final products from these 
committees are books; they are neither succinct nor readily available to clinicians. In the 2012 
report, the IOM concluded that the evidence is inadequate to accept or reject a causal relationship 
for 135 of 158 (85%) of vaccine-AEFI relationships studied. The 2014 report by the Agency for 
24 
Healthcare Research and Quality (AHRQ) entitled Safety of Vaccines Used for Routine 
Immunization in the United States: Evidence Report/Technology Assessment No. 215 [117, 227], 
was intended to expand upon and update the 2012 IOM report and was commissioned by HHS for 
the purpose of developing a federal vaccine safety research agenda. While these reports are useful 
for policy makers and vaccine safety scientists, they were not designed specifically for use by 
clinicians, and their length, writing style, and framing of causality assessments do not translate 
well to the practicing clinician. In addition, the IOM and AHRQ reports do not cover all AEFIs of 
current interest and many assessments are now out of date due to evidence emerging since their 
publications. An updated and comprehensive systematic literature review of vaccine safety tailored 




Vaccines Recommended During Childhood  
 
The Advisory Committee on Immunization Practices (ACIP), a committee of 15 experts which 
advises the Centers for Disease Control and Prevention (CDC) on vaccine practice, issues 
comprehensive statements on the recommended use of individual vaccines, including information 
on the burden of the disease the vaccine prevents, vaccine effectiveness, vaccine safety, 
indications, precautions, contraindications, and other critical information. Most relevant 
information is also provided in the CDC textbook entitled Epidemiology and Prevention of 
Vaccine-Preventable Diseases, also known as the “Pink Book” [40]. The CDC also reports 
vaccination coverage data via its VaxView websites. This information is summarized below for 
each vaccine recommended during childhood.  
The ACIP individual vaccine recommendations can be accessed at the following website:  
http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. The CDC’s Recommended Immunization 
Schedule for Children and Adolescents can be accessed at the following website: 
https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html. The Pink Book can be 
accessed at the following website: http://www.cdc.gov/ vaccines/pubs/pinkbook/index.html. The 




Haemophilus influenzae type b (Hib) 
 
Hib Disease 
Haemophilus influenzae is an aerobic gram-negative coccobacillus bacterium with encapsulated 
typeable strains and unencapsulated nontypeable strains. There are six serotypes of encapsulated 
Hib, identified by their antigenically and biochemically distinct polysaccharide capsules. Serotype 
b (Hib) was responsible for 95% of Haemophilus influenzae disease prior to vaccine introduction. 
Hib generally enters the body via respiratory droplets through the nasopharynx but can cause 
conjunctivitis or cellulitis from entry via the skin. Bacteremia occurs when Hib organisms invade 
the bloodstream and cause infection elsewhere. The most common clinical feature of invasive Hib 
disease is meningitis, which can then lead to residual hearing impairment, neurologic sequelae, or 
even death. Fatality rates range from 3%-6% for Hib meningitis, even despite appropriate 
antimicrobial therapy. Invasive Hib disease accounted for 50-65% of cases of bacterial meningitis 
prior to introduction of Hib vaccine. Other clinical features of Hib disease include otitis media, 
epiglottitis, pneumonia, septic arthritis, cellulitis, osteomyelitis, and bacteremia. Hib disease is 
uncommon after 5 years of age, presumably due to acquisition of immunity either from 
asymptomatic Hib infection or from exposure to other organisms with antigenic structures 
resembling the capsule of Hib (i.e. cross protection). Incidence of Hib has decreased by over 99% 
since the introduction of Hib vaccines [40].  
Hib Vaccine 
There are two conjugate Haemophilus influenzae type b (Hib) vaccines used in the United States: 
PRP-OMP (trade name: PedvaxHIB®) and PRP-T (trade names: ActHIB®, Hiberix®; also 
included in the DTaP-Hib-IPV combination vaccine Pentacel®). Hib polysaccharide is chemically 
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bound to a non-Hib protein carrier, creating a more effective antigen and therefore stimulating a 
better immune response, particularly in infants, than with the plain polysaccharide. PRP-OMP uses 
meningococcal group B outer membrane protein, and PRP-T uses tetanus toxoid protein.  
ACIP Recommendations 
The ACIP recommends that all infants without contraindications should receive the conjugate Hib 
vaccine series; either as 3 doses of PRP-OMP, or as 4 doses of PRP-T. Doses of Hib vaccine should 
be given at least 4 weeks apart, with the first dose administered at a minimum of 6 weeks of age. 
Doses are generally recommended to be given at 2 and 4 months of age, and for the PRP-T 
vaccines, 6 months of age as well. A booster dose should then be given a minimum of 8 weeks 
after the previous dose, generally between 12-15 months of age [40, 228, 229]. Although Hib 
vaccine is generally not recommended for those over 59 months of age, there are exceptions for 
certain persons at increased risk; for example, previously unimmunized asplenic patients should 
receive one dose of Hib vaccine, and recipients of a hematopoietic cell transplant should be given 
the full three-dose series beginning 6-12 months after the transplant regardless of their vaccination 
history [229]. 
The Hib-MenCY-TT combination vaccine MenHibrix® was discontinued in the United States in 
2016 [230]. The Hib-Hep B combination vaccine Comvax® was discontinued in the United States 
in 2014 [231]. 
Vaccine Coverage 
Hib vaccine coverage in 2017 among children aged 19-35 months was estimated at 92.8% (95%CI: 
91.9–93.6%) for the primary series and 80.7% (95%CI: 79.4–82.0%) for the full series. This is 
relatively consistent with the level of coverage seen over the past five years [14]. 
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Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further Hib vaccination. Current moderate to severe acute illness is a precaution 
to any vaccination [40].  
Vaccine Effectiveness 
Hib vaccines are very immunogenic in infants. Over 95% of primary series recipients develop 
immunity, and clinical efficacy has been estimated at 95-100% [40]. 
Vaccine Safety 
Minor local reactions such as pain, redness or swelling occur in approximately 5-30% of Hib 
vaccine recipients and usually resolve within a day or two. Systemic reactions such as irritability 






Hepatitis A Disease 
Hepatitis A Virus (HAV) is a nonenveloped RNA picornavirus that enters the body through the 
mouth via the fecal-oral route of transmission and replicates in the liver. Infected persons excrete 
virus beginning 10-12 days after infection and continuing up to 3 weeks after appearance of 
symptoms. The incubation period of HAV ranges from 15 to 50 days. Common symptoms are 
generalizable to all acute viral hepatitis disease, such as fever, malaise, nausea, anorexia, jaundice 
and dark urine, and generally persist no more than 2 months, although relapses may occur. About 
70% of infections in children under 6 years of age are asymptomatic. Rarely, infection results in 
fulminant hepatitis, a severe complication with mortality rates estimated to be up to 80% [40].  
Hepatitis A Vaccine 
Hepatitis A vaccines are aluminum hydroxide-adjuvanted formalin-inactivated whole virus 
vaccines. There are two hepatitis A vaccines used in the United States: Havrix®, which is prepared 
with the preservative 2-phenoxyethanol, and Vaqta®, which does not contain a preservative. These 
vaccines are available in pediatric and adult formulations. There is also a hepatitis A-hepatitis B 
combination vaccine (trade name: Twinrix®) that is approved for use in persons over 18 years of 
age with an indication for both hepatitis A and hepatitis B vaccine. This vaccine should be 
administered according to the recommended schedule for hepatitis B vaccine in this age group 
[40].  
ACIP Recommendations 
The ACIP recommends all infants without contraindications should receive two doses of hepatitis 
A vaccine between 12-23 months of age. Doses should be given at least 6 months apart. Infants 
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between 6-11 months of age traveling internationally to countries with high or intermediate 
endemicity should also receive hepatitis A vaccine. Such children should still receive hepatitis 
vaccine between 12-23 months of age as normally recommended. Older children and adults 
without contraindications who are at increased risk of hepatitis A infection (such as international 
travelers to countries with high or intermediate endemicity; men who have sex with men; illegal 
drug users; contacts of recent international adoptees from countries endemic with hepatitis A virus; 
persons working with hepatitis A-infected primates; and those with a clotting factor disorder) as 
well as persons at risk of severe complications from hepatitis A infection (such as those with 
chronic liver disease) should also be routinely vaccinated. Hepatitis A vaccine is also now 
recommended for post-exposure prophylaxis for all persons age one year and older [40, 232, 233]. 
Vaccine Coverage 
Hepatitis A vaccine coverage in 2017 among children aged 19-35 months was estimated at 86.0% 
(95%CI: 84.8–87.1%) for at least one dose and 59.7% (95%CI: 58.2–61.3%) for at least two doses. 
Coverage appears to have increased slightly since 2013 (83.1% for at least one dose and 54.7% for 
at least two doses) [14]. 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further vaccination with hepatitis A vaccine. Current moderate to severe acute 
illness is a precaution to any vaccination [40].  
Vaccine Effectiveness 
Hepatitis A vaccines are very immunogenic. Over 95% of adults and 97% of children and 
adolescents develop immunity within a month of the first dose of vaccine, and 96-100% of children 
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and adults develop immunity after the second dose. In clinical trials, vaccine efficacy of Havrix® 
was estimated to be 94% and Vaqta® estimated to be 100% [40]. 
Vaccine Safety 
Self-limited, minor local reactions such as pain, redness or swelling are reported in approximately 
20-50% of vaccine recipients. Mild systemic reactions such as fatigue, malaise and low-grade fever 
are reported in less than 10%. Besides very rare occurrences of anaphylaxis, no serious adverse 
events have been shown to be caused by to hepatitis A vaccination. Severe allergic reaction (e.g. 
anaphylaxis) to a previous dose or vaccine component is a contraindication to further hepatitis A 






Hepatitis B Disease 
Hepatitis B Virus (HBV) is a small, double-shelled DNA virus in the Hepadnaviridae family. 
HBV is transmitted via mucosal exposure to infected body fluids, often during birth, sexual 
contact, via blood or blood exposure, needlesticks, or injection drug use [40]. It is highly infectious 
to susceptible individuals exposed in these manners. Thirty percent of infected individuals in the 
US have no known exposures [234, 235]. The incubation period averages 120 days. Approximately 
90% of infants and 50% of adult infections are asymptomatic, and when there are symptoms, they 
are indistinguishable from those of other types of acute viral hepatitis. Initial symptoms include 
malaise, anorexia, nausea, vomiting, fever, headache, myalgia, arthralgia, arthritis and dark urine. 
Further symptoms such as jaundice, light or gray stools, hepatic tenderness and hepatomegaly 
typically last 1-3 weeks, and begin 3-10 days after the onset of most initial symptoms (1-2 days 
following the onset of dark urine). Most acute HBV infections result in complete recovery; 
however, 1-2% of cases result in fulminant hepatitis, which has a case-fatality rate of 63-93% and 
causes roughly 200-300 deaths in the United States annually. Up to 90% of infants infected at birth 
by their mothers become chronically infected, and about 25% of those chronically infected will 
die from cirrhosis or liver cancer. This risk of chronic infection decreases with age, to about 5% 
of acute infections in adults become chronic. Chronic infection is often asymptomatic until 
complications develop [40]. 
Hepatitis B Vaccine 
Hepatitis B vaccines are yeast-derived recombinant vaccines containing HBsAg protein. There are 
three hepatitis B vaccines used in the United States: Recombivax HB®, which is adjuvanted with 
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aluminum hydroxyphosphate sulfate; Engerix-B®, which is adjuvanted with aluminum hydroxide; 
and HEPLISAV-B™, which is adjuvanted with cytosine phosphoguanine (CpG) 1018. Engerix-
B® and Recombivax HB® are approved for use in all ages. HEPLISAV-B™ is only approved for 
use in persons aged 18 years and older, administered as two doses (0.5 mL each) given one month 
apart [40, 236]. 
There are also several combination vaccines that include hepatitis B vaccine. Hep A-Hep B 
(Twinrix®) is approved for use in persons over 18 years of age, administered in a three-dose series 
at 0, 1 and 6 months. DTaP-Hep B-IPV (Pediarix®) is approved for use at 2, 4 and 6 months of 
age. Pediarix® cannot be used before 6 weeks of age, but can be substituted for doses 2 or 3 of 
hepatitis B vaccine. Infants may also receive a fourth dose of hepatitis B vaccine as part of a 
combination vaccine schedule [40].  
The Hib-Hep B combination vaccine Comvax® was discontinued in the United States in 2014 
[231]. 
ACIP Recommendations 
The ACIP recommends that all medically stable infants weighing ≥2,000 grams without 
contraindications should receive the first dose of hepatitis B vaccine within 24 hours of birth. 
Certain infants at increased risk of acquisition of hepatitis B, such as infants born to hepatitis B-
infected mothers or mothers with unknown status, should receive hepatitis B vaccine as soon as 
possible after birth along with a dose of hepatitis B immune globulin. The second dose should be 
administered a minimum of 4 weeks after the first dose and between 1-2 months of age. The third 
dose should be administered a minimum of 8 weeks after the second and 16 weeks after the first, 
between 6-18 months of age. All children not previously vaccinated should receive the age-
appropriate dose of hepatitis b vaccine, preferably at 11 or 12 years but up to 18 years of age. The 
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usual schedule for adolescents is two doses separated by no less than 4 weeks, and a third dose at 
least 8 weeks from the second dose and 16 weeks from the first dose, and preferably 4 to 6 months 
after the second dose. An approved alternative schedule for adolescents 11 to 15 years of age is 
two 1.0-mL doses of the Recombivax HB® vaccine separated by 4 to 6 months [40, 236-239]. 
Vaccine Coverage 
Hepatitis B vaccine coverage in 2017 among children aged 19-35 months was estimated at 91.4% 
(95%CI: 90.5–92.3%) for at least three doses and 73.6% (95%CI: 72.0–75.2%) for the birth dose. 
This is relatively consistent with the level of coverage seen over the past five years [14]. 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further vaccination with hepatitis B vaccine. Current moderate to severe acute 
illness is a precaution to any vaccination [40].  
Vaccine Effectiveness 
Over 90% of adults and 95% of children develop protective antibody responses after three doses 
of Recombivax HB® or Engerix-B®. These vaccines are > 95% effective at preventing clinical 
disease and the chronic carrier state after infection, and estimated to be 80-100% effective in 
preventing hepatitis B infections after completion of the series. Although antibody levels decline, 
immunologic memory induced from vaccination persists and serologic responders have been 
shown to be protective for at least 20 years. Follow-up studies of infants vaccinated at birth have 
revealed that many adolescents do not develop an anamnestic response (i.e. renewed rapid 
antibody production on a subsequent encounter with the same antigen) to a booster dose of vaccine, 
but there is no evidence of an increased rate of breakthrough disease and no routine booster dose 
has been recommended [40]. 
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Studies of HEPLISAV-B™ have so far demonstrated high rates of seroprotection (90.0-100.0% 
of HEPLISAV-B™ recipients versus 70.5-90.2% of subjects in comparison group) [236].  
Vaccine Safety 
Anaphylaxis occurs approximately once per every 1.1 million doses of hepatitis B vaccine 
administered. Alopecia has been suggested to be rarely associated with hepatitis B vaccination. No 
causal association between any chronic illnesses and hepatitis B vaccine have been shown [40].  
Post-licensure safety studies will be carried out by the manufacturer and CDC independently to 
monitor the safety of the new vaccine HEPLISAV-B™ [236].  
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Human Papillomavirus (HPV) 
 
HPV Disease 
HPV is a small DNA virus that is transmitted by direct contact with an infected person. Over 120 
types of HPV have been identified, about 80 of which infect nonmucosal epithelium and 40 of 
which infect the mucosal and genital epithelium. Infection with one HPV type does not necessarily 
prevent later infection with another type.  
Genital HPV infection is generally transmitted via direct sexual contact but can rarely be 
transmitted by nonsexual routes. Risk of transmission is reduced but not eliminated by using 
physical barriers such as condoms. HPV is the most common sexually transmitted infection in the 
U.S., with an estimated 79 million persons currently infected. 14 million new infections are 
estimated to occur each year, about half of which are in persons 15-24 years old. HPV infection 
often occurs very soon after onset of sexual activity, further illuminating the need for vaccination 
well prior to the onset of sexual activity. Infected mothers can transmit HPV to their infants during 
childbirth resulting in juvenile onset recurrent respiratory papillomatosis. Onset can occur at up to 
18 years of age [240].  
Although HPV infection is quite common, most infections are asymptomatic and resolve 
spontaneously. Possible clinical manifestations include anogenital warts, recurrent respiratory 
papillomatosis, cervical intraepithelial neoplasia (CIN), and cancer [40]. High-risk HPV types, 
including types 16, 18, 31, 45 and others, can cause high-grade cervical lesions and cancer, as well 
as vulvar, vaginal, penile, anal, and oropharyngeal cancers. HPV has been detected in 99% of 
cervical cancers (of which 70% are types 16 and 18), as well as 70% of vulvar and vaginal cancers 
(49-55% type 16), 91% of anal cancers (77% type 16), 72% of oropharyngeal cancer (61% type 
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16), and 40-50% of penile cancers [240]. Infection with several low-risk HPV types (such as types 
6 and 11) can cause low-grade cervical cell abnormalities, anogenital warts, and laryngeal 
papillomas [40]. In the U.S. between 2006 and 2010, an average of 33,160 HPV-associated cancers 
were diagnosed annually, 62% were among females and 38% among males. Of these, cervical and 
oropharyngeal cancers were the most common, with an estimated 10,400 cervical cancers and 
9,000 oropharyngeal cancers (80% of which were in men) diagnosed annually [240].  
HPV Vaccine 
HPV vaccines are subunit vaccines using a recombinant HPV L1 major capsid protein as the 
vaccine antigen. These L1 proteins self-assemble into virus-like particles (VLP), which are both 
noninfectious and nononcogenic [40]. HPV vaccines include bivalent (abbreviation: 2vHPV; trade 
name: Cervarix®), quadrivalent (4vHPV; Gardasil®), and 9-valent (9vHPV; Gardasil 9®) 
vaccines. However, as of 2018, only 9vHPV is being distributed in the U.S. 9vHPV includes HPV 
types 16, 18, 6, 11, 31, 33, 45, 52, and 58 [241].  
ACIP Recommendations 
The ACIP recommends that all males and females without contraindications ages 11-12 years 
should receive two doses of HPV vaccine administered 6-12 months apart. Vaccination can be 
started as young as 9 years of age. Those who start the series after the age of 15 should receive 
three doses of HPV vaccine, with the second and third doses administered 1-2 months and 6 
months after the first dose, respectively. If not previously vaccinated, catch-up vaccination is 
recommended for all males through age 21 and females through age 26. Males ages 22-26 years 
may also be vaccinated. If doses are delayed there is no need to repeat doses since increasing the 
interval between doses is generally associated with enhanced immune responses [40, 241]. 
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Vaccine Coverage 
HPV vaccine coverage among adolescents in 2017 was estimated at 65.5% (95%CI: 64.3–66.7%) 
for at least one dose. Coverage was higher among females (68.6%) than males (62.6%) [242]. 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further HPV vaccination. 2vHPV is contraindicated for persons with 
anaphylactic latex allergy. 4vHPV and 9vHPV are contraindicated for persons with a history of 
immediate hypersensitivity to yeast. HPV vaccination is not recommended during pregnancy. 
Current moderate to severe acute illness is a precaution to any vaccination [40, 241, 243].  
Vaccine Effectiveness 
HPV vaccines are very immunogenic, with at least 97.9% of vaccine recipients developing 
antibody responses to all the types included in their respective vaccines after completing the two-
dose series. Estimates of efficacy against cervical intraepithelial neoplasia (CIN) after three doses 
have ranged from 93-97%, depending on the vaccine. 4vHPV efficacy against genital warts related 
to vaccine types after three doses was shown to be 99% in women and 88% in men. Studies 
comparing two doses to three doses and 9vHPV to 4vHPV have shown noninferior 
immunogenicity [40, 241, 243].  
Vaccine Safety 
Mild local reactions such as pain and swelling are the most common adverse reactions following 
HPV vaccination, reported in 20-90% of recipients [40]. Because syncope has been reported 
among adolescents receiving vaccinations, adolescent recipients should always receive the vaccine 
while sitting and not in view of others awaiting vaccination, and be observed for up to 15 minutes 
immediately after vaccination [244-247]. 
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HPV vaccines are among the most rigorously studied vaccines for safety; except for very rare 
occurrences of anaphylaxis, no serious adverse events have been associated with HPV vaccination. 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further HPV vaccination [40]. 
Receiving HPV vaccine at the recommended ages does not increase likelihood of sexual activity 








Influenza is caused by RNA viruses of three types. Type A influenza is the cause of most human 
illness and has many subtypes based on the variations in the surface antigens (i.e., hemagglutinin 
(H) and neuraminidase (N)), such as H1N1 or H3N2. Type B influenza also infects humans but 
generally causes milder illness. Type C only very rarely causes human disease [35, 40, 250].  
The surface antigens on influenza viruses are always evolving, faster than most other viruses that 
cause human disease. This continuous stream of minor mutations is called antigenic drift and is 
what makes influenza so adept at evading immunity induced by prior infection or vaccination. In 
most years, at least some of the circulating influenza strains have drifted compared to prior years, 
thus even those who were infected or vaccinated in years prior may develop influenza disease 
again [35, 40, 250, 251].  
Occasionally a major change in one or both surface antigens occurs, known as antigenic shift; the 
majority of the population is usually susceptible to the new virus. The new strains generated in this 
manner, such as the 2009 influenza A H1N1, have the potential to cause a worldwide pandemic 
[35, 40, 250, 251]. 
Influenza circulates throughout the United States seasonally every year, typically starting in late 
fall and remaining through spring [28, 30-32, 252-254]. The incubation period for influenza is 
generally 1-2 days [35, 40]. The major clinical symptoms typically last a median of 4 days without 
treatment and include sore throat, fever, headache, myalgia, and nonproductive cough [40, 255]. 
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Pneumonia is the most common complication of influenza. Other complications include Reye 
syndrome and myocarditis [40, 255].  
Most people infected with influenza recover without sequelae. However, influenza is capable of 
causing serious illness and death, especially in high risk groups such as older adults, young 
children, pregnant women, and people with certain medical conditions [28, 30-32, 35, 252-254]. 
The CDC estimated an average of 23,607 annual influenza-associated deaths in the United States 
between 1976 and 2007, although these estimates ranged widely from year to year [256]. Studies 
have also estimated an average of approximately 130,000 annual influenza-associated 
hospitalizations in the United States [257, 258]. There was an average of 113 annual pediatric 
deaths from influenza in the United States between 2010 and 2016, and about half of these were 
in children with no preexisting medical condition [259]. During the 2016-2017 U.S. influenza 
season, there were 18,256 laboratory-confirmed influenza-associated hospitalizations, which 
equates to a rate of 65.2 hospitalizations per 100,000 people (as of May 20, 2017). There were also 
110 influenza-associated pediatric deaths [260].  
Influenza Vaccine 
Two types of vaccines are available to protect against influenza: inactivated influenza vaccine 
(IIV) and live attenuated influenza vaccine (LAIV). LAIV (trade name: FluMist®) was not 
recommended for use during the 2016-2017 or 2017-2018 flu seasons due to problems with low 
effectiveness during the previous several seasons, but is again an option for the 2018-2019 season 
for non-pregnant persons 2-49 years of age for whom it is otherwise appropriate [261]. LAIV is 
administered intranasally using a single dose sprayer containing 0.2 mL, with about half (0.1 mL) 
sprayed in each nostril [40, 261, 262]. In the United States, quadrivalent IIV (IIV4) vaccines 
include Fluarix® Quadrivalent, FluLaval® Quadrivalent, and Fluzone® Quadrivalent; trivalent 
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IIV (IIV3) include Afluria®, Fluvirin®, and Fluzone®. There are two recombinant influenza 
vaccines, Flublok® (RIV3) and Flublok® Quadrivalent (RIV4). Trivalent vaccines contain one 
A/H3N2 strain, one A/H1N1 strain, and one B strain from one of the two B lineages (Yamagata 
and Victoria). The Quadrivalent vaccines contain a second B strain [40, 262]. The Food and Drug 
Administration (FDA) has recommended that the trivalent influenza vaccines used in the United 
States during the 2018-19 season contain an A/Michigan/45/2015 (H1N1)pdm09-like virus, an 
A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus, and a B/Colorado/06/2017-like 
(B/Victoria lineage) virus; and that the quadrivalent vaccines also contain a B/Phuket/3073/2013-
like (B/Yamagata lineage) virus [263]. 
ACIP Recommendations 
The ACIP recommends all persons without contraindications who are 6 months of age and older 
receive annual vaccination with influenza vaccine. IIV is recommended for all age groups and 
during pregnancy [262]. LAIV is also an option for non-pregnant persons between 2 and 49 years 
of age [261]. Influenza vaccine should be given as soon as it becomes available (usually between 
August and October in the U.S.) in order to ensure the highest possible level of protection before 
rates of transmission increase. Peak transmission season is usually between December and March 
in the United States [40]. Children less than 9 years of age receiving IIV for the first time ever 
should receive two doses at least one month apart; otherwise, one dose per year is sufficient [262]. 
Vaccine Coverage 
Seasonal influenza vaccine coverage in children between 6 months and 17 years old in the United 
States was reported at 57.9% for the 2017-2018 flu season. Coverage increased incrementally each 
year between the 2009-2010 (43.7%) and 2014-2015 (59.3%) seasons before plateauing in recent 
years. Seasonal influenza vaccine coverage in adults in the United States was reported at 37.1% 
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for the 2017-2018 flu season, the lowest mark of the last decade. Prior to this, adult coverage had 
remained between 38.8% and 43.6% since the 2009-2010 flu season [264].  
Influenza vaccine has been shown to be capable of inducing community protection (herd 
immunity) [265-267], but higher coverage rates are needed to fully realize the benefits of such 
protection [268].  
Contraindications and Precautions 
An important contraindication is having had a severe allergic reaction (e.g. anaphylaxis) to a 
vaccine component or previous vaccination. However, this does not include egg allergies, even 
though most influenza vaccines are grown in embryonated chicken eggs (an exception being the 
egg-free recombinant influenza vaccine, Flublok®) [262]. This is because the vaccines marketed 
in the United States have been found to contain extremely small amounts or undetectable amounts 
of egg protein and recent studies have indicated that egg allergic patients can safely receive 
influenza vaccines [269, 270]. The ACIP recommends that persons with a severe egg allergy (who 
have had associated angioedema, respiratory distress, lightheadedness, or recurrent emesis, or who 
required epinephrine or another emergency medical intervention following egg ingestion) can 
receive these vaccines, but the vaccine should be administered in an inpatient or outpatient medical 
setting [262]. However, the American Academy of Allergy, Asthma, and Immunology (AAAAI) 
and the American Academy of Pediatrics (AAP) do not recommend any special precaution because 
there does not appear to be any increased risk of severe allergic reactions to these vaccines in 
persons with egg allergy [271, 272].   
Precautions include moderate to severe acute illness with or without fever, as well as a diagnosis 




The effectiveness of influenza vaccines varies each year in relation to the match between the 
vaccine strains and the circulating strain. Effectiveness can also vary by the age and health status 
of the vaccine recipient [40]. Effectiveness has been shown to decline significantly over the first 
six months post-vaccination, albeit at different rates depending on the vaccine [273-275]. 
However, even in years when the vaccine has a lower effectiveness relative to other years, 
receiving the vaccine still reduces risk of infection, severe illness, hospitalization, and death due 
to influenza. In addition, high vaccine coverage prevents disease transmission and helps to protect 
those most vulnerable to serious influenza illness [276]. 
Vaccine Safety 
Common adverse reactions to IIV include local reactions such as soreness, erythema and 
induration at the injection site, which are reported at variable rates, but are usually mild and 
typically last no more than 2 days. Systemic symptoms such as sensation of fever, chills, malaise, 
and myalgia are also common. These symptoms typically begin within 6–12 hours of vaccination 
and usually last for only a few hours. Such symptoms are usually mild but have been reported in 
4-<30% of children receiving IIV [277-283]. Myalgia within a week of vaccination has been 
reported among 14-16% of adults receiving unadjuvanted IIV and 31-39% of adults receiving 
adjuvanted IIV [284], with even higher rates among recipients of the 2009 pandemic H1N1 vaccine 
[285].  
Rarely, allergic reactions such as hives, angioedema, allergic asthma, or systemic anaphylaxis 
occur after vaccination, probably due to hypersensitivity to a vaccine component.  
Influenza vaccination in recent years has been associated with a very small increased risk of GBS 
in adults, leading to about 1-3 excess cases of GBS per million persons vaccinated. This is much 
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less than the estimated risk after wild-type influenza infection, providing further evidence that the 
benefits of influenza vaccination greatly outweigh the risks [286, 287].  
IIV cannot cause influenza, as all viruses contained in the vaccine are inactivated and noninfectious 





Measles, Mumps and Rubella 
 
Measles, Mumps and Rubella Disease 
Measles is a highly contagious acute disease caused by an RNA paramyxovirus, genus 
Morbillivirus, with one antigenic type. Measles is transmitted via the respiratory route and 
secondary attack rates in families among susceptible persons are often greater than 90%. Measles 
virus can survive up to 2 hours in air or on surfaces. The average incubation period of 10-12 days 
is followed by cough, runny nose, and stepwise increase in fever up to 103-105°F. A 
maculopapular rash begins on the face and head a few days after onset of respiratory symptoms 
and persists for 5-6 days. Common complications include diarrhea, otitis media, and pneumonia, 
and rare complications include encephalitis, seizures, and death. Measles illness during pregnancy 
increases the risk of premature labor, low-birthweight children, spontaneous abortion, as well as 
pneumonia and encephalitis [40].   
Mumps is caused by an RNA paramyxovirus with one antigenic type and is acquired through 
respiratory transmission. The incubation period is 12-25 days. Symptoms are generally nonspecific 
at first, including myalgia, malaise, headache, and fever. Approximately one-third of mumps 
infections are asymptomatic; however, asymptomatic persons can transmit the virus. Possible 
complications of mumps infection include parotitis, orchitis, oophoritis, deafness, meningitis, 
encephalitis, and pancreatitis [40].   
Rubella, also known as “German measles”, is caused by an RNA togavirus, genus Rubivirus, with 
one antigenic type. Rubella is acquired through respiratory transmission and the incubation period 
is about 14 days. Symptoms include mild fever and malaise; up to 50% of cases are subclinical. A 
maculopapular rash lasting about 3 days generally occurs 14 to 17 days after infection, beginning 
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on the face and spreading downwards. This rash is usually fainter than the measles rash, and does 
not coalesce. Arthralgia and arthritis are common after puberty, especially in females [40]. Among 
pregnant women who are infected with wild-type rubella virus, transplacental infection of the fetus 
can occur, causing congenital defects or stillbirth [40, 290].  
Measles, Mumps and Rubella Vaccine 
Measles, mumps and rubella vaccines are all live attenuated viral vaccines that are only available 
in combination as MMR (trade name: M-M-R II®) in the United States. The MMRV vaccine (trade 
name: ProQuad®) also includes varicella vaccine [40].  
ACIP Recommendations 
The ACIP recommends that all children without contraindications should receive two doses of 
measles-mumps-rubella combination vaccine after 1 year of age and at least 4 weeks apart. The 
first dose is usually administered at a minimum of 12 months of age, and is generally given 
between 12 and 15 months of age. The second dose is usually given between 4 and 6 years of age, 
prior to entering school, although it can be given anytime at least 4 weeks after the first dose for 
children at increased risk of exposure. The CDC recommends that MMR and varicella vaccine be 
administered separately for the first dose in order to reduce the small increased risk of febrile 
seizures in toddlers associated with the measles-mumps-rubella-varicella combination vaccine 
compared to the separate but simultaneous administration of MMR and varicella vaccines. MMRV 
is generally preferred for the second dose [40, 290].  
Vaccine Coverage 
MMR vaccine coverage in 2017 among children aged 19-35 months was estimated at 91.5% 
(95%CI: 90.6–92.3%) for at least one dose. This is relatively consistent with the level of coverage 
seen over the past five years [14]. 
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Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component such as 
neomycin is a contraindication to further vaccination with MMR. Other contraindications include 
pregnancy, immunosuppression, and family history of altered immunocompetence. Current 
moderate to severe acute illness is a precaution to any vaccination. Other precautions for MMR 
vaccination include recent receipt of antibody-containing blood products and personal or family 
history of seizures [40, 244].  
Vaccine Effectiveness 
One dose of MMR vaccine is estimated to be 93% effective in preventing measles and 97% 
effective in preventing rubella. A second dose has been shown to increase the effectiveness of 
measles vaccine to an estimated 97%, mainly by producing immunity in those who failed to 
respond to the initial dose [40, 290, 291]. Effectiveness of two doses of MMR vaccine against 
mumps is estimated to be between 66 and 95%, and vaccine-induced protection has been shown 
to wane over time [292]. 
Vaccine Safety 
Mild illness in people receiving their first dose of MMR can occur due to replication of the 
attenuated measles vaccine virus. Between 5% and 15% develop a 1-2 day fever up to 103°F 
approximately 7 to 12 days after the first dose. A transient rash may also appear during this time 
frame, occurring in approximately 5% of those vaccinated [40]. 
Vaccines which may induce fever may also rarely induce febrile seizures. Febrile seizures are a 
common and typically benign childhood condition, occurring in 2-5% of children at some point 
during their first five years of life. Febrile seizures have an estimated background incidence of 
240–480 per 100,000 person-years in children under five years, although this varies considerably 
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by age, genetics, co-morbidities and environmental risk factors. There are no long-term effects of 
simple febrile seizures, with the possible exception of an increased risk of recurrence [293-296]. 
[5-8]. The rate of febrile seizures in the 7-10 days after vaccination was approximately 2-3 times 
higher for children who received MMRV as compared to MMR and varicella vaccines 
administered separately on the same day, and 4 times higher as compared to MMR alone [297]. 
There is no increased risk of fever or febrile seizures in children receiving their second dose of 
measles-containing vaccine at 4 to 6 years of age, whether given MMR or MMRV [40, 220].  
Mild, acute joint symptoms occur in approximately 25% of susceptible adult women after rubella 
vaccination, but are less common in men and rare in children. Rare adverse events from MMR 
vaccine include thrombocytopenia, parotitis, lymphadenopathy and encephalopathy. Very rare 
adverse events from MMR vaccine include measles inclusion body encephalitis (MIBE). Immune 
thrombocytopenia purpura (ITP) occurs after approximately 1 in 30,000 doses. Allergic reactions 








Neisseria meningitidis, or meningococcus, is an aerobic gram-negative diplococcus. 
Meningococci colonize the nasopharynx, and in less than 1% of colonized persons the organism 
invades the bloodstream. Most strains are not pathogenic; five serogroups cause almost all invasive 
disease (A, B, C, W, and Y). Serogroup prevalence depends heavily on geographic location as well 
as other factors including age. In the United States, groups B, C, and Y are primarily responsible 
for meningococcal disease. Rates of meningococcal disease in the US have been declining for the 
last few decades, so that in 2016, there were 375 reported cases in the entire US. N. meningitides 
can cause bacteremia, meningococcemia, meningitis, pneumonia, and/or septic arthritis. The 
average incubation period is 3-4 days for meningococcemia. Disease usually presents with an 
abrupt onset of fever, hypotension, and rash with or without meningeal symptoms. The most 
common presentation of invasive disease is meningitis, usually accompanied by fever, headache 
and stiff neck. Fatality rates range from 10%-15% (and up to 40% in meningococcemia) for 
meningococcal meningitis. Less common presentations include pneumonia (5-15%), arthritis 
(2%), otitis media (1%) and epiglottitis (<1%) [40].  
Meningococcal Vaccine 
There are several meningococcal conjugate vaccines (MCVs) licensed in the United States. The 
MCV4 vaccines MenACWY-D (Menactra®) and MenACWY-CRM (Menveo®) protect against 
serogroups A, C, W and Y [40], and the single-component vaccines MenB-FHbp (Trumenba®) 
and MenB-4C (Bexsero®) protect against serogroup B [298]. Both MenACWY-D and 
MenACWY-CRM are administered via intramuscular injection and contain no preservatives or 
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adjuvants. MenACWY-D is approved for use in persons 9 months through 55 years of age, and 
MenACWY-CRM is approved for use in persons 2-55 years of age [40]. MenB-FHbp and MenB-
4C are approved for use in persons 10-25 years of age [298]. Hib-MenCY-TT is approved for use 
as a four-dose series at 2, 4, 6, and 12-18 months of age.  
Quadrivalent meningococcal polysaccharide vaccine which was a plain polysaccharide vaccine 
not conjugated to protein, MPSV4 (Menomune®), is no longer recommended for routine use [40]. 
The Hib-MenCY-TT combination vaccine MenHibrix® was discontinued in the United States in 
2016 [230].  
ACIP Recommendations 
The ACIP recommends that all adolescents 11-18 years of age without contraindications should 
receive two doses of meningococcal conjugate, routinely given at 11 or 12 years of age and a 
booster at 16 years of age. Adolescents who receive a first dose after their 16th birthday do not 
need a booster dose unless they become at increased risk for meningococcal disease. Vaccination 
to prevent meningococcal disease is also recommended for all persons starting at 9 months of age 
who are at increased risk for meningococcal disease (such as travelers to hyperendemic or 
epidemic countries; those with asplenia; or those with persistent complement component 
deficiency). Serogroup B meningococcal vaccine is recommended for all persons starting at 10 
years of age who are at increased risk for serogroup B meningococcal disease (such as those with 
persistent complement component deficiencies; those with anatomic or functional asplenia; 
microbiologists routinely exposed to N. meningitides; and anyone identified to be at increased risk 
during an outbreak of serogroup B meningococcal disease). Adolescents and young adults aged 




MenACWY coverage among adolescents in 2017 was estimated at 85.1% (95%CI: 84.2–86.1%) 
for at least one dose [242]. 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further vaccination with meningococcal vaccines. Current moderate to severe 
acute illness is a precaution to any vaccination [40].  
Vaccine Effectiveness 
Meningococcal serogroups A and C polysaccharide vaccines have demonstrated estimated clinical 
efficacies of at least 85% among children and adults during outbreaks. Meningococcal conjugate 
vaccines were shown to achieve a seroresponse comparable to the MPSV4 and are able to elicit 
better immunologic memory [40]. 
Vaccine Safety 
The most common adverse events reported for MenACWY-D are fever (17%), headache (16%), 
injection-site erythema (15%), dizziness (13.4%), and syncope (10%); the most common reported 
for MenACWY-CRM are injection site reactions (20%), injection site erythema (14%), and 
syncope (9%) [40]. Because syncope has been reported among adolescents receiving vaccinations, 
adolescent recipients should always receive the vaccine while sitting and not in view of others 
awaiting vaccination, and be observed for up to 15 minutes immediately after vaccination [244-
247]. Serious adverse events are rare. Hib-MenCY-TT had rates of adverse events comparable to 
Hib-TT vaccine [40].  
The most common adverse reactions reported for both MenB-FHbp and MenB-4C included pain 










Streptococcus pneumoniae is a facultative anaerobic gram-positive bacterium. 92 serotypes of S. 
pneumoniae have been documented, classified by their antigenic polysaccharide capsules. 
Antibodies provide protection specific to serotype. Pneumococci are often asymptomatically 
carried in the respiratory tracts of healthy persons.  
Pneumococcal infections can cause pneumonia, sepsis, meningitis, otitis media, bone and joint 
infections, sinusitis, orbital cellulitis and skin infections. Pneumonia occurs at all ages and is the 
most common cause of death from Streptococcus pneumoniae. The incubation period of 
pneumococcal pneumonia is 1-3 days and is associated with fever, rigors (in adults), pleuritic chest 
pain, productive cough, dyspnea, tachypnea, hypoxia, tachycardia, malaise and weakness. 
Pneumococcal pneumonia has a case-fatality rate of 5-7% (may be substantially higher among the 
elderly). Roughly 25-30% of adult patients with pneumococcal pneumonia also develop 
pneumococcal bacteremia, which has a case-fatality rate of about 20% (may be as high as 60% 
among the elderly). Pneumococcal meningitis has a case-fatality rate of about 8% among children 
and 22% among adults, with neurologic sequelae often persisting among survivors. Over half of 
all cases of bacterial meningitis in the United States are caused by pneumococci [40]. WHO 
estimates that over 1.6 million people, including 0.7-1 million children under 2 years of age, die 
every year from pneumococcal infections worldwide [300]. 
Pneumococcal Vaccine 
The pneumococcal conjugate vaccine licensed for use in the United States is the aluminum 
phosphate-adjuvanted 13-valent PCV13 (trade name: Prevnar13®), which contains the purified 
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capsular polysaccharide from 13 serotypes of S. pneumoniae conjugated to a nontoxic diphtheria 
toxin known as CRM197. The pneumococcal polysaccharide vaccine licensed for use in the United 
States is PPSV23, which contains the purified capsular polysaccharide antigen from 23 serotypes 
of S. pneumoniae [40].  
ACIP Recommendations 
The ACIP recommends that all infants without contraindications should receive four doses of 
pneumococcal conjugate vaccine, beginning no earlier than 6 weeks of age. The primary series of 
three doses is generally administered at 2, 4 and 6 months of age. A booster dose should be 
administered between 12-15 months of age. The minimum interval between doses is 4 weeks for 
infants under one year of age, and 8 weeks for infants over one year of age. Children 6-18 years 
of age who have not previously received PCV13 or who have specific risk factors (such as 
anatomic asplenia including sickle-cell disease; immunocompromising conditions including HIV 
infection; cochlear implant; or cerebrospinal fluid leak) should receive a dose of PCV13 [40, 301].  
PPSV23 is also recommended for persons over 2 years of age with any of the following specific 
risk factors (anatomic or functional asplenia; cochlear implant; cerebrospinal fluid leak; 
immunocompromising conditions including HIV infection, disease, chemotherapy and steroids; 
chronic illness including heart, pulmonary and liver disease; alcoholism; or asthma or cigarette 
smoking in adults over 19 years of age), with a revaccination dose after 5 years, and a third dose 
after the 65th birthday at least 5 years from the second dose. When both the conjugate and plain 
polysaccharide pneumococcal vaccines are recommended for a given individual, the conjugate 
vaccine should be given first. If the plain polysaccharide vaccine was given first, the conjugate 




PCV coverage in 2017 among children aged 19-35 months was estimated at 91.9% (95%CI: 90.9–
92.8%) for at least three doses and 82.4% (95%CI: 81.1–83.6%) for at least four doses. This is 
relatively consistent with the level of coverage seen over the past five years [14]. 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further vaccination with pneumococcal vaccines. Current moderate to severe 
acute illness is a precaution to any vaccination [40].  
Vaccine Effectiveness 
PPSV23 is 60-70% effective against invasive pneumococcal disease caused by vaccine serotypes, 
although ineffective in children younger than 2 years of age. PCV13 is highly immunogenic and 
estimated to be over 90% effective in children against invasive pneumococcal disease caused by 
vaccine serotypes. In addition, PCV13 has been shown to reduce nasopharyngeal carriage of 
vaccine serotypes, which is important in reducing the disease burden by further limiting the spread 
of S. pneumonia from person to person [40]. 
Vaccine Safety 
Local reactions such as pain, redness and swelling occur in 30-50% of PPSV23 recipients and 5-
49% of PCV13 recipients. Moderate reactions such as fever and myalgia are uncommon (<1%) 
and severe adverse reactions are rare in PPSV23 recipients. However, about 8% of PCV13 local 
reactions are considered severe, for example causing tenderness that interferes with movement of 
the limb. Local reactions are typically more common after the fourth dose of PCV13 than after the 
first three. Fever over 100.4°F within 7 days after vaccination was reported in 24-35% of PCV13 
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recipients in clinical trials; high fever was reported in less than 1% [40]. Cellulitis-like reactions 
after Pneumovax 23® vaccination have also been reported in the literature [302, 303].  
Vaccines which may induce fever may also rarely induce febrile seizures. Febrile seizures are a 
common and typically benign childhood condition, occurring in 2-5% of children at some point 
during their first five years of life. Febrile seizures have an estimated background incidence of 
240–480 per 100,000 person-years in children under five years, although this varies considerably 
by age, genetics, co-morbidities and environmental risk factors. There are no long-term effects of 
simple febrile seizures, with the possible exception of an increased risk of recurrence [293-296]. 
Febrile seizures were estimated to occur at a rate of 5.3 per 100,000 doses in children aged 6-59 
months receiving PCV13, and 17.5 per 100,000 doses after receiving PCV13 and concomitant 
trivalent inactivated influenza vaccine. These risk differences varied with age due to the age-
dependent background rates of febrile seizures, with the highest estimates at 16 months and the 








Poliovirus is an RNA enterovirus of the Picornaviridae family. Transmission is primarily through 
the fecal oral route, and the virus replicates in the pharynx, local lymphatics and gastrointestinal 
tract. Spread of the virus from blood to nerves to the central nervous system can cause destruction 
of motor neurons. The incubation period is 3-6 days for nonparalytic poliomyelitis and 7-21 days 
for onset of paralysis in paralytic poliomyelitis. Up to 72% of all infections in children are 
asymptomatic, but these persons can shed the virus in their stool and respiratory secretions and 
transmit the virus to others. Approximately 24% of infections in children result in minor, 
nonspecific illness without viral spread to the central nervous symptoms, followed by complete 
recovery within a week. 1-5% of infected children experience nonparalytic aseptic meningitis, 
lasting between 2-10 days. Paralysis occurs in less than 1% of infections in children. Paralytic 
symptoms typically progress for 2 to 3 days then plateau as the fever subsides. Many of those with 
paralytic poliomyelitis recover completely, and most recover some muscle function. However, any 
paralysis or weakness that persists after the first year is generally permanent. Paralysis 
predominantly affects the proximal muscles, especially of the legs in an asymmetric fashion. 
Between 2-5% of cases of paralytic polio in children and 15-30% in adults die from the disease, 
primarily because of paralysis of the muscles of respiration [40].  
Polio Vaccine 
Inactivated poliovirus vaccine (abbreviation: IPV; trade name: Ipol®) is formaldehyde-inactivated 
and contains all three serotypes of polio vaccine virus. Combination vaccines that contain IPV 
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include DTaP-IPV (trade names: Kinrix®, Quadracel®), DTaP-Hep B-IPV (Pediarix®) and 
DTaP-Hib-IPV (Pentacel®) [40].  
Oral poliovirus vaccine (OPV) is a live-attenuated vaccine that is no longer used in the United 
States [40].  
ACIP Recommendations 
The ACIP recommends that all infants without contraindications should receive 3 doses of 
inactivated polio vaccine, given at least 4 weeks apart, with the first dose administered at a 
minimum of 6 weeks of age, routinely at 2, 4, and 6-18 months of age. A fourth dose is 
recommended at 4-6 years of age, though this dose is not needed if the third dose was received 
after 4 years of age and at least 6 months after the second dose [40, 304].  
The following is a direct excerpt from the 2009 ACIP recommendations which clarifies the 
vaccination schedule to be used for specific combination vaccines: “When DTaP-IPV/Hib 
(Pentacel®) is used to provide 4 doses at ages 2, 4, 6, and 15--18 months, an additional booster 
dose of age-appropriate IPV-containing vaccine (IPV [Ipol®] or DTaP-IPV [Kinrix®]) should be 
administered at age 4--6 years. This will result in a 5-dose IPV vaccine series, which is considered 
acceptable by ACIP. DTaP-IPV/Hib is not indicated for the booster dose at age 4--6 years. ACIP 
recommends that the minimum interval from dose 4 to dose 5 should be at least 6 months to provide 
an optimum booster response” [304]. 
Vaccine Coverage 
Polio vaccine coverage in 2017 among children aged 19-35 months was estimated at 92.7% 
(95%CI: 91.9–93.5%) for at least three doses. This is relatively consistent with the level of 
coverage seen over the past five years [14]. 
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Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component (such as 
streptomycin, polymyxin B, and neomycin) is a contraindication to further vaccination with IPV 
[40].  
Vaccine Effectiveness 
At least 90% of recipients of two doses of IPV develop immunity to all three poliovirus types, and 
at least 99% develop immunity after three doses. The exact duration of immunity is unknown but 
appears to be long term [40]. 
Vaccine Safety 








Rotavirus is a very stable double-stranded RNA virus of the Reoviridae family. There are five 
predominant strains which historically have accounted for 90% of isolates in the United States, 
75% of which being the G1 strain. Rotavirus is transmitted through the fecal-oral route and 
replicates in the epithelium of the small intestine. The incubation period is generally less than 48 
hours, after which decreased intestinal absorption of sodium, glucose and water can result in 
isotonic diarrhea. Clinical manifestations of rotavirus infection are nonspecific and range from 
asymptomatic to severe with fever, vomiting and dehydrating diarrhea. Potential complications 
include dehydration, electrolyte imbalance, and metabolic acidosis. Symptoms usually fully 
resolve within 3-7 days. However, if rotavirus infection is not treated, it can be fatal. Multiple 
infections are sometimes necessary to confer permanent immunity, although subsequent infections 
are typically less severe than the first and may even be asymptomatic [40, 305].  
Rotavirus Vaccine 
Rotavirus vaccines (RV) are live attenuated oral vaccines containing no preservatives. There are 
two rotavirus vaccines currently licensed in the United States: RV5 (RotaTeq®), which contains 
five reassortant rotaviruses suspended in a buffer solution, and RV1 (Rotarix®), which contains 
one attenuated strain of human rotavirus and is reconstituted from lyophilized powder prior to 
administration [40]. Both vaccines provide protection against the majority, but not all strains of 




The ACIP recommends that all infants without contraindications should receive the rotavirus 
vaccine series; consisting of either two oral doses of RV1 or three oral doses of RV5 beginning at 
about 2 months of age (no earlier than 6 weeks of age). Each dose should be separated by at least 
4 weeks, and given at the same time as other normal childhood vaccinations. Maximum age of the 
first dose of rotavirus vaccination is 14 weeks and 6 days, and maximum age for any dose is 8 
months [40, 305].  
Vaccine Coverage 
Rotavirus vaccine coverage in 2017 among children aged 19-35 months was estimated at 73.2% 
(95%CI: 71.6–74.7%). This is relatively consistent with the level of coverage seen over the past 
five years [14]. 
 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose, vaccine component or component 
of the oral applicator is a contraindication to further vaccination with RV. The oral applicator for 
RV1 vaccine contains latex, but the applicator for RV5 does not. Other contraindications for RV 
include severe combined immunodeficiency (SCID) and a history of intussusception. Altered 
immunocompetence other than SCID is a precaution to RV. Current moderate to severe acute 
illness is a precaution to any vaccination [40].  
Vaccine Effectiveness 
In very large clinical trials, effectiveness against severe gastroenteritis was estimated to be 85-98% 
and effectiveness against any rotavirus gastroenteritis was estimated to be 74-87% after 
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completion of a full series of RV. RV also significantly reduced physician visits related to diarrhea 
and hospitalization related to rotavirus [40]. 
Vaccine Safety 
In RV5 clinical trials, small but statistically significant increases were shown among vaccine 
versus placebo recipients in rates of diarrhea (18.1% vs 15.3%) and vomiting (11.6% vs 9.9%) 
within the first week after vaccination; slightly increased rates of diarrhea, vomiting, otitis media, 
nasopharyngitis and bronchospasm occurred within 42 days after vaccination. In RV1 clinical 
trials, small but statistically significant increases were shown among vaccine versus placebo 
recipients in Grade 3 cough (i.e. a cough that prevents normal everyday activities) or runny nose 
(3.6% vs 3.2%); increased rates of irritability and flatulence occurred within 31 days after 
vaccination [40]. Recent post-licensure studies in the United States have shown RV5 to be 
associated with approximately 1.1 excess cases of intussusception per 100,000 vaccine recipients 
in the 7 days after the first dose, and 1.5 excess cases per 100,000 recipients in the 21 days after 
the first dose. Data from some countries show an increased risk of intussusception with both RV5 
and RV1 of one to six excess cases per 100,000 vaccinated infants [306, 307]. However, this small 
risk is outweighed greatly by the large health benefit of RV [40, 220, 308]. 
Children with SCID have developed persistent diarrhea caused by rotavirus vaccines that was 
cured only after the infants received bone marrow transplants to correct the immune deficiency 
[309, 310]. Rarely, RV5 has been shown to cause moderate to severe diarrhea associated with 
internal recombination of the vaccine strains [40]. 
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Tetanus, Diphtheria and Pertussis 
 
Tetanus, Diphtheria and Pertussis Disease 
Diphtheria disease is mediated by the toxin of the aerobic gram-positive bacterium 
Corynebacterium diphtheria. The incubation period is generally 2-5 days. Diphtheria can infect 
almost any mucous membrane, but most commonly infects the pharynx and tonsils. Disease begins 
insidiously with mild symptoms such as malaise, sore throat, low-grade fever and anorexia. A 
membrane forms and expands within 2-3 days potentially causing respiratory obstruction, and 
sometimes results in coma and death within 6-10 days. Complications from diphtheria are mostly 
attributable to the toxin, and the most common complications other than respiratory obstruction 
are paralysis and myocarditis [40].   
Tetanus is caused by an exotoxin of the anaerobic gram-positive spore-forming bacterium 
Clostridium tetani. The spores can survive for years in harsh conditions and are widely distributed 
in animal feces and soil. The organism generally enters the human body through a cut in the skin 
at which point the spores germinate and toxins spread through the circulatory and lymphatic 
systems, interfering with neurotransmitters and leading to muscle contractions and spasms. 
Incubation averages 8 days but ranges from 3-21 days. The most common type of disease is 
generalized tetanus, which typically begins with lockjaw and culminates in frequent spasms lasting 
up to a month. Tetanus is fatal in approximately 11% of cases even when intensive care is 
available; the disease is twice as likely to be fatal in persons who have never been vaccinated. 
Neonatal tetanus, although rare in the U.S., can occur when infants are born to mothers who lack 
tetanus immunity, usually via infection in an unhealed umbilical stump. Because it is an 
environmental pathogen, there is no community protection (also known as “herd immunity”) [40]. 
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Pertussis, also known as whooping cough, is a highly communicable disease caused by the aerobic 
gram-negative rod bacterium Bordetella pertussis. The incubation period for pertussis most 
commonly is 7-10 days. The illness begins with runny nose, sneezing, low-grade fever and mild 
cough. This cough gradually becomes more severe, progressing into frequent bursts of numerous 
rapid coughs after 1-2 weeks. These coughing fits (paroxysms) result in the characteristic 
whooping sound during efforts to inspire. These coughing fits generally continue for 1-6 weeks 
but can persist up to 10 weeks. Infants are at the highest risk for complications associated with 
pertussis. The most common complication and cause of most deaths related to pertussis is 
pneumonia. Pertussis used to be a substantial cause of death in children in the U.S., but since 
introduction of the vaccine, incidence of pertussis has decreased by more than 80% [40]. However, 
incidence has risen steadily over the past ten years, and in 2012 the U.S. had its highest case 
number reported since 1955 at 48,277 [311], although this has decreased somewhat in recent years 
to 20,762 in 2015 and 15,737 in 2016 [312]. There has also been an increase in pertussis incidence 
in recent years among children worldwide [313]. Immunity from the acellular pertussis vaccine 
has been shown to wane over time, considered the main factor behind the recent pertussis 
resurgence [40]. In addition, acellular pertussis vaccine may not confer mucosal immunity and 
thus community protection (herd immunity) to the same degree as the previously used whole cell 
pertussis vaccines [314, 315]. Studies have suggested that clustering of unvaccinated individuals 
may be another factor behind recent U.S. pertussis outbreaks [57-59]. 
Tetanus, Diphtheria and Pertussis Vaccine 
Acellular pertussis vaccines are inactivated, subunit vaccines, and are only available in 
combination with diphtheria and tetanus toxoids. DTaP vaccine (trade names: Daptacel®, 
Infanrix®) is approved for children between six weeks and 7 years of age. Tdap vaccine (trade 
 
66 
names: Boostrix®, Adacel®) contains reduced antigen amounts for diphtheria and pertussis, and 
is approved for persons either 10 through 64 years (Boostrix®) or 11 through 64 years (Adacel®) 
of age [40].  
ACIP Recommendations 
The ACIP recommends that all infants without contraindications receive three doses of the child 
formulation of DTaP, given at 2, 4, and 6 months of age. A fourth dose should be given 6 to 12 
months after the third dose, preferably between 15 and 18 months of age. A fifth dose is 
recommended between 4 and 6 years of age. One dose of the Tdap should be given to all 
adolescents between the ages of 11 through 18 years.  
Vaccine Coverage 
DTaP coverage in 2017 among children aged 19-35 months was estimated at 94.0% (95%CI: 93.3–
94.7%) for at least three doses and 83.2% (95%CI: 82.0–84.3%) for at least four doses. This is 
relatively consistent with the level of coverage seen over the past five years [14]. Tdap coverage 
among adolescents in 2017 was estimated at 88.7% (95%CI: 87.8–89.6%) for at least one dose 
[242].  
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further vaccination with DTaP and Tdap. Another contraindication for both 
vaccines is encephalopathy within 7 days after previous vaccination without an identifiable 
alternative cause. Current moderate to severe acute illness is a precaution to any vaccination [40]. 
Precautions to DTaP include the following occurrences within 48 hours after previous vaccination: 
a hypotonic hyporesponsive episode, which is a sudden episode of unresponsiveness and limpness 
[316], a fever above 105°F, or persistent, inconsolable crying lasting over 3 hours. Other 
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precautions include convulsions within 3 days after previous vaccination or an unstable 
progressive neurologic disorder [40].   
Precautions to Tdap include a history of Guillain-Barré syndrome within 6 weeks after previous 
vaccination containing tetanus toxoid, or a history of a severe local reaction immediately following 
previous vaccination containing either tetanus or diphtheria toxoid [40].  
Vaccine Effectiveness 
A complete primary three-dose series of diphtheria toxoid and tetanus toxoid results in estimated 
clinical efficacies of 95% and 100%, respectively. The efficacy of the acellular pertussis 
component of DTaP vaccines licensed in the U.S. has been estimated to be 84% in the short-term 
(i.e., within 3 years of series completion). The antibody response to one dose of Tdap in adults is 
similar to that in infants after three doses of DTaP [38, 40, 317]. Infants born to mothers immunized 
during pregnancy have between 50-100% of the pertussis antibody titers of their mothers at birth, 
although this passive immunity wanes rapidly [318].  
Vaccine-induced active immunity also wanes over time. By ten years after vaccination, the tetanus 
antitoxin levels in some individuals decreases below the minimal protective level. Of particular 
concern is the more rapid waning immunity from the acellular pertussis vaccine, which has 
contributed to the resurgence of pertussis in the United States. The rapid waning of antibody is one 
of the main reasons for vaccinating with Tdap during every pregnancy [40].  
Vaccine Safety 
Local reactions including pain, redness and swelling occur in 20-40% of infants after the first three 
doses of DTaP. Self-limited fever of greater than 101°F occurs in 3-5% of DTaP recipients. 
Extensive swelling of the injection-site limb and increased local reactions and fever has been 
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reported after the fourth or fifth dose of DTaP. Moderate to severe systemic reactions such as fever 
above 105°F, febrile seizures, persistent crying lasting longer than 3 hours and hypotonic 
hyporesponsive episodes occur in less than 1 in 10,000 doses of DTaP [40]. 
Local reactions occur in 21-66% of adults after Tdap. Fever greater than 100.4°F occurs in 1.4% 
of Tdap recipients. Mild systemic reactions such as headache or drowsiness occasionally occur 
after vaccination. Besides very rare occurrences of anaphylaxis, no serious adverse events have 
been shown to be caused by Tdap vaccination. Severe allergic reaction (e.g. anaphylaxis) to a 
previous dose or vaccine component is a contraindication to further Tdap vaccination [40].  
Vaccines which may induce fever may also rarely induce febrile seizures. Febrile seizures are a 
common and typically benign childhood condition, occurring in 2-5% of children at some point 
during their first five years of life. Febrile seizures have an estimated background incidence of 
240–480 per 100,000 person-years in children under five years, although this varies considerably 
by age, genetics, co-morbidities and environmental risk factors. There are no long-term effects of 
simple febrile seizures, with the possible exception of an increased risk of recurrence [293-296].  
Because syncope has been reported among adolescents receiving vaccinations, adolescent 
recipients should always receive the vaccine while sitting and not in view of others awaiting 








Varicella is a highly infectious acute disease caused by the DNA herpesvirus varicella zoster virus 
(VZV). VZV is transmitted via the respiratory route. The incubation period generally lasts about 
15 days. Symptoms of primary infection with VZV, also known as chickenpox, include mild fever, 
malaise and a generalized vesicular rash.  
Although varicella disease is usually mild, there are potentially serious complications including 
bacterial infection of skin lesions, pneumonia, Reye syndrome, cerebellar ataxia, aseptic 
meningitis or encephalitis. Infants under 1 year of age have an increased risk of complications.  
Congenital varicella syndrome, resulting from maternal primary infection with varicella during the 
first 20 weeks of gestation, is associated with low birth weight, localized muscular atrophy, skin 
scarring and eye and neurologic abnormalities.  
Herpes zoster, also known as shingles, occurs after reactivation of latent VZV and is associated 
with aging, immunosuppression, and other factors. Between 0.5 and 1 million episodes of herpes 
zoster occur in the United States every year, and half of all persons living until age 85 will develop 
zoster [40].  
Varicella Vaccines 
Varicella vaccine (trade name: Varivax®) is a live attenuated viral vaccine. MMRV (trade name: 





The ACIP recommends that all children without contraindications receive two doses of varicella 
vaccine after 1 year of age and at least 3 months apart. The first dose should be administered 
between 12 and 15 months of age and the second between 4 and 6 years of age, generally at the 
same time as measles-mumps-rubella combination vaccine (MMR). The CDC recommends that 
MMR and varicella vaccine be administered separately albeit simultaneously for the first dose in 
order to reduce the risk of infant fever and febrile seizures, but MMRV can be administered for 
the second dose. The ACIP also recommends all persons over 13 years of age without evidence of 
varicella immunity receive 2 doses of varicella vaccine separated by a minimum of 4 weeks. 
Immunity to varicella is especially important for health care personnel [40, 319].  
Vaccine Coverage 
Varicella vaccine coverage in 2017 among children aged 19-35 months was estimated at 91.0% 
(95%CI: 90.1–91.8%) for at least one dose. This is relatively consistent with the level of coverage 
seen over the past five years [14]. 
Contraindications and Precautions 
Severe allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine component is a 
contraindication to further vaccination with any varicella-containing product. Other 
contraindications to vaccination with varicella-containing vaccines include pregnancy, altered 
immunity, and family history of altered immunocompetence [40, 244, 319]. The following is a 
direct excerpt from the 2007 ACIP recommendations regarding the contraindication of varicella 
vaccine in persons with altered immunity: 
“Single-antigen varicella and combination MMRV vaccines are not licensed for use in persons 
who have any malignant condition, including blood dyscrasias, leukemia, lymphomas of any type, 
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or other malignant neoplasms affecting the bone marrow or lymphatic systems. Combination 
MMRV vaccine should not be administered to persons with primary or acquired 
immunodeficiency, including immunosuppression associated with AIDS or other clinical 
manifestations of HIV infections, cellular immunodeficiencies, hypogammaglobulinemia, and 
dysgammaglobulinemia. Combination MMRV vaccine should not be administered as a substitute 
for the component vaccines when vaccinating HIV-infected children. 
“Varicella vaccines should not be administered to persons who have a family history of congenital 
or hereditary immunodeficiency in first-degree relatives (e.g., parents and siblings) unless the 
immune competence of the potential vaccine recipient has been clinically substantiated or verified 
by a laboratory. 
“Varicella vaccines should not be administered to persons receiving high-dose systemic 
immunosuppressive therapy, including persons on oral steroids >2 mg/kg of body weight or a total 
of >20 mg/day of prednisone or equivalent for persons who weigh >10 kg, when administered for 
>2 weeks. Such persons are more susceptible to infections than healthy persons. Administration 
of varicella vaccines can result in a more extensive vaccine-associated rash or disseminated disease 
in persons receiving immunosuppressive doses of corticosteroids. This contraindication does not 
apply to persons who are receiving inhaled, nasal, or topical corticosteroids or low-dose 
corticosteroids as are used commonly for asthma prophylaxis or for corticosteroid-replacement 
therapy.” [319] 
Current moderate to severe acute illness is a precaution to any vaccination. Recent receipt of 
antibody-containing blood products is a precaution to both varicella and MMRV vaccination and 
may require waiting until the antibodies wane before administering the vaccine. Personal or family 
history of seizures is a precaution to MMRV vaccination [40, 319]. “Receipt of specific antiviral 
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drugs (acyclovir, famiciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these 
antiviral drugs for 14 days after vaccination)” has also recently been added to the list of precautions 
in the CDC’s General Best Practice Guidelines for Immunization report [244]. 
Vaccine Effectiveness 
Varicella vaccine effectiveness after a single dose is estimated to be 76-94% in preventing 
clinically diagnosed or laboratory confirmed disease and 78-100% effective for prevention of 
severe cases of varicella in children [320-322]. Effectiveness decreases with time since vaccination 
[319]. Effectiveness after two doses is estimated to be 94% against any varicella and 98% against 
moderate or severe varicella [322].  
Vaccine Safety 
Mild injection site reactions such as pain and/or erythema are the most common adverse reactions 
following varicella vaccination, reported in roughly 21-25% of children within three days of 
vaccination. Rash is reported in 1-4% of children after varicella vaccination. Fever is reported in 
4-7% of children between 7 and 21 days after vaccination [319].  
Mild zoster illness resulting from a latent infection with varicella vaccine virus has been reported 
[323]. This has been very rarely associated with viral meningitis, although affected patients 
without immune deficiencies recover fully without any lasting effects. Varicella vaccine can also 
cause hepatitis if mistakenly administered to severely immune deficient individuals [40].  
Vaccines which may induce fever may also rarely induce febrile seizures. Febrile seizures are a 
common and typically benign childhood condition, occurring in 2-5% of children at some point 
during their first five years of life. Febrile seizures have an estimated background incidence of 
240–480 per 100,000 person-years in children under five years, although this varies considerably 
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by age, genetics, co-morbidities and environmental risk factors. There are no long-term effects of 
simple febrile seizures, with the possible exception of an increased risk of recurrence [293-296]. 
The rate of febrile seizures in the 7-10 days after vaccination was approximately 2-3 times higher 
for children who received MMRV as compared to MMR and varicella vaccines administered 
separately on the same day, and 4 times higher as compared to MMR alone [297]. There is no 
increased risk of fever or febrile seizures in children receiving their second dose of measles-
containing vaccine at 4 to 6 years of age, whether given MMR or MMRV [40, 220].  
Although transmission of varicella vaccine virus is rare, it may very occasionally occur if a recently 
vaccinated person develops a rash. To be safe, close contact with persons without varicella 
immunity at high risk of complications, especially those who are immunocompromised, should be 





Vaccines Recommended During Pregnancy  
 
ACIP Recommendations in Pregnancy 
 
The Advisory Committee on Immunization Practices (ACIP) recommends that pregnant women 
receive two vaccines during pregnancy: tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap), and seasonal inactivated influenza vaccine (IIV) [27, 28]. 
The recommendations of the American College of Obstetricians and Gynecologists (ACOG) are 
consistent with ACIP. From their 2013 publication entitled ACOG Committee Opinion No. 566: 
update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination: “Obstetric 
care providers should administer the tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis (Tdap) vaccine to all pregnant patients during each pregnancy, as early in the 27–36-
weeks-of-gestation window as possible. Pregnant women should be counseled that the 
administration of the Tdap vaccine during each pregnancy is safe and important to make sure that 
each newborn receives the highest possible protection against pertussis at birth. Obstetrician–
gynecologists are encouraged to stock and administer the Tdap vaccine in their offices” [324]. 
From their 2014 publication entitled ACOG Committee Opinion No. 608: influenza vaccination 
during pregnancy: “It is particularly important that women who are or will be pregnant during 
influenza season receive an inactivated influenza vaccine as soon as it is available. It is critically 
important that all obstetrician–gynecologists and all providers of obstetric care advocate for 
influenza vaccination, provide the influenza vaccine to their pregnant patients, and receive the 
influenza vaccine themselves every season” [325]. 
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This recommendation is meant to prevent pertussis and influenza disease in both the pregnant 
women themselves as well as in their infants [25-28]. Children too young to be vaccinated against 
pertussis are at high risk for contracting pertussis disease, and they also have the highest 
complication rates [27, 38, 324, 326]. Almost all pertussis deaths in the United States occur in 
children less than 6 months of age [27, 324]. For influenza, there is no licensed vaccine for infants 
less than 6 months of age, and this is the group at highest risk for influenza-associated 
hospitalization and death [39].  
 
Vaccine Coverage in Pregnancy 
 
Maternal vaccine coverage is much lower than childhood vaccine coverage, which is both 
understandable considering the relative ages of the recommendations and indicative of vast room 
for improvement. Influenza vaccine coverage among U.S. pregnant women has slowly risen over 
time before stagnating; coverage was 49% during the 2010-11 season, 53.6% during the 2016-17 
season, and 49.1% during the 2017-18 season [12, 327-332]. Tdap vaccine coverage among 
pregnant women was measured at 54.4% in the 2017-18 season [12]. During the 2017-18 season, 
pregnant white women had roughly equivalent coverage of influenza (52.5%) and higher coverage 
of Tdap (59.3%) vaccines than pregnant Hispanic women (51.3% for flu, 48.8% for Tdap), and 
much higher coverage than pregnant black women (36.5% for flu, 42.9% for Tdap). Pregnant 
women with at least a college degree had higher rates of coverage for influenza (59.7%) and Tdap 
(59.0%) than women who did not attend college (41.8% for flu, 46.2% for Tdap). Women whose 
provider recommended and offered the vaccine had substantially higher rates of coverage for flu 
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(63.8%) and Tdap (73.5%) than those who received a recommendation with no offer (37.6% for 
flu, 38.3% for Tdap) or no recommendation (9.0% for flu, 1.6% for Tdap) [12].  
Prospective cohort studies have found several attitudinal constructs associated with receiving 
maternal flu vaccination, including perceived susceptibility to influenza, perceived severity of 
influenza illness during pregnancy, perceived vaccine safety and effectiveness, perceived social 
norms, and self-efficacy [200, 203, 206].  
The Centers for Disease Control and Prevention (CDC) has pertinent information on vaccinating 
during pregnancy available online at https://www.cdc.gov/vaccines/pregnancy/pregnant-
women/index.html. ACOG also provides resources on vaccinating during pregnancy online at 
http://immunizationforwomen.org/patients/pregnancy/pregnancy.php.  
 
Influenza in Pregnancy and Infancy 
 
Influenza Disease in Pregnant Women and Young Infants 
Pregnant women and young children are at increased risk of complications and hospitalizations 
from influenza [29-37]. Infection with influenza during pregnancy has been associated with an 
increased risk of adverse outcomes to the mother, including respiratory hospitalization, 
pneumonia, adult respiratory distress syndrome, overwhelming sepsis and death [29]. A recent 
CDC study estimated that 12% of all pregnancy-related deaths during the 2009-2010 pandemic 
season were attributed to confirmed or possible infection with pandemic influenza [333]. Some 
studies have suggested associations between infection with influenza during pregnancy and an 
increased risk of adverse outcomes to the unborn infant, including preterm birth, low birth weight, 
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and stillbirth; however, these studies are limited in number and quality, preventing firm 
conclusions from being drawn [334, 335]. The biological mechanism for such adverse outcomes 
in infants is unclear, as influenza virus is rarely transmitted across the placenta; more likely 
potential mechanisms include maternal fever, inflammation, and other immunological responses 
[335].   
Maternal Influenza Vaccine 
Two types of vaccines are available to protect against influenza: inactivated influenza vaccine 
(IIV) and live attenuated influenza vaccine (LAIV). However, LAIV is contraindicated during 
pregnancy. Pregnant women may receive any licensed, recommended, age-appropriate influenza 
vaccine [28].  
Vaccination during pregnancy is beneficial both for the mother and her unborn child, as women 
who receive influenza vaccine during pregnancy transfer vaccine-specific antibody to their infants 
[336-342]. A prospective, controlled, blinded, randomized trial of 340 mothers in Bangladesh 
observed between August 2004 and December 2005 found that maternal vaccination with IIV 
reduced about one third of non-specific febrile respiratory illness in both pregnant women and 
their infants, and reduced laboratory-confirmed influenza illness in infants under 6 months of age 
by 63% [343]. The effectiveness of maternal vaccination in preventing infant influenza was most 
pronounced between March and November 2005. A case-control study among 492 pregnant 
women in California and Oregon during the 2010-2011 and 2011-2012 influenza seasons found 
that maternal vaccination with the current season’s influenza vaccine reduced the risk of 
laboratory-confirmed influenza-associated acute respiratory illness during that season by about 
half, and receipt of the prior season’s vaccine had an effect similar to receipt of the current season’s 
vaccine [344].  
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Not every study has found maternal influenza vaccination to be effective. In a cohort of almost 
50,000 live births in northern California, no reduction in hospital admissions and physician visits 
was found for pregnant women who received maternal influenza vaccination or for their infants, 
although this may have been due to the unreliability of typical influenza surveillance measures in 
distinguishing influenza from other respiratory illness [336]. A 2014 review of efficacy and 
effectiveness of maternal influenza vaccination found its effectiveness in pregnant women reported 
from -15% to +70% [336, 343, 345-348], and its effectiveness in infants reported from +41 to 
+91% [31, 336, 341, 343, 348-350]; however, many of these studies had major limitations [351].  
Maternal vaccination with IIV reduces the risk of low birthweight and premature birth [345, 352-
354]. Some studies also found that pregnant women who received influenza vaccine had a lower 
likelihood of stillbirth than those who did not [355-357], although the evidence for this is 
inconsistent and has methodological limitations [357-359].  
A large body of evidence demonstrates the safety of IIV for both pregnant women and their unborn 
children [348, 360-370]. Concomitant administration of Tdap and influenza vaccines during 
pregnancy is not associated with a higher risk of adverse outcomes compared to sequential 
vaccination [371]. 
Donahue et al. recently reported results from a case-control study examining the risk of 
spontaneous abortion (SAb) following receipt of inactivated influenza vaccines containing 
A/H1N1pdm2009 antigen in the 2010-11 and 2011-12 seasons [372]. The study found an 
association between influenza vaccine and SAb, particularly among women who had received 
pandemic H1N1 vaccine in the previous year as well [372]. The findings were most striking in the 
2010-2011 season, and were far less pronounced in the 2011-2012 season. The Donahue et al. 
findings need to be interpreted in the context of other epidemiological data [373]. One recent 
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randomized trial recruiting women at 17-34 weeks gestation [374], thirteen other observational 
studies [375-387], two systematic reviews [364, 388], and one meta-analysis [355] have assessed 
a potential association between influenza vaccine and SAb or a related outcome, and none have 
found an association. However, none of these studies examined the effect of multiple dosing. 
Studies are in progress to assess whether this association is seen in subsequent influenza seasons. 
 
Pertussis in Pregnancy and Infancy 
 
Pertussis Disease in Pregnant Women and Young Infants 
Almost all deaths from pertussis occur in the first few months of life. Infants under 3 months of 
age accounted for 83% of deaths from pertussis reported to the CDC between 2008 and 2011 [40]. 
Active immunization of infants against pertussis does not begin until 2 months of age, and the 
initial three-dose DTaP vaccine series is typically not completed until 6 months of age. Since 
several doses are needed to induce protection against pertussis in most infants, newborns and 
infants in the first few months of life are dependent on transplacentally acquired maternal pertussis 
antibodies and prevention of exposure from their mothers and other close contacts for protection 
against pertussis disease [27, 38, 324, 326].    
Maternal Tdap Vaccine 
One dose of Tdap is routinely recommended during each pregnancy, preferably between 27 and 
36 weeks of gestation. If a mother is not vaccinated during pregnancy and has never received the 




Vaccination during pregnancy is beneficial both for the mother and her unborn child, as women 
who receive Tdap vaccine during pregnancy transfer vaccine-specific antibody to their infants 
[318, 370, 390, 391]. Infants born to immunized mothers have between 50-100% of the pertussis 
antibody titers of their mothers [318]. Maternal Tdap vaccination was shown to be effective in 
preventing pertussis disease in infants when used as part of a large-scale vaccination effort in the 
United Kingdom [392].  
A large body of evidence demonstrates the safety of the Tdap vaccine for both pregnant women 
and their unborn children [27, 324, 367, 370, 393, 394]. Receipt of Tdap during pregnancy is not 
associated with an increased risk of hypertensive disorders of pregnancy or preterm or small for 
gestational age (SGA) birth [395].  
Waning immunity of acellular pertussis vaccine is one of the main rationales for vaccinating with 
Tdap during every pregnancy [40]. Having recently received a tetanus-containing vaccination does 
not increase the risk of adverse outcomes after Tdap vaccination in pregnancy [396]. Concomitant 
administration of Tdap and influenza vaccines during pregnancy is not associated with a higher 





Cocooning Vaccination Strategy 
 
Infants have the highest risk of complication, hospitalization and death from influenza and 
pertussis [38, 39], and are too young to complete the primary three dose series of pertussis vaccine 
or receive their first influenza vaccine until six months of age [28, 40]. Both the Advisory 
Committee on Immunization Practices (ACIP) and the American College of Obstetricians and 
Gynecologists (ACOG) recommend that pregnant women are vaccinated against influenza and 
pertussis during pregnancy to best protect themselves and their infants [25-28]. However, 
vaccination rates of pregnant women for pertussis and influenza are suboptimal [370, 397-399]. 
Influenza and Tdap vaccine coverage among U.S. pregnant women was 49.1% and 54.4% during 
the 2017-18 season, respectively [12]. Additional strategies are needed to optimally protect infants 
against these diseases.  
The majority of infants with pertussis (76-83%) were infected either by either a household contact 
or caregiver [41-45, 400-402]; and most commonly by either their mother (33%) or their father 
(16%) [401]. The cocoon vaccination strategy entails vaccinating as many of the close contacts of 
the incoming newborn as possible, thereby lowering the risk of disease transmission and forming 
a protective “cocoon” around the infant. In tandem with maternal vaccination, cocooning is a 
method of further lowering the risk of potentially deadly pertussis and influenza infections in 
young infants [46-48].  
This strategy is endorsed by ACIP, who “concluded that cocooning likely provides indirect 
protection to infants and firmly supports vaccination with Tdap for unvaccinated persons who 
anticipate close contact with an infant” [26]. ACIP recommends that all “adolescents and adults 
(e.g., parents, siblings, grandparents, child-care providers, and health-care personnel) who have or 
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anticipate having close contact with an infant aged less than 12 months should receive a single 
dose of Tdap to protect against pertussis if they have not received Tdap previously” [26, 27]. ACIP 
also recommends routine annual influenza vaccination for all persons over 6 months of age who 
do not have contraindications, and that “continued emphasis should be placed on vaccination of 
persons who live with or care for persons at higher risk for influenza-related complication”, such 
as “household contacts (including children) and caregivers of children aged ≤59 months (i.e., aged 
<5 years) and adults aged ≥50 years, particularly contacts of children aged <6 months” [28].  
Again, the recommendations of ACOG are consistent with ACIP. From their 2013 publication 
entitled ACOG Committee Opinion No. 566: update on immunization and pregnancy: tetanus, 
diphtheria, and pertussis vaccination: “Partners, family members, and infant caregivers should be 
offered the Tdap vaccine if they have not previously been vaccinated. Ideally, all family members 
should be vaccinated at least 2 weeks before coming in contact with the newborn” [324]. The 
recommendations of the American Academy of Pediatrics (AAP) are also consistent with ACIP 
and ACOG: “Special effort should be made to vaccinate individuals in the following groups… All 
household contacts and out-of-home care providers of children with high-risk conditions or 
younger than 5 years, especially infants younger than 6 months… Pediatric offices may choose to 
serve as an alternate venue for providing influenza vaccination for parents and other care providers 
of children, if the practice is acceptable to both pediatricians and the adults who are to be 
vaccinated” [403]. The recommendations of the Global Pertussis Initiative (GPI) are consistent 
with the ACIP as well: “all individuals having close contact with infants <6 months old be 
immunized consistent with local health authority guidelines. A high priority should be given to 
achieving a complete cocoon, defined as full immunization of the family, since the robustness of 
protection against pertussis is a function of the number of infant contacts vaccinated. If a complete 
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cocoon is not possible, then the next priority is vaccination of both parents, followed by the mother 
only” [46]. 
The efficiency of the cocoon strategy has been widely debated [46]. Some have argued that it is 
difficult, inefficient and resource-intensive [404-406], or even outright ineffective [407-410], as it 
is nearly impossible to vaccinate every contact of every infant. An analysis by Lim et al. 
demonstrated that a cocooning strategy would not be efficient to implement in Ontario, Canada, 
as their vaccine coverage is relatively high and disease incidence low [404]. Skowronski et al. in 
Quebec and British Columbia, Canada, and Meregaglia et al. in Italy both came to a similar 
conclusion, also primarily due to low disease incidence [405]. Carcione et al. found no reduction 
in pertussis diagnoses in infants whose parents were both vaccinated against pertussis in the first 
four weeks after the infant was born during a 2011-2012 Australian pertussis epidemic [407]. 
Healy et al. did not find a reduction in pertussis illness in infants under 6 months of age during a 
cocooning program in Houston [408]. Maltezou et al. found that although maternal postpartum 
influenza vaccination reduced influenza-related morbidity in infants in Greece, the postpartum 
vaccination of other household contacts showed no impact [409]. Althouse et al. suggested that 
asymptomatic transmission may be the main reason for the recent resurgence of pertussis, and 
would also help explain the failure of postnatal cocooning programs [410]. 
Some studies suggest that the cocoon strategy is beneficial and ultimately cost-effective [411-414]. 
Van Rie et al. ran computer simulations to predict the impact of various vaccination strategies in 
the United States, and found that the cocoon strategy had a predominantly indirect effect on young 
infants, and had the lowest number needed to vaccinate to prevent a case of typical pertussis in 
young infants when compared to routine childhood, adolescent and adult vaccination [411]. 
Coudeville et al. performed two analyses on adult pertussis vaccination strategies in the United 
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States: a compartmental, age-structured mathematical model using recent U.S. pertussis 
epidemiology data [412]; and an economic evaluation including dynamic population effects that 
had been lacking from previous studies [413]. Both analyses concluded that the cocoon strategy in 
combination with by a single adult booster dose was the most cost-effective option for controlling 
pertussis nationwide, and that the impact of the cocoon strategy would be greatest among young 
children [412, 413]. Westra et al. analyzed various pertussis vaccination strategies in the 
Netherlands and found that both maternal immunization and cocooning were likely to be cost-
effective. Although cocooning was the most expensive intervention to implement, it also resulted 
in the highest number of quality-adjusted life-years gained [414]. 
Some have argued that although the cocoon strategy is effective, it is a much less cost-effective 
option compared to maternal pertussis vaccination, and thus resources should primarily be focused 
on increasing maternal vaccination coverage [415, 416]. Finally, a 2014 systematic review 
concluded that the evidence is insufficient to determine whether cocooning is a cost-effective 
strategy or not due to a lack of evidence showing the efficacy of the strategy in preventing disease 
[417]. 
An Australian government-funded cocooning program starting in 2009 was shown to be effective, 
with a reduction in pertussis in infants under 4 months of age of 51% when both parents were 
immunized (up from 42% when just the mother was immunized) [418]. However, other cocooning 
programs have proven difficult to implement [46, 401, 419-427], despite the willingness of many 
close contacts of pregnant women and infants to be vaccinated [428, 429]. ACIP has stated: 
“Programmatic challenges make implementation of cocooning programs complex and also impede 
program expansion and sustainability” [26]. The GPI has outlined challenges to implementation 
such as cost, logistics, family acceptance, and local sociologic factors, and suggested that some of 
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these challenges can be overcome by providing education and making vaccines easily accessible 
to family members [46]. Healy et al. also provided insight into some of these challenges and how 
they could potentially be conquered: “Establishing a platform to vaccinate family and household 
contacts is particularly challenging. Ideally, this platform should deliver the service prior to the 
infant's birth, thus allowing time for protective immunity to develop before the infant's birth. In 
practice, this is unlikely to occur, given that preventative services often are not a priority for 
healthy adults… Ideally, the service should be delivered either before or as soon as possible after 
birth and not restricted to 8 am to 5 pm on Monday through Friday, but scheduled for the 
convenience of working contacts. A variety of vaccination providers should be used. It is only 
through the investment of time and finances and by using innovative models in a co-operative 
fashion that a successful infant cocoon program can be achieved.” [401]  
Free provision of cocooning vaccines has been shown to increase coverage [402, 430]. The 
previously mentioned Australian government-funded cocooning program had excellent uptake of 
the vaccine among both mothers (80%) and fathers (70%) [430]. A California hospital-based 
vaccine clinic found that offering free Tdap vaccine to family members of newborns was effective 
in increasing coverage, with 76% of households during the intervention period reporting a 
complete cocoon compared to 29.3% of households during the control period [402]. However, free 
provision of vaccines is not always a viable option, highlighting the importance of identifying 
other successful strategies.  
Although certain hospital-based cocooning programs have achieved some levels of success [402, 
431-436], as well as certain pediatric office-based programs [420, 437], a pharmacy-based 
cocooning program has certain advantages that may allow it to be more effective than previously 
attempted programs [438]. Using a pharmacy-based cocooning program fits the directives from 
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Healy et al. to use innovative methods and a variety of vaccine providers to offer the vaccine in a 
convenient manner and on a flexible schedule not limited by the normal work week.  
There is a precedent for a successful Walgreens pharmacy-led education-based cocooning 
program, although this particular Walgreens pharmacy was on-site in a women’s hospital, which 
may have offered it convenience advantages to family visiting the mother and infant just after birth 
[436]. In a study by Buttenheim et al., the delivery of retail pharmacy vouchers during newborn 
visits (covering either the full amount or $5 off of the Tdap vaccine depending on study arm) was 
not shown to be an effective strategy for promoting vaccination of adult caregivers with Tdap (only 
1 of 95 participants had confirmed voucher redemption, although vaccination itself was not 
confirmed) [439]. To avoid a similar fate, pharmacy-based cocooning programs should learn from 
the lessons of the Buttenheim study. Implementation issues reported in the article included 
delaying planned vaccination, perceived inconvenient pharmacy locations, and false beliefs about 
pertussis risk and severity. This study did not intervene until after the infant was born; the issue of 
delayed planned vaccination could potentially be mitigated by intervening earlier on in pregnancy. 
Vaccinating adult caregivers earlier also has the benefit of allowing enough time for the caregivers 
to benefit from the vaccine’s full protection prior to the birth of the child; for example, maximum 
antibody titer generally takes up to 14 days to be reached after pertussis vaccine in women of 
childbearing age [401, 440]. The vouchers were only redeemable at four nearby branches of the 
chosen national retail pharmacy chain; making the vouchers redeemable at any location of a 
national retail pharmacy chain may reduce the barrier of perceived inconvenient pharmacy 
locations. The reported barrier regarding beliefs about pertussis risk and severity implies a need 
for education.  
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Factors associated with higher rates of cocooning in the U.S. include maternal vaccination, 
obstetrician recommendation, high perceived benefits of vaccine, high perceived susceptibility to 
disease, and low perceived barriers to vaccination [49]. Studies in Europe have also identified 
factors influencing intention to accept pertussis vaccine for cocooning, such as risk perception, 
outcome expectations, general vaccination beliefs, moral norms, opinion of others, perceived 
autonomy, anticipated regret, decisional uncertainty, and perceived organizational barriers [441, 
442]. One potential intervention to influence perceived benefits of vaccine and susceptibility to 
disease is education. Another potential intervention that may be able to reduce perceived barriers 









In 2015, the Community Preventive Services Task Force (CPSTF), an independent, nonfederal, 
unpaid panel of public health and prevention experts appointed by the Director of the Centers for 
Disease Control and Prevention (CDC), performed systematic reviews of intervention approaches 
for increasing vaccination (see: https://www.thecommunityguide.org/content/task-force-findings-
increasing-vaccination) and found insufficient evidence to determine if education was effective in 
increasing vaccination rates when implemented alone [443]. The majority of included studies of 
clinic-based education provided sufficient evidence of effectiveness but were limited to 
pneumococcal polysaccharide vaccine among older adults [444-448], and included studies of 
community-wide education showed inconsistent results in limited populations [449-455]. CPSTF 
did find strong evidence that education used in combination with other health care system-based 
or community-based interventions was effective in increasing vaccination rates.  
There are few examples of stand-alone patient education programs that have had success in 
increasing vaccine uptake. Educational pamphlets given to pregnant women in the northeastern 
U.S. were associated with significant increases in perceptions of the safety and benefit of maternal 
influenza vaccine as well as overall uptake [456]. An 8-minute video focusing on parental accounts 
of their children contracting vaccine-preventable diseases, shown exclusively to vaccine-hesitant 
parents via a laptop in pediatric waiting rooms, was associated with a significant decrease in Parent 
Attitudes about Childhood Vaccines (PACV) survey score measured two months later, although 
no difference in timely receipt of vaccines was shown [457]. A 3-arm, randomized controlled trial 
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conducted in Colorado from 2013-2016 found that infants of pregnant women assigned to a 
website with vaccine information and interactive social media components were statistically 
significantly more likely to be up-to-date on recommended vaccines at 200 days of age than infants 
of pregnant women given usual care, whereas infants of pregnant women assigned to a website 
with vaccine information but without interactive social media components were non-statistically 
significantly more likely to be up-to-date on recommended vaccines at 200 days of age than infants 
of pregnant women given usual care [458]. Among 272 mothers with vaccine concerns from 
Tennessee and California, distribution of vaccine information pamphlets and Vaccine Information 
Statements (VIS) significantly improved vaccine attitudes, although vaccine uptake was not 
measured [211]. 
Other patient education programs have been unsuccessful in increasing vaccine uptake. Strategies 
based on correcting vaccine misinformation or exposure to fear appeals have shown mixed results 
[459-461]. Despite demonstrating some effectiveness in knowledge gain [462], correcting vaccine 
misinformation often leaves vaccine intentions unchanged, and has even been shown to further 
reducing the vaccine intentions of some sub groups [459-461]. This backfiring effect has been 
shown to be especially likely among those with high levels of preexisting vaccine hesitancy [460, 
461]. 
Attitudes and beliefs about vaccines vary substantially among adults [134, 463]. These attitudes 
and beliefs influence the response to vaccine messages [460, 461]. This highlights the need for 
individual tailoring of vaccine messaging depending on these underlying attitudes and beliefs.  
When given in combination with other effective interventions, and tailored to each individual’s 





Educational Vaccine Apps 
Several educational vaccine apps have been developed previously [464-467]. Dempsey et. al 
provided a tailored, interactive website to 42 parents in waiting rooms of primary care clinics and 
found a slight but non-statistically significant increase in mean adolescent vaccination intention, 
yet no increase in actual adolescent vaccination [464]. Atkinson et. al studied the effect of 
ImmunizeCA, a Pan-Canadian immunization app, in in a cohort of 50 childbearing women [465]. 
Although changes in vaccine attitudes occurred in both directions, about a third of these women 
perceived that the app increased their likelihood of vaccinating on time. Fadda et. al found that 
smartphone-based interventions using gamification features and videos in combination with text 
messages increased vaccine knowledge, intent, and decision confidence among parents of young 
children in Italy [466]. Bednarczyk et. al describe the global reach of their mobile smartphone app 
ReadyVax, which provides access to evidence-based vaccine information for both providers and 
patients, but does not test its effect on vaccine knowledge, attitudes or intention [467]. None of 




Financial incentives have mostly been shown to be effective in encouraging relatively discrete, 
infrequent behaviors, particularly among low income groups [468, 469]. As most vaccinations are 




In 2015, the Community Preventive Services Task Force (CPSTF) recommended “client or family 
incentive rewards, used alone or in combination with additional interventions, based on sufficient 
evidence of effectiveness in increasing vaccination rates in children and adults”, as stated in their 
Task Force Finding and Rationale Statement available at 
https://www.thecommunityguide.org/findings/vaccination-programs-client-or-family-incentive-
rewards [443].   
In low- and middle-income countries, there is conflicting evidence for whether financial incentive 
programs increase vaccine coverage. A 2016 Cochrane Database Systematic Review found that 
monetary incentives in these countries may have little or no effect on childhood immunization 
coverage in unless combined with regular outreach [471]. Similarly, a 2013 systematic review and 
meta-analysis found that financial incentives have no effect on coverage of individual vaccines in 
such countries, although a small and nonsignificant increase in coverage of full, age-appropriate 
immunization was noted [472]. A 2015 systematic review and meta-analysis found that incentives 
led to a significantly higher receipt of childhood vaccines; however, this may be misleading as 
their analysis pooled both monetary and non-monetary incentives together [473]. A recent cluster 
randomized controlled trial in Kenya showed that text message reminders combined with mobile-
money incentives successfully improved timely childhood immunization, even in a setting with 
high baseline vaccine coverage [474].  
In high-income countries such as the United States, the evidence base for financial incentive 
programs increasing vaccine coverage is more promising. A 1999 review found several successful 
examples both financial and non-financial (such as lottery tickets or food vouchers) incentive 
programs for increasing immunization coverage in the U.S. and the U.K. [475]. A 2002 meta-
analysis found that patient financial incentives increased coverage of influenza and pneumococcal 
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vaccines in adults, with an adjusted odds ratio of 3.42 (95% CI: 2.89–4.06) [476]. A 2014 
systematic review of parental financial incentives for increasing preschool vaccination uptake 
found insufficient evidence to conclude whether such interventions were effective [477]. Monetary 
incentives were shown to be effective in increasing adherence to the multi-dose hepatitis B vaccine 
series among drug users [478-483], as well as increasing coverage of influenza vaccine in the 







A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+) 
 
P3+ (full title: A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage) is 
sponsored by the National Institutes of Health (NIH) via an R01 grant (1R01AI11048201A) and 
is a collaboration between Emory University Rollins School of Public Health and School of 
Medicine, Johns Hopkins Bloomberg School of Public Health (JHSPH), and University of 
Colorado Anschutz Medical Campus. The mPrincipal Investigators are Saad B. Omer, MBBS 
MPH PhD (Emory) and Daniel Salmon, PhD MPH (JHSPH).  
P3+ is one of the first large randomized controlled trials of a prenatal intervention package to 
increase uptake of maternal and infant vaccines. The intervention package was developed to meet 
the diverse and complex information needs of mothers in a novel, innovative, evidence based and 
comprehensive manner, and intervenes at the Practice, Provider, and Patient (P3) levels. Practice-
level interventions include: establishment of immunization champions; introduction of standing 
orders; addition of immunization information to the practice website; and provision of 
immunization rate feedback via the AFIX program (Assessment, Feedback, Incentives, and 
eXchange). Provider-level interventions include: a provider training module eligible for 
continuing education credits on how to talk to patients about vaccines; Maintenance of 
Certification (MOC) Part 4 credit for completion of the training modules and attendance at AFIX 
meetings; and a comprehensive written resource on vaccines, vaccine recommendations, vaccine-
preventable diseases, and systematic reviews of a large number of vaccine safety concerns, with 
 
94 
standardized talking points on each topic for use during discussions with patients. Some of the 
content from this written resource (systematic reviews of safety concerns) is a portion of this 
dissertation and the entire resource is being published by Springer in October 2018. The patient-
level intervention includes: a text message reminder program for upcoming vaccinations due; and 
an individually-tailored educational application for smartphones, tablets and computers. This app, 
called MomsTalkShots, collects patient-level survey data to monitor changes in vaccine 
knowledge, attitudes and beliefs over time, and delivers a selection of educational videos about 
vaccines specific to each individual’s responses to these survey questions. 
The JHSPH study team members that overlap both the P3+ and Walgreens Cocooning studies were 
primarily responsible for the development of the P3+ patient-level app (and the surveys and 
educational videos that comprise it). This app is the one piece of the P3+ intervention package that 
is also used in the Cocooning study. The app has been updated to fit the Cocooning study, and the 
surveys and videos edited to reflect the change in target population (from pregnant women to their 
close contacts).   
Final analysis will primarily focus on vaccine uptake both for pregnant women and for their 
children, through 20 months of age, to test the hypothesis that increasing acceptability of vaccines 




Development of the P3+ intervention package was guided by the Systems Model of Clinical 
Preventive Care, as it encouraged the development of a comprehensive intervention acting at 
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multiple levels (e.g., practice, provider, and patient) [488]. Development of the P3+ patient-level 
educational app was guided by the Elaboration Likelihood Model (ELM), a behavior change model 




The intervention is currently taking place in a geographically and socio-demographically diverse 
set of obstetrician-gynecologist offices in Georgia and Colorado. Recruitment goals of enrolling 




The study uses a two-by-two factorial design, randomizing at both the practice and the patient level 
(Figure 1). Obstetric and midwife practices in both Georgia and Colorado have been randomized 
to be either an intervention practice or a control practice, and each patient that is enrolled into the 
study at any of these practices is randomized to be either an intervention patient or a control patient. 
Intervention patients receive the patient-level intervention regardless of whether they are enrolled 
at an intervention or control practice; both intervention and control patients enrolled at an 
intervention practice benefit from the practice- and provider-level interventions. This will allow 
for independent assessment of the practice- and provider-level interventions versus the patient-









All P3+ participants receive three surveys: one at baseline, one at approximately 30 days post-
birth of infant, and a final follow-up survey at approximately 18 months post-birth of infant. 
Survey reminders are being sent by email and text. All surveys are administered through the 









and levels of trust (see Appendix 1: Baseline Survey for Pregnant Women in P3+). Upon 





Walgreens Cocooning Study 
 
As part of an add-on study sponsored by Walgreens, the MomsTalkShots app from P3+ 
encouraged its users to refer their close friends and family to the app as well. The app then 
administered surveys and provided individually-tailored educational videos to these referred 
contacts, as well as linking them to a Walgreens Balance Rewards points incentive redeemable for 
use in any Walgreens store immediately after vaccination at a Walgreens pharmacy. This study 
will evaluate these interventions in improving cocooning among the infants’ family and friends.    
Pharmacies such as Walgreens are numerous and widespread throughout the United States. As of 
August 2016, there were 8,175 total Walgreens drugstores in the U.S., located across all 50 states, 
the District of Columbia, Puerto Rico and U.S. Virgin Islands [490]. Walgreens purchased an 
additional 1,932 Rite Aid stores in 2017 [491]. There is a Walgreens store within 5 miles of each 
P3+ practice; most are within 1 mile.  
Many Walgreens pharmacies are located in areas that are otherwise medically underserved. These 
pharmacies provide convenient locations for obtaining certain vaccinations, most notably seasonal 
influenza vaccine. For example, over 43% of the United States population resides in medically 
underserved areas (MUAs), and almost half of this population is served by Walgreens pharmacies. 
During the 2009-2010 influenza season, over one third of influenza immunizations were 
administered by pharmacies located in MUAs [492]. Pharmacies such as Walgreens also provide 
convenient hours, as working-age adults in particular generally prefer to receive vaccines during 
non-working hours, when traditional vaccine providers are often unavailable [438]. Finally, 
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receiving a vaccine at a pharmacy does not require the additional time and costs inherent in 
scheduling an appointment with a primary care provider [493]. 
Pharmacies providing vaccinations greatly improves vaccine accessibility, which is especially 
important for adult vaccinations for which coverage is typically low [438]. Although regulatory 
barriers and logistic challenges must be accounted for during program implementation [494], 
including pharmacies in influenza and pertussis vaccination efforts has been shown to be 
successful in increasing vaccine coverage [495, 496], and patients consistently report satisfaction 
with pharmacist-led vaccinations [493, 496].  
The Walgreens Balance Rewards program is free to join and allows its members to accrue points 
for each purchase that can be used towards future Walgreens purchases. Prospective members must 
be at least 13 years of age to enroll. Further information is available at 
https://www.walgreens.com/topic/balancerewards/balance-program-details.jsp [497].  Walgreens 




Development of the Cocooning study intervention package was guided by the Health Belief Model 
(HBM), as it tries to identify beliefs that influence behavior change, such as perceived 
susceptibility and severity of a negative health outcome, and perceived benefits of and barriers to 
adapting a preventive health behavior [498]. Perceived benefits and barriers have consistently been 
shown to be the strongest predictors included in HBM [499]. HBM has been studied in the context 
of childhood vaccines, and parents who delay or refuse vaccines are more likely to have safety 
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concerns and perceive fewer benefits associated with vaccines than parents who vaccinate on time 
[217]. By offering a financial incentive, we hope to increase the perceived benefits of cocooning 
vaccinations, and by offering these vaccines at Walgreens pharmacies, we hope to reduce the 
barriers to receiving these vaccines, especially for working adults who do not regularly see a 
doctor. Perceived susceptibility and severity of pertussis and influenza disease are also addressed 
in the educational videos offered in the patient-level app. 
Development of the Cocooning study intervention package was also guided by Social Cognitive 
Theory (SCT), which examines the influence of one’s social environment on health behavior at 
the interpersonal level [500]. This intervention package adheres to SCT’s concept of reciprocal 
determinism by concurrently affecting both environmental and personal factors; it alters the 
environment surrounding cocooning vaccination via financial incentives and more convenient 
pharmacy access, and influences personal attitudes via the educational videos in the app. These 
videos will also ideally empower pregnant women to talk to their close contacts about vaccination 
by providing them confidence through increased knowledge; this will then hopefully increase the 
self-efficacy of these women in regards to discussing this topic with their friends and family, as 





The Cocooning study targets close contacts of pregnant women to accomplish cocooning. The 
Cocooning study makes use of the study population of P3+ to recruit its own study participants, 
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by having the app encourage all P3+ intervention patients (maximum n=1100) to refer friends and 
family members to the app if they so choose upon finishing one of their first two surveys. P3+ 
intervention patients are then asked to identify the first name of and relationship to up to six 
contacts (as well as the contact’s email address and/or phone number) with whom they speak most 
about vaccine-related issues and will likely come into regular contact with the infant (maximum 
n=6600). These contacts can be friends, relatives, significant others, etc. This recruitment process 
is included in the P3+ protocol and has been approved by the Emory IRB. For referring friends 
and family, P3+ intervention patients receive a $10 gift card. The contacts identified during this 
process are then recruited to enroll in the Cocooning study by email (see Appendix 2: Email to 




The Cocooning study has three study arms: Education and Financial Intervention, Financial 
Intervention Only, and Control. Roughly one third of participants in the Cocooning study are 
enrolled into each study arm (depending on how many contacts are successfully recruited for each 
pregnant woman, as all contacts of a particular pregnant woman are enrolled into the same arm). 
The randomization of contacts into these three study arms takes place at the level of the P3+ 
intervention patient before they are asked to join the study; that is, all contacts of a particular P3+ 
intervention patient are in the same study arm (Figure 2). Randomization is stratified by P3+ study 
clinic to ensure a geographic spread in each arm and reduce the chance of residual confounding by 





Figure 2. Randomization for Cocooning Study 
 
Contacts randomized to either the Education and Financial Intervention or the Financial 
Intervention Only arm (to be referred to as intervention contacts) are eligible to receive a financial 
incentive for vaccination at Walgreens, and are enrolled in the app developed for P3+ and given 
the baseline survey there. Contacts randomized to the Education and Financial Intervention arm 
receive the educational intervention immediately after completing the baseline survey. The 
educational intervention consists of educational videos originally developed for P3+. Contacts 
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The financial incentive for vaccination is the receipt of Walgreens Balance Rewards points in 
exchange for purchasing one or both of the vaccines of interest (i.e., influenza and Tdap) at a 
Walgreens. This incentive is only made available to those who vaccinate at a Walgreens as 
confirmed through Walgreens’ internal system upon vaccination. Intervention contacts who 
receive the influenza and/or the Tdap vaccine at Walgreens would benefit from $10 worth of 
Walgreens Balance Rewards points for each vaccine (those who receive both vaccines would 
benefit from a total of $20 worth of Walgreens Balance Rewards points). To receive these 
incentives, participants must be enrolled in the Walgreens Balance Rewards program; therefore 
immediately after the baseline survey the app redirects intervention contacts to the Walgreens 
Balance Rewards program website, where they are encouraged to either login to an existing 
account or sign up for a new account. Immediately upon receiving vaccinations, participants’ 
accounts would be credited with the balance rewards points, which participants could then use for 
front-of-store purchases on the same visit. Walgreens then tracks this purchase data, as well as 
other pertinent sales data such as the number of new pharmacy patients and new Balance Rewards 
members, and provide it to our JHSPH study team securely via Box, so that we are able to use this 
data to determine the financial viability of this incentive program from Walgreens perspective. 
Participant consent includes that Walgreens may track purchase data via the balance rewards 
program for analysis purposes. If the data shows the incentive program to be financially viable, 






All intervention contacts are assigned both baseline and follow-up surveys, with survey reminders 
sent by email and text. The baseline survey was administered through the MomsTalkShots app and 
collected data on baseline vaccine intentions, knowledge, attitudes and beliefs, as well as any 
changes to vaccine intentions after notification of eligibility for the financial incentive (see 
Appendix 3: Intervention Contact Registration Survey). Contacts randomized to the Education and 
Financial Intervention arm also received a short survey immediately after watching their assigned 
educational videos to assess the usability of the app and identify any subsequent changes in vaccine 
intentions, knowledge, attitudes and beliefs (see Appendix 4: Intervention Contact Post-Video 
Survey).  
The follow-up survey is administered to both intervention and control contacts approximately 60 
days after the P3+ intervention patient who referred them gives birth (see Appendix 5: Intervention 
Contact 60 Day Post-Birth Survey and Appendix 6: Control Contact 60 Day Post-Birth Survey). 
The primary objective of the follow-up survey is to assess whether the vaccines of interest were 
received by the contact during the pregnancy of the P3+ intervention patient, and if so, when and 
where. However, for the intervention contacts, the follow-up survey also collects data on changes 
to vaccine knowledge, attitudes and beliefs, the feasibility of the Walgreens Balance Rewards 
system, contacts’ experience receiving the vaccine at Walgreens, and facilitators and barriers to 
the receipt of these vaccines at Walgreens and redeeming the Balance Rewards incentives as 
implemented in this study (if applicable).  
For enrolling and completing the baseline survey, intervention contacts received a $20 gift card. 
For completing the follow-up survey, intervention and control contacts receive a $10 gift card. 
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These gift cards are not the same as the financial incentive for vaccination; they are simply an 
incentive to get study participants to enroll and complete the surveys (Figure 4).  
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Which adverse events following immunization (AEFI) have been shown to be caused by vaccines, 
and which have not? 
 
Findings 
For 12 of the 47 AEFI studied, a causal relationship has been established. For the other 35, there 
are no studies of quality that show an association with routine immunization in the United States. 
 
Meaning 
Although vaccines currently recommended for the general population in the U.S. do cause some 
adverse reactions, vaccines have an excellent safety profile overall and provide protection against 








Vaccine safety concerns contribute to gaps in immunization coverage and disease outbreaks. 
Health care providers desire objective and clear information on a broad range of vaccine safety 
issues to assist them in answering patient questions. There have been no recent comprehensive 
reviews on adverse events following immunization (AEFI), and previous reviews were not written 
for providers. 
Objective 
This systematic review provides an update to the scientific evidence assessing possible causal 
associations of AEFI compiled in the 2012 report from the Institute of Medicine (IOM) and the 
2014 report from the Agency for Healthcare Research and Quality (AHRQ), along with refined 
causality conclusions intended for health care providers.  
Evidence Review 
We updated the evidence base for 44 AEFI studied in the 2012 IOM and 2014 AHRQ reports using 
systematic English-language PubMed literature reviews. We also reviewed 3 other AEFI and 2 
special topics which have been raised as concerns among the media. We provide causality 





For 12 of the 47 AEFI studied, a causal relationship has been established with at least one vaccine 
currently routinely recommended to the general population in the United States. These 12 
confirmed adverse reactions are: anaphylaxis, arthralgia/arthritis (mild, acute and transient, not 
chronic), deltoid bursitis (when vaccine is administered improperly), disseminated varicella 
infection (in immune deficient individuals for whom the varicella vaccine is contraindicated), 
encephalitis, febrile seizures, Guillain-Barré Syndrome, hepatitis (in immune deficient individuals 
for whom the varicella vaccine is contraindicated), herpes zoster, immune thrombocytopenic 
purpura, meningitis, and syncope. Most of these adverse reactions are rare. For the other 35 AEFIs, 
the evidence does not support a causal relationship with vaccines recommended for routine use in 
the U.S. In-depth evidence bases for each AEFI are available in the Full Vaccine Safety Review 
section at the end of this thesis document; examples of which for three of the most common vaccine 
safety concerns expressed by parents (autism, vaccine ingredients, and simultaneous vaccination) 
are presented in this manuscript. 
Conclusions and Relevance 
Although vaccines currently recommended for the general population in the U.S. do cause some 
adverse reactions, vaccines have an excellent safety profile overall and provide protection against 








Immunization is one of the most effective ways to prevent morbidity and mortality from infectious 
diseases [13]. Vaccine coverage among children in the United States remains high [14]. However, 
vaccine hesitancy (concerns about the decision to vaccinate oneself or one’s children) has risen in 
recent decades [1-4], and clustering of vaccine refusal has contributed to outbreaks of vaccine 
preventable diseases [5-11].  
Most patients and parents, including parents who are vaccine hesitant, rely on health care providers 
as their most frequently used and credible source for vaccine information [15-17]. Providers need 
information on a broad range of vaccine safety issues to be confident in answering patient 
questions about vaccine safety as those questions become more specific, complex and wide-
ranging. Clinicians desire vaccine safety information which is evidence-based, objective, and 
provides clear guidance on whether or not vaccines cause specific adverse event following 
immunization (AEFI), and the risk for AEFI that caused by vaccines [18-23]. 
Websites that include reliable sources of vaccine safety information for providers include the 
Centers for Disease Control and Prevention (CDC) [219, 220], the American Academy of 
Pediatrics, the Food and Drug Administration, and the Immunization Action Coalition [221]. 
However, much of the information available is not based on systematic comprehensive reviews 
and lacks clear statements on causality. The most comprehensive source of vaccine safety 
information available to date is the independent 2012 report by the Institute of Medicine (IOM), 
now called the National Academy of Medicine (NAM), entitled Adverse Effects of Vaccines: 
Evidence and Causality, [222] which builds on previous vaccine safety reports from the IOM [113, 
114, 223-225]. These extraordinarily comprehensive reviews were conducted at the request of the 
Department of Health and Human Services (HHS) and its agencies, for the primary purpose of 
updating the National Vaccine Injury Compensation Program [226]. Final products from these 
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committees are books; they are neither succinct nor readily available to clinicians. In the 2012 
report, the IOM concluded that the evidence is inadequate to accept or reject a causal relationship 
for 135 of 158 (85%) of vaccine-AEFI relationships studied. The 2014 report by the Agency for 
Healthcare Research and Quality (AHRQ) entitled Safety of Vaccines Used for Routine 
Immunization in the United States: Evidence Report/Technology Assessment No. 215 [117, 227], 
was intended to expand upon and update the 2012 IOM report and was commissioned by HHS for 
the purpose of developing a federal vaccine safety research agenda. While these reports are useful 
for policy makers and vaccine safety scientists, they were not designed specifically for use by 
clinicians, and their length, writing style, and framing of causality assessments do not translate 
well to the practicing clinician. In addition, the IOM and AHRQ reports do not cover all AEFIs of 
current interest and many assessments are now out of date due to evidence emerging since their 
publications.  
This systematic review presents providers with accurate, succinct and useful causality conclusions 
for a comprehensive list of AEFIs based on an objective and thorough systematic examination of 




We systematically reviewed the current scientific evidence to determine if a causal relationship 
could be established for 47 AEFIs of interest to the public and clinicians. This list of AEFIs was 
determined by reviewing prior IOM reports [113, 114, 222-225], the AHRQ report [117, 227], and 
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surveys of the public and clinicians that identified AEFIs of concern [23, 82, 131-133, 136, 137, 
501-505].   
Our search strategy expanded upon that of the IOM and AHRQ reports. Searches were performed 
in PubMed and combined Medical Subject Headings (MeSH) indexing terms for vaccines and 
vaccination with terms specific to each AEFI on our list. MeSH and free text terms for each AEFI 
and their relevant synonyms (listed as Entry Terms on the MeSH page) were included. Searches 
for AEFI included in the above reports were restricted to articles published since the end of the 
searches performed in those reports. Searches for topics not included in the above reports were not 
restricted by date of publication. Articles were excluded from consideration for epidemiological 
evidence if they: did not have human data; did not have appropriate controls; only included passive 
surveillance data (such as from the Vaccine Adverse Event Reporting System); had insufficient 
sample size to study the AEFI; reported on vaccines not currently routinely recommended for the 
general U.S. population; reported no primary data; were simulations, cross-sectional studies, or 
ecological studies; were letters, editorials, commentaries, or news articles; or were not in English. 
Case reports and uncontrolled cases series were only considered for inclusion for review of the 
proposed biological mechanism section, not the epidemiologic evidence section. Search results 
were exported to EndNote (Clarivate Analytics) and upon review relevant articles were added to 
the evidence base for each topic. Searches were initially performed in 2015 and updated in July 
2018. General search terms used are listed in Appendix 1, and terms for each AEFI are in Appendix 
2. 
For each AEFI, the authors reviewed the epidemiological evidence and proposed biological 
mechanisms and drew conclusions using standardized categories of causality conclusions that were 
devised to be both scientifically accurate and useful to health care providers (Table 1). To be 
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considered a confirmed causal association, the evidence had to show a clear association between 
the event and at least one vaccine routinely recommended in the U.S. The frequency of confirmed 





Our combined searches identified 25,103 unique articles (Figure 1). Excluded were: articles 
published prior to the IOM and AHRQ reports (20,690), non-contributing article types (394), non-
human studies (849), and non-English articles (253). Articles indexed as case reports (203) were 
not considered as epidemiologic evidence. After review of the remaining 2,714 articles, 155 unique 
articles were added to the existing epidemiologic evidence base from the IOM and AHRQ reports 
(Appendix 3), cited a total of 198 times due to overlap among multiple AEFIs (Tables 3 and 4). 
A causal relationship has been established for 12 of the 47 AEFI reviewed (Table 3). These 12 
confirmed adverse reactions are: anaphylaxis, arthralgia/arthritis (mild, acute and transient, not 
chronic), deltoid bursitis (when vaccine is administered improperly), disseminated varicella 
infection (in immune deficient individuals for whom the varicella vaccine is contraindicated), 
encephalitis, febrile seizures, Guillain-Barré Syndrome, hepatitis (in immune deficient individuals 
for whom the varicella vaccine is contraindicated), herpes zoster, immune thrombocytopenic 
purpura, meningitis, and syncope. Most of these adverse reactions are rare. For 35 AEFI, there are 
no studies of quality that establish a causal association with routine vaccines used in the United 
States (Table 4). In particular, the evidence shows a clear lack of association between certain 
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vaccines and AEFIs: influenza vaccines do not cause asthma, childhood vaccines do not cause 
autism, vaccines do not cause diabetes, vaccines given to immunocompetent persons do not cause 
hepatitis, influenza vaccines do not cause Multiple Sclerosis (MS) in adults, and DTP and hepatitis 
B vaccines do not cause Sudden Infant Death Syndrome (SIDS).  
Below we present the full evidence supporting conclusions for autism, vaccine ingredients, and 
simultaneous vaccination as these topics are frequently raised by parents [501, 502]. The evidence 
supporting all other conclusions is available in the Full Vaccine Safety Review section at the end 
of this thesis document, as well as on the website for the Johns Hopkins Institute for Vaccine 
Safety (IVS), http://www.vaccinesafety.edu/, and in the book entitled The Clinician’s Vaccine 
Safety Resource Guide: Optimizing Prevention of Vaccine-Preventable Diseases Across the 





Epidemiological evidence: There have been 15 methodologically sound, controlled 
epidemiological studies exploring an association between ASD and receipt of MMR vaccine [105-
112], thimerosal in vaccines [112, 508-512], and simultaneous vaccination with multiple vaccines 
[513, 514], in addition to the relevant systematic reviews [113-117] and one meta-analysis [118]. 
Together, these studies included more than 1.8 million children. Notwithstanding 11 studies from 
a pair of authors [515-525], all of which had substantial methodological flaws [114-116, 526], the 
epidemiological evidence consistently shows no association between MMR vaccine, thimerosal in 
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vaccines, or simultaneous vaccination and ASD. One recent study suggested a possible increased 
risk of ASD among children whose mothers received an influenza vaccination during their first 
trimester of pregnancy, although this association was not statistically significant after a post hoc 
analysis adjusting for multiple comparisons, and there was no association between ASD and 
influenza vaccination received during any trimester [527]. Another recent study showed that 
receiving Tdap vaccine during pregnancy is not associated with increased risk of ASD in the child 
[528].  
Proposed biological mechanism: The overlapping times of childhood vaccine administration and 
usual onset of ASD symptoms have led to speculations about a possible causal pathway; however, 
the proposed links have been unsubstantiated [529]. Several different theories were proposed to 
attribute the cause of ASD to vaccines. In his since retracted 1998 study, Wakefield suggested that 
a dysregulated immune response to measles antigen in the MMR vaccine led to persistent intestinal 
infection, allowing “toxins” to enter the blood stream and enter the central nervous system leading 
to developmental regression in children [96]. He claimed support for this because of his alleged 
detection of measles virus RNA in bowel specimens of several children with ASD. However, his 
referenced study was found to be fraudulent, and no evidence of persistent infection has been 
shown in studies that used appropriate methods [530-532]. Another proposed trigger for ASD was 
thimerosal, an ethylmercury-containing preservative that used to be present in some vaccines, 
although not in the MMR vaccine. This theory was based on observed similarities in some features 
of ASD and mercury poisoning [119]; however, the degree of these similarities and the plausibility 
of this suspected association was refuted by neurologists [121]. The IOM found no valid 
mechanistic evidence connecting MMR or thimerosal-containing vaccines and ASD [114, 222]. 
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Conclusion: Childhood vaccines do not cause autism.  Maternal vaccines have not been shown 
to cause autism. The IOM concluded in 2004 that the body of evidence favors rejection of a causal 
relationship between autism and MMR vaccine and thimerosal-containing vaccines [114, 222]. No 
evidence has become available since the IOM report that changes this conclusion. MMR vaccine 




Epidemiological evidence: A few studies have reported an association between vaccines 
containing aluminum adjuvants and persistent nodules at the injection site, at an estimated rate of 
0.03-0.83% [533-536]. Two studies examining infant exposure to aluminum from both diet and 
vaccines concluded that aluminum adjuvants at the levels of in vaccines are well below the 
calculated safe body burden [537, 538]. A 2017 review found that current data do not support a 
causal relationship between aluminum containing vaccines and a variety of autoimmune disorders 
[539]. A meta-analysis of clinical trials of 25,056 children under 10 years of age who received 
vaccines with newer adjuvants AS01, AS02, AS03 or MF59 found no safety concerns [540].  
Allergic reactions to vaccines (including immediate hypersensitivity reactions) have been 
estimated to occur approximately once per 50,000-1,000,000 doses. Anaphylaxis, the most 
concerning type of such reactions, has been estimated to occur approximately once per 100,000-
1,000,000 doses for most commonly administered vaccines [272]. Rates of anaphylaxis can differ 
depending on the vaccine, age of the recipient, and gender; for example, adult females are at a 
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relatively higher risk of hypersensitivity reactions, including anaphylaxis, than males [541]. Hives 
occurs more commonly, but no precise rate is available.  
A review of data on substances sometimes found in certain vaccines in very small quantities, such 
as aluminum, gelatin, human serum albumin, formaldehyde, antibiotics, egg proteins, and yeast 
proteins, found no evidence of harm other than rare instances of hypersensitivity reactions such as 
anaphylaxis in those with severe allergies to either gelatin or egg proteins [542].  
Conclusion: Certain ingredients that are present in some vaccines (other than disease-specific 
antigens), such as gelatin or neomycin, can very rarely cause severe hypersensitivity reactions 
(e.g. anaphylaxis) in vaccines with those specific allergies. Allergic reactions occur approximately 
once every 50,000-1,000,000 doses and anaphylaxis occurs approximately once every 100,000-
1,000,000 doses for most commonly administered vaccines. 
Some adjuvants can cause increased rates of local reactions, and alum containing adjuvants can 
cause nodules at the injection site (at an estimated rate of 0.03-0.83%).  
Ingredients in vaccines currently routinely recommended to the general population in the U.S.* 




Epidemiological evidence: Vaccines which may induce fever may also rarely induce febrile 
seizures. Febrile seizures are a common and typically benign childhood condition, occurring in 2-
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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5% of children at some point during their first five years of life. Febrile seizures have an estimated 
background incidence of 240–480 per 100,000 person-years in children under five years, although 
this varies by age, genetics, co-morbidities and environmental risk factors. Although potentially 
frightening to witness, there are no long-term effects of simple febrile seizures [293-296].  
Febrile seizures occurred at a rate of 26.4 per 1000 person-years after MMR and 84.6 per 1,000 
person-years after MMRV (ProQuad®) in the 7-10 days after vaccination [297]. Several studies 
have confirmed that MMRV combination vaccine has a higher risk of febrile convulsions than 
simultaneous yet separate administration of the first dose of MMR and varicella vaccine 
(Varivax®), resulting in 1 additional febrile seizure for every approximately 2300-4587 MMRV 
doses administered [297, 543-547]. There is no increased risk of fever or febrile seizures in 
children receiving their second dose of measles-containing vaccine at 4 to 6 years of age, whether 
given MMR or MMRV [40, 220]. Delaying MMR or MMRV vaccines past 15 months of age 
results in a higher risk of seizures than vaccinating according to the recommended schedule [548, 
549].  
Febrile seizures were estimated to occur at a rate of 17.5 per 100,000 doses in children aged 6-59 
months after receiving concomitant trivalent inactivated influenza vaccine (abbreviation: TIV) and 
13-valent pneumococcal conjugate vaccine (abbreviation: PCV13; trade name: Prevnar13®); 
lower rates of 4.9 per 100,000 doses and 5.3 per 100,000 doses were estimated in children who 
received TIV without concomitant PCV13 and in children who received PCV13 without 
concomitant TIV, respectively, resulting in an additional 7.3 febrile seizures per 100,000 doses of 
concomitant TIV and PCV13 versus separate day administration. However, these risk differences 
varied substantially with age due to the age-dependent background rates of febrile seizures, with 
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the highest estimates at 16 months (45 per 100,000 doses of concomitant vaccination) and the 
lowest at 59 months (4 per 100,000 doses of concomitant vaccination) [296].  
A large cohort study found a small increased risk of febrile seizures after the first two doses of the 
DTaP-IPV-Hib combination vaccine in Denmark, with an absolute risk of less than 4 per 100,000 
vaccinations [550]. A large Vaccine Safety Datalink (VSD) study found no association between 
seizures and the DTaP-IPV combination vaccine (Kinrix®) among children 4 to 6 years of age 
[551]. 
The 2012 IOM report found that the evidence favors rejection of a causal relationship between 
multiple immunizations and increased risk for infections and for type I diabetes [224].  
A 2013 IOM report uncovered no evidence of major safety concerns associated with adherence to 
the childhood immunization schedule [552]. 
A randomized trial in France and Belgium during the 2014–2015 influenza season found no 
difference in rates of symptoms among older adults comparing co-administration of quadrivalent 
inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (abbreviation: 
PPSV23; trade name: Pneumovax 23®) with separate administration, with the exception of 
injection site pain which occurred more frequently in the co-administration group [553]. A 2016 
report summarizing ten phase 3 and 4 studies found no impact on vaccine reactogenicity or safety 
when co-administering routine vaccines with meningococcal conjugate vaccine (abbreviation: 
MenACWY-CRM; trade name: Menveo®) [554]. A phase II randomized study found that co-




Retrospective cohort studies using the VSD found no increase in risk of acute adverse reactions or 
adverse birth outcomes among those vaccinated with Tdap or influenza vaccines during pregnancy 
[556], as well as among those vaccinated with Tdap during pregnancy when comparing those who 
had received a tetanus toxoid containing vaccine relatively recently with those who had not [396]. 
In addition, no increase in risk of acute adverse reactions or adverse birth outcomes were found 
among those vaccinated concurrently with Tdap and influenza vaccines during pregnancy 
compared to those vaccinated sequentially [371].  
A VSD nested case-control study of nearly half a million children found no significant difference 
in estimated cumulative vaccine antigen exposure through the first 23 months of life comparing 
children ages 2 to 4 years with infections not targeted by the vaccines versus children without such 
infections [557]. 
Conclusion: Certain combination vaccines or simultaneous administration of vaccines that are 
known to cause fever can rarely cause febrile seizures in infants and young children at rates that 
are higher than the rates from individually administered vaccines. The rate of febrile seizures in 
the 7-10 days after vaccination was approximately 2-3 times higher for children who received 
MMRV as compared to MMR and varicella vaccines administered separately on the same day, 
and 4 times higher as compared to MMR alone (resulting in 1 additional febrile seizure for every 
approximately 2300-4587 MMRV doses administered) [297]. When influenza and pneumococcal 
conjugate vaccines are given simultaneously as opposed to on separate visits in children 6-59 
months of age, the risk of febrile seizures in the 24 hours after vaccination increases from roughly 
10.2 to 17.5 per 100,000 doses [296]. 
Simultaneous administration of Tdap and influenza vaccines during pregnancy does not increase 
the risk of acute adverse reactions or adverse birth outcomes. Combination vaccines and 
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simultaneous administration of vaccines currently routinely recommended to the general 
population in the U.S.* have not been shown to cause any other adverse reactions at a greater rate 




This comprehensive systematic review provides strong evidence that vaccines are very safe. For 
some major AEFIs of concern to the public and clinicians such as autism, the evidence supports 
that vaccines do not cause the AEFI. For those where there is evidence that the vaccine causes the 
AEFI, the rate of the reaction is often rare (e.g., roughly 4 febrile seizures per 100,000 children 
vaccinated) or very rare (e.g., 1-3 cases of Guillain-Barré Syndrome (GBS) per million influenza 
vaccinations).   
The causality conclusions of this review mostly align with those of the previous IOM and AHRQ 
reports. However, there are a few notable differences due to the emergence of new evidence since 
these reports’ publication: The IOM concluded that the evidence was inadequate to accept or reject 
a causal relationship between influenza vaccine and GBS, and the AHRQ report concluded that 
strength of evidence (SoE) was high for an association between 2009 monovalent H1N1 vaccine 
and GBS; our review concluded that influenza vaccine can cause GBS very rarely in adults. The 
IOM report only assessed the relationship between immune thrombocytopenic purpura (ITP) and 
tetanus-, diphtheria- or pertussis-containing vaccines, and the AHRQ report concluded that SoE 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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was moderate for an association between MMR vaccine and thrombocytopenic purpura; our 
review concluded that MMR vaccine can very rarely cause ITP in children. The AHRQ report 
concluded that SoE was insufficient and the IOM report concluded that the evidence was 
inadequate to accept or reject a causal relationship between tetanus-, diphtheria- or pertussis-
containing vaccines and SIDS, and neither report studied other vaccines and SIDS; our review 
concluded that both DTP and hepatitis B vaccines do not cause SIDS. The AHRQ report concluded 
that SoE was insufficient and the IOM report concluded that the evidence was inadequate to accept 
or reject a causal relationship between influenza vaccines and multiple sclerosis (MS); our review 
concluded that influenza vaccines do not cause MS in adults. 
Our review has several limitations. Firstly, there is potential for misunderstanding or 
misrepresentation of our causality conclusion of “vaccines have not been shown to cause”, as 
evidence that the AEFI has not been evaluated and therefore likely based on personal anecdotes. 
In most of these instances, the specific condition in question is quite rare in the general population 
and there are no signals indicating the need for large scale expensive studies; in others there are 
limited studies indicating no evidence of increased risk associated with vaccines. In almost all 
cases where we reach this conclusion, if there were a risk greater than our category of ‘very rare,’ 
(<1:10,000), that risk would have been detected under existing surveillance systems.  
Secondly, space limitations prevent us from sharing the entirety of the evidence used to derive 
each causality conclusion presented, and full evidence is provided for only 3 topics (autism, 
vaccine ingredients, and simultaneous vaccination). These topics were chosen as they are 
frequently raised by parents [501, 502]; however, they are not the only topics of interest for 
providers or the public. The evidence supporting all other conclusions is available in the Full 






Although vaccines currently recommended for the general population in the U.S. do cause some 
adverse reactions, vaccines have an excellent safety profile overall and provide protection against 
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Figures and Tables 
 
Table 1. Categories of Causality Conclusions* 
Categories Definitions 
Vaccines can cause the 
event. 
The evidence shows a clear association between the event and at least one vaccine 
routinely recommended in the U.S.  
Vaccines did cause the 
event. 
The evidence showed a clear association between the event and at least one 
previously recommended vaccine. However, these vaccine(s) are no longer used in 
the U.S., if they ever were.  
Vaccines have not been 
shown to cause the event. 
The evidence of an association between the event and vaccines currently routinely 
recommended to the general population in the United States is insufficient or non-
existent. 
Vaccines do not cause the 
event. 
The evidence shows clear lack of association between the event and vaccines 
currently routinely recommended to the general population in the United States.  
 
  
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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Table 2. Standard Categories of Frequency for Adverse Drug Reactions (provided by "Guidelines for 
Preparing Core Clinical-Safety Information on Drugs" - Report of CIOMS Working Group III, 1995) 
Categories Definitions 
Very common ≥ 1/10 (≥ 10%) 
Common ≥ 1/100 and < 1/10 (~1%-10%) 
Uncommon ≥ 1/1,000 and < 1/100 (~0.1-1%) 
Rare ≥ 1/10,000 and < 1/1,000 (~0.01-0.1%) 





Table 3. Causal Relationship Established between Adverse Event Following Immunization (AEFI) and at 




Evidence added to 
IOM/AHRQ reports 




McCarthy et al. 2013 
Daley et al. 2014 
Kawai et al. 2014 
Turner et al. 2015b, 
2015a 
Vichnin et al. 2015 
McNeil et al. 2016 
Baxter et al. 2017 
Arthralgia/Arthritis 
(mild, acute, 
transient – not 
chronic) 
Rubella-containing vaccines can cause mild, 
acute, transient arthralgia or arthritis, very 
commonly in adult women but rarely in 
children. Other U.S. vaccines have not been 
shown to cause arthralgia or arthritis. 
Vaccines have not been shown to cause 
chronic arthralgia/arthritis, as stated in the 







Deltoid Bursitis Incorrect administration of vaccines can 
cause deltoid bursitis. 
n/a  
Disseminated 
Varicella Infection  
Varicella vaccine can rarely cause 
disseminated varicella infection in immune 
deficient individuals for whom the vaccine is 
contraindicated. 
n/a  
Encephalitis Measles vaccine can very rarely cause 
encephalitis. Mumps vaccine used in other 
countries did cause encephalitis (but not the 
vaccine licensed in the U.S.). 
IOM found 




Daley et al. 2014 
Kawai et al. 2014  
Klein et al. 2015 
Hansen et al. 2016 
Ghaderi et al. 2017 
Febrile Seizures  Vaccines that induce fever in infants and 
young children, such as MMRV, influenza, 
3.92/100,000 
(all vaccines 
Rowhani-Rahbar et al. 
2013 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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and PCV vaccines, can rarely cause febrile 
seizures.  
given ages 3-5 
months) 
Daley et al. 2014 
Hambidge et al. 2014 
Klopfer et al. 2014 
MacDonald et al. 2014 
Schink et al. 2014 
Bakken et al. 2015 
Kawai et al. 2015 
Li-Kim-Moy et al. 
2015 
Ma et al. 2015 
Macartney et al. 2015 
Duffy et al. 2016 
Hansen et al. 2016 
Kuter et al. 2016 
Li et al. 2016 
Duffy et al. 2017 
Macartney et al. 2017 
Guillain-Barré 
Syndrome (GBS) 
Influenza vaccine can cause GBS very rarely 
in adults. An old formulation of rabies 
vaccine did cause GBS (but is no longer 
available). Other vaccines, including current 
rabies vaccine, have not been shown to cause 
GBS.  
1-3/ 1,000,000 Dodd et al. 2013 
Galeotti et al. 2013 
Greene et al. 2013 
Huang et al. 2013 
Kwong et al. 2013 
McCarthy et al. 2013 
Kawai et al. 2014 
Prestel et al. 2014 
Vellozzi, Iqbal, and 
Broder 2014 
Martin Arias et al. 
2015 
Vichnin et al. 2015 
Hansen et al. 2016 
Andrews, Stowe, and 
Miller 2017 






Miranda et al. 2017 
Sandhu et al. 2017 
Hepatitis Varicella vaccine can rarely cause hepatitis if 
administered to persons with certain immune 
deficiencies. Vaccines given to 
immunocompetent persons do not cause 
hepatitis.  
n/a  
Herpes Zoster Varicella vaccine can rarely cause herpes 











MMR vaccine can very rarely cause ITP in 
children.  
1-3/100,000 Huang et al. 2013 
Villa et al. 2013 
Hansen et al. 2016 
Kharbanda et al. 2016 
Meningitis Reactivation of varicella vaccine can very 
rarely cause meningitis. Mumps vaccine 
used in other countries did cause meningitis 






Daley et al. 2014 
Kawai et al. 2014  
Klein et al. 2015 
Hansen et al. 2016 




Armed Forces Health 
Surveillance Center 
2013 
Table 4. No Causal Relationship Established between Adverse Event Following Immunization (AEFI) and 
Vaccines Currently Routinely Recommended for the General Population in the United States* 
AEFI Conclusion 
Evidence added to 
IOM/AHRQ reports 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 






An old formulation of rabies vaccine did cause ADEM (but is no 
longer available). Other vaccines, including current rabies vaccine, 
have not been shown to cause ADEM.  
Langer-Gould et al. 
2014 
Persson et al. 2014 
Scheller et al. 2015 
Baxter, Lewis, 
Goddard, et al. 2016 
Arthralgia/Arthritis 
(chronic) 
Vaccines have not been shown to cause chronic arthralgia/arthritis.  
Asthma Influenza vaccines do not cause asthma. Other vaccines have not 
been shown to cause asthma.  
Halsey et al. 2015 
Timmermann et al. 
2015 
Turner et al. 2015b, 
2015a 
Baxter et al. 2017 
Ataxia Vaccines have not been shown to cause ataxia. Klein et al. 2015 
Autism Childhood vaccines do not cause autism.  Maternal vaccines have not 
been shown to cause autism. 
Taylor, Swerdfeger, 
and Eslick 2014 
Jain et al. 2015 
Uno et al. 2015 
Zerbo et al. 2017 
Becerra-Culqui et al. 
2018 
Bell’s Palsy One influenza vaccine used in other countries did cause Bell’s Palsy 
(but is no longer available). U.S. vaccines have not been shown to 
cause Bell’s Palsy. 
Tseng et al. 2017 
Wijnans et al. 2017 
 
Brachial Neuritis Vaccines have not been shown to cause brachial neuritis.  
Chronic Fatigue 
Syndrome 
Vaccines have not been shown to cause chronic fatigue syndrome. Donegan et al. 2013 
Magnus et al. 2015 






Vaccines have not been shown to cause CIDP.  
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Chronic Urticaria Vaccines have not been shown to cause chronic urticaria. Bergfors et al. 2014 




Vaccines have not been shown to cause CRPS. Moreira et al. 2016 
Diabetes Vaccines do not cause diabetes.  Kharbanda et al. 2013 
Naleway et al. 2014 
Fabiani et al. 2015 
Hansen et al. 2016 
Karnchanasorn et al. 
2016 
Kharbanda et al. 2016 
Morgan et al. 2016 
Vaarala et al. 2017 
Elding Larsson et al. 
2018 
Epilepsy Vaccines have not been shown to cause epilepsy.  
Erythema Nodosum Vaccines have not been shown to cause erythema nodosum.  
Fibromyalgia  Vaccines have not been shown to cause fibromyalgia.  
Hearing Loss Vaccines have not been shown to cause hearing loss. Baxter, Lewis, 
Bohrer, et al. 2016 
Infantile Spasms Vaccines have not been shown to cause infantile spasms.  
Multiple Sclerosis 
(MS) 
Influenza vaccines do not cause MS in adults. Influenza vaccines 
have not been shown to cause MS in children. Other vaccines have 
not been shown to cause MS.  
Langer-Gould et al. 
2014 
Persson et al. 2014 
Halsey et al. 2015 
Scheller et al. 2015 







Vaccines have not been shown to cause MI. Macintyre et al. 2013 
Hebsur et al. 2014 
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Lavallee et al. 2014 
Lin et al. 2014 
Ochoa-Gondar et al. 
2014 
Clar et al. 2015 
Vlachopoulos et al. 
2015 
Hsu et al. 2016 
Chiang et al. 2017 
Myocarditis   Smallpox vaccine can very rarely cause myocarditis, but is not 
routinely recommended to the general population in the U.S. Other 
vaccines have not been shown to cause myocarditis.  
Engler et al. 2015 
Kharbanda et al. 2016 
Narcolepsy Current vaccines have not been shown to cause narcolepsy. AS03-
adjuvanted 2009 pandemic H1N1 influenza vaccine used in Europe 
did very rarely cause narcolepsy (but was not used in the U.S.). 
Tsai et al. 2011 
ECDC 2012 
Nohynek et al. 2012 
Partinen et al. 2012 
Arnheim-Dahlström 
et al. 2013 
Dauvilliers et al. 2013 
Szakacs, Darin, and 
Hallbook 2013 
Heier et al. 2013 
McCarthy et al. 2013 
Miller et al. 2013 
Wijnans et al. 2013 
Ahmed et al. 2014 
Duffy et al. 2014 
Johansen 2014 
Montplaisir et al. 
2014 
O'Flanagan et al. 2014 
Partinen et al. 2014 
Persson et al. 2014 
Feltelius et al. 2015 
Stowe et al. 2016 
Baxter et al. 2017 
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Oberle et al. 2017 
Sarkanen et al. 2018 
Neuromyelitis 
Optica 




Two influenza vaccines used in Canada (but not used in the U.S.) did 
commonly cause ORS. Changes made to the formulation of these 





Vaccines have not been shown to cause opsoclonus myoclonus 
syndrome. 
 
Optic Neuritis  Vaccines have not been shown to cause optic neuritis. Scheller et al. 2015 
Baxter, Lewis, 
Fireman, et al. 2016 
Sridhar et al. 2017 
Frederiksen and 
Topsoe Mailand 2017 
Polyarteritis 
Nodosa 
Vaccines have not been shown to cause polyarteritis nodosa.  
Primary Ovarian 
Insufficiency (POI) 
Vaccines have not been shown to cause POI. Naleway et al. 2018 
Serum Sickness Vaccines have not been shown to cause serum sickness.  
Small Fiber 
Neuropathy 
Vaccines have not been shown to cause small fiber neuropathy.  
Spontaneous 
Abortion 
Vaccines have not been shown to cause spontaneous abortion. Tookey et al. 1991 
Badilla et al. 2007 
Dana et al. 2009 
Garland et al. 2009 
Wacholder et al. 2010 
Forinash et al. 2011 
Sato et al. 2011 
Tavares et al. 2011 
Bednarczyk, Adjaye-




Heikkinen et al. 2012 
Makris et al. 2012 
Oppermann et al. 
2012 
Pasternak et al. 2012 
Sammon et al. 2012 
Chambers et al. 2013 
Chavant et al. 2013 
Irving et al. 2013 
Angelo et al. 2014 
de Vries et al. 2014 
Huang et al. 2014 
Ma et al. 2014 
Badell et al. 2015 
Baril et al. 2015 
Bratton et al. 2015 
Goss et al. 2015 
Ludvigsson et al. 
2015 
McMillan et al. 2015 
Panagiotou et al. 2015 
Vichnin et al. 2015 
Bonde et al. 2016 
Chambers et al. 2016 
Donahue et al. 2017 
Scheller et al. 2017 
Steinhoff et al. 2017 
Stroke Vaccines have not been shown to cause stroke. Daley et al. 2014 
Lavallee et al. 2014 
Lin et al. 2014 
Siriwardena, Asghar, 
and Coupland 2014 
Vila-Corcoles et al. 
2014 
Asghar, Coupland, 
and Siriwardena 2015 
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Clar et al. 2015 
Fullerton et al. 2015 
Vichnin et al. 2015 
Vlachopoulos et al. 
2015 
Hsu et al. 2016 
Chiang et al. 2017 




DTP and hepatitis B vaccines do not cause SIDS. Other vaccines 
have not been shown to cause SIDS. 
Hansen et al. 2016 




Vaccines have not been shown to cause SLE. Pellegrino, Radice, 
and Clementi 2015 
Huang et al. 2016 
Liao et al. 2016 
Puges et al. 2016 
Dhar et al. 2017 
Transverse Myelitis Vaccines have not been shown to cause transverse myelitis. Nordin et al. 2014 
Scheller et al. 2015 
Vasculitis Vaccines have not been shown to cause vasculitis. Abrams et al. 2015 
Jeffs et al. 2015 
Da Dalt et al. 2016 
Kerneis et al. 2016 









25,103 unique articles 
returned by initial PubMed 
searches
20,690 excluded by 
publication date 
limitations (to avoid 
redundancy with the IOM 
and AHRQ reports)
394 excluded by article 
type limitations (letters, 
editorials, commentaries, 
news articles)
849 excluded by restricting 
to human studies
253 excluded by restricting 
to articles published in 
English
203 articles indexed as 
case reports and thus not 
considered epidemiologic 
evidence
2,714 articles reviewed for 
epidemiologic evidence
155 unique articles (cited a total of 198 times due to some 
articles addressing multiple AEFIs) added to the existing base of 






Appendix 1. General Search Terms 




("Vaccines"[Mesh] OR "Vaccination"[Mesh]) 
Date 
Limitation 
If AE was included in 2014 
AHRQ report, limited date 
to the end of their review. 
("2013/08/01"[PDAT] : "3000/12/31"[PDAT]) 
Exclusion 
Criteria 
No comments, editorials, 
letters, or news; human 
studies only; English 
language only; full text only 
NOT (Comment[ptyp] OR Editorial[ptyp] OR 
Letter[ptyp] OR News[ptyp] OR Newspaper 
Article[ptyp]) NOT ("animals"[Mesh] NOT 






Appendix 2. Adverse Event Following Immunization (AEFI) Search Terms 




(“Encephalomyelitis, Acute Disseminated”[Mesh] OR “acute disseminated 
encephalomyelitis”[tw] OR “acute disseminated encephalomyelitides”[tw] 
OR "ADEM"[tw]) 
Arthralgia, Arthritis (“Arthritis”[Mesh] OR “Arthritis”[tw] OR “Arthritides”[tw] OR 
“Polyarthritis”[tw] OR “Polyarthritides”[tw] OR “arthrochondritis”[tw] OR 
“arthrosynovitis”[tw] OR “joint inflammation”[tw] OR “joint 
inflammations”[tw] OR “oligoarthritis”[tw] OR “Arthralgia”[Mesh] OR 
“Arthralgia”[tw] OR “Arthralgias”[tw] OR “Polyarthralgia”[tw] OR 
“Polyarthralgias”[tw] OR “joint pain”[tw] OR “joint pains”[tw]) 
Asthma (“Asthma”[Mesh] OR “asthma”[tw] OR “asthmatic”[tw] OR 
“asthmas”[tw]) 
Ataxia ("Ataxia"[Mesh] OR "Ataxia"[tw] OR  "Ataxias"[tw] OR  "Ataxy"[tw] OR 
"Dyssynergia"[tw] OR  "Coordination Impairment"[tw] OR  "Coordination 
Impairments"[tw] OR  "Lack of Coordination"[tw] OR  
"Incoordination"[tw] OR  "Incoordinations"[tw]) 
Autism ("Autism Spectrum Disorder"[Mesh] OR "Autism"[tw] OR "Autistic"[tw] 
OR "Asperger"[tw]) 
Bell’s Palsy (“Bell Palsy”[Mesh] OR “Bell Palsy”[tw] OR “Bells Palsy”[tw] OR “Bell's 
Palsy”[tw] OR “Bell Palsies”[tw] OR “Bells Palsies”[tw] OR “Bell's 
Palsies”[tw] OR “facial neuropathy”[tw] OR “facial paralysis”[tw] OR 
“facial paralyses”[tw] OR “facial palsy”[tw] OR “facial palsies”[tw]) 
Brachial Neuritis (“Brachial Plexus Neuritis”[Mesh] OR “Neuralgia”[Mesh] OR 
“neuritis”[tw] OR “neuritides”[tw] OR “neuralgia”[tw] OR 
“neuralgias”[tw] OR “neuralgic”[tw] OR “neuropathy”[tw] OR 
“neuropathic”[tw] OR “Parsonage Aldren Turner Syndrome”[tw] OR 
“Parsonage-Aldren-Turner Syndrome”[tw] OR “Parsonage Turner 




("Chronic Inflammatory Disseminated Polyneuropathy"[tw] OR 
"CIDP"[tw]) 
Complex Regional Pain 
Syndrome (CRPS) 
("Complex Regional Pain Syndromes"[Mesh] OR "Complex Regional Pain 
Syndromes"[tw] OR "Complex Regional Pain Syndrome"[tw] OR 
"Causalgia"[tw] OR "Reflex Sympathetic Dystrophy"[tw]) 
Deltoid Bursitis (“Bursitis”[Mesh] OR “Bursitis”[tw] OR “Bursitides”[tw] OR “Adhesive 
Capsulitis”[tw] OR “Adhesive Capsulitides”[tw] OR “Shoulder 
Impingement Syndrome”[Mesh] OR “Shoulder Impingement 
Syndrome”[tw] OR ((“periarthritis”[Mesh] OR “periarthritis”[tw] OR 
“tenosynovitus”[tw]) AND (“shoulder”[tw] OR “deltoid”[tw] OR 
“humeroscapular”[tw] OR “humeroscapularis”[tw] OR 
“scapulohumeral”[tw] OR “scapulohumeralis”[tw] OR “scapulo”[tw] OR 
“scapularis”[tw])) OR “UAIRVA”[tw] OR “frozen shoulder”[tw] OR 
“shoulder pain”[tw] OR “shoulder injury”[tw] OR “shoulder 
dysfunction”[tw] OR “shoulder stiffness”[tw] OR “stiff shoulder”[tw] OR 
“rigid shoulder”[tw] OR “shoulder rigidity”[tw]) 





"Disseminated Varicella Infection"[tw] 
Erythema Nodosum ("Erythema Nodosum"[Mesh] OR "Erythema Nodosum"[tw]) 
Fibromyalgia, Chronic 
Fatigue Syndrome 
("Fatigue Syndrome, Chronic"[Mesh] OR "Fibromyalgia"[Mesh] OR 
"Chronic Fatigue"[tw] OR "Fibromyalgia"[tw] OR "Fibromyalgias"[tw] OR 
"Fibromyositis"[tw] OR "Fibrositis"[tw] OR "Fibrositides"[tw] OR 
"Diffuse Myofascial Pain Syndrome"[tw] OR "Myalgic 
Encephalomyelitis"[tw] OR "Postviral Fatigue Syndrome"[tw] OR 
"Postviral Fatigue Syndromes"[tw] OR "Royal Free Disease"[tw] OR 
"Systemic Exertion Intolerance Disease"[tw]) 
Guillain-Barré 
Syndrome (GBS) 
(“Guillain-Barre Syndrome”[Mesh] OR “Guillain Barre”[tw] OR “Guillain-
Barre”[tw] OR “Guillain-Barré”[tw] OR “Miller Fisher Syndrome”[Mesh] 
OR “Miller Fisher”[tw] OR“Miller-Fisher”[tw] OR “Fisher Syndrome”[tw] 
OR “Acute Inflammatory Polyneuropathy”[tw] OR “Acute Inflammatory 
Polyneuropathies”[tw] OR “Acute Inflammatory Demyelinating 
Polyneuropathy”[tw] OR “Acute Inflammatory Demyelinating 
Polyradiculoneuropathy”[tw] OR “Acute Inflammatory 
Polyradiculoneuropathy”[tw] OR“Acute Inflammatory 
Polyradiculoneuropathies”[tw] OR “Acute Inflammatory Demyelinating 
Polyradiculoneuropathy”[tw] OR “Acute Inflammatory Demyelinating 
Polyradiculoneuropathies”[tw] OR “Acute Autoimmune Neuropathy”[tw] 
OR “Acute Autoimmune Neuropathies”[tw]) 
Hearing Loss ("Hearing Loss"[Mesh] OR "Hearing Loss"[tw] OR "Hearing 
Impairment"[tw] OR "Hypoacusis"[tw] OR "Hypoacuses"[tw] OR 
"Deafness"[tw]) 
Hepatitis (("Hepatitis"[Mesh] OR "Hepatitis"[tw] OR "Hepatitides"[tw]) AND "Viral 
Reactivation"[tw]) 




(“Anaphylaxis”[Mesh] OR “anaphylaxis”[tw] OR “anaphylactic”[tw] OR 
“Angioedema”[Mesh] OR “angioedema”[tw] OR “quincke edema”[tw] OR 
“quincke’s edema”[tw] OR “quinckes edema”[tw] OR “angioneurotic 
edema”[tw] OR “facial edema”[tw] OR “quincke oedema”[tw] OR 
“quincke’s oedema”[tw] OR “quinckes oedema”[tw] OR “angioneurotic 
oedema”[tw] OR “facial oedema”[tw] OR “Hypersensitivity”[Mesh] OR 
“hypersensitivity”[tw] OR “hypersensitivities”[tw] OR “allergy”[tw] OR 
“allergies”[tw] OR “allergic”[tw] OR “Urticaria”[Mesh] OR “urticaria”[tw] 




(“Purpura, Thrombocytopenic, Idiopathic”[Mesh] OR 
“Thrombocytopenia”[Mesh] OR “Purpura”[Mesh] OR “ITP”[tw] OR 
“Werlhof's Disease”[tw] OR “Werlhofs Disease”[tw] OR “Werlhof 
Disease”[tw] OR “morbus werlhof”[tw] OR “thrombocytopenic”[tw] OR 
“thrombocytopenia”[tw] OR “thrombocytopenias”[tw] OR 
“thrombopenia”[tw] OR “thrombopenias”[tw] OR 
“macrothrombocytopenia”[tw] OR “macrothrombocytopenias”[tw] OR 
“platelet deficiency”[tw] OR “platelet deficiencies”[tw] OR “thrombocyte 
deficiency”[tw] OR “thrombocyte deficiencies”[tw] OR 
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("Encephalitis"[Mesh] OR "Encephalomyelitis"[Mesh] OR 
“encephalitis”[tw] OR “encephalitides”[tw] OR “encephalomyelitis”[tw] 
OR “encephalomyelitides”[tw] OR "Rasmussen Syndrome"[tw] OR 
"Rasmussen's Syndrome"[tw] OR "Rasmussens Syndrome"[tw] OR 
“encephalopathy”[tw] OR “encephalon”[tw] OR “encephalopathia”[tw] OR 
“panencephalopathy”[tw] OR “Leigh Disease”[Mesh] OR “leigh 
disease”[tw] OR “leigh's disease”[tw] OR “leighs disease”[tw] OR “leigh 
syndrome”[tw] OR “encephalomyopathy”[tw] OR 
“encephalomyopathies”[tw] OR “brain inflammation”[tw] OR 
“cerebritis”[tw] OR “Meningitis”[Mesh] OR “meningitis”[tw] OR 
“meningitides”[tw] OR “pachymeningitis”[tw] OR 
“pachymeningitides”[tw]) 
Multiple Sclerosis (MS) (“Multiple Sclerosis”[Mesh] OR “multiple sclerosis”[tw] OR “disseminated 
sclerosis”[tw] OR “insular sclerosis”[tw]) 
Myocardial Infarction, 
Stroke 
("Myocardial Infarction"[Mesh] OR "Myocardial Infarction"[tw] OR 
"Myocardial Infarctions"[tw] OR "Myocardial Infarct"[tw] OR "Myocardial 
Infarcts"[tw] OR "Heart Attack"[tw] OR "Heart Attacks"[tw] OR 




("Myocarditis"[Mesh] OR "Myocarditis"[tw] OR "Myocarditides"[tw] OR 
"Carditis"[tw] OR "Myocardopathy"[tw] OR "Myocardopathies"[tw] OR 
"Cardiomyopathies"[Mesh] OR "Cardiomyopathies"[tw] OR 
"Cardiomyopathy"[tw] OR "Myocardial Disease"[tw] OR "Myocardial 
Diseases"[tw]) 
Narcolepsy (“Narcolepsy”[Mesh] OR “Cataplexy”[Mesh] OR “Narcolepsy”[tw] OR 
“Cataplexy”[tw] OR “Narcolepsy-Cataplexy”[tw] OR “Paroxysmal 
Sleep”[tw] OR “Gelineau Syndrome”[tw] OR “Gelineau's Syndrome”[tw] 
OR “Gelineaus Syndrome”[tw] OR “Gelineau Syndromes”[tw] OR 
“Gelineau's Syndromes”[tw] OR “Gelineaus Syndromes”[tw] OR “sleep 







("Opsoclonus-Myoclonus Syndrome"[Mesh] OR "Opsoclonus-Myoclonus 
Syndrome"[tw] OR "Opsoclonus Myoclonus Syndrome"[tw] OR 
"Opsoclonus-Myoclonus Ataxia"[tw] OR "Opsoclonus Myoclonus 
Ataxia"[tw] OR "Dancing Eyes-Dancing Feet Syndrome"[tw] OR "Dancing 
Eyes Dancing Feet Syndrome"[tw] OR "Kinsbourne Syndrome"[tw] OR 
"Myoclonic Encephalopathies"[tw] OR "Myoclonic Encephalopathy"[tw]) 
Optic Neuritis, 
Neuromyelitis Optica 
("Optic Neuritis"[Mesh] OR "Optic Neuritis"[tw] OR "Optic 
Neuritides"[tw]  OR "Retrobulbar Neuritis"[tw] OR "Retrobulbar 
Neuritides"[tw] OR "Neuropapillitis"[tw] OR "Neuropapillitides"[tw] OR 
"Neuromyelitis Optica"[Mesh] OR "Neuromyelitis Optica"[tw] OR "NMO 
Spectrum"[tw] OR "Devic Disease"[tw] OR "Devic's Disease"[tw] OR 
"Devics Disease"[tw] OR "Devic Syndrome"[tw] OR "Devic's 





("Primary Ovarian Insufficiency"[Mesh] OR "Primary Ovarian 
Insufficiency"[tw] OR "Ovarian Failure"[tw] OR "Resistant Ovary 
Syndrome"[tw]) 
Seizures (e.g., Febrile, 
Epilepsy, Infantile 
Spasms) 
("Seizures"[Mesh] OR "Seizures, Febrile"[Mesh] OR "Epilepsy"[Mesh] OR 
"Seizure"[tw] OR "Seizures"[tw] OR "Convulsion"[tw] OR 
"Convulsions"[tw] OR "Epilepsy"[tw] OR "Epilepsies"[tw]) 
Serum Sickness ("Serum Sickness"[Mesh] OR "Serum Sickness"[tw] OR "Serum 
Sicknesses"[tw]) 
Small Fiber Neuropathy ("Small Fiber Neuropathy"[Mesh] OR "Small Fiber Neuropathy"[tw] OR 
"Small Fiber Neuropathies"[tw] OR "Small Nerve Fiber Neuropathy"[tw] 
OR "Small Nerve Fiber Neuropathies"[tw] OR "Small Fibre 
Neuropathy"[tw] OR "Small Fibre Neuropathies"[tw] OR "Small Nerve 
Fibre Neuropathy"[tw] OR "Small Nerve Fibre Neuropathies"[tw]) 
Spontaneous Abortion ("Abortion, Spontaneous"[Mesh] OR "Spontaneous Abortion"[tw] OR 
"Spontaneous Abortions"[tw] OR "Miscarriage"[tw] OR 
"Miscarriages"[tw] OR "Early Pregnancy Loss"[tw] OR "Early Pregnancy 
Losses"[tw] OR "Tubal Abortion"[tw] OR "Tubal Abortions"[tw]) 
Sudden Infant Death 
Syndrome (SIDS) 
("Sudden Infant Death"[Mesh] OR "Sudden Infant Death"[tw] OR 
"SIDS"[tw] OR "Crib Death"[tw] OR "Cot Death"[tw]) 
Syncope ("Syncope"[Mesh] OR "Syncope"[tw] OR "Syncopal"[tw] OR 
"Fainting"[tw] OR "Faints"[tw] OR "Syncopal"[tw] OR "Presyncope"[tw] 
OR "Presyncopes"[tw] OR "Drop Attack"[tw] OR "Drop Attacks"[tw]) 
Systemic Lupus 
Erythematosus (SLE) 
("Lupus Erythematosus, Systemic"[Mesh] OR "Lupus Erythematosus"[tw] 
OR "Libman-Sacks Disease"[tw] OR "Libman Sacks Disease"[tw]) 
Transverse Myelitis (“Myelitis, Transverse”[Mesh] OR “Myelitis”[tw] OR “Myelitides”[tw] OR 
“Myelopathy”[tw] OR “Myelopathies”[tw] OR “Spinal Cord 
Inflammation”[tw] OR “Spinal Cord Inflammations”[tw] OR “Spinal 
Inflammation”[tw] OR “Spinal Inflammations”[tw]) 
Vasculitis, Polyarteritis 
Nodosa 
("Vasculitis"[Mesh] OR "Vasculitis"[tw] OR "Vasculitides"[tw] OR 
"Angiitis"[tw] OR "Angiitides"[tw] OR "Polyarteritis Nodosa"[Mesh] OR 
"Polyarteritis Nodosa"[tw] OR "Periarteritis Nodosa"[tw] OR "Necrotizing 
Arteritis"[tw] OR "Necrotizing Arteritides"[tw] OR "Essential 



















d (not in 
humans) 
Exclude











ADEM 698 653 10 1 5 16 13 4 
Arthralgia, 
Arthritis 
1566 1293 15 44 13 18 183 0 
Asthma 1328 1111 14 28 10 4 161 5 
Ataxia 135 117 1 4 0 4 9 1 
Autism 677 583 17 1 5 0 71 5 
Bell’s Palsy 105 92 0 1 0 2 10 2 
Brachial 
Neuritis 
639 521 7 4 14 15 78 0 
CIDP 5 4 0 0 0 1 0 0 
CRPS 21 7 2 0 1 1 10 1 
Deltoid Bursitis 25 17 1 0 0 6 1 0 




3 3 0 0 0 0 0 0 
Erythema 
Nodosum 




73 51 3 0 1 0 18 3 
GBS 512 405 12 2 5 8 80 17 
Hearing Loss 203 169 3 2 1 4 24 1 
Hepatitis 9 6 0 0 0 0 3 0 







8752 7987 58 135 38 37 497 10 




9156 7735 115 190 86 50 980 5 
Multiple 
Sclerosis 








318 271 4 18 0 2 23 4 
Narcolepsy 153 n/a 39 2 12 5 95 23 








116 93 1 0 2 6 14 4 
POI 15 n/a 5 2 0 2 6 1 
Seizures 893 730 15 1 7 5 135 17 
Serum Sickness 120 117 0 1 1 1 0 0 
Small Fiber 
Neuropathy 
5 1 0 0 0 1 3 0 
Spontaneous 
Abortion 
671 n/a 29 399 59 2 182 35 
SIDS 126 116 1 0 0 0 9 2 
Syncope 83 56 1 0 1 2 23 1 
SLE 391 309 6 3 5 7 61 5 
Transverse 
Myelitis 






404 340 7 2 4 19 32 5 
Total* 25103 20690 394 849 253 203 2714 155 
*total calculated by combining all individual searches into one search, thus accounting for overlap of articles 
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What are the baseline maternal and infant vaccine intentions, attitudes, beliefs, norms, and levels 
of trust among pregnant women in Georgia and Colorado? 
 
Findings 
Pregnant women demonstrated suboptimal maternal vaccine knowledge and intentions, and first-
time pregnant women were substantially less certain in their vaccine knowledge and intentions 
than women with prior children. However, the vast majority of women trusted the information 
provided by their obstetrician or midwife about both maternal and infant vaccines. 
 
Meaning 
Obstetricians and midwives are in a unique position to provide accurate vaccine information to 
soon-to-be mothers and their partners before they make vaccine decisions for themselves and their 






Maternal vaccine coverage is poor and a substantial proportion of parents have concerns about 
vaccines. Most parents seek out vaccine information during and immediately after their first 
pregnancy. A better understanding of the vaccine attitudes and beliefs of pregnant women is 
needed to develop effective interventions to increase maternal and infant vaccine coverage. This 
article presents maternal and infant vaccine attitudes and beliefs of pregnant women.  
Design 
Pregnant women were surveyed to assess their maternal and infant vaccine intentions, attitudes, 
beliefs, norms, and levels of trust in information sources.  
Setting 
Pregnant women were recruited from a geographically and socio-demographically diverse 
obstetrician-gynecologist offices in Georgia and Colorado.  
Participants 
Two thousand two hundred and ten pregnant women were recruited to participate, roughly half 
from each state.  
Results 
Fifty-six percent of women intended to receive both influenza and Tdap vaccines while pregnant 
compared to 68% intending their infant to receive all recommended vaccines on time, although 
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this varied substantially by ethnicity and education. Women pregnant with their first child were 
less likely to intend to vaccinate themselves (52% versus 59%) and their children (62% versus 
73%) and more likely to be unsure about both maternal (19% versus 8%) and infant (14% versus 
4%) vaccines than women who had prior children (P<0.01). Of all constructs assessed, confidence 
in vaccine safety and efficacy were the most strongly associated with intention to receive maternal 
and infant vaccines. The vast majority (92-93%) of women trusted the information provided by 
their obstetrician or midwife about both maternal and infant vaccines. 
Conclusions and Relevance 
Pregnant women demonstrated suboptimal maternal vaccine knowledge and intentions. First-time 
pregnant women were substantially less certain in their vaccine knowledge and intentions than 
women with prior children, demonstrating the opportunity for vaccine education to increase 
vaccine confidence and informed decision making at this stage of life, especially coming from 
highly trusted sources of vaccine information for pregnant women such as obstetricians and 
gynecologists. Such educational interventions should be individually tailored and focus on 
improvements to constructs such as perceived susceptibility to and severity of VPDs as well as 
confidence in vaccine safety and efficacy.  
Trial Registration 
The survey informing this article was part of a randomized controlled trial funded by the National 







Immunization is one of the most effective ways to prevent infectious diseases and their associated 
morbidity and mortality [13]. Vaccine coverage among children in the United States remains high 
[14]. However, vaccine hesitancy has emerged in recent decades as a threat to this high coverage 
[1-4], leading to the clustering of vaccine refusal and associated outbreaks of vaccine preventable 
diseases (VPDs) [5-9, 11, 558]. Vaccine coverage for maternal vaccines is poor, with only about 
half of pregnant women receiving influenza and pertussis vaccines [12].  
Although most parents believe vaccines to be important, safe and effective, concerns are very 
prevalent [2, 10, 15, 82, 125-142]. There are substantial differences in vaccine knowledge, 
attitudes and beliefs by gender, education, socioeconomic status, ethnicity and race [133, 151, 159, 
163, 166, 173-193]. Knowledge, attitudes and beliefs of pregnant women toward maternal 
vaccines also indicate ample room for improvement, though have not been as well characterized 
as parental attitudes and beliefs towards infant vaccines [22, 49, 194-210]. 
Most parents primarily seek out vaccine information during and immediately after their first 
pregnancy [211-214]. The first pregnancy may be a “teachable moment” – a key opportunity to 
provide accurate information about both maternal and infant vaccinations – since one’s vaccine 
attitudes and beliefs may not be fully solidified at this point [24]. The vast majority of parents [16, 
123, 129] and pregnant women [22, 195, 198, 200, 202, 204, 208] cite health care providers as 
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their most trusted source of vaccine information. However, many pregnant women do not receive 
information about infant vaccines directly from their obstetrician/gynecologist or midwife [207].   
The objective of this study was to determine, among a diverse population of pregnant women: 1) 
knowledge, attitudes and beliefs regarding maternal and infant vaccines; 2) trust in vaccine 
information sources; 3) intention to vaccinate; 4) associations between vaccine intentions and 
vaccine knowledge, attitudes, beliefs and trust; and 5) differences by sociodemographic 
characteristics such as education, ethnicity, and having prior children. We also aimed to identify 
homogeneity among groups of pregnant women based on their vaccine attitudes and beliefs to 




Data Collection  
 
Survey data were collected as part of a large randomized controlled trial of a prenatal intervention 
to increase uptake of maternal and infant vaccines. Pregnant women were recruited by study staff 
from waiting rooms of a geographically and socio-demographically diverse set of obstetrician-
gynecologist offices in Georgia and Colorado. Women were eligible for participation if they were 
18-50 years old, 8-26 weeks pregnant, and had not yet received maternal vaccines during their 
current pregnancy. This paper examines the survey data collected from the participating pregnant 
women at baseline.  
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The baseline survey included 3 multiple choice questions assessing vaccine intentions and number 
of prior children and 58 Likert scale statements assessing attitudes and beliefs (Tables 2 and 3). 
Survey statements assessed constructs found in behavioral models such as the Health Belief Model 
(HBM) [498]. Response options were strongly agree, agree, disagree, and strongly disagree; 
knowledge and trust statements also included a “don’t know” option; and trust statements 
regarding pediatricians and naturopathic/chiropractic doctors included options for “I don’t have a 
pediatrician yet” and “I don't see this type of doctor”, respectively. Specific vaccine safety concern 
statements were automatically administered only to participants who expressed a lack of 
confidence in the safety of a particular vaccine using survey skip logic. Twenty questions were 
randomly administered to about three quarters of the sample in order to keep surveys short to 
reduce respondent burden. Sociodemographic information such as state of residence, ethnicity and 




Responses to the survey questions were first explored through univariate analyses. Vaccine 
intention questions were dichotomized to represent those who intended to receive recommended 
maternal flu, Tdap, and all infant vaccines versus those who did not. Likert scale statements were 
dichotomized to represent those who agreed or strongly agreed versus those who did not. For 
statements that included an option for “don’t know”, dichotomous variables were also created 
representing those who disagreed or strongly disagreed with the survey statements versus those 
who did not, and those who chose “don’t know” versus those who did not. Dichotomous variables 
both including and not including responses to the options for “I don’t have a pediatrician yet” and 
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“I don't see this type of doctor” were created to represent trust statements regarding pediatricians 
and naturopathic/chiropractic doctors, respectively. Categorical variables representing the number 
of specific vaccine safety concern statements agreed or strongly agreed to were created. Ethnicity 
categories were collapsed to white, black, Hispanic, or other. Education categories were collapsed 
to having a graduate degree (Master’s, Doctoral, or Professional), having an undergraduate degree 
(Bachelor’s or Associate’s), having at least an undergraduate degree, and not having a degree. 
Number of prior children was collapsed to having children prior to this pregnancy versus not. 
Categorical and dichotomous variables for vaccine intentions and dichotomous variables for 
survey statements were stratified by sociodemographic characteristics. Pearson’s chi-squared test 
for independence was used to assess differences in vaccine intentions by sociodemographic 
characteristics. McNemar’s test was used to assess differences in frequency of agreement to survey 
statements. All P-values were two-sided and P<0.05 was considered statistically significant. 
Simple logistic regressions were performed separately with dichotomous indicators for maternal 
flu, maternal Tdap, and infant vaccine intentions as the dependent variables and the dichotomous 
indicators for other survey items as independent variables. Odds ratios (ORs) and 95% confidence 
intervals (95%CIs) were calculated for all logistic regressions. 95%CIs that did not overlap 1 were 
considered statistically significant. 
Three best-fit multiple logistic regression models (dependent variables: intention to receive 
maternal influenza vaccine, intention to receive maternal Tdap vaccine, intention to get baby all 
recommended vaccines on time) were created by backwards selection to include only those 
variables with statistical significance (P<0.05) in both the simple and multiple models. The 
categorical variable for number of vaccine safety concerns as well as individual vaccine safety 
concern variables were not included due to their collinearity with the confidence in vaccine safety 
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variables. Nested models were compared using the Bayesian information criterion and the 
likelihood ratio test. 
Latent class analysis was performed to identify homogeneous groups of women based on their 
responses to the aforementioned survey items. The number of clusters was sequentially increased 
from two and the Lo-Mendell-Rubin likelihood ratio test was performed at each iteration to 
determine the number of classes that best fit the model while remaining as parsimonious as 
possible.  
All analysis was performed using Stata/IC 12.1 (STATA Corp., College Station, TX, USA), except 
for the latent class analysis, which was performed using Mplus version 8 (Muthén & Muthén, Los 






The baseline survey was taken by 2210 pregnant women, about half from each state (Table 1 and 
Appendix 14). First-time pregnant women made up 46% of the sample. Of women who provided 
education information, 27% had an advanced degree and 45% had an associate’s or bachelor’s 





Confidence in Vaccine Safety 
 
Over three quarters of women were confident that getting influenza and Tdap vaccines during 
pregnancy was safe both for themselves (75% for flu, 80% for Tdap) and their unborn babies (77% 
for flu, 81% for Tdap) (Table 2). Eighty-six percent of women were confident that vaccines were 
safe for their babies after birth (Table 3). Confidence in vaccine safety was higher among white 
women, women with prior children, and women of higher education than non-white women, first-
time pregnant women, and women of lower education, respectively (Appendix 6).  
 
Specific Vaccine Safety Concerns 
Sixty-nine percent of women were confident in both maternal and infant vaccine safety and thus 
identified no specific safety concerns. Of those who were not confident in vaccine safety, 33% 
identified 1-4 concerns, 30% identified 5-8 concerns, 23% identified 9-12 concerns, and 14% 
identified 13-16 concerns (Appendix 9). The most common vaccine safety concerns identified 
from these women were that vaccine ingredients were unsafe and unnatural, and that babies were 
better off receiving fewer vaccines within a short time span (Appendix 3). Concerns were fewer 
among white women, women with prior children, and women of higher education than non-white 
women, first-time pregnant women, and women of lower education, respectively (Appendix 10).  
 




Most women perceived influenza (86%) and whooping cough (76%) as dangerous for pregnant 
women (Table 2 and Appendix 4). Participants worried more about getting influenza (61%) than 
whooping cough (39%) while pregnant (P<0.01) (Appendix 15). Almost all women perceived 
whooping cough as dangerous for babies (92%); fewer worried about their baby getting whooping 
cough (61%) (P<0.01) (Table 3 and Appendix 4). More women perceived a reduction in disease 
risk for themselves (69% for flu, 75% for Tdap) than for their unborn baby (47% for flu, 62% for 
Tdap) by vaccinating during pregnancy (P<0.01); although 73% of women perceived a reduction 
in their baby’s risk of whooping cough from the infant vaccine.  
Nearly every woman considered getting vaccines for themselves during pregnancy (98%) or for 
their baby after birth (96%) as in their control. Most women thought that the majority of their 
friends and family would encourage her to get the vaccines recommended during pregnancy (72%) 
and the vaccines recommended for babies (81%). Most women thought they already had most of 
the important information they needed to make a decision about vaccines during pregnancy (83%) 
and for their babies (84%).  
Vaccine knowledge, attitudes and beliefs varied by sociodemographic characteristics (Appendix 
7). Of particular interest, first-time pregnant women were less likely than women with prior 
children to perceive having enough information about maternal (74% versus 90%, P<0.01) and 
infant (74% versus 93%, P<0.01) vaccines or know enough about maternal influenza (74% versus 
89%, P<0.01), maternal Tdap (59% versus 81%, P<0.01) and infant DTaP (65% versus 87%, 
P<0.01) vaccine safety to make informed vaccine decisions. A substantial portion of this difference 
was due to less first-time pregnant women than women with prior children strongly agreeing to 
having enough information about maternal (21% versus 32%) and infant (22% versus 38%) 
vaccines and knowing enough about maternal influenza (24% versus 31%), maternal Tdap (18% 
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versus 26%) and infant DTaP (20% versus 33%) vaccine safety. First time pregnant women were 
also less likely to be confident in vaccine efficacy and perceive that the majority of their friends 
and family would get recommended vaccines than women with prior children.  
 
Trust in Vaccine Information Sources 
 
The vast majority of women trusted the information provided by their obstetrician or midwife 
about both maternal (92%) and infant (93%) vaccines (Table 2, Table 3 and Appendix 5). Among 
those who had already seen a pediatrician, the vast majority of women trusted the information they 
provided about maternal (92%) and infant (94%) vaccines. Over a third of women reported not 
seeing naturopathic and/or chiropractic doctors; 63-64% of the remaining women reported trusting 
vaccine information provided by naturopathic and/or chiropractic doctors. Most women trusted 
vaccine information provided by federal agencies such as the Centers for Disease Control and 
Prevention (CDC) (81%) and by scientists and doctors at universities and academic institutions 
(82%). Levels of trust in vaccine information sources varied by sociodemographic characteristics 
(Appendix 8).  
 
Intentions to Vaccinate 
 
Sixty-three percent of pregnant women intended to receive maternal influenza vaccine, and 65% 
intended to receive maternal Tdap vaccine (Table 1). Fifty-six percent of women intended to 
receive both maternal vaccines, 15% intended to receive neither vaccine, and 13% were unsure 
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(Appendix 1). Maternal vaccine intentions varied substantially by sociodemographic 
characteristics. Frequency of maternal vaccine intentions was higher among white women, women 
with prior children, women living in Colorado, and women of higher education, than non-white 
women, first-time pregnant women, women living in Georgia, and women of lower education, 
respectively. First-time pregnant women were more likely to be uncertain about maternal vaccines 
compared to women with prior children (8% vs. 19%, P<0.01).   
Sixty-eight percent of women intended their baby to receive all recommended vaccines on time 
(Table 1). Twelve percent of women intended their baby to receive all recommended vaccines but 
spread out past the recommended ages. Five percent of women intended their baby to receive only 
some vaccines but on time, and 3% intended their baby to receive only some vaccines spread out 
past the recommended ages. Two percent intended their baby to receive no vaccines, and 9% were 
still unsure (Appendix 1). Frequency of infant vaccine intentions was again higher among white 
women, women with prior children, and women of higher education than non-white women, first-
time pregnant women, and women of lower education, respectively. Fourteen percent of first-time 




Associations between Vaccine Intentions and Vaccine Knowledge, Attitudes, Beliefs and Trust  
 
Maternal Vaccines 
Confidence that maternal influenza vaccine is safe for the mother (OR: 37.11; 95%CI: 27.22-
50.59) and for the unborn baby (OR: 26.41; 95%CI: 19.84-35.17) was strongly associated with 
intention to receive maternal influenza vaccine (Table 2 and Appendix 11). Likewise, confidence 
that maternal Tdap vaccine is safe for the mother (OR: 29.17; 95%CI: 21.23-40.09) and for the 
unborn baby (OR: 18.27; 95%CI: 13.72-24.32) was strongly associated with intention to receive 
maternal Tdap vaccine. Identifying maternal vaccine safety concerns was strongly negatively 
associated with intention to receive maternal vaccines.  
Belief in maternal vaccine efficacy, high perceived susceptibility to and severity of maternal 
VPDs, perceived pro-maternal vaccine descriptive and injunctive norms, and high perception of 
maternal vaccine knowledge were all positively associated with intention to receive maternal 
vaccines. Of these, the largest effects were seen with belief in maternal vaccine efficacy: agreement 
with the statement “getting the flu vaccine will reduce my risk of getting the flu during my 
pregnancy” had 19.04 (95%CI: 14.63-24.80) times higher odds of intention to receive maternal 
influenza vaccine, and agreement with the statement “whooping cough vaccine will reduce my 
chances of getting whooping cough” had 11 (95%CI: 8.47-14.30) times higher odds of intention 
to receive maternal Tdap vaccine.  
Trust in maternal vaccine information from obstetricians and midwives, pediatricians, the CDC 
and universities were all positively associated with intention to receive maternal vaccines. In 
contrast, trust in maternal vaccine information from naturopathic and/or chiropractic doctors was 
negatively associated with intention to receive maternal influenza vaccines, and not seeing 
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naturopathic and/or chiropractic doctors was positively associated with intention to receive 
maternal vaccines. 
The best-fit model for intention to receive maternal influenza vaccine reduced to include the 
following as statistically significant predictors (Table 4): education, state (Colorado versus 
Georgia), number of maternal influenza vaccine safety concerns, perceived maternal susceptibility 
to flu, confidence in maternal influenza vaccine efficacy for both the mother and unborn baby, 
confidence in maternal influenza vaccine safety for the mother, pro-maternal vaccine descriptive 
and injunctive norms, and knowing enough about maternal influenza vaccine safety to make an 
informed decision. All predictors were positively associated with intention except for the number 
of concerns.  
The best-fit model for intention to receive maternal Tdap vaccine reduced to include the following 
as statistically significant predictors (Table 4): ethnicity, prior children, number of maternal Tdap 
vaccine safety concerns, perceived susceptibility of baby contracting pertussis from the mother, 
confidence in maternal Tdap vaccine efficacy for the unborn baby, confidence in maternal Tdap 
vaccine safety for the mother, pro-maternal vaccine injunctive norms, and knowing enough about 
maternal Tdap vaccine safety to make an informed decision. All predictors were positively 
associated with intention except for ethnicity (black and Hispanic women had lower odds of 
intention than white women) and number of concerns.  
 
Infant Vaccines 
Confidence that vaccines are safe for babies after birth was strongly associated (OR: 16.90; 
95%CI: 12.26-23.3) with intention to receive all recommended infant vaccines on time (Table 3 
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and Appendix 12). Identifying infant vaccine safety concerns was strongly negatively associated 
with intention to receive all infant vaccines on time. 
Belief in infant vaccine efficacy, high perceived susceptibility to and severity of infant VPDs, 
perceived pro-infant vaccine descriptive and injunctive norms, and high perception of infant 
vaccine knowledge were all positively associated with intention to receive all infant vaccines on 
time. Agreement with the statement: “I believe it is better for my baby to develop their own 
immunity by getting sick rather than by getting a vaccine” corresponded with 74% lower odds of 
intention to receive all infant vaccines on time. 
Trust in infant vaccine information from obstetricians and midwives, pediatricians, the CDC and 
universities were all positively associated with intention to receive infant vaccines. Not seeing 
naturopathic and/or chiropractic doctors was also positively associated with intention to receive 
infant vaccines. 
The best-fit model for intention to get all recommended infant vaccines on time reduced to include 
the following as statistically significant predictors of referring contacts (Table 4): prior children, 
number of infant vaccine safety concerns, pro-infant vaccine injunctive norms, having enough 
information about infant vaccines to make an informed decision, and trust in vaccine information 
from pediatricians, naturopathic and/or chiropractic doctors, and academic institutions. All 
predictors were positively associated with intention except for number of concerns and trust in 
vaccine information from naturopathic and/or chiropractic doctors. 
 




Three latent classes of pregnant women were found based on their vaccine intentions, knowledge, 
attitudes, beliefs, and trust (Appendix 13). The first class identified by this model, containing 36% 
of pregnant women, was characterized by “vaccine enthusiasts”, or women with strong positive 
attitudes towards vaccination. Eighty-one percent of women in this class intended to get both 
recommended maternal vaccines and 90% intended to get all recommended vaccines for their baby 
on time. The majority of vaccine enthusiasts chose “strongly agree” for statements assessing 
constructs such as confidence in vaccine safety, VPD severity, vaccine efficacy, self-efficacy, pro-
vaccine norms, and having enough vaccine information, and for statements assessing trust in 
vaccine information from obstetricians or midwives, pediatricians, the CDC and universities.  
The largest class (41%) was characterized by “vaccine acceptors”, or women with mostly positive 
attitudes towards vaccination but stated with less conviction and more variability. Sixty-two 
percent of women in this class intended to get both recommended maternal vaccines while 14% 
were not sure. Seventy-three percent intended to get all recommended vaccines for their baby on 
time, 16% intended to get their baby all recommended vaccines but some spread out past the 
recommended ages, and 4% were unsure. The majority of vaccine acceptors chose “agree” for 
statements assessing constructs such as confidence in vaccine safety, VPD severity, vaccine 
efficacy, self-efficacy, pro-vaccine descriptive and injunctive norms, and having enough vaccine 
information, and for statements assessing trust in vaccine information from obstetricians or 
midwives, pediatricians, the CDC and universities. 
The smallest class (23%) was characterized by “vaccine skeptics”, or women with more common 
negative attitudes towards vaccination. Only 8% percent of women in this class intended to get 
both recommended maternal vaccines whereas 49% intended to get no maternal vaccines and 26% 
were unsure. Likewise, only 25% intended to get all recommended vaccines for their baby on time, 
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whereas 9% intended to get no vaccines for their baby and 29% were unsure. Vaccine skeptics 
most frequently chose “disagree” or “don’t know” for statements assessing constructs such as 
confidence in vaccine safety, VPD susceptibility, and vaccine efficacy, although many also chose 
“agree” for statements assessing constructs such as VPD severity and self-efficacy. Vaccine 




Over half the pregnant women in our sample intended to receive all recommended maternal 
vaccines. This aligns with recent national data showing 49.1% coverage for maternal influenza 
and 54.4% for maternal Tdap vaccine [12]. Over two thirds intended for their baby to receive all 
recommended infant vaccines on time, which was also consistent with the most recent national 
data [2]. Although this shows vaccination is the norm, there were a substantial proportion of 
pregnant woman who did not intend to vaccinate themselves or their children according to the 
immunization schedule.   
Most attitudinal constructs assessed were associated with vaccine intention, although confidence 
in vaccine safety and efficacy showed the strongest associations. The most consistent predictors 
of intention to receive vaccines when adjusted for other variables were confidence in vaccine 
safety, pro-vaccine norms, and feeling informed. This aligns with the findings of previous 
prospective cohort studies [200, 203, 206]. Since maternal vaccine acceptance is known to be 
influenced by perceived susceptibility to and severity of maternal VPDs [559, 560], educational 
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interventions focusing on these constructs along with maternal vaccine safety and efficacy may be 
best suited to impact maternal vaccine intention and coverage.  
Considerable variation was apparent in maternal and infant vaccine intentions, knowledge, 
attitudes, beliefs, and trust when stratified by ethnicity, education, and having prior children. 
Women pregnant with their first child were less likely to intend to vaccinate themselves and their 
children and more likely to be unsure about both maternal and infant vaccines than women who 
had prior children. First-time pregnant women were also less likely to perceive having enough 
information to make informed maternal and infant vaccine decisions. This supports the idea that 
the first pregnancy is a “teachable moment” due to vaccine attitudes and beliefs not being as 
solidified at this point as they are after having a child [24]. However, among first-time pregnant 
women, only 19% reported being unsure about their decision to get maternal vaccines, only 14% 
reported being unsure about their decision to get infant vaccines, and only 26% reported not having 
enough information about maternal and infant vaccines. These data indicate the need for 
educational interventions before pregnancy as well, perhaps during adolescent vaccinations such 
as HPV. 
The vast majority of women trusted the vaccine information provided by their and their baby’s 
doctors, which is echoed throughout the literature [22, 195, 198, 200, 202, 204, 208]. The vast 
majority of women were also confident in the safety of both maternal and infant vaccines. 
However, about 20-25% were not confident in the safety of maternal vaccines, and about 14% 
were not confident in the safety of infant vaccines. Women recognized the severity of influenza 
and whooping cough much more frequently than they did their or their baby’s own susceptibility 
to the disease. Women were also more likely to perceive the efficacy of maternal vaccines in 
protecting themselves from the disease than protecting their unborn baby. For whooping cough in 
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particular (due to its severity in infancy and the crucial protection provided by maternal antibodies 
during an otherwise vulnerable time), this demonstrates a gap in common knowledge and an 
opportunity for obstetricians and midwifes to educate their patients on the true purpose and 
importance of Tdap vaccination in pregnancy.  
Our latent class analysis (LCA) produced three groups of pregnant women: those with strong 
positive vaccine attitudes (36% of women), those with moderately positive vaccine attitudes 
(41%), and those with negative vaccine attitudes (23%). This is a similar finding to the LCA 
performed by Weiss et al. among Swiss mothers which also identified three latent classes: positive 
attitudes (58%), fearful/uncertain attitudes (28%), and critical attitudes (14%) [218]. However, the 
description of the classes and the percentages in each do not align completely between the two 
analyses. This discrepancy could be due to many factors, including differences in nationality and 
culture, differences between current pregnant women and mothers of young children, and 
differences in the nature of the survey questions analyzed.  
There are several limitations of this paper. Firstly, these data are not nationally generalizable. 
Although the study sites were chosen to capture as wide a range of demographics and vaccine 
hesitancy as possible, the sample consists solely of pregnant women from two states who were 
willing to participate in a randomized controlled trial over several years; participating pregnant 
women may be different than those who chose not to participate and pregnant women in general. 
Reasons for eligible women declining study participation include being too busy to screen (18%), 
not being interested in the study (40%), being wary of the study (5%), and not being able to 
communicate or read in English (13%). Our study population contained a higher proportion of 
educated, white women than indicated by CDC data on the demographics of U.S. births in 2016 in 
Colorado and Georgia [561]. In addition, some women in the sample did not complete the survey 
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and thus questions near the end of the survey had slightly lower response rates than questions 
towards the beginning. These data represent a cross-sectional snapshot of a specific population 
and trends over time cannot be analyzed. More surveys of vaccine intentions, attitudes and beliefs 
among all age groups and demographics are needed, especially nationally representative, 
standardized surveys administered regularly over time. 
Despite these limitations, this paper provides useful insight into vaccine intentions, attitudes and 
beliefs of current U.S. pregnant women. Increasing perceived susceptibility to and severity of 
VPDs as well as confidence in vaccine safety and efficacy may also increase intention to receive 
maternal and infant vaccines. Tailored educational interventions targeting pregnant women, 




Pregnant women demonstrated suboptimal maternal vaccine knowledge and intentions. First-time 
pregnant women were substantially less certain in their vaccine knowledge and intentions than 
women with prior children, demonstrating the opportunity for vaccine education to increase 
vaccine confidence and informed decision making at this stage of life, especially coming from 
highly trusted sources of vaccine information for pregnant women such as obstetricians and 
gynecologists. Such educational interventions should be individually tailored and focus on 
improvements to constructs such as perceived susceptibility to and severity of VPDs as well as 
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Figures and Tables 
 
Table 1. Frequency of Pregnant Women Intending to Receive Maternal and Infant Vaccines, Stratified by 

















All 2210 1,388 (63)  1,434 (65)  1,502 (68)  
        
State        
Colorado 
1104 (50) 736 (67) 
<0.0
1 
738 (67) 0.05 749 (68) 0.74 
Georgia 1106 (50) 652 (59)  696 (63)  753 (69)  
total 2210 1,388 (63)  1,434 (65)  1,502 (68)  
        
Education**        
Graduate degree 









Undergraduate degree 817 (45) 521 (64)  552 (68)  569 (70)  
No college degree 520 (29) 261 (50)  297 (57)  311 (60)  
total 1,822 1,159 (64)  1,220 (67)  1,269 (70)  
        
Ethnicity        
Black/African 
American 









Hispanic/Latino 212 (11) 118 (56)  110 (52)  139 (66)  
White 1,181 (63) 821 (70)  882 (75)  867 (74)  
Other 166 (9) 99 (60)  97 (58)  111 (67)  
total 1,873 1,187 (63)  1,243 (66)  1,290 (69)  
        
Number of Prior Children        
0 









1 785 (36) 542 (69)  571 (73)  587 (75)  
2 267 (12) 169 (63)  182 (68)  194 (73)  
3 92 (4) 47 (51)  46 (50)  59 (64)  
4+ 45 (2) 25 (56)  28 (62)  28 (62)  
total 2206 1,387 (63)  1,433 (65)  1,502 (68)  
*P-value for the Pearson chi-squared proportion test at significance level of () 5%; bolded if significant 
**Graduate degree includes Master’s, Doctoral, and Professional degrees; Undergraduate degree includes 




Table 2. Frequency of Pregnant Women Agreeing with Maternal Vaccine Related Statements, and Odds Ratios for those Women Intending to 









Total (N=2210)    
    
Number of Vaccine Safety Concerns Identified**    
Maternal influenza vaccine concerns (0-6)    
0 (reference) 1,639 (74) 1  
1-2 135 (6) 0.08 (0.05-0.11)  
3-4 199 (9) 0.03 (0.02-0.04)  
5-6 237 (11) 0.01 (0.00-0.02)  
Maternal Tdap vaccine concerns (0-6)    
0 (reference) 1,750 (79)  1 
1-2 106 (5)  0.08 (0.05-0.13) 
3-4 207 (9)  0.04 (0.03-0.06) 
5-6 147 (7)  0.02 (0.01-0.04) 
    
Confidence in Vaccine Safety Statements    
I am confident that getting the flu vaccine during my pregnancy is safe for 
me. 
1670 (75) 37.11 (27.22-50.59)  
I am confident that getting the flu vaccine during my pregnancy is safe for 
my unborn baby. 
1683 (77) 26.41 (19.84-35.17)  
I am confident that getting the whooping cough vaccine during my 
pregnancy is safe for me. 
1762 (80)  29.17 (21.23-40.09) 
I am confident that getting the whooping cough vaccine during my 
pregnancy is safe for my unborn baby. 
1779 (81)  18.27 (13.72-24.32) 
    
Vaccine Knowledge, Attitude and Belief Statements    
I worry that I could get the flu while I am pregnant. 1002 (61) 4.74 (3.83-5.88)  
The flu is dangerous for pregnant women. 1410 (86) 2.54 (1.93-3.35)  
The flu is more dangerous for pregnant women than for women who are 
not pregnant. 
1304 (79) 2.19 (1.73-2.79)  
Getting the flu vaccine will reduce my risk of getting the flu during my 
pregnancy. 
1142 (69) 19.04 (14.63-24.80)  
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Getting the flu vaccine while I am pregnant will reduce my unborn baby's 
risk of getting the flu. 
779 (47) 6.20 (4.91-7.83)  
I worry that I could get whooping cough while I am pregnant. 650 (39)  3.60 (2.86-4.54) 
I worry that I could give whooping cough to my baby after birth. 937 (57)  6.20 (4.96-7.75) 
Whooping cough is dangerous for pregnant women. 1260 (76)  2.63 (2.09-3.31) 
Whooping cough vaccine will reduce my chances of getting whooping 
cough. 
1241 (75)  11.00 (8.47-14.30) 
Whooping cough vaccine will reduce the chance of me giving whooping 
cough to my unborn baby. 
1150 (69)  7.55 (5.98-9.53) 
Getting the whooping cough vaccine while I am pregnant will reduce my 
unborn baby's risk of getting whooping cough. 
1021 (62)  6.48 (5.19-8.10) 
It is in my control whether or not I get vaccines during my pregnancy. 1608 (98) 1.71 (0.93-3.13) 1.68 (0.92-3.09) 
The majority of my friends and family would get the vaccines that are 
recommended during pregnancy. 
1615 (74) 7.99 (6.46-9.89) 6.14 (5.00-7.53) 
The majority of my friends and family would encourage me to get the 
vaccines that are recommended during pregnancy. 
1584 (72) 9.89 (7.97-12.26) 7.21 (5.87-8.85) 
I have most of the important information I need to make a decision about 
vaccines given during pregnancy. 
1815 (83) 4.16 (3.30-5.25) 3.92 (3.12-4.93) 
I know enough about the safety of the flu vaccine to make a decision 
about getting the vaccine for myself while pregnant. 
1352 (81) 4.62 (3.54-6.03)  
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for myself while pregnant. 
1176 (71)  4.53 (3.61-5.68) 
    
Trust in Vaccine Information Source Statements    
I trust the information provided by my obstetrician or midwife about 
vaccines during pregnancy. 
2042 (92) 8.68 (5.78-13.04) 6.75 (4.66-9.80) 
I trust the information provided by my baby's doctor about vaccines 
during pregnancy.*** 
1880 (92) 8.42 (5.61-12.62) 6.95 (4.77-10.11) 
I trust the information provided by naturopathic and/or chiropractic 
doctors about vaccines during pregnancy.*** 
924 (64) 0.65 (0.52-0.81) 0.72 (0.57-0.90) 
I trust the information provided by federal agencies such as the Centers 
for Disease Control and Prevention (CDC) about vaccines during 
pregnancy. 
1776 (81) 6.35 (5.03-8.03) 5.55 (4.42-6.97) 
I trust the information provided by scientists and doctors at universities 
and academic institutions about vaccines during pregnancy. 
1808 (82) 3.86 (3.07-4.84) 3.56 (2.84-4.46) 
*Odds Ratio (95% Confidence Interval) for intention to receive maternal influenza or Tdap vaccine by agreement with survey statement; bolded if significant 
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**specific safety concerns were only obtained from those who did not agree that the vaccine in question was safe 
***removed those who stated they hadn’t yet seen this type of provider from this analysis 
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Table 3. Frequency of Pregnant Women Agreeing with Infant Vaccine Related Statements, and Odds Ratios for those Women Intending to Get 





All Infant Vaccines 
on Time, OR 
(95%CI)* 
Total (N=2203)   
   
Number of Infant Vaccine Safety Concerns Identified (0-4)**   
0 (reference) 1,916 (87) 1 
1-2 94 (4) 0.11 (0.07-0.18) 
3-4 200 (9) 0.02 (0.01-0.04) 
   
Confidence in Vaccine Safety Statements   
I am confident that vaccines are safe for my baby after birth. 1894 (86) 16.90 (12.26-23.30) 
   
Vaccine Knowledge, Attitude and Belief Statements   
I worry that my baby could get whooping cough after birth. 1012 (61) 2.52 (2.04-3.11) 
Whooping cough is dangerous for babies. 1523 (92) 2.43 (1.69-3.49) 
Whooping cough is more dangerous for babies than older children or adults. 1420 (86) 2.46 (1.86-3.26) 
Getting the whooping cough vaccine for my baby after birth will reduce my baby's chances of 
getting whooping cough. 
1201 (73) 4.46 (3.54-5.61) 
It is in my control whether or not my baby gets his/her vaccines. 1590 (96) 1.58 (0.94-2.63) 
I believe it is better for my baby to develop their own immunity by getting sick rather than by 
getting a vaccine. 
475 (29) 0.26 (0.20-0.32) 
The majority of my friends and family would get all of the vaccines recommended for their 
babies after birth. 
1796 (82) 4.73 (3.77-5.93) 
The majority of my friends and family would encourage me to get all of the vaccines 
recommended for my baby after birth. 
1776 (81) 5.85 (4.66-7.34) 
I have most of the important information I need to make a decision about vaccines for my baby 
after birth. 
1852 (84) 4.38 (3.45-5.56) 
I know enough about the safety of the whooping cough vaccine to make a decision about getting 
the vaccine for my baby after birth. 
1691 (77) 3.12 (2.54-3.83) 
   
Trust in Vaccine Information Source Statements   
I trust the information provided by my obstetrician or midwife about vaccines for babies after 
birth. 
2044 (93) 15.33 (9.75-24.10) 
 
192 
I trust the information provided by my baby's doctor about vaccines for babies after birth.*** 1879 (94) 26.75 (14.62-48.95) 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines for 
babies after birth.*** 
869 (63) 0.87 (0.70-1.10) 
I trust the information provided by federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines for babies after birth. 
1783 (81) 7.29 (5.77-9.22) 
I trust the information provided by scientists and doctors at universities and academic 
institutions about vaccines for babies after birth. 
1816 (82) 4.70 (3.73-5.91) 
*Odds Ratio (95% Confidence Interval) for intention to get infant all vaccines on time by agreement with survey statement; bolded if significant 
**specific safety concerns were only obtained from those who did not agree that the vaccine in question was safe 





Table 4. Frequency and Adjusted Odds Ratios of Pregnant Women Intending to Receive Maternal and Infant Vaccines by Associated 
Demographics and Vaccine Beliefs 






   
Intention to Receive Maternal Influenza Vaccine 1,388 (63)  
Having at least a college degree 898 (69) 2.05 (1.42-2.96) 
State  1.51 (1.07-2.13) 
Colorado 736 (67)  
Georgia 652 (59)  
Statements Agreed or Strongly Agreed to****   
I worry that I could get the flu while I am pregnant.  778 (78) 2.54 (1.80-3.59) 
Getting the flu vaccine will reduce my risk of getting the flu during my pregnancy. 950 (83) 5.50 (3.66-8.27) 
Getting the flu vaccine while I am pregnant will reduce my unborn baby's risk of getting the flu. 654 (84) 1.46 (1.01-2.11) 
I am confident that getting the flu vaccine during my pregnancy is safe for me. 1,334 (80) 6.01 (3.35-10.76) 
I am confident that getting the flu vaccine during my pregnancy is safe for my unborn baby. 1,323 (79) 2.59 (1.48-4.55) 
The majority of my friends and family would get the vaccines that are recommended during 
pregnancy. 
1,221 (76) 1.79 (1.12-2.86) 
The majority of my friends and family would encourage me to get the vaccines that are recommended 
during pregnancy. 
1,226 (77) 1.97 (1.23-3.13) 
I have most of the important information I need to make a decision about vaccines given during 
pregnancy. 
1,250 (69) 1.94 (1.22-3.08) 
   
Intention to Receive Maternal Tdap Vaccine 1,434 (65)  
Ethnicity   
     White (reference) 882 (75) 1 
     Black 154 (49) 0.49 (0.33-0.72) 
     Hispanic 110 (52) 0.51 (0.32-0.82) 
Prior Children 827 (70) 1.39 (1.02-1.89) 
Statements Agreed or Strongly Agreed to****   
I worry that I could give whooping cough to my baby after birth. 767 (82) 3.47 (2.57-4.67) 
Whooping cough vaccine will reduce my chances of getting whooping cough. 969 (78) 2.68 (1.84-3.89) 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for me. 1,382 (78) 6.82 (4.44-10.48) 
The majority of my friends and family would encourage me to get the vaccines that are recommended 
during pregnancy. 
1,230 (78) 2.64 (1.89-3.68) 
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I know enough about the safety of the whooping cough vaccine to make a decision about getting the 
vaccine for myself while pregnant. 
880 (75) 2.02 (1.46-2.80) 
   
Intention to Get All Infant Vaccines on Time 1,502 (68)  
Prior Children 868 (73) 1.73 (1.27-2.36) 
Statements Agreed or Strongly Agreed to****   
I am confident that vaccines are safe for my baby after birth. 1,451 (77) 5.19 (3.1-8.69) 
I believe it is better for my baby to develop their own immunity by getting sick rather than by getting a 
vaccine. 
223 (47) 0.59 (0.42-0.81) 
The majority of my friends and family would encourage me to get all of the vaccines recommended for 
my baby after birth. 
1,351 (76) 2.47 (1.67-3.66) 
I trust the information provided by my baby's doctor about vaccines for babies after birth.***** 1,393 (74) 8.11 (3.39-19.4) 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines for babies 
after birth.***** 
527 (61) 0.53 (0.37-0.75) 
I trust the information provided by scientists and doctors at universities and academic institutions 
about vaccines for babies after birth. 
1,353 (75) 2.05 (1.29-3.28) 
*number and percentage of those agreeing with survey statement who intend to vaccinate 
**adjusted Odds Ratio (95% Confidence Interval) for intention to vaccinate by agreement with survey statement 
***variables chosen for best-fit multiple logistic regression (MLR) model using backwards stepwise selection at significance level of P<0.05 
****20 questions deemed non-essential were included in surveys for only ~75% of the sample (based on randomly assigned groups) in order to keep surveys 
short enough to obtain high completion rates 












Total N (%) 
First Child, N (%) Education*, N (%) Ethnicity, N (%) 
Yes No High Low Black White Hispanic Other 
Maternal 2210 (100)         
Flu and Tdap 1234 (56) 529 (52) 704 (59) 813 (62) 229 (44) 118 (38) 764 (65) 96 (45) 83 (50) 
Flu not Tdap 154 (7) 75 (7) 79 (7) 85 (7) 32 (6) 31 (10) 57 (5) 22 (10) 16 (10) 
Tdap not Flu 200 (9) 77 (8) 123 (10) 110 (8) 68 (13) 36 (11) 118 (10) 14 (7) 14 (8) 
neither 328 (15) 139 (14) 187 (16) 148 (11) 100 (19) 67 (21) 122 (10) 43 (20) 27 (16) 
unsure 294 (13) 197 (19) 96 (8) 146 (11) 91 (18) 62 (20) 120 (10) 37 (17) 26 (16) 
P-value**  <0.01 <0.01 <0.01 
          
Infant  2203 (100)         
all on time 1502 (68) 634 (62) 868 (73) 958 (74) 311 (60) 173 (55) 867 (74) 139 (66) 111 (67) 
all delayed 272 (12) 118 (12) 154 (13) 152 (12) 67 (13) 34 (11) 158 (13) 21 (10) 16 (10) 
some on time 121 (5) 70 (7) 51 (4) 51 (4) 42 (8) 32 (10) 42 (4) 15 (7) 12 (7) 
some delayed 68 (3) 36 (4) 32 (3) 36 (3) 17 (3) 10 (3) 31 (3) 6 (3) 4 (2) 
none 48 (2) 14 (1) 34 (3) 19 (1) 18 (3) 9 (3) 21 (2) 9 (4) 3 (2) 
unsure 192 (9) 144 (14) 48 (4) 82 (6) 65 (13) 56 (18) 60 (5) 21 (10) 20 (12) 
P-value**  <0.01 <0.01 <0.01 
*Education=High for Doctoral or Professional degree, Master’s degree, Bachelor’s degree, Associate’s degree; Education=Low for Postsecondary nondegree 
award, Some college no degree, High school diploma or equivalent, No formal educational credential  

















, N (%) Total 
I am confident that getting the flu vaccine during my pregnancy is safe for me. 622 (28) 1048 (47) 414 (19) 124 (6) 2,208 
I am confident that getting the flu vaccine during my pregnancy is safe for my unborn 
baby. 
524 (24) 1159 (53) 432 (20) 92 (4) 2,207 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for 
me. 
534 (24) 1228 (56) 372 (17) 70 (3) 2,204 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for 
my unborn baby. 
498 (23) 1281 (58) 355 (16) 69 (3) 2,203 



















N (%) Total* 
The flu vaccine is more likely to make me sick than protect me from 
getting the flu. 
94 (17) 234 (43) 88 (16) 16 (3) 112 (21) 544 
I worry that the ingredients in the flu vaccine are not safe for me to have 
while I am pregnant. 
130 (24) 322 (60) 78 (15) 6 (1)  536 
The flu vaccine is more likely to make me sick than protect my unborn 
baby from getting the flu. 
54 (10) 216 (41) 88 (17) 11 (2) 155 (30) 524 
I do not want to put the flu vaccine into my body when I am pregnant 
because I think it is unnatural. 
116 (19) 347 (56) 139 (23) 15 (2)  617 
I worry that the flu vaccine will cause birth defects. 53 (10) 193 (37) 262 (50) 16 (3)  524 
I worry that the ingredients in the flu vaccine given to me during pregnancy 
are not safe for my unborn baby. 
89 (17) 354 (68) 79 (15) 1 (0)  523 
The whooping cough vaccine is more likely to cause me to get sick than 
protect me from getting whooping cough. 
34 (8) 130 (29) 69 (16) 6 (1) 204 (46) 443 
I worry that the ingredients in the whooping cough vaccine are not safe for 
me to have while I am pregnant. 
81 (18) 303 (68) 55 (12) 4 (1)  443 
The whooping cough vaccine is more likely to cause me to get sick than 
protect my unborn baby from getting whooping cough. 
34 (8) 141 (33) 59 (14) 6 (1) 184 (43) 424 
I do not want to put the whooping cough vaccine into my body when I am 
pregnant because I think it is unnatural. 
92 (18) 295 (58) 108 (21) 10 (2)  505 
I worry that the whooping cough vaccine will cause birth defects. 56 (13) 199 (47) 162 (38) 7 (2)  424 
I worry that the ingredients in the whooping cough vaccine given to me 
during pregnancy are not safe for my unborn baby. 
66 (16) 288 (68) 64 (15) 6 (1)  424 
It is better for babies to get fewer vaccines at the same time. 76 (25) 162 (52) 65 (21) 6 (2)  309 
Babies get more vaccines in their first two years of life than are good for 
them. 
70 (23) 148 (48) 71 (23) 20 (6)  309 
Vaccines often cause serious side effects in babies. 56 (18) 140 (45) 109 (35) 4 (1)  309 
The ingredients in vaccines are not safe for my baby. 67 (22) 149 (48) 90 (29) 3 (1)  309 
*specific safety concerns were only obtained from those who did not agree that the vaccine in question was safe 










Agree,   
N (%) 
Disagree
, N (%) 
Strongly 
Disagree






I worry that I could get the flu while I am pregnant. 259 (16) 743 (45) 520 (31) 133 (8)  1,655 
The flu is dangerous for pregnant women. 555 (34) 855 (52) 84 (5) 27 (2) 134 (8) 1,655 
The flu is more dangerous for pregnant women than for women who are 
not pregnant. 
512 (31) 792 (48) 139 (8) 27 (2) 186 (11) 1,656 
Getting the flu vaccine will reduce my risk of getting the flu during my 
pregnancy.  
385 (23) 757 (46) 247 (15) 79 (5) 188 (11) 1,656 
Getting the flu vaccine while I am pregnant will reduce my unborn baby’s 
risk of getting the flu.  
235 (14) 544 (33) 298 (18) 73 (4) 503 (30) 1,653 
I worry that I could get whooping cough while I am pregnant.  121 (7) 529 (32) 853 (52) 151 (9)  1,654 
I worry that I could give whooping cough to my baby after birth.  263 (16) 674 (41) 605 (37) 112 (7)  1,654 
Whooping cough is dangerous for pregnant women.  395 (24) 865 (52) 73 (4) 7 (0) 314 (19) 1,654 
Whooping cough vaccine will reduce my chances of getting whooping 
cough.  
423 (26) 818 (49) 110 (7) 30 (2) 273 (17) 1,654 
Whooping cough vaccine will reduce the chance of me giving whooping 
cough to my unborn baby.  
421 (25) 729 (44) 139 (8) 32 (2) 333 (20) 1,654 
Getting the whooping cough vaccine while I am pregnant will reduce my 
unborn baby’s risk of getting whooping cough. 
347 (21) 674 (41) 166 (10) 40 (2) 426 (26) 1,653 
It is in my control whether or not I get vaccines during my pregnancy. 884 (54) 724 (44) 28 (2) 15 (1)   1,651 
The majority of my friends and family would get the vaccines that are 
recommended during pregnancy. 
591 (27) 1024 (47) 190 (9) 47 (2) 350 (16) 2,202 
The majority of my friends and family would encourage me to get the 
vaccines that are recommended during pregnancy. 
572 (26) 1012 (46) 278 (13) 57 (3) 283 (13) 2,202 
I have most of the important information I need to make a decision about 
vaccines given during pregnancy. 
592 (27) 1223 (56) 334 (15) 52 (2) 
 
2,201 
I know enough about the safety of the flu vaccine to make a decision about 
getting the vaccine for myself while pregnant. 
454 (27) 898 (54) 271 (16) 29 (2) 
 
1,652 
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for myself while pregnant. 
369 (22) 807 (49) 417 (25) 60 (4) 
 
1,653 
I worry that my baby could get whooping cough after birth.  266 (16) 746 (45) 544 (33) 96 (6)  1,652 
Whooping cough is dangerous for babies. 808 (49) 715 (43) 16 (1) 8 (0) 105 (6) 1,652 
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Whooping cough is more dangerous for babies than older children or 
adults.  
770 (47) 650 (39) 31 (2) 7 (0) 195 (12) 1,653 
Getting the whooping cough vaccine for my baby after birth will reduce 
my baby’s chances of getting whooping cough. 
465 (28) 736 (45) 99 (6) 23 (1) 329 (20) 1,652 
It is in my control whether or not my baby gets his/her vaccines. 909 (55) 681 (41) 50 (3) 13 (1)   1,653 
I believe it is better for my baby to develop their own immunity by getting 
sick rather than by getting a vaccine. 
152 (9) 323 (20) 731 (44) 446 (27)   1,652 
The majority of my friends and family would get all of the vaccines 
recommended for their babies after birth. 
663 (30) 1133 (52) 131 (6) 30 (1) 243 (11) 2,200 
The majority of my friends and family would encourage me to get all of 
the vaccines recommended for my baby after birth. 
682 (31) 1094 (50) 155 (7) 35 (2) 236 (11) 2,202 
I have most of the important information I need to make a decision about 
vaccines for my baby after birth. 
676 (31) 1176 (53) 298 (14) 53 (2) 
 
2,203 
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for my baby after birth.  
592 (27) 1099 (50) 456 (21) 56 (3) 
 
2,203 
*20 questions deemed non-essential were included in surveys for only ~75% of the sample (based on randomly assigned groups) in order to keep surveys short 
enough to obtain high completion rates 











Agree,   
N (%) 
Disagree
, N (%) 
Strongly 
Disagree








I trust the information provided by…        
…my obstetrician or midwife about vaccines during pregnancy. 976 (44) 1066 (48) 54 (2) 13 (1) 95 (4)  2,204 
…my obstetrician or midwife about vaccines for babies after 
birth. 
949 (43) 1095 (50) 51 (2) 18 (1) 90 (4) 
 
2,203 
…my baby's doctor about vaccines during pregnancy. 906 (41) 974 (44) 64 (3) 18 (1) 74 (3) 168 (8) 2,204 
…my baby's doctor about vaccines for babies after birth. 897 (41) 982 (45) 43 (2) 17 (1) 64 (3) 201 (9) 2,204 
…naturopathic and/or chiropractic doctors about vaccines during 
pregnancy. 
282 (13) 642 (29) 219 (10) 75 (3) 222 (10) 762 (35) 2,203 
…naturopathic and/or chiropractic doctors about vaccines for 
babies after birth. 
257 (12) 612 (28) 218 (10) 78 (4) 211 (10) 827 (38) 2,203 
…federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines during pregnancy. 
745 (34) 1031 (47) 132 (6) 69 (3) 227 (10) 
 
2,204 
…federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines for babies after birth. 
748 (34) 1035 (47) 126 (6) 68 (3) 226 (10) 
 
2,203 
…scientists and doctors at universities and academic institutions 
about vaccines during pregnancy. 
682 (31) 1126 (51) 102 (5) 22 (1) 271 (12) 
 
2,203 
…scientists and doctors at universities and academic institutions 
about vaccines for babies after birth. 
670 (30) 1146 (52) 91 (4) 23 (1) 274 (12) 
 
2,204 
*Not Seen: for baby’s doctor statements, answer option for “I don’t have a pediatrician yet” included; for naturopathic and/or chiropractic doctor statements, 





Appendix 6. Frequency of Pregnant Women Agreeing or Strongly Agreeing with Statements Assessing Confidence in Vaccine Safety, Stratified by 
First Child, State, Degree and Ethnicity 
Total % 
Agreed 
First Child, % State*, % Education*, % Ethnicity*, % 
Yes No P** CO GA P** High Low P** Black White Hispanic Other P** 
I am confident that getting the flu vaccine during my pregnancy is safe for me. 
76 74 78 0.03 78 73 0.01 78 70 <0.01 60 82 75 73 <0.01 
I am confident that getting the flu vaccine during my pregnancy is safe for my unborn baby.  
76 73 79 <0.01 78 75 0.13 80 69 <0.01 61 82 73 75 <0.01 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for me.  
80 78 82 0.04 81 79 0.19 83 75 <0.01 66 86 75 79 <0.01 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for my unborn baby.  
81 78 83 <0.01 81 80 0.71 84 76 <0.01 70 86 73 78 <0.01 
I am confident that vaccines are safe for my baby after birth. 
86 84 88 0.01 86 86 0.67 88 83 <0.01 78 90 84 83 <0.01 
*State: CO=Colorado, GA=Georgia; Education=High for Doctoral or Professional degree, Master’s degree, Bachelor’s degree, Associate’s degree; 
Education=Low for Postsecondary nondegree award, Some college no degree, High school diploma or equivalent, No formal educational credential 





Appendix 7. Frequency of Pregnant Women Agreeing or Strongly Agreeing with Statements Assessing Vaccine Knowledge, Attitudes, and Beliefs, 
Stratified by First Child, State, Degree and Ethnicity 
Total % 
Agreed 
First Child, % State*, % Education*, % Ethnicity*, % 
Yes No P** CO GA P** High Low P** Black White Hispanic Other P** 
I worry that I could get the flu while I am pregnant. 
61 58 62 0.10 62 59 0.11 64 54 <0.01 43 66 59 59 <0.01 
The flu is dangerous for pregnant women. 
85 85 85 0.75 83 87 0.05 88 81 <0.01 88 87 80 82 0.08 
The flu is more dangerous for pregnant women than for women who are not pregnant. 
79 80 77 0.15 80 77 0.18 82 71 <0.01 76 82 71 74 <0.01 
Getting the flu vaccine will reduce MY risk of getting the flu during my pregnancy. 
69 67 71 0.11 72 66 0.01 74 61 <0.01 54 77 61 61 <0.01 
Getting the flu vaccine while I am pregnant will reduce my unborn baby's risk of getting the flu. 
47 44 50 0.01 50 44 0.03 50 41 0.01 40 52 39 44 <0.01 
I worry that I could get whooping cough while I am pregnant. 
39 37 41 0.08 43 36 <0.01 42 37 0.10 25 43 44 40 <0.01 
I worry that I could give whooping cough to my baby after birth. 
57 54 59 0.05 58 55 0.34 61 53 <0.01 43 64 56 51 <0.01 
Whooping cough is dangerous for pregnant women. 
76 75 77 0.21 77 75 0.38 80 73 0.01 79 79 68 79 0.04 
Whooping cough vaccine will reduce MY chances of getting whooping cough. 
75 72 77 0.01 77 73 0.07 80 68 <0.01 61 83 66 73 <0.01 
Whooping cough vaccine will reduce the chance of me giving whooping cough to my unborn baby. 
70 67 72 0.05 72 67 0.03 74 62 <0.01 56 77 61 62 <0.01 
Getting the whooping cough vaccine while I am pregnant will reduce my unborn baby's risk of getting whooping cough. 
62 57 66 <0.01 64 59 0.06 65 58 0.02 48 69 54 63 <0.01 
It is in my control whether or not I get vaccines during my pregnancy. 
97 97 98 0.52 97 98 0.46 98 97 0.38 98 98 97 95 0.32 
The majority of my friends and family would get the vaccines that are recommended during pregnancy. 
73 70 76 <0.01 76 71 0.01 79 64 <0.01 61 80 67 68 <0.01 
The majority of my friends and family would encourage me to get the vaccines that are recommended during pregnancy. 
72 70 74 0.07 74 70 0.07 77 64 <0.01 61 79 64 67 <0.01 
I have most of the important information I need to make a decision about vaccines given during pregnancy. 
82 74 90 <0.01 82 83 0.29 84 82 0.35 77 86 80 82 <0.01 
I know enough about the safety of the flu vaccine to make a decision about getting the vaccine for myself while pregnant. 
82 74 89 <0.01 82 82 0.85 83 80 0.30 77 85 79 80 0.01 
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I know enough about the safety of the whooping cough vaccine to make a decision about getting the vaccine for myself while pregnant. 
71 59 81 <0.01 73 70 0.17 73 69 0.08 65 75 69 64 <0.01 
I worry that my baby could get whooping cough after birth. 
61 62 61 0.77 66 56 <0.01 67 52 <0.01 36 70 60 58 <0.01 
Whooping cough is dangerous for babies. 
92 91 93 0.14 93 91 0.14 94 90 0.01 88 95 88 91 <0.01 
Whooping cough is more dangerous for babies than older children or adults. 
86 83 88 0.01 87 85 0.14 89 84 0.01 81 90 81 86 <0.01 
Getting the whooping cough vaccine for my baby after birth will reduce my baby's chances of getting whooping cough. 
73 68 76 <0.01 76 69 <0.01 77 68 <0.01 63 79 66 73 <0.01 
It is in my control whether or not my baby gets his/her vaccines. 
96 96 97 0.32 97 95 0.01 96 95 0.41 94 97 97 95 0.24 
I believe it is better for my baby to develop their own immunity by getting sick rather than by getting a vaccine. 
29 30 27 0.19 29 29 0.88 24 38 <0.01 39 21 33 46 <0.01 
The majority of my friends and family would get all of the vaccines recommended for their babies after birth. 
82 79 84 <0.01 82 81 0.53 86 74 <0.01 75 86 76 76 <0.01 
The majority of my friends and family would encourage me to get all of the vaccines recommended for my baby after birth. 
81 79 82 0.10 81 81 0.95 84 74 <0.01 74 85 74 74 <0.01 
I have most of the important information I need to make a decision about vaccines for my baby after birth. 
84 74 93 <0.01 84 84 0.63 85 82 0.10 80 87 82 85 0.02 
I know enough about the safety of the whooping cough vaccine to make a decision about getting the vaccine for my baby after birth. 
77 65 87 <0.01 77 77 0.80 78 75 0.27 71 80 74 73 <0.01 
*State: CO=Colorado, GA=Georgia; Education=High for Doctoral or Professional degree, Master’s degree, Bachelor’s degree, Associate’s degree; 
Education=Low for Postsecondary nondegree award, Some college no degree, High school diploma or equivalent, No formal educational credential 





Appendix 8. Frequency of Pregnant Women Agreeing or Strongly Agreeing with Statements Assessing Trust in Vaccine Information Sources, 
Stratified by First Child, State, Degree and Ethnicity 
Total % 
Agreed 
First Child, % State*, % Education*, % Ethnicity*, % 
Yes No P** CO GA P** High Low P** Black White Hispanic Other P** 
I trust the information provided by my obstetrician or midwife about vaccines during pregnancy. 
93 92 93 0.13 92 93 0.76 95 89 <0.01 90 95 91 90 0.01 
I trust the information provided by my obstetrician or midwife about vaccines for babies after birth. 
93 92 93 0.21 93 92 0.35 94 90 <0.01 90 94 94 90 0.02 
I trust the information provided by my baby's doctor about vaccines during pregnancy.*** 
92 93 92 0.26 93 91 0.07 94 89 <0.01 89 94 91 88 <0.01 
I trust the information provided by my baby's doctor about vaccines for babies after birth.*** 
94 94 93 0.34 94 93 0.28 95 91 <0.01 91 95 95 92 0.06 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines during pregnancy.*** 
64 61 67 0.04 63 65 0.58 56 80 <0.01 73 60 78 57 <0.01 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines for babies after birth.*** 
63 60 66 0.05 64 63 0.67 55 79 <0.01 74 59 76 57 <0.01 
I trust the information provided by federal agencies such as the Centers for Disease Control and Prevention (CDC) about vaccines during 
pregnancy. 
81 80 81 0.36 81 80 0.37 85 73 <0.01 74 85 77 74 <0.01 
I trust the information provided by federal agencies such as the Centers for Disease Control and Prevention (CDC) about vaccines for babies 
after birth. 
81 80 82 0.32 81 81 0.71 85 74 <0.01 75 85 76 78 <0.01 
I trust the information provided by scientists and doctors at universities and academic institutions about vaccines during pregnancy. 
82 82 82 0.68 86 78 <0.01 87 76 <0.01 75 87 80 79 <0.01 
I trust the information provided by scientists and doctors at universities and academic institutions about vaccines for babies after birth. 
82 82 83 0.37 86 79 <0.01 87 77 <0.01 75 87 82 80 <0.01 
*State: CO=Colorado, GA=Georgia; Education=High for Doctoral or Professional degree, Master’s degree, Bachelor’s degree, Associate’s degree; 
Education=Low for Postsecondary nondegree award, Some college no degree, High school diploma or equivalent, No formal educational credential 
**P-value for the Pearson chi-squared proportion test at significance level of () 5%; bolded if significant 





Appendix 9. Number of Specific Vaccine Safety Concerns Identified Per Pregnant Woman* 
Number of concerns N % of total % of those with at least one concern 
0 1,532 69 0 
1 39 2 6 
2 71 3 10 
3 64 3 9 
4 57 3 8 
5 67 3 10 
6 62 3 9 
7 35 2 5 
8 39 2 6 
9 38 2 6 
10 33 1 5 
11 37 2 5 
12 45 2 7 
13 18 1 3 
14 26 1 4 
15 24 1 4 
16 23 1 3 
total 2,210 100 100 





Appendix 10. Number of Specific Vaccine Safety Concerns Identified, Stratified by First Child, State, Degree and Ethnicity  
Number of 
Concerns 
Total N (%) 
First Child, N (%) Education*, N (%) Ethnicity, N (%) 
Yes No High Low Black White Hispanic Other 
0 1,532 (69) 666 (65) 865 (73) 953 (73) 325 (63) 160 (51) 905 (77) 138 (65) 108 (65) 
1-4 231 (10) 116 (11) 113 (10) 122 (9) 65 (13) 43 (14) 105 (9) 25 (12) 19 (11) 
5-8 203 (9) 113 (11) 89 (7) 110 (8) 53 (10) 53 (17) 84 (7) 17 (8) 18 (11) 
9-12 153 (7) 80 (8) 73 (6) 72 (6) 48 (9) 37 (12) 52 (4) 20 (9) 16 (10) 
13-16 91 (4) 42 (4) 49 (4) 45 (3) 29 (6) 21 (7) 35 (3) 12 (6) 5 (3) 
P-value**  <0.01 <0.01 <0.01 
*Education=High for Doctoral or Professional degree, Master’s degree, Bachelor’s degree, Associate’s degree; Education=Low for Postsecondary nondegree 
award, Some college no degree, High school diploma or equivalent, No formal educational credential  





Appendix 11. Odds Ratios Assessing Associations between Pregnant Women’s Maternal Vaccine Intentions and their Maternal Vaccine 
Knowledge, Attitudes, Beliefs and Trust 
Survey 
Statement 
OR (95%CI) with Maternal Vaccine Intentions** 
Influenza Vaccine NO Influenza Vaccine Tdap Vaccine NO Tdap Vaccine Unsure 
      
Confidence in Vaccine Safety 
I am confident that getting the flu vaccine during my pregnancy is safe for me. 
Agree* 37.11 (27.22-50.59) 0.06 (0.04-0.07)   0.37 (0.28-0.47) 
I am confident that getting the flu vaccine during my pregnancy is safe for my unborn baby. 
Agree* 26.41 (19.84-35.17) 0.07 (0.06-0.09)   0.34 (0.26-0.44) 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for me. 
Agree*   29.17 (21.23-40.09) 0.08 (0.06-0.10) 0.30 (0.23-0.39) 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for my unborn baby. 
Agree*   18.27 (13.72-24.32) 0.10 (0.08-0.13) 0.34 (0.26-0.44) 
      
Specific Vaccine Safety Concerns*** 
The flu vaccine is more likely to make me sick than protect me from getting the flu. 
Agree* 0.14 (0.07-0.26) 2.22 (1.54-3.19)   1.01 (0.67-1.52) 
Disagree* 8.79 (4.93-15.68) 0.52 (0.33-0.80)   0.42 (0.23-0.79) 
Unsure* 0.98 (0.50-1.92) 0.61 (0.40-0.93)   1.85 (1.17-2.93) 
I do not want to put the flu vaccine into my body when I am pregnant because I think it is unnatural. 
Agree* 0.17 (0.10-0.28) 3.14 (2.13-4.61)   0.88 (0.57-1.35) 
I worry that the ingredients in the flu vaccine are not safe for me to have while I am pregnant. 
Agree* 0.30 (0.16-0.56) 2.37 (1.48-3.81)   0.71 (0.42-1.20) 
The flu vaccine is more likely to make me sick than protect my unborn baby from getting the flu. 
Agree* 0.22 (0.12-0.41) 2.51 (1.74-3.62)   0.70 (0.47-1.05) 
Disagree* 3.93 (2.25-6.86) 0.54 (0.35-0.84)   0.81 (0.48-1.38) 
Unsure* 1.39 (0.80-2.41) 0.55 (0.37-0.81)   1.72 (1.13-2.63) 
I worry that the flu vaccine will cause birth defects. 
Agree* 0.28 (0.15-0.51) 1.69 (1.18-2.43)   1.02 (0.68-1.52) 
I worry that the ingredients in the flu vaccine given to me during pregnancy are not safe for my unborn baby. 
Agree* 0.44 (0.24-0.81) 1.52 (0.94-2.46)   1.04 (0.59-1.81) 
The whooping cough vaccine is more likely to cause me to get sick than protect me from getting whooping cough. 
Agree*   0.52 (0.26-1.02) 2.63 (1.71-4.03) 0.43 (0.26-0.69) 
Disagree*   2.18 (1.11-4.30) 0.69 (0.42-1.14) 0.99 (0.56-1.73) 
Unsure*   1.04 (0.57-1.89) 0.52 (0.36-0.77) 2.12 (1.38-3.26) 
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I do not want to put the whooping cough vaccine into my body when I am pregnant because I think it is unnatural. 
Agree*   0.16 (0.09-0.27) 5.30 (3.30-8.51) 0.64 (0.40-1.01) 
I worry that the ingredients in the whooping cough vaccine are not safe for me to have while I am pregnant. 
Agree*   0.42 (0.20-0.86) 2.54 (1.45-4.43) 0.57 (0.32-1.01) 
The whooping cough vaccine is more likely to cause me to get sick than protect my unborn baby from getting whooping cough. 
Agree*   0.34 (0.18-0.63) 3.69 (2.40-5.66) 0.38 (0.23-0.62) 
Disagree*   4.13 (2.26-7.54) 0.50 (0.29-0.85) 0.69 (0.36-1.33) 
Unsure*   0.98 (0.58-1.68) 0.43 (0.29-0.64) 2.93 (1.86-4.61) 
I worry that the whooping cough vaccine will cause birth defects. 
Agree*   0.92 (0.54-1.58) 1.28 (0.86-1.90) 0.78 (0.50-1.21) 
I worry that the ingredients in the whooping cough vaccine given to me during pregnancy are not safe for my unborn baby. 
Agree*   0.36 (0.20-0.67) 2.74 (1.62-4.65) 0.65 (0.37-1.12) 
      
Other Vaccine Knowledge, Attitudes and Beliefs 
I worry that I could get the flu while I am pregnant. 
Agree* 4.74 (3.83-5.88) 0.18 (0.14-0.23)   0.67 (0.50-0.89) 
The flu is dangerous for pregnant women. 
Agree* 2.54 (1.93-3.35) 0.47 (0.35-0.63)   0.56 (0.39-0.80) 
Disagree* 0.49 (0.34-0.73) 2.60 (1.75-3.86)   0.73 (0.39-1.39) 
Unsure* 0.38 (0.26-0.54) 1.56 (1.06-2.29)   2.79 (1.85-4.22) 
The flu is more dangerous for pregnant women than for women who are not pregnant. 
Agree* 2.19 (1.73-2.79) 0.53 (0.41-0.69)   0.58 (0.42-0.81) 
Disagree* 0.5 (0.37-0.70) 2.55 (1.83-3.55)   0.75 (0.44-1.26) 
Unsure* 0.50 (0.37-0.68) 1.16 (0.82-1.65)   2.64 (1.83-3.81) 
Getting the flu vaccine will reduce my risk of getting the flu during my pregnancy. 
Agree* 19.04 (14.63-24.8) 0.07 (0.06-0.10)   0.29 (0.22-0.40) 
Disagree* 0.06 (0.04-0.08) 16.53 (12.40-22.03)   1.37 (0.97-1.92) 
Unsure* 0.21 (0.15-0.29) 1.74 (1.25-2.41)   5.13 (3.64-7.23) 
Getting the flu vaccine while I am pregnant will reduce my unborn baby's risk of getting the flu. 
Agree* 6.20 (4.91-7.83) 0.17 (0.13-0.22)   0.36 (0.26-0.50) 
Disagree* 0.22 (0.17-0.28) 5.92 (4.59-7.63)   1.01 (0.71-1.42) 
Unsure* 0.53 (0.43-0.65) 1.16 (0.91-1.48)   2.72 (2.03-3.65) 
I worry that I could get whooping cough while I am pregnant. 
Agree*   3.6 (2.86-4.54) 0.19 (0.14-0.26) 0.74 (0.55-1.00) 
I worry that I could give whooping cough to my baby after birth. 
Agree*   6.20 (4.96-7.75) 0.12 (0.09-0.17) 0.55 (0.41-0.73) 
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Whooping cough is dangerous for pregnant women. 
Agree*   2.63 (2.09-3.31) 0.52 (0.41-0.68) 0.43 (0.32-0.58) 
Disagree*   0.73 (0.46-1.15) 1.98 (1.23-3.18) 0.52 (0.22-1.21) 
Unsure*   0.35 (0.28-0.46) 1.72 (1.31-2.26) 2.88 (2.12-3.93) 
Whooping cough vaccine will reduce my chances of getting whooping cough. 
Agree*   11.00 (8.47-14.30) 0.16 (0.12-0.21) 0.26 (0.19-0.35) 
Disagree*   0.11 (0.07-0.17) 9.37 (6.43-13.66) 1.03 (0.62-1.71) 
Unsure*   0.14 (0.11-0.19) 2.81 (2.12-3.71) 5.02 (3.68-6.84) 
Whooping cough vaccine will reduce the chance of me giving whooping cough to my unborn baby. 
Agree*   7.55 (5.98-9.53) 0.17 (0.13-0.22) 0.35 (0.26-0.47) 
Disagree*   0.21 (0.15-0.29) 7.45 (5.32-10.42) 0.51 (0.28-0.91) 
Unsure*   0.19 (0.15-0.25) 2.51 (1.93-3.26) 4.34 (3.21-5.86) 
Getting the whooping cough vaccine while I am pregnant will reduce my unborn baby's risk of getting whooping cough. 
Agree*   6.48 (5.19-8.10) 0.19 (0.15-0.25) 0.33 (0.25-0.44) 
Disagree*   0.23 (0.17-0.31) 6.17 (4.54-8.39) 0.72 (0.45-1.15) 
Unsure*   0.27 (0.21-0.34) 2.00 (1.56-2.57) 3.9 (2.91-5.24) 
It is in my control whether or not I get vaccines during my pregnancy. 
Agree* 1.71 (0.93-3.13) 0.46 (0.24-0.85) 1.68 (0.92-3.09) 0.45 (0.24-0.85) 1.45 (0.51-4.1) 
The majority of my friends and family would get the vaccines that are recommended during pregnancy. 
Agree* 7.99 (6.46-9.89) 0.21 (0.17-0.25) 6.14 (5.00-7.53) 0.25 (0.21-0.31) 0.30 (0.23-0.38) 
Disagree* 0.15 (0.11-0.21) 5.92 (4.47-7.85) 0.19 (0.14-0.26) 5.18 (3.92-6.86) 1.38 (0.96-1.99) 
Unsure* 0.20 (0.15-0.25) 2.39 (1.88-3.05) 0.25 (0.20-0.32) 1.94 (1.51-2.49) 3.97 (3.02-5.22) 
The majority of my friends and family would encourage me to get the vaccines that are recommended during pregnancy. 
Agree* 9.89 (7.97-12.26) 0.15 (0.12-0.19) 7.21 (5.87-8.85) 0.20 (0.16-0.24) 0.32 (0.25-0.41) 
Disagree* 0.10 (0.07-0.13) 8.45 (6.56-10.88) 0.14 (0.10-0.18) 7.07 (5.51-9.07) 1.49 (1.09-2.04) 
Unsure* 0.24 (0.19-0.32) 1.93 (1.48-2.52) 0.31 (0.24-0.40) 1.51 (1.14-2.00) 3.86 (2.89-5.15) 
I have most of the important information I need to make a decision about vaccines given during pregnancy. 
Agree* 4.16 (3.30-5.25) 0.54 (0.43-0.69) 3.92 (3.12-4.93) 0.56 (0.44-0.72) 0.23 (0.17-0.30) 
I know enough about the safety of the flu vaccine to make a decision about getting the vaccine for myself while pregnant. 
Agree* 4.62 (3.54-6.03) 0.62 (0.47-0.81)   0.16 (0.12-0.22) 
I know enough about the safety of the whooping cough vaccine to make a decision about getting the vaccine for myself while pregnant. 
Agree*   4.53 (3.61-5.68) 0.50 (0.39-0.63) 0.18 (0.13-0.24) 
      
Trust in Vaccine Information Sources 
I trust the information provided by my obstetrician or midwife about vaccines during pregnancy. 
Agree* 8.68 (5.78-13.04) 0.19 (0.14-0.26) 6.75 (4.66-9.80) 0.21 (0.15-0.29) 0.48 (0.33-0.71) 
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Disagree* 0.11 (0.06-0.21) 8.13 (4.77-13.86) 0.13 (0.07-0.24) 7.46 (4.46-12.49) 1.01 (0.50-2.07) 
Unsure* 0.14 (0.08-0.23) 3.48 (2.30-5.28) 0.18 (0.11-0.28) 3.02 (1.99-4.59) 2.91 (1.84-4.60) 
I trust the information provided by my baby's doctor about vaccines during pregnancy. 
Agree* 3.84 (3.00-4.92) 0.31 (0.24-0.40) 4.04 (3.16-5.17) 0.28 (0.22-0.36) 0.56 (0.41-0.77) 
Disagree* 0.12 (0.07-0.22) 7.57 (4.70-12.19) 0.15 (0.09-0.26) 6.86 (4.32-10.89) 1.01 (0.53-1.93) 
Unsure* 0.15 (0.09-0.27) 3.36 (2.10-5.35) 0.19 (0.11-0.32) 3.03 (1.89-4.85) 2.71 (1.61-4.56) 
Unseen* 0.55 (0.40-0.75) 1.52 (1.08-2.14) 0.45 (0.33-0.62) 1.96 (1.40-2.74) 1.60 (1.07-2.40) 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines during pregnancy. 
Agree* 0.55 (0.46-0.65) 1.81 (1.48-2.20) 0.63 (0.53-0.75) 1.53 (1.25-1.88) 1.31 (1.03-1.68) 
Disagree* 1.40 (1.08-1.83) 0.79 (0.59-1.07) 1.41 (1.08-1.85) 0.78 (0.57-1.07) 0.71 (0.48-1.06) 
Unsure* 0.84 (0.63-1.11) 1.11 (0.81-1.53) 0.79 (0.59-1.05) 1.21 (0.87-1.66) 1.20 (0.82-1.77) 
Unseen* 1.77 (1.47-2.14) 0.54 (0.43-0.68) 1.55 (1.28-1.87) 0.64 (0.51-0.80) 0.80 (0.61-1.05) 
I trust the information provided by federal agencies such as the Centers for Disease Control and Prevention (CDC) about vaccines during 
pregnancy. 
Agree* 6.35 (5.03-8.03) 0.19 (0.15-0.23) 5.55 (4.42-6.97) 0.20 (0.16-0.25) 0.55 (0.41-0.72) 
Disagree* 0.12 (0.08-0.17) 8.43 (6.16-11.55) 0.13 (0.09-0.19) 8.22 (6.03-11.21) 1.01 (0.66-1.55) 
Unsure* 0.29 (0.21-0.38) 2.27 (1.71-3.03) 0.33 (0.25-0.44) 2.00 (1.49-2.69) 2.47 (1.78-3.44) 
I trust the information provided by scientists and doctors at universities and academic institutions about vaccines during pregnancy. 
Agree* 3.86 (3.07-4.84) 0.28 (0.22-0.35) 3.56 (2.84-4.46) 0.29 (0.23-0.37) 0.64 (0.48-0.86) 
Disagree* 0.13 (0.09-0.21) 6.66 (4.54-9.76) 0.18 (0.12-0.27) 5.67 (3.91-8.23) 1.19 (0.72-1.97) 
Unsure* 0.41 (0.31-0.53) 2.11 (1.61-2.76) 0.41 (0.32-0.53) 2.13 (1.62-2.80) 1.67 (1.20-2.32) 
*Agree indicates a response of either Agree or Strongly Agree; Disagree indicates a response of either Disagree or Strongly Disagree, Unsure indicates a 
response of Don’t Know (provided as an answer option only for knowledge- and trust-based questions), and Unseen indicates a response of “I don’t have a 
pediatrician yet” or “I don't see this type of doctor” for the trust in in baby’s doctor and naturopathic/chiropractic doctors, respectively 
**OR: Odds Ratio; 95%CI: 95% Confidence Interval; bolded if statistically significant 




Appendix 12. Odds Ratios Assessing Associations between Pregnant Women’s Vaccine Intentions for their Baby and their Infant Vaccine 
Knowledge, Attitudes, Beliefs and Trust 
Survey 
Statement 
OR (95%CI) with Infant Vaccine Intentions** 
All On Time 
All But Spread 
Out 
Some But On 
Time 
Some and Spread 
Out None Unsure 
       
Confidence in Vaccine Safety 
I am confident that vaccines are safe for my baby after birth. 
Agree* 16.90 (12.26-23.30) 1.20 (0.82-1.77) 0.30 (0.20-0.45) 0.06 (0.04-0.11) 0.01 (0.00-0.04) 0.12 (0.09-0.17) 
       
Specific Vaccine Safety Concerns*** 
It is better for babies to get fewer vaccines at the same time. 
Agree* 0.47 (0.25-0.91) 2.32 (0.79-6.85) 1.22 (0.54-2.79) 2.25 (0.92-5.55) 1.40 (0.62-3.18) 0.64 (0.37-1.11) 
Babies get more vaccines in their first two years of life than are good for them. 
Agree* 0.36 (0.19-0.66) 7.38 (1.73-31.51) 1.29 (0.60-2.77) 2.70 (1.16-6.27) 0.69 (0.35-1.35) 0.79 (0.47-1.33) 
Vaccines often cause serious side effects in babies. 
Agree* 0.18 (0.09-0.34) 0.66 (0.32-1.37) 1.40 (0.68-2.88) 1.14 (0.59-2.19) 5.37 (2.05-14.05) 1.44 (0.86-2.41) 
The ingredients in vaccines are not safe for my baby. 
Agree* 0.15 (0.08-0.28) 0.99 (0.45-2.17) 1.01 (0.49-2.08) 1.99 (0.92-4.31) 7.03 (2.12-23.32) 1.28 (0.74-2.19) 
       
Other Vaccine Knowledge, Attitudes and Beliefs 
I worry that my baby could get whooping cough after birth. 
Agree* 2.52 (2.04-3.11) 0.74 (0.55-1.00) 0.39 (0.25-0.59) 0.48 (0.28-0.82) 0.26 (0.13-0.52) 0.47 (0.33-0.66) 
Whooping cough is dangerous for babies. 
Agree* 2.43 (1.69-3.49) 1.93 (0.97-3.87) 0.38 (0.22-0.67) 0.68 (0.29-1.62) 0.47 (0.19-1.14) 0.27 (0.17-0.42) 
Disagree
* 0.40 (0.18-0.90) n/a 4.55 (1.66-12.47) 2.7 (0.62-11.79) 8.84 (2.88-27.19) 0.94 (0.22-4.06) 
Unsure* 0.43 (0.29-0.64) 0.66 (0.33-1.32) 2.06 (1.06-4.00) 1.16 (0.41-3.28) 0.77 (0.18-3.24) 4.44 (2.77-7.12) 
Whooping cough is more dangerous for babies than older children or adults. 
Agree* 2.46 (1.86-3.26) 1.32 (0.83-2.08) 0.45 (0.28-0.73) 0.42 (0.23-0.78) 0.48 (0.23-1.00) 0.30 (0.21-0.45) 
Disagree
* 0.42 (0.22-0.81) 0.61 (0.19-2.00) 1.99 (0.69-5.74) 3.61 (1.23-10.55) 3.66 (1.08-12.42) 1.99 (0.82-4.84) 
Unsure* 0.43 (0.31-0.58) 0.80 (0.49-1.31) 2.14 (1.27-3.59) 1.92 (0.97-3.79) 1.61 (0.70-3.69) 3.33 (2.23-4.96) 
Getting the whooping cough vaccine for my baby after birth will reduce my baby's chances of getting whooping cough. 




* 0.14 (0.09-0.21) 1.27 (0.75-2.14) 2.57 (1.43-4.63) 5.22 (2.80-9.76) 67.64 (30.29-151.06) 1.04 (0.55-1.98) 
Unsure* 0.37 (0.29-0.48) 0.73 (0.49-1.09) 2.19 (1.40-3.42) 1.84 (1.03-3.31) 0.44 (0.16-1.25) 6.75 (4.73-9.65) 
It is in my control whether or not my baby gets his/her vaccines. 
Agree* 1.58 (0.94-2.63) 1.06 (0.48-2.36) 0.87 (0.31-2.46) 0.33 (0.13-0.86) n/a 0.50 (0.25-1.00) 
I believe it is better for my baby to develop their own immunity by getting sick rather than by getting a vaccine. 
Agree* 0.26 (0.20-0.32) 1.27 (0.92-1.74) 2.46 (1.61-3.75) 4.11 (2.29-7.37) 12.69 (5.23-30.77) 3.86 (2.73-5.47) 
The majority of my friends and family would get all of the vaccines recommended for their babies after birth. 
Agree* 4.73 (3.77-5.93) 1.15 (0.82-1.62) 0.34 (0.23-0.50) 0.40 (0.24-0.66) 0.11 (0.06-0.21) 0.15 (0.11-0.21) 
Disagree
* 0.16 (0.11-0.23) 1.20 (0.76-1.90) 3.72 (2.32-5.97) 4.60 (2.59-8.17) 12.25 (6.77-22.18) 2.42 (1.56-3.75) 
Unsure* 0.34 (0.26-0.44) 0.68 (0.43-1.07) 1.76 (1.08-2.87) 0.92 (0.42-2.04) 1.89 (0.90-3.95) 6.89 (4.95-9.59) 
The majority of my friends and family would encourage me to get all of the vaccines recommended for my baby after birth. 
Agree* 5.85 (4.66-7.34) 0.99 (0.72-1.36) 0.29 (0.20-0.42) 0.31 (0.19-0.50) 0.07 (0.04-0.14) 0.15 (0.11-0.21) 
Disagree
* 0.12 (0.09-0.17) 1.50 (1.00-2.24) 4.16 (2.68-6.46) 4.81 (2.79-8.3) 15.70 (8.69-28.39) 2.56 (1.71-3.83) 
Unsure* 0.32 (0.24-0.42) 0.67 (0.42-1.06) 1.82 (1.12-2.98) 1.28 (0.63-2.62) 1.96 (0.94-4.10) 6.75 (4.84-9.42) 
I have most of the important information I need to make a decision about vaccines for my baby after birth. 
Agree* 4.38 (3.45-5.56) 0.92 (0.66-1.29) 0.42 (0.28-0.63) 0.44 (0.26-0.75) 2.11 (0.75-5.91) 0.11 (0.08-0.15) 
I know enough about the safety of the whooping cough vaccine to make a decision about getting the vaccine for my baby after birth. 
Agree* 3.12 (2.54-3.83) 0.96 (0.71-1.29) 0.45 (0.31-0.66) 0.42 (0.26-0.69) 2.15 (0.91-5.08) 0.15 (0.11-0.20) 
       
Trust in Vaccine Information Sources 
I trust the information provided by my obstetrician or midwife about vaccines for babies after birth. 
Agree* 15.33 (9.75-24.10) 1.27 (0.75-2.17) 0.44 (0.26-0.76) 0.11 (0.07-0.19) 0.06 (0.03-0.11) 0.15 (0.10-0.22) 
Disagree
* 0.09 (0.05-0.17) 0.67 (0.29-1.56) 1.67 (0.71-3.94) 10.90 (5.78-20.54) 30.69 (16.18-58.19) 1.82 (0.91-3.61) 
Unsure* 0.06 (0.03-0.11) 0.89 (0.46-1.75) 2.57 (1.33-4.97) 4.48 (2.21-9.10) 2.87 (1.11-7.42) 11.69 (7.47-18.31) 
I trust the information provided by my baby's doctor about vaccines for babies after birth. 
Agree* 5.65 (4.39-7.28) 1.34 (0.91-1.97) 0.48 (0.31-0.73) 0.14 (0.08-0.23) 0.10 (0.06-0.19) 0.16 (0.12-0.22) 
Disagree
* 0.04 (0.02-0.10) 1.09 (0.51-2.33) 1.96 (0.83-4.65) 11.77 (6.11-22.70) 37.77 (19.65-72.60) 1.40 (0.63-3.12) 
Unsure* 0.05 (0.02-0.12) 0.47 (0.17-1.29) 4.30 (2.23-8.29) 3.47 (1.44-8.34) 4.13 (1.58-10.81) 10.77 (6.42-18.05) 
Unseen* 0.40 (0.30-0.54) 0.77 (0.48-1.25) 1.22 (0.67-2.21) 3.26 (1.83-5.83) 0.91 (0.32-2.56) 4.37 (3.04-6.28) 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines for babies after birth. 




* 1.08 (0.83-1.41) 1.09 (0.76-1.57) 0.91 (0.52-1.58) 0.98 (0.48-2.00) 1.72 (0.85-3.49) 0.60 (0.36-1.01) 
Unsure* 0.55 (0.41-0.74) 1.10 (0.72-1.68) 1.15 (0.64-2.08) 1.67 (0.84-3.31) 1.37 (0.57-3.25) 2.44 (1.64-3.61) 
Unseen* 2.28 (1.87-2.79) 0.36 (0.26-0.49) 0.72 (0.48-1.07) 0.59 (0.34-1.02) 0.28 (0.12-0.62) 0.76 (0.55-1.04) 
I trust the information provided by federal agencies such as the Centers for Disease Control and Prevention (CDC) about vaccines for babies 
after birth. 
Agree* 7.29 (5.77-9.22) 1.11 (0.80-1.55) 0.37 (0.25-0.54) 0.09 (0.05-0.15) 0.03 (0.01-0.07) 0.15 (0.11-0.21) 
Disagree
* 0.10 (0.07-0.14) 1.05 (0.68-1.64) 2.95 (1.85-4.70) 14.07 (8.51-23.27) 30.27 (15.91-57.57) 2.38 (1.58-3.58) 
Unsure* 0.27 (0.20-0.36) 0.79 (0.50-1.24) 1.81 (1.10-2.99) 1.93 (1.02-3.66) 1.79 (0.82-3.86) 7.28 (5.21-10.19) 
I trust the information provided by scientists and doctors at universities and academic institutions about vaccines for babies after birth. 
Agree* 4.70 (3.73-5.91) 1.03 (0.73-1.44) 0.37 (0.25-0.55) 0.33 (0.20-0.54) 0.06 (0.03-0.11) 0.21 (0.16-0.29) 
Disagree
* 0.09 (0.06-0.15) 0.99 (0.56-1.76) 2.83 (1.59-5.05) 9.05 (5.16-15.86) 22.94 (12.54-41.97) 2.37 (1.43-3.94) 
Unsure* 0.35 (0.27-0.46) 0.97 (0.66-1.43) 2.13 (1.36-3.34) 0.67 (0.29-1.57) 2.70 (1.41-5.16) 4.67 (3.36-6.50) 
*Agree indicates a response of either Agree or Strongly Agree; Disagree indicates a response of either Disagree or Strongly Disagree, Unsure indicates a 
response of Don’t Know (provided as an answer option only for knowledge- and trust-based questions), and Unseen indicates a response of “I don’t have a 
pediatrician yet” or “I don't see this type of doctor” for the trust in in baby’s doctor and naturopathic/chiropractic doctors, respectively 
**OR: Odds Ratio; 95%CI: 95% Confidence Interval; bolded if statistically significant 















Total 36 41 23 
    
Vaccine Intentions    
Current guidelines suggest pregnant women to receive two vaccines while pregnant, flu and whooping cough. I intend to get: 
both flu and whooping cough vaccines 81 62 7 
flu but not whooping cough vaccine 5 9 6 
whooping cough but not flu vaccine 6 11 12 
not sure 5 14 25 
no vaccines 3 5 49 
Current guidelines suggest babies receive several vaccines. Regarding the vaccinations my doctor recommends for my baby after birth, I intend 
to get my baby: 
all recommended vaccines on time 91 73 25 
all recommended vaccines but some spread out past the recommended ages 7 16 14 
some recommended vaccines but each on time 1 5 13 
some recommended vaccines spread out past the recommended ages 0 2 10 
I'm not sure yet 1 4 29 
no vaccines 0 0 9 
    
Confidence in Vaccine Safety    
Number of Specific Vaccine Safety Concerns Identified 
0 93 85 6 
1-4 4 11 20 
5-8 3 4 27 
9-12 0 0 29 
13-16 0 0 18 
I am confident that getting the flu vaccine during my pregnancy is safe for me. 
strongly agree 66 11 2 
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agree 30 80 19 
disagree 3 9 59 
strongly disagree 2 1 21 
I am confident that getting the flu vaccine during my pregnancy is safe for my unborn baby. 
strongly agree 58 7 2 
agree 38 84 20 
disagree 4 9 62 
strongly disagree 1 0 16 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for me. 
strongly agree 62 4 1 
agree 34 92 25 
disagree 3 4 61 
strongly disagree 1 0 13 
I am confident that getting the whooping cough vaccine during my pregnancy is safe for my unborn baby. 
strongly agree 59 3 2 
agree 38 93 28 
disagree 3 4 57 
strongly disagree 0 0 13 
I am confident that vaccines are safe for my baby after birth. 
strongly agree 80 13 6 
agree 20 84 41 
disagree 1 3 41 
strongly disagree 0 0 13 
    
Other Vaccine Knowledge, Attitudes and Beliefs*    
I worry that I could get the flu while I am pregnant. 
strongly agree 31 8 6 
agree 43 57 27 
disagree 20 33 46 
strongly disagree 5 3 21 
The flu is dangerous for pregnant women. 
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strongly agree 56 21 20 
agree 36 65 52 
don't know** 4 8 15 
disagree 3 4 11 
strongly disagree 1 2 2 
The flu is more dangerous for pregnant women than for women who are not pregnant. 
strongly agree 54 19 15 
agree 32 60 50 
don't know** 6 13 17 
disagree 6 7 15 
strongly disagree 1 1 3 
Getting the flu vaccine will reduce my risk of getting the flu during my pregnancy. 
strongly agree 53 9 2 
agree 37 69 18 
don't know** 4 11 23 
disagree 5 9 41 
strongly disagree 1 1 17 
Getting the flu vaccine while I am pregnant will reduce my unborn baby's risk of getting the flu. 
strongly agree 35 4 0 
agree 31 47 11 
don't know** 22 33 40 
disagree 9 16 36 
strongly disagree 3 1 13 
I worry that I could get whooping cough while I am pregnant. 
strongly agree 17 2 2 
agree 38 37 15 
disagree 36 58 64 
strongly disagree 9 3 19 
I worry that I could give whooping cough to my baby after birth. 
strongly agree 38 5 3 
agree 40 53 21 
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disagree 16 40 60 
strongly disagree 6 2 16 
Whooping cough is dangerous for pregnant women. 
strongly agree 47 11 12 
agree 39 67 47 
don't know** 10 18 34 
disagree 3 4 6 
strongly disagree 0 0 1 
Whooping cough vaccine will reduce my chances of getting whooping cough. 
strongly agree 62 8 2 
agree 31 78 28 
don't know** 5 12 41 
disagree 1 3 22 
strongly disagree 1 0 7 
Whooping cough vaccine will reduce the chance of me giving whooping cough to my unborn baby. 
strongly agree 61 9 2 
agree 27 70 24 
don't know** 8 16 45 
disagree 3 4 23 
strongly disagree 1 1 6 
Getting the whooping cough vaccine while I am pregnant will reduce my unborn baby's risk of getting whooping cough. 
strongly agree 54 5 0 
agree 29 65 16 
don't know** 13 23 50 
disagree 4 7 25 
strongly disagree 0 1 8 
It is in my control whether or not I get vaccines during my pregnancy. 
strongly agree 80 33 48 
agree 19 64 48 
disagree 1 2 3 
strongly disagree 0 1 2 
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The majority of my friends and family would get the vaccines that are recommended during pregnancy. 
strongly agree 61 9 6 
agree 31 70 30 
don't know** 5 15 35 
disagree 3 6 22 
strongly disagree 1 1 7 
The majority of my friends and family would encourage me to get the vaccines that are recommended during pregnancy. 
strongly agree 60 9 5 
agree 32 69 26 
don't know** 5 14 24 
disagree 3 8 35 
strongly disagree 1 0 10 
I have most of the important information I need to make a decision about vaccines given during pregnancy. 
strongly agree 60 6 13 
agree 34 80 47 
disagree 5 14 32 
strongly disagree 1 0 8 
I know enough about the safety of the flu vaccine to make a decision about getting the vaccine for myself while pregnant. 
strongly agree 62 4 15 
agree 32 80 44 
disagree 5 16 35 
strongly disagree 1 1 5 
I know enough about the safety of the whooping cough vaccine to make a decision about getting the vaccine for myself while pregnant. 
strongly agree 55 2 10 
agree 35 70 34 
disagree 9 27 47 
strongly disagree 1 2 10 
I worry that my baby could get whooping cough after birth. 
strongly agree 38 5 3 
agree 41 57 30 
disagree 15 36 54 
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strongly disagree 5 2 14 
Whooping cough is dangerous for babies. 
strongly agree 86 33 22 
agree 13 60 59 
don't know** 2 5 16 
disagree 0 1 2 
strongly disagree 0 1 1 
Whooping cough is more dangerous for babies than older children or adults. 
strongly agree 81 31 23 
agree 14 56 48 
don't know** 5 11 24 
disagree 0 2 5 
strongly disagree 0 1 1 
Getting the whooping cough vaccine for my baby after birth will reduce my baby's chances of getting whooping cough. 
strongly agree 65 10 5 
agree 25 70 31 
don't know** 9 17 41 
disagree 1 3 18 
strongly disagree 0 0 5 
It is in my control whether or not my baby gets his/her vaccines. 
strongly agree 86 35 42 
agree 13 61 50 
disagree 1 3 6 
strongly disagree 0 1 1 
I believe it is better for my baby to develop their own immunity by getting sick rather than by getting a vaccine. 
strongly agree 16 2 11 
agree 4 20 42 
disagree 28 61 41 
strongly disagree 52 17 6 
The majority of my friends and family would get all of the vaccines recommended for their babies after birth. 
strongly agree 65 10 12 
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agree 29 76 42 
don't know** 3 10 24 
disagree 2 4 17 
strongly disagree 1 0 5 
The majority of my friends and family would encourage me to get all of the vaccines recommended for my baby after birth. 
strongly agree 67 11 11 
agree 28 76 38 
don't know** 3 9 25 
disagree 2 4 21 
strongly disagree 1 0 6 
I have most of the important information I need to make a decision about vaccines for my baby after birth. 
strongly agree 69 6 15 
agree 27 81 46 
disagree 3 13 31 
strongly disagree 1 0 9 
I know enough about the safety of the whooping cough vaccine to make a decision about getting the vaccine for my baby after birth. 
strongly agree 65 3 11 
agree 29 75 38 
disagree 6 22 42 
strongly disagree 1 1 9 
    
Trust in Vaccine Information Sources    
I trust the information provided by my obstetrician or midwife about vaccines during pregnancy. 
strongly agree 93 18 15 
agree 7 80 57 
don't know** 0 1 17 
disagree 0 1 10 
strongly disagree 0 0 2 
I trust the information provided by my obstetrician or midwife about vaccines for babies after birth. 
strongly agree 92 17 15 
agree 8 81 58 
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don't know** 0 1 16 
disagree 0 1 9 
strongly disagree 0 0 3 
I trust the information provided by my baby's doctor about vaccines during pregnancy. 
strongly agree 88 16 12 
agree 8 76 45 
don't know** 0 1 13 
I don’t have a pediatrician yet  3 6 17 
disagree 0 1 10 
strongly disagree 0 0 3 
I trust the information provided by my baby's doctor about vaccines for babies after birth. 
strongly agree 88 16 12 
agree 7 75 48 
don't know** 0 0 11 
I don’t have a pediatrician yet  4 8 18 
disagree 0 0 8 
strongly disagree 0 0 3 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines during pregnancy. 
strongly agree 26 3 9 
agree 11 41 38 
don't know** 7 10 15 
I don't see this type of doctor  41 34 26 
disagree 10 10 10 
strongly disagree 6 2 3 
I trust the information provided by naturopathic and/or chiropractic doctors about vaccines for babies after birth. 
strongly agree 24 3 9 
agree 11 38 37 
don't know** 6 10 15 
I don't see this type of doctor  45 37 27 
disagree 9 10 10 
strongly disagree 6 2 3 
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I trust the information provided by federal agencies such as the Centers for Disease Control and Prevention (CDC) about vaccines during 
pregnancy. 
strongly agree 80 10 5 
agree 18 80 34 
don't know** 2 9 26 
disagree 0 2 22 
strongly disagree 0 0 13 
I trust the information provided by federal agencies such as the Centers for Disease Control and Prevention (CDC) about vaccines for babies 
after birth. 
strongly agree 81 9 5 
agree 17 80 36 
don't know** 2 9 26 
disagree 0 2 21 
strongly disagree 0 0 12 
I trust the information provided by scientists and doctors at universities and academic institutions about vaccines during pregnancy. 
strongly agree 74 8 6 
agree 22 79 47 
don't know** 4 12 27 
disagree 1 2 16 
strongly disagree 0 0 4 
I trust the information provided by scientists and doctors at universities and academic institutions about vaccines for babies after birth. 
strongly agree 72 8 6 
agree 23 79 48 
don't know** 4 12 27 
disagree 1 2 14 
strongly disagree 0 0 4 
*20 questions deemed non-essential were included in surveys for only ~75% of the sample (based on randomly assigned groups) in order to keep surveys short 
enough to obtain high completion rates 





Appendix 14. First Child, Degree and Ethnicity Stratified by State  
State Total N (%) 
First Child, N (%) Education*, N (%) Ethnicity, N (%) 
Yes No High Low Black White Hispanic Other 
GA 1,106 (50) 504 (46) 598 (54) 661 (72) 258 (28) 257 (27) 534 (57) 61 (7) 85 (9) 
CO 1,104 (50) 513 (46) 591 (54) 641 (71) 262 (29) 57 (6) 647 (69) 151 (16) 81 (9) 
P-value**  0.73 0.66 <0.01 
*Education=High for Doctoral or Professional degree, Master’s degree, Bachelor’s degree, Associate’s degree; Education=Low for Postsecondary nondegree 
award, Some college no degree, High school diploma or equivalent, No formal educational credential  






Appendix 15. Comparisons of Constructs by Vaccine  






N (%) P* 
Maternal 




Confidence in Vaccine Safety       
Confidence in Vaccine Safety (for the mother) 





Confidence in Vaccine Safety (for the infant) 























Vaccine Efficacy (for the mother) 





Vaccine Efficacy (for the infant) 







Self-Efficacy 1608 (98)    1590 (96) 0.03 
Descriptive Norms 











Perception of Vaccine Knowledge    1815 (83) 1852 (84) 0.02 
Perception of Vaccine Safety Knowledge 







Trust in Vaccine Information Sources       
Trust in obstetricians, midwives    2042 (92) 2044 (93) 0.66 
Trust in pediatricians 
   1880 (92) 1879 (94) 
<0.0
1 
Trust in naturopaths, chiropractors    924 (64) 869 (63) 0.02 
Trust in CDC    1776 (81) 1783 (81) 0.27 
Trust in academia    1808 (82) 1816 (82) 0.36 
*P-value for McNemar’s test comparing maternal influenza vaccine to maternal Tdap vaccine at significance level of () 5%; bolded if significant 
**P-value for McNemar’s test comparing maternal vaccines (either maternal vaccines in general or just maternal Tdap vaccine, depending on statement) to 







Appendix 16. Comparing Frequency of Agreement with Maternal Vaccine Related Statements between Pregnant Women Intending to Receive 
Only Maternal Influenza Vaccine and Pregnant Women Intending to Receive Only Tdap Vaccine 
Maternal Vaccine Related Survey Statements 
Agree or 
Strongly Agree, 
N (%) – Total 
Agree or 
Strongly Agree, 




N (%) – Tdap 
Only** 
P*** 
Confidence in Vaccine Safety Statements     
I am confident that getting the flu vaccine during my 
pregnancy is safe for me. 
1670 (75) 142 (92) 93 (47) <0.01 
I am confident that getting the flu vaccine during my 
pregnancy is safe for my unborn baby. 
1683 (77) 140 (91) 105 (53) <0.01 
I am confident that getting the whooping cough vaccine 
during my pregnancy is safe for me. 
1762 (80) 110 (71) 179 (90) <0.01 
I am confident that getting the whooping cough vaccine 
during my pregnancy is safe for my unborn baby. 
1779 (81) 113 (73) 169 (85) 0.01 
     
Vaccine Knowledge, Attitude and Belief Statements     
I worry that I could get the flu while I am pregnant. 1002 (61) 70 (62) 47 (33) <0.01 
The flu is dangerous for pregnant women. 1410 (86) 96 (85) 116 (81) 0.36 
The flu is more dangerous for pregnant women than for 
women who are not pregnant. 
1304 (79) 97 (86) 108 (75) 0.03 
Getting the flu vaccine will reduce my risk of getting the flu 
during my pregnancy. 
1142 (69) 87 (76) 47 (33) <0.01 
Getting the flu vaccine while I am pregnant will reduce my 
unborn baby's risk of getting the flu. 
779 (47) 58 (51) 34 (24) <0.01 
I worry that I could get whooping cough while I am pregnant. 650 (39) 20 (18) 56 (38) <0.01 
I worry that I could give whooping cough to my baby after 
birth. 
937 (57) 28 (25) 97 (65) <0.01 
Whooping cough is dangerous for pregnant women. 1260 (76) 78 (70) 114 (77) 0.21 
Whooping cough vaccine will reduce my chances of getting 
whooping cough. 
1241 (75) 77 (69) 122 (82) 0.01 
Whooping cough vaccine will reduce the chance of me giving 
whooping cough to my unborn baby. 
1150 (69) 68 (60) 118 (79) <0.01 
Getting the whooping cough vaccine while I am pregnant will 
reduce my unborn baby's risk of getting whooping cough. 
1021 (62) 59 (52) 100 (68) 0.01 
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It is in my control whether or not I get vaccines during my 
pregnancy. 
1608 (98) 108 (95) 137 (95) 0.88 
The majority of my friends and family would get the vaccines 
that are recommended during pregnancy. 
1615 (74) 124 (81) 133 (67) <0.01 
The majority of my friends and family would encourage me to 
get the vaccines that are recommended during pregnancy. 
1584 (72) 121 (79) 125 (63) <0.01 
I have most of the important information I need to make a 
decision about vaccines given during pregnancy. 
1815 (83) 121 (79) 154 (77) 0.73 
I know enough about the safety of the flu vaccine to make a 
decision about getting the vaccine for myself while pregnant. 
1352 (81) 101 (89) 109 (76) <0.01 
I know enough about the safety of the whooping cough 
vaccine to make a decision about getting the vaccine for 
myself while pregnant. 
1176 (71) 60 (53) 115 (77) <0.01 
     
Trust in Vaccine Information Source Statements     
I trust the information provided by my obstetrician or midwife 
about vaccines during pregnancy. 
2042 (92) 144 (94) 181 (91) 0.31 
I trust the information provided by my baby's doctor about 
vaccines during pregnancy.**** 
1880 (92) 130 (84) 172 (86) 0.68 
I trust the information provided by naturopathic and/or 
chiropractic doctors about vaccines during pregnancy.**** 
924 (64) 61 (40) 99 (50) 0.06 
I trust the information provided by federal agencies such as 
the Centers for Disease Control and Prevention (CDC) about 
vaccines during pregnancy. 
1776 (81) 123 (80) 150 (75) 0.28 
I trust the information provided by scientists and doctors at 
universities and academic institutions about vaccines during 
pregnancy. 
1808 (82) 123 (80) 154 (77) 0.52 
*number and percentage of those agreeing with survey statement who intend to receive maternal influenza vaccine only 
**number and percentage of those agreeing with survey statement who intend to receive maternal Tdap vaccine only 
***P-value for the Pearson chi-squared proportion test comparing those who intend to receive maternal influenza vaccine only and those who intend to receive 
maternal Tdap vaccine only at significance level of () 5%; bolded if significant 
****removed those who stated they hadn’t yet seen this type of provider from this analysis  
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What makes a pregnant woman more or less likely to refer friends and family for vaccine 
information? 
Findings 
Pregnant women were more likely to refer an educational app about vaccines to their close friends 
and family if they trusted vaccine information from academic institutions, perceived influenza as 
dangerous for pregnant women, perceived maternal vaccines as safe and effective, or perceived 
their friends and family to be pro-maternal vaccines.  
Meaning 
Pregnant women who recognize the importance of maternal vaccines are willing to refer an 






Vaccine hesitancy is a threat to high vaccine coverage and controlling diseases. Maternal vaccine 
coverage is substantially lower than infant vaccine coverage, leaving young infants vulnerable to 
influenza and pertussis infections. Cocooning is a strategy to limit risk of infection among 
vulnerable infants by vaccinating those who will come into contact with the infant. Perceived 
norms have been shown to affect vaccine intentions and coverage. Distribution of accurate and 
accessible vaccine information through existing social networks could be an important tool in 
increasing vaccine confidence and coverage. This article presents data on factors associated with 
pregnant women referring their close friends and family to an educational app about vaccines.  
Design 
Pregnant women were given a 71-question survey to assess their vaccine intentions, attitudes, 
beliefs, norms, and levels of trust and provided educational videos about vaccines through an 
electronic tablet application. Information on ethnicity, education, and number of prior children was 
also collected by the app. Pregnant women were then given the opportunity to refer up to six 
contacts to enroll in the app.  
Setting 
Pregnant women were recruited from a geographically and socio-demographically diverse set of 




One thousand one hundred and five pregnant women (545 from Colorado and 560 from Georgia) 
provided survey data and were given the opportunity to refer up to 6 contacts to the app. 
Results 
Two hundred and eighty of these women (25%) chose to refer contacts, for an average of 2.75 
contacts per referring woman. The vast majority referred by pregnant women were their partners, 
parents, siblings, relatives, or close friends. Constructs associated with increased likelihood of 
referring contacts included: perceived safety and efficacy of maternal vaccines, perceived 
susceptibility to and severity of influenza; pro-maternal vaccine descriptive norms, and trust in 
vaccine information from the CDC and academic institutions. Belief that babies are better off 
developing immunity through natural illness rather than vaccination was associated with decreased 
likelihood of referring contacts.  
Conclusions and Relevance 
Pregnant women who valued vaccination and perceived their social network to value vaccination 
were more likely to refer an educational app about vaccines to their close friends and family. 
Further research is needed to determine the potential impact of this app referral strategy on vaccine 
coverage when implemented on a large scale.  
Trial Registration 
The survey informing this article was part of a randomized controlled trial funded by the National 







Immunization is one of the most effective ways to prevent infectious diseases and their associated 
morbidity and mortality [13]. Vaccine hesitancy is a threat to high vaccine coverage and 
controlling diseases [1-11]. Although vaccine coverage among children in the United States 
remains high [14], maternal vaccine coverage is substantially lower [12], leaving infants too young 
to receive their own vaccines vulnerable to potentially deadly influenza and pertussis infections 
[28, 38-40].  
Cocooning, or vaccinating close contacts of the incoming newborn, is strategy to limit risk of 
infection among vulnerable infants [46-48]. Factors derived from the Health Belief Model (HBM) 
[498] such as high perceived benefits of vaccine, high perceived susceptibility to disease, and low 
perceived barriers to vaccination have been associated with higher rates of cocooning [49]. 
Distribution of vaccine information and financial incentives for vaccination are potential 
interventions to influence these factors.  
Vaccine decisions, like many other types of decisions, have been shown to be influenced by one’s 
peers within their social network [200, 562-564], especially among those with vaccine concerns 
[565]. Thus, changes in vaccine confidence and decisions of individuals within in a social network 
may also impact the vaccine confidence and decisions of other individuals within that social 
network.   
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As part of an NIH-funded large randomized controlled trial of a prenatal intervention to increase 
uptake of maternal and infant vaccines (referred to as P3+), we developed an application for 
pregnant women called MomsTalkShots that can be used on smartphones, tablets and computers. 
The app collects survey data on vaccine knowledge, attitudes and beliefs and then delivers 
educational videos about vaccines tailored to the individual’s survey responses. Videos were 
designed to present information in a scientifically accurate yet engaging manner with easily 
understandable language and a broad range of ethnicities represented. This was done so that the 
app would have broad appeal to a variety of ethnicities and levels of education. Upon conclusion 
of the videos, the app encouraged a selection of pregnant women in P3+ to refer their close friends 
and family to the app so they could receive the individually-tailored educational videos as well as 
a small financial incentive for receiving cocooning vaccinations at Walgreens.  
This study used Social Cognitive Theory (SCT), which examines the influence of one’s social 
environment on health behavior at the interpersonal level [500]. Access to the MomsTalkShots 
app alters the environment of cocooning vaccinations by providing financial incentives and more 
convenient pharmacy access to vaccination, while concurrently influencing personal vaccine 
knowledge and attitudes via the educational videos, aligning with SCT’s concept of reciprocal 
determinism. The study also takes advantage of the interpersonal influence on behavior, by 
empowering pregnant women to share vaccine knowledge and opinions with their close contacts 
and vice versa with increased self-efficacy due to increased knowledge of the benefits and 
importance of vaccination.  
This article examines which factors (e.g., vaccine intentions, knowledge, attitudes, beliefs, 
perceived norms, trust in information sources, and demographics) were associated with an 
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increased likelihood of pregnant women referring contacts, as well as what types of contacts were 




Data Collection  
 
Survey data was collected through the MomsTalkShots app as part of the P3+ study. Pregnant 
women were recruited for the study from a geographically and socio-demographically diverse set 
of obstetrician-gynecologist offices in Georgia (GA) and Colorado (CO). Women entering these 
offices for regularly scheduled appointments were approached to be screened by study staff, and 
were eligible for participation if they were between 18 and 50 years old, between 8 and 26 weeks 
pregnant, and had not yet received influenza or Tdap vaccine during their current pregnancy. At 
first, only first-time pregnant women were recruited for the study, although recruitment was 
eventually expanded to include all pregnant women in order to increase the sample size. Sample 
size calculations were based on maternal Tdap vaccine coverage, and were thus recalculated to 
account for the increase in coverage between the time of the study proposal and study initiation.  
The baseline survey included 71 total questions: 3 multiple choice questions assessing vaccine 
intentions and number of prior children, 60 statements with Likert scale answer options, and 8 
open-ended questions with an optional free form answer box which were not analyzed in this paper. 
Likert scale options were limited to strongly agree, agree, disagree, and strongly disagree for most 
statements; knowledge and trust statements also included a “don’t know” option, and trust 
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statements regarding pediatricians and naturopathic/chiropractic doctors included options for “I 
don’t have a pediatrician yet” and “I don't see this type of doctor”, respectively. Response options 
for the question assessing maternal vaccine intentions were: “both flu and whooping cough 
vaccines”, “flu but not whooping cough vaccine”, “whooping cough but not flu vaccine”, “no 
vaccines”, and “not sure”. Response options for the question assessing infant vaccine intentions 
were: “all recommended vaccines on time”, “all recommended vaccines but some spread out past 
the recommended ages”, “some recommended vaccines but each on time”, “some recommended 
vaccines spread out past the recommended ages”, “no vaccines”, and “not sure yet”. Twenty-nine 
of these questions were deemed essential and administered to all participants; these included the 3 
multiple choice questions, statements assessing belief in vaccine safety and efficacy, and 
statements assessing constructs such as descriptive norms, injunctive norms, perception of vaccine 
knowledge, and trust in vaccine information sources. Twenty-three questions were specific vaccine 
safety concern questions which were automatically administered only to participants who 
expressed a lack of confidence in the safety of a particular vaccine based on their responses to the 
vaccine safety questions. Two of these specific vaccine safety concern questions were potentially 
administered to survey participants twice due to this skip logic (“I do not want to put the flu vaccine 
into my body when I am pregnant because I think it is unnatural” and “I do not want to put the 
whooping cough vaccine into my body when I am pregnant because I think it is unnatural”). 
Twenty questions were deemed non-essential and administered to about three quarters of the 
sample (based on randomly assigned groups) in order to keep surveys short enough to obtain high 
completion rates; these questions covered constructs including perceived susceptibility to VPDs, 
perceived severity of VPDs, response efficacy, and self-efficacy. Demographic information such 
as state of residence, ethnicity and education was collected. 
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Half of all participants selected at random were given the opportunity to refer up to 6 friends and 
family members to be invited to enroll in the app for a related study. Those who referred at least 
one contact received a $10 gift card. A subset of roughly two thirds of the referred contacts selected 
at random were then sent up to 10 emails each spaced out by at least a week inviting them to join 




Vaccine intention questions were dichotomized to represent those who intended to receive 
recommended maternal flu, Tdap, and all infant vaccines versus those who did not, and Likert 
scale statements were dichotomized to represent those who agreed or strongly agreed versus those 
who did not. Responses to the two specific vaccine safety concern questions that were potentially 
administered to survey participants twice due to skip logic were combined to each form one 
variable in the dataset. A categorical variable representing the number of specific vaccine safety 
concern statements agreed or strongly agreed to (0-16) per woman was created. Ethnicity 
categories were collapsed to white, black, Hispanic, or other; education categories were collapsed 
to having a graduate degree (Master’s, Doctoral, or Professional), having an undergraduate degree 
(Bachelor’s or Associate’s), and not having a degree; and number of prior children was collapsed 
to having children prior to this pregnancy versus not. 
Sociodemographic characteristics and survey responses were each analyzed as independent 
variables in simple logistic regressions with a dichotomous variable for having referred contacts 
versus not having referred contacts as the dependent variable, and odds ratios (ORs) were 
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calculated. A best-fit multiple logistic regression model was then created by backwards selection 
to include only those variables with statistical significance (P<0.05) in both the simple and multiple 
models. The categorical variable for number of vaccine safety concerns as well as individual 
vaccine safety concern variables were not included due to their collinearity with the confidence in 
vaccine safety variables. Nested models were compared using the Akaike information criterion 
(AIC), the Bayesian information criterion (BIC), and the likelihood ratio test. 
Percentages of contacts referred and enrolled in the app by type of relationship to the referrer were 
calculated. Pearson’s chi-squared test for independence was used to assess differences in 
enrollment rates by relationship type. 
All P-values were two-sided and P<0.05 was considered statistically significant. Analysis was 




One thousand one hundred and five pregnant women (545 from Colorado and 560 from Georgia) 
provided survey data and were given the opportunity to refer up to 6 contacts to the app (Table 1). 
Twenty-six percent of women who provided education information had an advanced degree and 
44% had an associate’s or bachelor’s degree. Sixty-two percent of women who provided their 
ethnicity identified as white; 17% identified as black and 12% as Hispanic or Latino. Forty-eight 
percent of women were pregnant for the first time. No statistically significant associations between 
likelihood of referring contacts to the app and ethnicity, education, state, or having prior children 
were found.  
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Two hundred and eighty women (25%) referred at least one contact to the app. Of these women, 
37% referred one contact, 21% referred two contacts, 12% referred three contacts, 6% referred 
four contacts, 4% referred five contacts, and 19% referred the maximum of six contacts (Table 2).  
A total of 772 contacts were referred, or an average of 2.75 contacts per referring woman (Table 
3). Nineteen percent of referred contacts were listed as partners; 25% as parents; 16% as siblings; 
15% as other relatives; 20% as close friends; 2% as casual friends, 2% as caregivers to the infant; 
and 2% as other.  
Several statistically significant associations were found between pregnant women who referred 
contacts and their vaccine intentions, knowledge, attitudes, beliefs and trust (Table 4). Women 
who were unsure about their infant vaccine intentions were less likely to refer contacts to the app 
(OR: 0.45; P=0.01). Women were more likely to refer contacts to the app if they were confident 
in the safety and efficacy of maternal vaccines, had high perceived susceptibility to and severity 
of influenza during pregnancy, reported pro-maternal vaccine descriptive norms, and reported trust 
in vaccine information from the CDC and academic institutions. Conversely, women were less 
likely to refer contacts to the app if they agreed with the statement “I believe it is better for my 
baby to develop their own immunity by getting sick rather than by getting a vaccine” (OR: 0.58; 
P=0.03).   
Other associations were suggested albeit not statistically significantly (Appendix 1). For example, 
pregnant women who intended to receive maternal influenza (OR: 1.29; P=0.08) and Tdap (OR: 
1.29; P=0.09) vaccines appeared slightly more likely to refer contacts to the app than women 
without such intention. Although associations varied somewhat by relationships to referred 
contacts, no statistically significant contrasting effects between relationship types were found.  
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The best-fit model reduced to include agreement with only two survey statements as statistically 
significant predictors of referring contacts: “the flu is more dangerous for pregnant women than 
for women who are not pregnant” (OR: 2.07; P=0.01); and “getting the flu vaccine will reduce my 
risk of getting the flu during my pregnancy” (OR: 1.61; P=0.04). 
Four hundred twenty-two (55%) of the contacts referred were randomly selected to be invited by 
email to join the study and enroll in the app (Table 5). Of these, 274 enrolled in the app (65% 
response rate). No statistically significant difference in enrollment rates by type of relationship to 




Pregnant women were more likely to refer their friends and family to an educational app about 
vaccines if they were confident in the safety and efficacy of maternal vaccines, perceived 
themselves susceptible to influenza during pregnancy and recognized its severity, reported pro-
vaccine norms, and trusted vaccine information from the CDC and academic institutions. The most 
consistent predictors of referring friends and family when adjusted for other variables were 
perceiving VPD severity and vaccine efficacy.  
The vast majority of contacts referred to an educational app about vaccines by pregnant women 
were their partners, parents, siblings, relatives, or close friends. Very few users referred casual 
friends or caregivers. No difference was seen in the likelihood of the referred contact enrolling in 
the app based on the type of relationship with the referring pregnant woman.  
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The positive association between referring contacts to the app and trust in vaccine information 
from academic institutions makes sense, as the app was clearly labeled as a product of the three 
universities collaborating on this study (Emory University, University of Colorado Anschutz 
Medical Campus, and Johns Hopkins Bloomberg School of Public Health).  
Perceived pro-vaccine attitudes of women’s friends and family was positively associated with 
referring them to an educational app about vaccines, indicating that women were more comfortable 
sharing information with their family and friends that they knew would resonate with their pre-
existing beliefs; or perhaps that some were hesitant to share information they thought would be 
contradictory to their family and friends’ pre-existing beliefs. This may limit the ability of this 
referral strategy to decrease vaccine hesitancy if most referred contacts are already confident in 
vaccines; however, it could still have an impact on cocooning vaccine coverage through the 
reinforcement of the importance of vaccination to an audience predisposed to agree with this 
message.  
A belief that babies are better off developing immunity through natural illness rather than 
vaccination was significantly associated with decreased likelihood of referring contacts. This 
indicates that perceived lack of severity of disease or benefit of vaccination (or both) may decrease 
desire to share an educational app about vaccines with friends and family. If women who already 
value vaccination are substantially more likely to refer their friends and family to the app than 
women who do not, that would limit the amount of improvement in women’s vaccine attitudes and 
beliefs possible through this strategy. 
In addition, women with uncertain infant vaccine intentions were less likely to refer contacts to 
the app than those who had already made up their mind, which limits the potential of this strategy 
to influence women’s vaccine intentions for their children through educating her social network. 
 
242 
However, no statistically significant effect was seen for women with uncertain maternal vaccine 
intentions, for which much greater frequency of uncertainty existed, implying that this strategy 
could still have an impact on maternal vaccine intentions.  
The ethnicity, education and state of residence (CO vs GA) of the pregnant women using the 
MomsTalkShots app did not appear to impact their likelihood of referring contacts, nor did having 
prior children. These data may indicate the broad appeal of this app and referral strategy to the 
general population regardless of ethnicity or education level. 
There are several limitations of this study. Firstly, these data are not nationally generalizable. This 
study was embedded into an existing clinical trial analyzing a comprehensive intervention to 
increase vaccination among pregnant women; thus, the pregnant women who chose to enroll in 
the preexisting trial and thus were available to participate in this study may be different than those 
who did not and pregnant women in general. Reasons for eligible women declining study 
participation include being too busy to screen (18%), not being interested in the study (40%), being 
wary of the study (5%), and not being able to communicate or read in English (13%). Our study 
population contained a higher proportion of educated, white women than indicated by CDC data 
on the demographics of U.S. births in 2016 in Colorado and Georgia [561]. In addition, the income 
level of pregnant women participating in this trial was not collected, so we are unable to properly 
control for this in our analysis. Because pregnant women were offered a $10 gift card as an 
incentive for referring contacts to the app, they may have been primarily motivated to do so 
because of the financial incentive, instead of because of any of the factors we measured and 
analyzed. Somewhat reassuring is that having at least a college degree was not statistically 
significantly associated with referring contacts to the app, as education is associated with income. 
Whether a referred contact enrolled in the app or not may have been impacted by email habits and 
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spam filters, which may explain why no statistically significant difference was seen in likelihood 
of enrolling in the app by type of relationship with the referring pregnant woman.  
As providing financial incentives for referring contacts would likely be impractical on a large 
scale, further research into the impact and sustainability of this type of app referral strategy without 
incentives is needed. Further research is also needed to assess whether vaccination attitudes, 
intentions and uptake are impacted among referred contacts, and whether this in turn has any effect 
on the referring pregnant woman. If successful, such a strategy could increase vaccine confidence 
and maternal and cocooning vaccine coverage for very little cost, by spreading accurate, 
individually tailored vaccine information through existing social networks of pregnant women. 
This app referral strategy could then also be refined for populations other than pregnant women, 




Pregnant women who valued vaccination and perceived their social network to value vaccination 
were more likely to refer an educational app about vaccines to their close friends and family. 
Further research is needed to determine the potential impact of this app referral strategy on vaccine 
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Figures and Tables 
 
Table 1. Percentage of Pregnant Women who Referred Contacts to Educational App about Vaccines, 
Stratified by State, Education, Ethnicity and First Child 
Selected Characteristics Total, N (%) Referred Contacts, N (%)* P** 
All 1105 280 (25)  
    
State    
Colorado 545 (49) 145 (27) 0.34 
Georgia 560 (51) 135 (24)  
total 1,105 280 (25)  
    
Education    
Graduate degree*** 230 (26) 74 (32) 0.10 
Undergraduate degree*** 392 (44) 97 (25)  
No college degree 279 (31) 70 (25)  
total 901 241 (27)  
    
Ethnicity    
Black or African American 159 (17) 34 (21) 0.24 
Hispanic or Latino 116 (12) 32 (28)  
White 574 (62) 150 (26)  
Other 84 (9) 28 (33)  
total 933 244 (26)  
    
First Child    
Yes 525 (48) 137 (26) 0.62 
No 577 (52) 143 (25)  
total 1,102 280 (25)  
*number and percentage in each sociodemographic group who referred contacts to app 
**P-value for the Pearson chi-squared proportion test at significance level of () 5%; bolded if significant 
***Graduate degree includes Master’s, Doctoral, and Professional degrees; Undergraduate degree includes 





Table 2. Number of Contacts Referred to Educational App about Vaccines per Pregnant Woman 
Number of Contacts Referred N (%) 
0 825 (75) 
1+ 280 (25) 
1 104 (9) 
2 60 (5) 
3 34 (3) 
4 18 (2) 
5 10 (1) 
6 (maximum allowed) 54 (5) 





Table 3. Contacts Referred to Educational App about Vaccines by Relationship to Pregnant Women Who 
Referred Them  
Relationship Referred, N (%) 
Partner 142 (19) 
Parent 189 (25) 
Sibling 124 (16) 
Other Relative 114 (15) 
Close Friend 152 (20) 
Casual Friend 16 (2) 
Caregiver 13 (2) 
Other 14 (2) 
total* 764 (100) 





Table 4. Odds Ratios for Vaccine Intentions, Knowledge, Attitudes, Beliefs and Trust Found to be Associated with Pregnant Women Referring 






Vaccine Intentions  
Uncertain Infant Vaccine Intentions 0.45 (0.25, 0.83) 
  
Survey Statements - Agreed or Strongly Agreed  
Confidence in Vaccine Safety  
I am confident that getting the whooping cough vaccine during my pregnancy is safe for me. 1.59 (1.09, 2.33) 
  
Other Vaccine Knowledge, Attitudes and Beliefs  
I worry that I could get the flu while I am pregnant.  1.51 (1.02, 2.25) 
The flu is more dangerous for pregnant women than for women who are not pregnant.  2.25 (1.29, 3.92) 
Getting the flu vaccine will reduce my risk of getting the flu during my pregnancy.  1.75 (1.11, 2.77) 
Getting the whooping cough vaccine while I am pregnant will reduce my unborn baby’s risk of 
getting whooping cough. 
1.60 (1.05, 2.45) 
The majority of my friends and family would get the vaccines that are recommended during 
pregnancy. 
1.44 (1.04, 1.98) 
I believe it is better for my baby to develop their own immunity by getting sick rather than by 
getting a vaccine.  
0.58 (0.36, 0.94) 
I trust the information provided by federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines during pregnancy. 
1.50 (1.05, 2.14) 
I trust the information provided by federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines for babies after birth. 
1.53 (1.06, 2.20) 
I trust the information provided by scientists and doctors at universities and academic 
institutions about vaccines during pregnancy. 
1.60 (1.10, 2.34) 
I trust the information provided by scientists and doctors at universities and academic 
institutions about vaccines for babies after birth. 
1.86 (1.25, 2.77) 





Table 5. Contacts Who Chose to Enroll in Educational App about Vaccines by Relationship to Pregnant 
Women Who Referred Them** 
Relationship 





Partner 31 (38) 50 (62) 81 
Parent 29 (31) 64 (69) 93 
Sibling 18 (27) 48 (73) 66 
Other Relative 25 (36) 45 (64) 70 
Close Friend 36 (41) 52 (59) 88 
Casual Friend 4 (67) 2 (33) 6 
Caregiver 3 (38) 5 (63) 8 
Other 2 (20) 8 (80) 10 
total* 148 (35) 274 (65) 422 
*Only 422 of 772 referred contacts (55%) invited to enroll 





Appendix 1. Odds Ratios for Pregnant Women Referring Various Types of Contacts to Educational App about Vaccines Based on their Vaccine 




















       
Vaccine Intentions       
Maternal Vaccines       
Intention to receive maternal 
flu vaccine 1.29 (0.97, 1.72) 1.28 (0.89, 1.84) 1.13 (0.78, 1.63) 0.86 (0.57, 1.30) 0.93 (0.57, 1.50) 1.17 (0.75, 1.82) 
Intention to not receive 
maternal flu vaccine 0.77 (0.56, 1.08) 0.79 (0.52, 1.20) 0.94 (0.62, 1.42) 0.89 (0.54, 1.45) 1.06 (0.62, 1.83) 0.71 (0.42, 1.22) 
Intention to receive maternal 
Tdap vaccine 1.29 (0.96, 1.72) 1.13 (0.79, 1.61) 1.54 (1.04, 2.28) 0.86 (0.56, 1.31) 1.02 (0.62, 1.67) 0.84 (0.54, 1.28) 
Intention to not receive 
maternal Tdap vaccine 0.77 (0.55, 1.09) 0.94 (0.62, 1.42) 0.60 (0.37, 0.98) 0.88 (0.53, 1.47) 0.94 (0.53, 1.68) 1.13 (0.69, 1.85) 
Not sure 0.88 (0.59, 1.32) 0.86 (0.51, 1.46) 0.86 (0.50, 1.47) 1.54 (0.91, 2.61) 1.05 (0.53, 2.08) 1.18 (0.66, 2.11) 
Infant Vaccines       
Intention to get baby all 
recommended vaccines on 
time 
1.16 (0.87, 1.57) 1.28 (0.87, 1.86) 1.13 (0.77, 1.65) 0.70 (0.46, 1.07) 0.93 (0.57, 1.53) 0.77 (0.50, 1.19) 
Intention to get baby all 
recommended vaccines but 
some spread out past the 
recommended ages 
1.05 (0.71, 1.56) 0.88 (0.52, 1.50) 1.09 (0.65, 1.82) 1.94 (1.16, 3.23) 1.29 (0.67, 2.49) 1.67 (0.97, 2.88) 
Intention to get baby some 
recommended vaccines but 
each on time 
1.46 (0.82, 2.61) 1.01 (0.48, 2.12) 0.64 (0.26, 1.60) 0.74 (0.27, 2.05) 1.59 (0.68, 3.75) 0.58 (0.18, 1.85) 
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Intention to get baby some 
recommended vaccines 
spread out past the 
recommended ages 
0.98 (0.44, 2.21) 0.89 (0.32, 2.48) 0.95 (0.34, 2.64) 1.39 (0.49, 3.89) 0.89 (0.21, 3.72) 1.89 (0.74, 4.82) 
Intention to get baby no 
vaccines 0.69 (0.23, 2.06) 0.95 (0.29, 3.10) 1.01 (0.31, 3.30) 0.46 (0.06, 3.38) 0.62 (0.08, 4.59) 1.57 (0.48, 5.14) 
Not sure yet 0.45 (0.25, 0.83) 0.6 (0.29, 1.24) 0.82 (0.42, 1.59) 1.09 (0.54, 2.20) 0.61 (0.22, 1.69) 0.73 (0.32, 1.70) 
       
Survey Statements - Agreed 
or Strongly Agreed       
Confidence in Vaccine Safety       
I am confident that getting 
the flu vaccine during my 
pregnancy is safe for me. 
1.26 (0.91, 1.75) 1.36 (0.89, 2.08) 1.05 (0.70, 1.58) 0.73 (0.47, 1.15) 1.35 (0.75, 2.43) 1.56 (0.90, 2.69) 
I am confident that getting 
the flu vaccine during my 
pregnancy is safe for my 
unborn baby. 
1.04 (0.75, 1.44) 1.31 (0.86, 2.01) 0.97 (0.65, 1.45) 0.79 (0.50, 1.24) 0.86 (0.51, 1.47) 1.29 (0.77, 2.18) 
I am confident that getting 
the whooping cough vaccine 
during my pregnancy is safe 
for me. 
1.59 (1.09, 2.33) 1.6 (0.98, 2.59) 1.81 (1.08, 3.04) 1.49 (0.84, 2.66) 1.26 (0.67, 2.37) 1.18 (0.68, 2.05) 
I am confident that getting 
the whooping cough vaccine 
during my pregnancy is safe 
for my unborn baby. 
1.31 (0.90, 1.89) 1.72 (1.04, 2.85) 1.50 (0.91, 2.47) 1.11 (0.65, 1.90) 0.90 (0.51, 1.61) 1.04 (0.61, 1.78) 
I am confident that vaccines 
are safe for my baby after 
birth. 
1.08 (0.71, 1.65) 1.32 (0.78, 2.26) 1.33 (0.77, 2.31) 1.14 (0.62, 2.12) 0.90 (0.47, 1.73) 1.07 (0.58, 1.99) 
Total number of specific 
vaccine safety concern 
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statements agreed or strongly 
agreed to (0-16) 
0 (reference) 1 1 1 1 1 1 
1-4 0.74 (0.46-1.19) 0.58 (0.30-1.13) 0.74 (0.39-1.40) 1.04 (0.53-2.05) 1.40 (0.70-2.81) 0.99 (0.50-1.95) 
5-8 0.84 (0.52-1.37) 0.96 (0.54-1.70) 1.44 (0.85-2.44) 1.57 (0.85-2.90) 1.10 (0.49-2.47) 1.13 (0.57-2.24) 
9-12 0.79 (0.45-1.39) 0.62 (0.28-1.36) 1.03 (0.53-2.03) 1.10 (0.49-2.44) 1.48 (0.66-3.34) 0.59 (0.21-1.63) 
13-16 0.45 (0.19-1.09) 0.44 (0.14-1.42) 1 (n/a)** 0.52 (0.12-2.14) 1 (n/a)** 0.24 (0.03-1.77) 
       
Other Vaccine Knowledge, 
Attitudes and Beliefs       
I worry that I could get the 
flu while I am pregnant.  1.51 (1.02, 2.25) 1.29 (0.79, 2.11) 1.53 (0.89, 2.65) 0.89 (0.49, 1.62) 2.06 (0.92, 4.60) 0.91 (0.51, 1.63) 
The flu is dangerous for 
pregnant women.  1.15 (0.65, 2.02) 0.99 (0.52, 1.92) 1.20 (0.57, 2.56) 1.37 (0.53, 3.50) 5.67 (0.77, 41.66) 0.75 (0.36, 1.56) 
The flu is more dangerous for 
pregnant women than for 
women who are not pregnant.  
2.25 (1.29, 3.92) 3.17 (1.37, 7.37) 2.64 (1.13, 6.16) 1.26 (0.58, 2.72) 4.26 (1.01, 17.89) 0.80 (0.41, 1.56) 
Getting the flu vaccine will 
reduce my risk of getting the 
flu during my pregnancy.  
1.75 (1.11, 2.77) 1.98 (1.10, 3.58) 1.46 (0.81, 2.63) 0.81 (0.44, 1.51) 2.56 (0.98, 6.66) 1.49 (0.75, 2.95) 
Getting the flu vaccine while 
I am pregnant will reduce my 
unborn baby’s risk of getting 
the flu.  
1.35 (0.92, 1.98) 1.50 (0.94, 2.40) 1.24 (0.75, 2.06) 1.03 (0.56, 1.87) 1.20 (0.60, 2.38) 0.87 (0.49, 1.55) 
I worry that I could get 
whooping cough while I am 
pregnant.  
0.92 (0.61, 1.40) 0.68 (0.41, 1.14) 0.92 (0.57, 1.50) 0.96 (0.55, 1.70) 0.86 (0.44, 1.67) 0.69 (0.36, 1.31) 
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I worry that I could give 
whooping cough to my baby 
after birth.  
1.07 (0.73, 1.58) 0.99 (0.61, 1.59) 1.07 (0.67, 1.73) 0.96 (0.55, 1.68) 0.52 (0.27, 1.00) 0.87 (0.48, 1.58) 
Whooping cough is 
dangerous for pregnant 
women. 
0.88 (0.57, 1.35) 0.85 (0.50, 1.46) 0.82 (0.48, 1.39) 0.76 (0.41, 1.41) 0.49 (0.25, 0.94) 0.97 (0.48, 1.92) 
Whooping cough vaccine 
will reduce my chances of 
getting whooping cough. 
1.10 (0.70, 1.72) 0.91 (0.53, 1.55) 1.02 (0.59, 1.75) 1.00 (0.53, 1.89) 0.74 (0.37, 1.48) 1.34 (0.64, 2.81) 
Whooping cough vaccine 
will reduce the chance of me 
giving whooping cough to 
my unborn baby. 
1.59 (1.00, 2.53) 1.53 (0.87, 2.70) 2.30 (1.23, 4.30) 1.66 (0.84, 3.25) 1.12 (0.55, 2.26) 1.55 (0.76, 3.16) 
Getting the whooping cough 
vaccine while I am pregnant 
will reduce my unborn 
baby’s risk of getting 
whooping cough. 
1.60 (1.05, 2.45) 1.40 (0.84, 2.33) 2.10 (1.21, 3.65) 1.18 (0.66, 2.10) 0.72 (0.38, 1.36) 1.54 (0.80, 2.96) 
It is in my control whether or 
not I get vaccines during my 
pregnancy. 
0.80 (0.20, 3.13) 2.00 (0.27, 14.71) 1 (n/a)** 1 (n/a)** 0.40 (0.09, 1.74) 1.24 (0.17, 9.18) 
The majority of my friends 
and family would get the 
vaccines that are 
recommended during 
pregnancy. 
1.44 (1.04, 1.98) 1.41 (0.93, 2.13) 1.37 (0.90, 2.08) 1.08 (0.67, 1.73) 1.09 (0.64, 1.88) 1.88 (1.07, 3.3) 
The majority of my friends 
and family would encourage 
me to get the vaccines that 
are recommended during 
pregnancy. 
1.34 (0.97, 1.84) 1.39 (0.93, 2.09) 1.29 (0.86, 1.93) 1.18 (0.74, 1.89) 1.27 (0.73, 2.21) 1.61 (0.95, 2.72) 
I have most of the important 
information I need to make a 
1.27 (0.89, 1.83) 1.34 (0.83, 2.18) 1.05 (0.66, 1.66) 0.65 (0.40, 1.06) 0.68 (0.39, 1.18) 0.70 (0.42, 1.15) 
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decision about vaccines 
given during pregnancy. 
I know enough about the 
safety of the flu vaccine to 
make a decision about getting 
the vaccine for myself while 
pregnant.  
1.26 (0.75, 2.12) 1.28 (0.67, 2.47) 1.35 (0.66, 2.76) 1.42 (0.59, 3.38) 2.25 (0.68, 7.41) 1.08 (0.50, 2.34) 
I know enough about the 
safety of the whooping cough 
vaccine to make a decision 
about getting the vaccine for 
myself while pregnant.  
1.19 (0.78, 1.82) 1.20 (0.70, 2.08) 1.00 (0.60, 1.69) 0.64 (0.36, 1.13) 0.42 (0.22, 0.79) 0.90 (0.47, 1.70) 
I worry that my baby could 
get whooping cough after 
birth.  
0.95 (0.64, 1.40) 0.81 (0.50, 1.31) 1.06 (0.65, 1.72) 0.86 (0.49, 1.50) 0.53 (0.28, 1.01) 1.04 (0.57, 1.92) 
Whooping cough is 
dangerous for babies.  0.78 (0.39, 1.53) 1.44 (0.52, 4.01) 0.66 (0.31, 1.42) 0.64 (0.27, 1.52) 0.57 (0.22, 1.47) 1.19 (0.36, 3.90) 
Whooping cough is more 
dangerous for babies than 
older children or adults.  
1.16 (0.66, 2.04) 1.14 (0.56, 2.32) 1.04 (0.52, 2.05) 0.90 (0.42, 1.94) 0.54 (0.25, 1.15) 1.32 (0.52, 3.38) 
Getting the whooping cough 
vaccine for my baby after 
birth will reduce my baby’s 
chances of getting whooping 
cough.  
1.36 (0.86, 2.15) 1.89 (1.01, 3.55) 1.35 (0.77, 2.38) 2.11 (0.98, 4.51) 0.95 (0.47, 1.93) 1.32 (0.65, 2.70) 
It is in my control whether or 
not my baby gets his/her 
vaccines.  
0.56 (0.24, 1.31) 0.93 (0.29, 3.05) 0.78 (0.24, 2.57) 0.85 (0.20, 3.58) 0.38 (0.11, 1.30) 0.57 (0.17, 1.89) 
I believe it is better for my 
baby to develop their own 
immunity by getting sick 
0.58 (0.36, 0.94) 0.33 (0.16, 0.67) 0.40 (0.20, 0.82) 0.45 (0.20, 1.01) 0.66 (0.29, 1.54) 0.66 (0.33, 1.34) 
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rather than by getting a 
vaccine.  
The majority of my friends 
and family would get all of 
the vaccines recommended 
for their babies after birth.  
1.02 (0.71, 1.46) 0.97 (0.63, 1.50) 0.81 (0.53, 1.24) 1.05 (0.61, 1.79) 0.62 (0.36, 1.05) 1.06 (0.61, 1.83) 
The majority of my friends 
and family would encourage 
me to get all of the vaccines 
recommended for my baby 
after birth.  
0.93 (0.66, 1.32) 1.15 (0.74, 1.80) 0.79 (0.52, 1.20) 0.97 (0.58, 1.62) 0.77 (0.44, 1.34) 1.61 (0.87, 2.98) 
I have most of the important 
information I need to make a 
decision about vaccines for 
my baby after birth.  
1.23 (0.85, 1.80) 1.55 (0.91, 2.65) 1.18 (0.72, 1.94) 1.02 (0.58, 1.80) 0.78 (0.43, 1.41) 0.96 (0.54, 1.69) 
I know enough about the 
safety of the whooping cough 
vaccine to make a decision 
about getting the vaccine for 
my baby after birth.  
1.17 (0.84, 1.62) 1.16 (0.77, 1.76) 1.24 (0.80, 1.91) 0.90 (0.56, 1.45) 0.73 (0.43, 1.22) 0.71 (0.45, 1.12) 
       
Trust in Vaccine Information 
Sources       
I trust the information 
provided by my obstetrician 
or midwife about vaccines 
during pregnancy. 
0.95 (0.57, 1.60) 1.20 (0.60, 2.41) 0.90 (0.47, 1.69) 0.76 (0.37, 1.53) 1.36 (0.49, 3.78) 0.72 (0.36, 1.46) 
I trust the information 
provided by my obstetrician 
or midwife about vaccines 
for babies after birth. 
1.15 (0.67, 1.98) 1.35 (0.65, 2.80) 0.98 (0.50, 1.90) 0.85 (0.40, 1.78) 1.82 (0.57, 5.84) 0.71 (0.35, 1.43) 
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I trust the information 
provided by my baby's doctor 
about vaccines during 
pregnancy. 
0.89 (0.60, 1.30) 1.01 (0.63, 1.63) 1.00 (0.61, 1.63) 0.79 (0.46, 1.36) 1.21 (0.60, 2.46) 0.75 (0.44, 1.29) 
I trust the information 
provided by my baby's doctor 
about vaccines for babies 
after birth. 
0.99 (0.67, 1.45) 0.96 (0.60, 1.53) 0.84 (0.53, 1.34) 0.74 (0.44, 1.25) 1.40 (0.66, 2.94) 0.75 (0.44, 1.29) 
I trust the information 
provided by naturopathic 
and/or chiropractic doctors 
about vaccines during 
pregnancy. 
0.76 (0.57, 1.00) 0.63 (0.44, 0.91) 0.91 (0.64, 1.29) 0.79 (0.51, 1.20) 0.93 (0.58, 1.50) 0.80 (0.52, 1.24) 
I trust the information 
provided by naturopathic 
and/or chiropractic doctors 
about vaccines for babies 
after birth. 
0.82 (0.62, 1.09) 0.70 (0.49, 1.01) 0.98 (0.69, 1.40) 0.92 (0.60, 1.40) 0.98 (0.60, 1.58) 0.90 (0.58, 1.38) 
I trust the information 
provided by federal agencies 
such as the Centers for 
Disease Control and 
Prevention (CDC) about 
vaccines during pregnancy. 
1.50 (1.05, 2.14) 1.29 (0.81, 2.04) 1.07 (0.69, 1.68) 1.05 (0.62, 1.77) 0.84 (0.48, 1.48) 1.15 (0.66, 1.99) 
I trust the information 
provided by federal agencies 
such as the Centers for 
Disease Control and 
Prevention (CDC) about 
vaccines for babies after 
birth. 
1.53 (1.06, 2.20) 1.41 (0.88, 2.26) 1.11 (0.70, 1.74) 1.10 (0.64, 1.88) 0.89 (0.50, 1.59) 1.12 (0.65, 1.95) 
I trust the information 
provided by scientists and 
doctors at universities and 
1.60 (1.10, 2.34) 1.57 (0.95, 2.60) 1.46 (0.88, 2.43) 1.19 (0.68, 2.08) 1.10 (0.58, 2.06) 1.34 (0.74, 2.44) 
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academic institutions about 
vaccines during pregnancy. 
I trust the information 
provided by scientists and 
doctors at universities and 
academic institutions about 
vaccines for babies after 
birth. 
1.86 (1.25, 2.77) 1.90 (1.10, 3.28) 2.10 (1.17, 3.75) 1.38 (0.76, 2.51) 1.07 (0.57, 2.01) 1.20 (0.67, 2.14) 
       
App Usability       
This app provided me 
information that was helpful. 1.02 (0.39-2.66) 0.71 (0.23-2.16) 0.57 (0.20-1.59) 0.65 (0.19-2.30) 0.26 (0.09-0.75) 
2.17 (0.28-
16.52) 
I trust the information 
provided about vaccines in 
this app. 
1.89 (0.71-5.07) 1.41 (0.42-4.81) 1.52 (0.45-5.17) 1.45 (0.33-6.33) 0.72 (0.21-2.51) 1 (n/a)** 
The vaccine information in 
this app was interesting. 0.35 (0.12-1.03) 0.55 (0.15-2.04) 0.26 (0.08-0.85) 0.52 (0.11-2.42) 0.93 (0.12-7.32) 0.54 (0.12-2.49) 
The vaccine information in 
this app was clear to 
understand. 
1 (n/a)** 1 (n/a)** 1 (n/a)** 1 (n/a)** 1 (n/a)** 1 (n/a)** 
*OR=Odds Ratio of Referring Contacts, 95%CI=95% Confidence Interval, bolded if statistically significant 





Appendix 2. Pregnant Women’s Vaccine Intentions, Knowledge, Attitudes, Beliefs and Trust Associated 
with Number of Contacts Referred to Educational App about Vaccines (Regression Coefficient and P-
value) 
Survey Items RC* P* 
Vaccine Intentions   
Current guidelines suggest pregnant women to receive two vaccines while 
pregnant, flu and whooping cough. I intend to get both flu and whooping cough 
vaccines. 0.07 0.43 
Current guidelines suggest babies receive several vaccines. Regarding the 
vaccinations my doctor recommends for my baby after birth, I intend to get my 
baby all recommended vaccines on time. 0.03 0.73 
   
Confidence in Vaccine Safety   
I am confident that getting the flu vaccine during my pregnancy is safe for me. 0.08 0.48 
I am confident that getting the flu vaccine during my pregnancy is safe for my 
unborn baby. -0.01 0.95 
I am confident that getting the whooping cough vaccine during my pregnancy is 
safe for me. 0.17 0.15 
I am confident that getting the whooping cough vaccine during my pregnancy is 
safe for my unborn baby. 0.11 0.36 
I am confident that vaccines are safe for my baby after birth. -0.01 0.96 
   
Other Vaccine Knowledge, Attitudes and Beliefs   
I worry that I could get the flu while I am pregnant.  0.28 0.03 
The flu is dangerous for pregnant women.  0.12 0.53 
The flu is more dangerous for pregnant women than for women who are not 
pregnant.  0.36 0.02 
Getting the flu vaccine will reduce my risk of getting the flu during my 
pregnancy.  0.17 0.23 
Getting the flu vaccine while I am pregnant will reduce my unborn baby’s risk of 
getting the flu.  0.15 0.23 
I worry that I could get whooping cough while I am pregnant.  -0.01 0.97 
I worry that I could give whooping cough to my baby after birth.  -0.02 0.87 
Whooping cough is dangerous for pregnant women. -0.08 0.60 
Whooping cough vaccine will reduce my chances of getting whooping cough. -0.04 0.77 
Whooping cough vaccine will reduce the chance of me giving whooping cough 
to my unborn baby. 0.14 0.35 
Getting the whooping cough vaccine while I am pregnant will reduce my unborn 
baby’s risk of getting whooping cough. 0.11 0.42 
It is in my control whether or not I get vaccines during my pregnancy. -0.22 0.65 
The majority of my friends and family would get the vaccines that are 
recommended during pregnancy. 0.27 0.01 
The majority of my friends and family would encourage me to get the vaccines 
that are recommended during pregnancy. 0.20 0.06 
I have most of the important information I need to make a decision about 
vaccines given during pregnancy. -0.08 0.48 
I know enough about the safety of the flu vaccine to make a decision about 
getting the vaccine for myself while pregnant.  0.12 0.49 
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for myself while pregnant.  -0.07 0.61 
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I worry that my baby could get whooping cough after birth.  -0.05 0.69 
Whooping cough is dangerous for babies.  -0.16 0.51 
Whooping cough is more dangerous for babies than older children or adults.  -0.07 0.73 
Getting the whooping cough vaccine for my baby after birth will reduce my 
baby’s chances of getting whooping cough.  0.24 0.11 
It is in my control whether or not my baby gets his/her vaccines.  -0.33 0.30 
I believe it is better for my baby to develop their own immunity by getting sick 
rather than by getting a vaccine.  -0.39 0.01 
The majority of my friends and family would get all of the vaccines 
recommended for their babies after birth.  -0.07 0.55 
The majority of my friends and family would encourage me to get all of the 
vaccines recommended for my baby after birth.  0.01 0.92 
I have most of the important information I need to make a decision about 
vaccines for my baby after birth.  0.06 0.61 
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for my baby after birth.  -0.03 0.77 
   
Trust in Vaccine Information Sources   
I trust the information provided by my obstetrician or midwife about vaccines 
during pregnancy. -0.07 0.71 
I trust the information provided by my obstetrician or midwife about vaccines for 
babies after birth. 0.01 0.96 
I trust the information provided by my baby's doctor about vaccines during 
pregnancy. -0.11 0.58 
I trust the information provided by my baby's doctor about vaccines for babies 
after birth. -0.20 0.34 
I trust the information provided by naturopathic and/or chiropractic doctors about 
vaccines during pregnancy. -0.17 0.07 
I trust the information provided by naturopathic and/or chiropractic doctors about 
vaccines for babies after birth. -0.14 0.15 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines during pregnancy. 0.17 0.15 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines for babies after birth. 0.18 0.12 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines during pregnancy. 0.30 0.01 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines for babies after birth. 0.34 0.01 
I trust the information provided about vaccines in this app. 0.10 0.75 





Appendix 3. Specific Vaccine Concerns Among Pregnant Women Not Confident in Vaccine Safety 
Associated with Referring Contacts to Educational App about Vaccines (Odds Ratios and P-values)  
Specific Vaccine Safety Concern Statements** OR* P* 
The flu vaccine is more likely to make me sick than protect me from getting the flu. 0.64 0.14 
I worry that the ingredients in the flu vaccine are not safe for me to have while I am 
pregnant. 
0.81 0.62 
The flu vaccine is more likely to make me sick than protect my unborn baby from 
getting the flu. 
0.52 0.02 
I do not want to put the flu vaccine into my body when I am pregnant because I think 
it is unnatural. 
0.62 0.12 
I worry that the flu vaccine will cause birth defects. 1.19 0.54 
I worry that the ingredients in the flu vaccine given to me during pregnancy are not 
safe for my unborn baby. 
1.03 0.93 
The whooping cough vaccine is more likely to cause me to get sick than protect me 
from getting whooping cough. 
0.50 0.08 
I worry that the ingredients in the whooping cough vaccine are not safe for me to have 
while I am pregnant. 
0.44 0.07 
The whooping cough vaccine is more likely to cause me to get sick than protect my 
unborn baby from getting whooping cough. 
0.59 0.15 
I do not want to put the whooping cough vaccine into my body when I am pregnant 
because I think it is unnatural. 
0.52 0.09 
I worry that the whooping cough vaccine will cause birth defects. 1.45 0.31 
I worry that the ingredients in the whooping cough vaccine given to me during 
pregnancy are not safe for my unborn baby. 
1.05 0.92 
It is better for babies to get fewer vaccines at the same time. 0.83 0.70 
Babies get more vaccines in their first two years of life than are good for them. 0.76 0.54 
Vaccines often cause serious side effects in babies. 0.68 0.35 
The ingredients in vaccines are not safe for my baby. 0.80 0.62 
* OR: Odds Ratio of Referring Contacts; P-value considered significant if <.05; bolded if statistically significant 






Appendix 4. Odds Ratios for Vaccine Intentions, Knowledge, Attitudes, Beliefs and Trust Found to be Associated with Pregnant Women Referring 






Vaccine Intentions  
Uncertain Infant Vaccine Intentions 0.50 (0.27-0.93) 
  
Survey Statements - Agreed or Strongly Agreed  
Confidence in Vaccine Safety  
I am confident that getting the whooping cough vaccine during my pregnancy is safe for me. 1.43 (0.96-2.14) 
  
Other Vaccine Knowledge, Attitudes and Beliefs  
I worry that I could get the flu while I am pregnant.  1.46 (0.97-2.18) 
The flu is more dangerous for pregnant women than for women who are not pregnant.  2.18 (1.24-3.82) 
Getting the flu vaccine will reduce my risk of getting the flu during my pregnancy.  1.72 (1.06-2.78) 
Getting the whooping cough vaccine while I am pregnant will reduce my unborn baby’s risk of 
getting whooping cough. 
1.41 (0.90-2.21) 
The majority of my friends and family would get the vaccines that are recommended during 
pregnancy. 
0.60 (0.37-0.98) 
I believe it is better for my baby to develop their own immunity by getting sick rather than by 
getting a vaccine.  
1.40 (0.96-2.04) 
I trust the information provided by federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines during pregnancy. 
1.45 (0.99-2.11) 
I trust the information provided by federal agencies such as the Centers for Disease Control and 
Prevention (CDC) about vaccines for babies after birth. 
1.48 (1.00-2.18) 
I trust the information provided by scientists and doctors at universities and academic 
institutions about vaccines during pregnancy. 
1.73 (1.16-2.59) 
I trust the information provided by scientists and doctors at universities and academic 
institutions about vaccines for babies after birth. 
1.46 (0.97-2.18) 
*aOR=Adjusted Odds Ratio of Referring Contacts (multiple logistic regression including independent variable of interest along with variable for descriptive 
norms indicating agreement with the statement “the majority of my friends and family would get the vaccines that are recommended during pregnancy”), 







Results of Hypotheses Testing 
 
The results for the hypothesis testing performed for each research question is summarized below. 
 
Manuscript 2: Characterizing pregnant women’s vaccine attitudes and beliefs  
Secondary Research Question 1: Do these intentions, attitudes, beliefs, norms, and levels of trust 
differ by state, ethnicity, education, and having prior children? 
H10: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust do not 
differ by state, ethnicity, education, or having prior children. 
H1A: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust do differ 
by state, ethnicity, education, or having prior children. 
Result: H10 rejected, H1A accepted. 
Secondary Research Question 2: Which attitudes, beliefs, norms, and levels of trust affect vaccine 
intentions? 
H10: Pregnant women’s vaccine attitudes, beliefs, norms, and levels of trust do not affect their 
vaccine intentions. 
H1A: Pregnant women’s vaccine attitudes, beliefs, norms, and levels of trust do affect their vaccine 
intentions. 
Result: H10 rejected, H1A accepted. 
Secondary Research Question 3: Which demographics, attitudes, beliefs, norms, and levels of trust 
are the best predictors of vaccine intentions? 
H10: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust do 
not affect their vaccine intentions when adjusted for each other. 
H1A: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust do 
affect their vaccine intentions when adjusted for each other. 
Result: H10 rejected, H1A accepted. 
Secondary Research Question 4: How many groups of pregnant women with distinct patterns of  
vaccine intentions, attitudes, beliefs, norms, and levels of trust can be identified, and how are they 
characterized?  
H10: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust are best 
characterized by one homogenous group. 
H1A: Pregnant women’s vaccine intentions, attitudes, beliefs, norms, and levels of trust are best 
characterized by multiple homogenous groups. 
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Result: H10 rejected, H1A accepted. 
 
Manuscript 3: Factors associated with referring close contacts to an app with individually-
tailored vaccine information 
Primary Research Question: Which demographics and vaccine intentions, attitudes, beliefs, norms, 
and levels of trust are associated with higher likelihood of a pregnant woman referring friends and 
family to an educational app about vaccines? 
H10: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust 
are not associated with likelihood of referring contacts to app. 
H1A: Pregnant women’s demographics and vaccine attitudes, beliefs, norms, and levels of trust 
are associated with likelihood of referring contacts to app. 
Result: H10 rejected, H1A accepted. 
Secondary Research Question 2: Which types of contacts based on relationship to the referring 
pregnant woman are more likely to enroll in such an app upon invitation to do so? 
H10: Contacts who enroll in app do not differ from contacts who do not enroll in app based on 
relationship to the referring pregnant woman. 
H1A: Contacts who enroll in app do differ from contacts who do not enroll in app based on 
relationship to the referring pregnant woman. 






Thesis Appendix 1: Baseline Survey for Pregnant Women in P3+ 
 
Note: The survey provided in this Appendix was drafted by Rupali J. Limaye, PhD, Assistant 
Scientist at Johns Hopkins Bloomberg School of Public Health, in tandem with Matthew Dudley. 
 
Question Construct 
Current guidelines suggest pregnant women to receive two vaccines while 
pregnant, flu and whooping cough. I intend to get: 
vaccine intentions-
maternal 
I worry that I could get the flu (influenza) while I am pregnant. 
susceptibility-
maternal 
The flu is dangerous for pregnant women. severity-maternal 
The flu is more dangerous for pregnant women than for women who are not 
pregnant. 
severity-maternal 




Getting the flu vaccine while I am pregnant will reduce MY UNBORN 
BABY'S risk of getting the flu. 
response efficacy-
pediatric 
I am confident that getting the flu vaccine during my pregnancy is safe for ME.  
beliefs in vaccine 
safety-maternal 




I do not want to put the flu vaccine into my body when I am pregnant because I 
think it is unnatural. 
specific concern-
maternal 
I worry that the ingredients in the flu vaccine are not safe for ME to have while 
I am pregnant. 
specific concern-
maternal 




I am confident that getting the flu vaccine during my pregnancy is safe for MY 
UNBORN BABY.  
beliefs in vaccine 
safety-maternal 
The flu vaccine is more likely to make me sick than protect MY UNBORN 
BABY from getting the flu. 
specific concern-
maternal 
I do not want to put the flu vaccine into my body when I am pregnant because I 
think it is unnatural. 
specific concern-
maternal 
I worry that the flu vaccine will cause birth defects. 
specific concern-
maternal 
I worry that the ingredients in the flu vaccine given to me during pregnancy are 
not safe for MY UNBORN BABY.  
specific concern-
maternal 
Please let us know why else you believe that the flu vaccine is not safe for 
YOUR UNBORN BABY:  
specific concern-
maternal 
I worry that I could get whooping cough (pertussis) while I am pregnant. 
susceptibility-
maternal 
I worry that I could give whooping cough to MY BABY AFTER BIRTH.  
susceptibility-
maternal 
Whooping cough is dangerous for pregnant women. severity-maternal 
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Whooping cough vaccine will reduce MY chances of getting whooping cough. 
response efficacy-
maternal 
Whooping cough vaccine will reduce the chance of me giving whooping cough 
to MY UNBORN BABY.  
response efficacy-
maternal 
Getting the whooping cough vaccine while I am pregnant will reduce MY 
UNBORN BABY'S risk of getting whooping cough. 
response efficacy-
maternal 
I am confident that getting the whooping cough vaccine during my pregnancy 
is safe for ME.  
beliefs in vaccine 
safety-maternal 
The whooping cough vaccine is more likely to cause me to get sick than protect 
ME from getting whooping cough. 
specific concern-
maternal 
I do not want to put the whooping cough vaccine into my body when I am 
pregnant because I think it is unnatural. 
specific concern-
maternal 
I worry that the ingredients in the whooping cough vaccine are not safe for ME 
to have while I am pregnant. 
specific concern-
maternal 
Please let us know why else you believe that the whooping cough vaccine is not 
safe for YOU:  
specific concern-
maternal 
I am confident that getting the whooping cough vaccine during my pregnancy 
is safe for MY UNBORN BABY.  
beliefs in vaccine 
safety-maternal 
The whooping cough vaccine is more likely to cause me to get sick than protect 
MY UNBORN BABY from getting whooping cough. 
specific concern-
maternal 
I do not want to put the whooping cough vaccine into my body when I am 
pregnant because I think it is unnatural. 
specific concern-
maternal 
I worry that the whooping cough vaccine will cause birth defects. 
specific concern-
maternal 
I worry that the ingredients in the whooping cough vaccine given to me during 
pregnancy are not safe for MY UNBORN BABY.  
specific concern-
maternal 
Please let us know why else you believe that the whooping cough vaccine is not 
safe for YOUR UNBORN BABY:  
specific concern-
maternal 
It is in my control whether or not I get vaccines during my pregnancy. 
self-efficacy-
maternal 
The majority of my friends and family would get the vaccines that are 
recommended during pregnancy.  
descriptive norm-
maternal 
The majority of my friends and family would encourage me to get the vaccines 
that are recommended during pregnancy.  
injunctive norm-
maternal 
I have most of the important information I need to make a decision about 
vaccines given during pregnancy.  
perception of 
knowledge 
I know enough about the safety of the flu vaccine to make a decision about 
getting the vaccine for myself while pregnant. 
perception of 
knowledge 
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for myself while pregnant. 
perception of 
knowledge 




Current guidelines suggest babies receive several vaccines. Regarding the 
vaccinations my doctor recommends for MY BABY AFTER BIRTH, I intend 
to get my baby: 
vaccine intentions-
pediatric 
Please let us know which vaccines you plan not to get: 
vaccine intentions-
pediatric 
I worry that my baby could get whooping cough after birth. 
susceptibility-
pediatric 
Whooping cough is dangerous for babies. severity-pediatric 
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Whooping cough is more dangerous for babies than older children or adults. severity-pediatric 
Getting the whooping cough vaccine for MY BABY AFTER BIRTH will 
reduce my baby's chances of getting whooping cough. 
response efficacy-
pediatric 
I am confident that vaccines are safe for MY BABY AFTER BIRTH.  
beliefs in vaccine 
safety-pediatric 
It is better for babies to get fewer vaccines at the same time. 
specific concern-
pediatric 
Babies get more vaccines in their first two years of life than are good for them. 
specific concern-
pediatric 
Vaccines often cause serious side effects in babies. 
specific concern-
pediatric 
The ingredients in vaccines are not safe for my baby. 
specific concern-
pediatric 
Please let us know why else you believe that vaccines are not safe for YOUR 
BABY AFTER BIRTH:  
specific concern-
pediatric 
It is in my control whether or not my baby gets his/her vaccines. 
self-efficacy-
pediatric 
Vaccines improve immunity. I believe it is better for my baby to develop their 
own immunity by getting sick rather than by getting a vaccine. 
self-efficacy-
pediatric 
The majority of my friends and family would get all of the vaccines 
recommended for THEIR BABIES AFTER BIRTH.  
descriptive norm-
pediatric 
The majority of my friends and family would encourage me to get all of the 
vaccines recommended for MY BABY AFTER BIRTH.  
injunctive norm-
pediatric 
I have most of the important information I need to make a decision about 
vaccines for MY BABY AFTER BIRTH.  
perception of 
knowledge 
I know enough about the safety of the whooping cough vaccine to make a 
decision about getting the vaccine for MY BABY AFTER BIRTH.  
perception of 
knowledge 
I trust the information provided by my obstetrician or midwife about vaccines 
during pregnancy. 
information source 
I trust the information provided by my obstetrician or midwife about vaccines 
for babies after birth. 
information source 
I trust the information provided by my baby's doctor about vaccines during 
pregnancy. 
information source 
I trust the information provided by my baby's doctor about vaccines for babies 
after birth. 
information source 
I trust the information provided by naturopathic and/or chiropractic doctors 
about vaccines during pregnancy. 
information source 
I trust the information provided by naturopathic and/or chiropractic doctors 
about vaccines for babies after birth. 
information source 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines during pregnancy. 
information source 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines for babies after birth. 
information source 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines during pregnancy. 
information source 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines for babies after birth. 
information source 
Most of the information about vaccines for babies after birth that I trust, I 
receive from: 
information source 







Thesis Appendix 2: Email to Invite Close Contacts to Join the Cocooning Study 
 
Note: The email provided in this Appendix was drafted by Matthew Dudley and edited by Rupali 
J. Limaye, PhD, Assistant Scientist at Johns Hopkins Bloomberg School of Public Health. 
 
 
Subject: Invitation to participate in the MomsTalkShots project 
Text: (referred contact name), 
(referring user name) has invited you to participate in a research project on the topic of maternal 
and childhood vaccines. MomsTalkShots, an app that helps mothers and family members make 
decisions about immunizations during pregnancy and after giving birth, would like to hear your 
thoughts about these vaccines. If you choose to participate, you will be asked to enroll in the app 
and complete a brief survey, for which you will receive a $20 gift card upon completion to thank 
you for your time. You will also receive a $10 gift card upon completion of a very brief follow-
up survey. If you then choose to receive flu and/or whooping cough vaccinations at a Walgreens, 
you will receive $10 worth of Walgreens Balance Rewards points for each vaccine received. If 
you choose to participate, please access the app by clicking here: (INSERT LINK).  
Thank you for your consideration! 
Sincerely,  
Matthew Z. Dudley, MSPH 
Project Coordinator 





Thesis Appendix 3: Intervention Contact Registration Survey 
 
Note: The survey provided in this Appendix was drafted by Matthew Dudley in tandem with 
Rupali J. Limaye, PhD, Assistant Scientist at Johns Hopkins Bloomberg School of Public Health. 
 
Question Construct 
Current guidelines suggest close friends and family members of pregnant 
women to receive two vaccines, flu and whooping cough. I intend to get: 
vaccine intentions-
contact 
I worry that the woman who referred me to this study could get the flu 
(influenza) while pregnant. 
susceptibility-
maternal 
The flu is dangerous for pregnant women. severity-maternal 
The flu is more dangerous for pregnant women than for women who are not 
pregnant. severity-maternal 
Getting the flu vaccine will reduce the chance of me giving the flu to both the 
pregnant woman who referred me to this study and to her baby.  
response efficacy-
maternal 
I am confident that getting the flu vaccine is safe.  
beliefs in vaccine 
safety-maternal 




I do not want to put the flu vaccine into my body because I think it is unnatural. 
specific concern-
maternal 
I worry that the ingredients in the flu vaccine are not safe. 
specific concern-
maternal 
Please let us know why else you believe that the flu vaccine is not safe:  
specific concern-
maternal 
I worry that the woman who referred me to this study could get whooping 
cough (pertussis) while pregnant. 
susceptibility-
maternal 
I worry that the baby of the woman who referred me to this study could get 
whooping cough after birth. 
susceptibility-
maternal 
Whooping cough is dangerous for pregnant women. severity-maternal 
Getting the whooping cough vaccine will reduce the chance of me giving 
whooping cough to both the pregnant woman who referred me to this study and 
to her baby. 
response efficacy-
maternal 
I am confident that getting the whooping cough vaccine is safe. 
beliefs in vaccine 
safety-maternal 
The whooping cough vaccine is more likely to cause me to get sick than protect 
me from getting whooping cough. 
specific concern-
maternal 
I do not want to put the whooping cough vaccine into my body because I think 
it is unnatural. 
specific concern-
maternal 
I worry that the ingredients in the whooping cough vaccine are not safe. 
specific concern-
maternal 




It is in my control whether or not I get vaccines. 
self-efficacy-
maternal 
The majority of my friends and family, IF THEY GOT PREGNANT TODAY, 





IF I OR MY PARTNER GOT PREGNANT TODAY, the majority of my 
friends and family would encourage us to get the vaccines that are 
recommended during pregnancy.  
injunctive norm-
maternal 




I know enough about the whooping cough vaccine to make a decision about 
getting the vaccine. 
perception of 
knowledge 
Whooping cough is dangerous for babies. severity-pediatric 
Whooping cough is more dangerous for babies than older children or adults. severity-pediatric 
I am confident that vaccines are safe for babies. 
beliefs in vaccine 
safety-pediatric 
It is better for babies to get fewer vaccines at the same time. 
specific concern-
pediatric 
Babies get more vaccines in their first two years of life than are good for them. 
specific concern-
pediatric 
Vaccines often cause serious side effects in babies. 
specific concern-
pediatric 
The ingredients in vaccines are not safe for babies. 
specific concern-
pediatric 
Please let us know why else you believe that vaccines are not safe for babies: 
specific concern-
pediatric 
Vaccines improve immunity. I believe it is better to develop immunity by 
getting sick rather than by getting a vaccine. 
self-efficacy-
pediatric 
The majority of my friends and family, IF THEY OR THEIR PARTNER GOT 
PREGNANT TODAY, would get all of the vaccines recommended for their 
baby after birth.  
descriptive norm-
pediatric 
IF I OR MY PARTNER GOT PREGNANT TODAY, the majority of my 
friends and family would encourage US to get all of the vaccines recommended 
for our baby after birth.  
injunctive norm-
pediatric 
I trust the information provided by my doctor about vaccines. information source 
I trust the information provided by naturopathic and/or chiropractic doctors 
about vaccines. information source 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines. information source 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines. information source 
Most of the information about vaccines that I trust, I receive from: information source 
I am comfortable receiving vaccines at a pharmacy instead of a doctor's office.   
Do you have any children?  
How old is your youngest child?  
What is your age?  
What is your gender?  
What is your annual income?  
What is your relationship to the pregnant woman who referred you to this 
study?  
On average, how often do you speak with her (the pregnant woman who 
referred you to this study)?  
On average, how often do you see her in person?  
I would encourage her to get the DTaP vaccine for her new baby.  
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I would encourage her to get the flu vaccine for her new baby.  
I got (or will get) the DTaP vaccine for my youngest child.  





Thesis Appendix 4: Intervention Contact Post-Video Survey 
 
Note: The survey provided in this Appendix was drafted by Matthew Dudley in tandem with 
Rupali J. Limaye, PhD, Assistant Scientist at Johns Hopkins Bloomberg School of Public Health. 
  
The vaccine information in this app was interesting. 
The vaccine information in this app was clear to understand. 
This app provided me information that was helpful. 
I trust the information provided about vaccines in this app. 
I know enough about the flu vaccine to make a decision about getting the vaccine. 
I know enough about the whooping cough vaccine to make a decision about getting the vaccine. 
Current guidelines suggest close friends and family members of pregnant women to receive two 
vaccines, flu and whooping cough. I intend to get: 





Thesis Appendix 5: Intervention Contact 60 Day Post-Birth Survey 
 
Note: The survey provided in this Appendix was drafted by Matthew Dudley in tandem with 
Rupali J. Limaye, PhD, Assistant Scientist at Johns Hopkins Bloomberg School of Public Health. 
 
Question Construct 
During the past year, I received: 
vaccine intentions-
contact 
Did you receive either vaccine at Walgreens? 
vaccine intentions-
contact 
Please enter the approximate date you received the flu vaccine.  
vaccine intentions-
contact 
Where did you receive your flu vaccine? 
vaccine intentions-
contact 
Please enter the approximate date you received the whooping cough vaccine.  
vaccine intentions-
contact 
Where did you receive your whooping cough vaccine? 
vaccine intentions-
contact 
I was satisfied with my experience receiving vaccines at Walgreens.  
I was satisfied with the Walgreens Balance Rewards Program.  
What did you like best about your experience at Walgreens?   
What could have been done to make this experience better?   
I am comfortable receiving vaccines at a pharmacy instead of a doctor's 
office.   
The flu is dangerous for pregnant women. severity-maternal 
The flu is more dangerous for pregnant women than for women who are not 
pregnant. severity-maternal 
Getting the flu vaccine (would have) reduced the chance of me giving the flu 
to both the pregnant woman who referred me to this study and to her baby.  
response efficacy-
maternal 
I am confident that getting the flu vaccine is safe.  
beliefs in vaccine 
safety-maternal 








I worry that the ingredients in the flu vaccine are not safe. 
specific concern-
maternal 
Please let us know why else you believe that the flu vaccine is not safe:  
specific concern-
maternal 
Whooping cough is dangerous for pregnant women. severity-maternal 
Getting the whooping cough vaccine (would have) reduced the chance of me 
giving whooping cough to both the pregnant woman who referred me to this 
study and to her baby. 
response efficacy-
maternal 
I am confident that getting the whooping cough vaccine is safe. 
beliefs in vaccine 
safety-maternal 
The whooping cough vaccine is more likely to cause me to get sick than 





I do not want to put the whooping cough vaccine into my body because I 
think it is unnatural. 
specific concern-
maternal 
I worry that the ingredients in the whooping cough vaccine are not safe. 
specific concern-
maternal 




It is in my control whether or not I get vaccines. 
self-efficacy-
maternal 
The majority of my friends and family, IF THEY GOT PREGNANT 
TODAY, would get the vaccines that are recommended during pregnancy.  
descriptive norm-
maternal 
IF I OR MY PARTNER GOT PREGNANT TODAY, the majority of my 
friends and family would encourage us to get the vaccines that are 
recommended during pregnancy.  
injunctive norm-
maternal 




I know enough about the whooping cough vaccine to make a decision about 
getting the vaccine. 
perception of 
knowledge 
Whooping cough is dangerous for babies. severity-pediatric 
Whooping cough is more dangerous for babies than older children or adults. severity-pediatric 
I am confident that vaccines are safe for babies. 
beliefs in vaccine 
safety-pediatric 
It is better for babies to get fewer vaccines at the same time. 
specific concern-
pediatric 




Vaccines often cause serious side effects in babies. 
specific concern-
pediatric 
The ingredients in vaccines are not safe for babies. 
specific concern-
pediatric 
Please let us know why else you believe that vaccines are not safe for babies: 
specific concern-
pediatric 
Vaccines improve immunity. I believe it is better to develop immunity by 
getting sick rather than by getting a vaccine. 
self-efficacy-
pediatric 
The majority of my friends and family, IF THEY OR THEIR PARTNER 
GOT PREGNANT TODAY, would get all of the vaccines recommended for 
their baby after birth.  
descriptive norm-
pediatric 
IF I OR MY PARTNER GOT PREGNANT TODAY, the majority of my 
friends and family would encourage US to get all of the vaccines 
recommended for our baby after birth.  
injunctive norm-
pediatric 
I trust the information provided by my doctor about vaccines. information source 
I trust the information provided by naturopathic and/or chiropractic doctors 
about vaccines. information source 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines. information source 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines. information source 





Thesis Appendix 6: Control Contact 60 Day Post-Birth Survey 
 
Note: The survey provided in this Appendix was drafted by Matthew Dudley in tandem with 
Rupali J. Limaye, PhD, Assistant Scientist at Johns Hopkins Bloomberg School of Public Health. 
 
Question Construct 
During the past year, I received: 
vaccine intentions-
contact 
Did you receive either vaccine at Walgreens? 
vaccine intentions-
contact 
Please enter the approximate date you received the flu vaccine.  
vaccine intentions-
contact 
Where did you receive your flu vaccine? 
vaccine intentions-
contact 
Please enter the approximate date you received the whooping cough vaccine.  
vaccine intentions-
contact 
Where did you receive your whooping cough vaccine? 
vaccine intentions-
contact 
I was satisfied with my experience receiving vaccines at Walgreens. cocooning 
I was satisfied with the Walgreens Balance Rewards Program. cocooning 
What did you like best about your experience at Walgreens?  cocooning 
What could have been done to make this experience better?  cocooning 
I am comfortable receiving vaccines at a pharmacy instead of a doctor's office.  cocooning 
The flu is dangerous for pregnant women. severity-maternal 
The flu is more dangerous for pregnant women than for women who are not 
pregnant. severity-maternal 
Getting the flu vaccine (would have) reduced the chance of me giving the flu 
to both the pregnant woman who referred me to this study and to her baby.  
response efficacy-
maternal 
I am confident that getting the flu vaccine is safe.  
beliefs in vaccine 
safety-maternal 








I worry that the ingredients in the flu vaccine are not safe. 
specific concern-
maternal 
Please let us know why else you believe that the flu vaccine is not safe:  
specific concern-
maternal 
Whooping cough is dangerous for pregnant women. severity-maternal 
Getting the whooping cough vaccine (would have) reduced the chance of me 
giving whooping cough to both the pregnant woman who referred me to this 
study and to her baby. 
response efficacy-
maternal 
I am confident that getting the whooping cough vaccine is safe. 
beliefs in vaccine 
safety-maternal 
The whooping cough vaccine is more likely to cause me to get sick than 





I do not want to put the whooping cough vaccine into my body because I think 
it is unnatural. 
specific concern-
maternal 
I worry that the ingredients in the whooping cough vaccine are not safe. 
specific concern-
maternal 




It is in my control whether or not I get vaccines. 
self-efficacy-
maternal 
The majority of my friends and family, IF THEY GOT PREGNANT TODAY, 
would get the vaccines that are recommended during pregnancy.  
descriptive norm-
maternal 
IF I OR MY PARTNER GOT PREGNANT TODAY, the majority of my 
friends and family would encourage us to get the vaccines that are 
recommended during pregnancy.  
injunctive norm-
maternal 




I know enough about the whooping cough vaccine to make a decision about 
getting the vaccine. 
perception of 
knowledge 
Whooping cough is dangerous for babies. severity-pediatric 
Whooping cough is more dangerous for babies than older children or adults. severity-pediatric 
I am confident that vaccines are safe for babies. 
beliefs in vaccine 
safety-pediatric 
It is better for babies to get fewer vaccines at the same time. 
specific concern-
pediatric 
Babies get more vaccines in their first two years of life than are good for them. 
specific concern-
pediatric 
Vaccines often cause serious side effects in babies. 
specific concern-
pediatric 
The ingredients in vaccines are not safe for babies. 
specific concern-
pediatric 
Please let us know why else you believe that vaccines are not safe for babies: 
specific concern-
pediatric 
Vaccines improve immunity. I believe it is better to develop immunity by 
getting sick rather than by getting a vaccine. 
self-efficacy-
pediatric 
The majority of my friends and family, IF THEY OR THEIR PARTNER GOT 
PREGNANT TODAY, would get all of the vaccines recommended for their 
baby after birth.  
descriptive norm-
pediatric 
IF I OR MY PARTNER GOT PREGNANT TODAY, the majority of my 
friends and family would encourage US to get all of the vaccines 
recommended for our baby after birth.  
injunctive norm-
pediatric 
I trust the information provided by my doctor about vaccines. information source 
I trust the information provided by naturopathic and/or chiropractic doctors 
about vaccines. information source 
I trust the information provided by federal agencies such as the Centers for 
Disease Control and Prevention (CDC) about vaccines. information source 
I trust the information provided by scientists and doctors at universities and 
academic institutions about vaccines. information source 
Most of the information about vaccines that I trust, I receive from: information source 
Do you have any children?  
How old is your youngest child?  
What is your age?  
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What is your gender?  
What is your annual income?  
What is your relationship to the pregnant woman who referred you to this 
study?  
On average, how often do you speak with her (the pregnant woman who 
referred you to this study)?  
On average, how often do you see her in person?  
I would encourage her to get the DTaP vaccine for her new baby.  
I would encourage her to get the flu vaccine for her new baby.  
I got (or will get) the DTaP vaccine for my youngest child.  





Full Vaccine Safety Review 
 
This section includes the full evidence supporting conclusions from Tables 3 and 4 of Manuscript 1 (The 
State of Vaccine Safety Science: Systematic Reviews of the Evidence). It is included here instead of within 
Manuscript 1 to keep the manuscript at a publishable length. The contents of this section are also found on 
the website for the Johns Hopkins Institute for Vaccine Safety (IVS), http://www.vaccinesafety.edu/, and 
in the book entitled The Clinician’s Vaccine Safety Resource Guide: Optimizing Prevention of Vaccine-
Preventable Diseases Across the Lifespan, written by the authors of this Manuscript 1 (with Matthew 
Dudley as first author) and published by Springer Publishing Company [506, 507].  
All content in this section was drafted by Matthew Dudley but reviewed and edited at length by the other 
book authors. Additional feedback on some of this content was given by other non-author reviewers, 
including: Kevin Ault, Steven Black, Allison Chamberlain, Robert Chen, Mindy Christianson, Kathryn 
Edwards, Laura Riley, Kawsar Talaat, Oladeji Oloko, Tina Proveaux, and the members of the Brighton 
Collaboration (Nick Andrews, Jim Buttery, Yolanda Guerra Mendoza, Jyoti Joshi, Daniel Keene, Bettina 
Klug, Philipp Lambach, Barbara Law, Noni MacDonald, Giuseppe Monaco, David Nalin, James M. Oleske, 








Do Combination Vaccines or Simultaneous Vaccination Increase the Risk of Adverse 
Events?  
 
Conclusion: Certain combination vaccines or simultaneous administration of vaccines that are 
known to cause fever can rarely cause febrile seizures in infants and young children beyond the 
risk presented by individually administered vaccines. Specifically, the rate of febrile seizures in 
the 7-10 days after vaccination was approximately 2-3 times higher for children who received 
MMRV as compared to MMR and varicella vaccines administered separately on the same day and 
4 times higher as compared to MMR alone, and when influenza and pneumococcal conjugate 
vaccines are given simultaneously as opposed to separately in children 6-59 months of age, the 
risk of febrile seizures in the 24 hours after vaccination increases from roughly 5 to 17.5 per 
100,000 doses.  
 
Simultaneous administration of Tdap and influenza vaccines during pregnancy does not increase 
the risk of acute adverse events or adverse birth outcomes. Combination vaccines and 
simultaneous administration of vaccines currently routinely recommended to the general 
population in the U.S.10F* have not been shown to cause any other adverse events at a greater rate 
than their individual vaccine components.  
 
Why this is an issue: Prior to 1985, vaccines protecting against seven diseases total were 
recommended for children under two years of age. As new vaccines have been developed, the 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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number of vaccines that are recommended for children and the number of diseases they protect 
against have increased correspondingly. According to the 2018 Immunization Schedule, available 
on the website of the Centers for Disease Control and Prevention (CDC) at 
http://www.cdc.gov/vaccines/schedules/, the vaccinations recommended by the Advisory 
Committee on Immunization Practices (ACIP) for children under two has now increased to protect 
against 14 different diseases. This is good news; it means our children are protected against more 
serious diseases than before possible. However, it is understandable that this increase has raised 
some concern regarding the safety of vaccinating infants and young children with multiple 
immunizations in a short period of time. 
 
Nonetheless, these concerns are unfounded. The immune systems of infants and children encounter 
millions of antigens in their environment every day; vaccines only contain a tiny fraction of a 
typical child’s daily exposure to antigens. New vaccines are tested extensively for safety and 
effectiveness at the recommended ages and with other recommended vaccines for years prior to 
introduction in the U.S. as part of the rigorous FDA requirements for licensure. The recommended 
schedule for children is then carefully constructed by the ACIP in collaboration with major 
physician organizations including the American Academy of Pediatrics and the American 
Academy of Family Physicians in order to provide the greatest possible safety and protection 
against disease. Refusing or delaying vaccines, or following alternative schedules, has been shown 
to increase risk of disease [6, 59, 93, 566-574].  
 
Epidemiological evidence:  Vaccines which may induce fever may also rarely induce febrile 
seizures. Febrile seizures are a common and typically benign childhood condition, occurring in 2-
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5% of children at some point during their first five years of life. Febrile seizures have an estimated 
background incidence of 240–480 per 100,000 person-years in children under five years, although 
this varies considerably by age, genetics, co-morbidities and environmental risk factors. There are 
no long-term effects of simple febrile seizures, [293-296]. See the Do Vaccines Cause Seizures? 
summary for more details. 
 
Febrile seizures occurred at a rate of 26.4 per 1000 person-years after MMR and 84.6 per 1,000 
person-years after MMRV (ProQuad®) in the 7-10 days after vaccination [297]. Several studies 
have confirmed that MMRV combination vaccine has a higher risk of febrile convulsions than 
simultaneous yet separate administration of the first dose of MMR and varicella vaccine 
(Varivax®) [297, 543-547]. There is no increased risk of fever or febrile seizures in children 
receiving their second dose of measles-containing vaccine at 4 to 6 years of age, whether given 
MMR or MMRV [40, 220]. Delaying MMR or MMRV vaccines past 15 months of age results in 
a higher risk of seizures than vaccinating according to the recommended schedule [548, 549].  
 
Febrile seizures were estimated to occur at a rate of 17.5 per 100,000 doses in children aged 6-59 
months after receiving concomitant trivalent inactivated influenza vaccine (abbreviation: TIV) and 
13-valent pneumococcal conjugate vaccine (abbreviation: PCV13; trade name: Prevnar13®); 
lower rates of 4.9 per 100,000 doses and 5.3 per 100,000 doses were estimated in children who 
received TIV without concomitant PCV13 and in children who received PCV13 without 
concomitant TIV, respectively. However, these risk differences varied substantially with age due 
to the age-dependent background rates of febrile seizures, with the highest estimates at 16 months 




A large cohort study found a small increased risk of febrile seizures after the first two doses of the 
DTaP-IPV-Hib combination vaccine in Denmark, with an absolute risk of less than 4 per 100,000 
vaccinations [550]. A large Vaccine Safety Datalink (VSD) study found no association between 
seizures and the DTaP-IPV combination vaccine (Kinrix®) among children 4 to 6 years of age 
[551]. 
 
Two methodologically sound, controlled epidemiological studies found no association between 
autism spectrum disorder (ASD) and simultaneous vaccination with multiple vaccines [513, 514], 
as well as a meta-analysis [118]. See the Do Vaccines Cause Autism? summary for more details. 
 
A 2002 report by the Institute of Medicine (IOM), now called the National Academy of Medicine 
(NAM), entitled Immunization Safety Review: Multiple Immunizations and Immune Dysfunction, 
found that the evidence favors rejection of a causal relationship between multiple immunizations 
and increased risk for infections and for type I diabetes [224].  
 
A 2013 IOM report entitled The Childhood Immunization Schedule and Safety: Stakeholder 
Concerns, Scientific Evidence, and Future Studies, the most comprehensive examination of the 
immunization schedule to date, uncovered no evidence of major safety concerns associated with 
adherence to the childhood immunization schedule [552]. 
 
A randomized trial in France and Belgium during the 2014–2015 influenza season found no 
difference in rates of symptoms among older adults comparing co-administration of IIV4 and 
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PPV23 with separate administration, with the exception of injection site pain which occurred more 
frequently in the co-administration group [553]. A 2016 report summarizing ten phase 3 and 4 
studies found no impact on vaccine reactogenicity or safety when co-administering routine 
vaccines with MenACWY-CRM [554]. A phase II randomized study found that co-administration 
of bivalent meningococcal B vaccine and DTaP/IPV was safe and well tolerated [555]. 
 
Retrospective cohort studies using the VSD found no increase in risk of acute adverse events or 
adverse birth outcomes among those vaccinated with Tdap or influenza vaccines during pregnancy 
[556], as well as among those vaccinated with Tdap during pregnancy when comparing those who 
had received a tetanus toxoid containing vaccine relatively recently with those who had not [396]. 
In addition, no increase in risk of acute adverse events or adverse birth outcomes were found 
among those vaccinated concurrently with Tdap and influenza vaccines during pregnancy 
compared to those vaccinated sequentially [371].  
 
A VSD nested case-control study of nearly half a million children found no significant difference 
in estimated cumulative vaccine antigen exposure through the first 23 months of life comparing 





Do Vaccine Ingredients Cause Adverse Events?  
 
Conclusion: Certain ingredients that are present in some vaccines (other than disease-specific 
antigens), such as gelatin or neomycin, can very rarely cause severe hypersensitivity reactions 
(e.g. anaphylaxis) in vaccinees with those specific allergies. In addition, some adjuvants can cause 
increased rates of local reactions, and alum containing adjuvants can cause nodules at the injection 
site. 
 
Vaccine ingredients, including the preservative thimerosal, do not cause autism. Ingredients in 
vaccines currently routinely recommended to the general population in the U.S. 11F* have not been 
shown to cause any other adverse events.  
 
Why this is an issue: As part of the Food and Drug Administration (FDA) Modernization Act of 
1997, the FDA conducted an analysis on exposure to mercury in children. This led them to examine 
the risk of thimerosal, an  ethylmercury containing preservative that was present in some vaccines 
at the time. The FDA risk assessment revealed no evidence of harm caused by the doses of 
thimerosal in vaccines other than local hypersensitivity reactions [120]. However, the exposure 
exceeded the United States Environmental Protection Agency (EPA) guidelines for 
methylmercury exposure; there were no available guidelines for ethylmercury, which is now 
known to have a shorter half-life than methylmercury. Long term follow-up of children to evaluate 
the risk of mild neurologic effects from ethylmercury had not been conducted at that time. Because 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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of the uncertainty in the risk assessment, as a precautionary measure thimerosal was removed as a 
preservative from most vaccines administered to children (small amounts of thimerosal are still 
present in multi-dose vials of influenza vaccine).  
 
Around this time, concern about autism and MMR vaccine had also begun to increase (see the Do 
Vaccines Cause Autism? summary for more details). As evidence mounted that MMR vaccine was 
not associated with autism, some autism interest groups shifted their hypothesis from MMR 
vaccine to the belief that thimerosal was causing autism in children. This theory was based upon 
observed similarities in some features of autism spectrum disorder (ASD) and mercury poisoning 
[119]. The plausibility of this suspected association was refuted by neurologists and several large 
studies have documented that thimerosal was not associated with an increased risk of autism 
spectrum disorder [121]. More information is available on the website of the Centers for Disease 
Control and Prevention (CDC) at http://www.cdc.gov/vaccinesafety/concerns/ thimerosal.  
 
Other vaccine ingredients including preservatives, adjuvants, or manufacturing residuals, can 
sound scary to the general public, especially when they are poorly understood. This has caused 
some understandable, albeit unfounded, concerns regarding the safety of these ingredients. 
Examples of this are aluminum and formaldehyde, which are known toxins for humans when 
consumed in large quantities. However, one must always keep the dosage in mind, as a great many 
things can be toxic with a high enough exposure. In the case of these vaccine ingredients, they 
present no danger in the miniscule quantities in which they are used in vaccines (which is typically 
much less than is found naturally in the body, common food or the environment), and serve only 
to stabilize the vaccine or enhance the immune response [542]. More information is available on 
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the FDA website at the following link: http://www.fda.gov/BiologicsBloodVaccines/ 
SafetyAvailability/VaccineSafety/ucm187810.htm. A full list of components by vaccine can be 
found at the Johns Hopkins Institute for Vaccine Safety website at the following link: 
http://www.vaccinesafety.edu/components.htm.  
 
Epidemiological evidence: Six methodologically sound, controlled epidemiological studies found 
no association between autism spectrum disorder (ASD) and thimerosal in vaccines [112, 508-
512], as well as the relevant systematic reviews [115, 116] and a meta-analysis [118]. The Institute 
of Medicine (IOM), now called the National Academy of Medicine (NAM), concluded that the 
body of evidence favors rejection of a causal relationship between autism and thimerosal-
containing vaccines [114]. See the Do Vaccines Cause Autism? summary for more details. 
 
A few studies have reported an association between vaccines containing aluminum adjuvants and 
persistent nodules at the injection site, at an estimated rate of 0.03-0.83% [533-536]. Two studies 
examining infant exposure to aluminum from both diet and vaccines concluded that aluminum 
adjuvants at the levels of in vaccines are well below the calculated safe body burden [537, 538]. 
A 2017 review found that current data do not support a causal relationship between aluminum 
containing vaccines and a variety of autoimmune disorders [539]. A meta-analysis of clinical trials 
of 25,056 children under 10 years of age who received vaccines with newer adjuvants AS01, AS02, 
AS03 or MF59 found no safety concerns [540].  
 
A review of data on substances sometimes found in certain vaccines in very small quantities, such 
as thimerosal, aluminum, gelatin, human serum albumin, formaldehyde, antibiotics, egg proteins, 
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and yeast proteins, found no evidence of harm other than rare instances of hypersensitivity 
reactions such as anaphylaxis in those with severe allergies to either gelatin or egg proteins [542]. 




Do Vaccines Cause Acute Disseminated Encephalomyelitis (ADEM)? 
 
Conclusion: Older formulations of rabies vaccine did cause Acute Disseminated 
Encephalomyelitis (ADEM), but newer formulations of rabies vaccine have not been shown to 
cause ADEM, and rabies vaccine is not routinely recommended to the general population in the 
United States. Other vaccines that are currently routinely recommended to the general population 
in the U.S.12F* have not been shown to cause ADEM. 
 
Epidemiological evidence: The Institute of Medicine (IOM), now called the National Academy 
of Medicine (NAM), found no relevant studies of quality in the literature assessing an association 
between vaccination and ADEM, since the only applicable studies available used passive 
surveillance systems and therefore lacked an unvaccinated comparison group [222]. Studies 
published since the 2012 IOM report have found no association between ADEM and the pandemic 
H1N1 influenza vaccine Pandremix [575], quadrivalent HPV vaccine (Gardasil®) [576-578] or 
hepatitis B vaccine [577]. However, one recent Vaccine Safety Datalink study did find a possible 
association between ADEM and Tdap vaccine estimated at no more than 1.16 excess cases per 
million vaccines administered [579].  
 
Proposed biological mechanism: ADEM has been reported very rarely after natural infections 
with wild-type measles, mumps, rubella, varicella, influenza, hepatitis A, and other viruses [222]. 
However, the pathophysiology of ADEM is not fully understood. Also, ADEM has been reported 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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very rarely after immunizations, but in most instances infections with other agents have not been 
ruled out and there is no available test to determine a causal association with a particular infection 
or vaccine. Biological mechanisms proposed to explain the immunogenic etiology of ADEM 
following infection or immunization include direct destruction [580] and molecular mimicry [581, 
582], which refers to the possibility that similar epitopes shared between self-peptides and foreign 
peptides (introduced via infection or immunization) inadvertently cause the activation of 
autoreactive T or B cells, leading to autoimmunity. In the case of ADEM, this abnormal immune 
response would be directed against the host’s myelin protein [583]. Although a temporal 
association with ADEM has been described for vaccines such as Japanese encephalitis, yellow 
fever, measles, influenza, varicella, and hepatitis [584-586], the only clear pathological association 
ever demonstrated was with the Semple rabies vaccine [587].  
 
The 2012 IOM report described two cases of ADEM after administration of the Engerix-B® 
hepatitis B vaccine showing a reoccurrence of symptoms after vaccine rechallenge [588, 589]; 
however, these were insufficient to conclude a causal association [222]. The report also described 
one case of ADEM after tetanus toxoid vaccination [590]; however, even after considering 
knowledge about the aforementioned natural infection, the IOM concluded that this mechanistic 
evidence was weak. The IOM concluded that the only mechanistic evidence for an association 
between ADEM and MMR, varicella or influenza vaccines was knowledge about the natural 
infections, and that there was no mechanistic evidence for all other vaccines, as the publications 




Do Vaccines Cause Arthralgia or Arthritis? 
 
Conclusion: Infections may trigger or contribute to the pathogenesis of arthritis. Thus, vaccines 
may prevent arthritis by protecting against natural infections. Rubella-containing vaccines (e.g. 
MMR) can cause mild, acute, transient arthralgia or arthritis, rarely in children but commonly in 
certain adult women (between 10-25% of adult female vaccinees without preexisting rubella 
immunity), usually beginning 1-3 weeks after vaccination and then persisting up to 3 weeks. Other 
vaccines currently routinely recommended to the general population in the U.S. 13F* have not been 
shown to cause chronic arthralgia or arthritis.  
 
Epidemiological evidence: Mild, acute, transient arthralgia occurs in approximately 25% of adult 
women without preexisting rubella immunity after rubella vaccination, and mild, acute, transient 
arthritis occurs in approximately 10%, usually beginning 1-3 weeks after vaccination and then 
persisting up to 3 weeks. Both are less common in men and rare in children [40].  
 
The 2012 report by the Institute of Medicine (IOM) [222], now called the National Academy of 
Medicine (NAM), described four studies in women [591-594] and seven studies in children [595-
601] that generally reported an increased risk of transient arthralgia after rubella or MMR 
vaccination. Also described are two studies assessing chronic arthralgia and arthritis in women 
[593, 594] and two studies assessing arthropathy in men [602, 603] after rubella or MMR 
vaccination; one study assessing the association between HPV vaccine and transient arthralgia 
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[604]; one study assessing the association between hepatitis B vaccination and exacerbation of 
rheumatoid arthritis [605]; and two studies assessing the association between diphtheria or tetanus 
toxoid vaccination and chronic arthritis [603, 606]; however, these studies did not provide 
convincing evidence due to a lack of validity and precision. The IOM found no relevant studies of 
quality in the literature providing evidence of an association between any other vaccines and 
chronic arthropathy [222].  
 
Most studies published since the 2012 IOM report did not show a statistically significant 
association between influenza and HPV vaccines and arthralgia [607-610]. One study found a 
relative risk of arthralgia of 2.0 (95% CI: 1.6-2.5) after receipt of a vero-cell culture-derived 
trivalent influenza vaccine [611], and another study found an odds ratio of grade 3 arthralgias of 
2.68 (95% CI: 1.29-5.59) after receipt of the AS04-adjuvanted HPV-16/18 vaccine (Cervarix®) 
among women in Korea [612]. No association has been found between vaccination and arthritis 
[576, 613-616]. Studies in patients with autoimmune inflammatory arthritis showed no change in 
disease severity or relapse rates after influenza vaccination [617-623].  
 
Proposed biological mechanism: Environmental factors such as infections may trigger or 
contribute to the pathogenesis of arthritis; however, the exact mechanisms are still unclear [624-
627].  
 
Based on both cases reviewed and knowledge about the natural infection, the IOM concluded that 
there was some mechanistic evidence in support of a causal relationship between rubella vaccine 
in women and arthralgia [591, 628-630]; however, there was less evidence for a relationship 
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between rubella vaccine in women and chronic arthralgia [630-632] or arthritis [629, 632]. There 
was little evidence for a relationship between rubella vaccine and arthropathy in men, transient 
arthralgia in children or chronic arthropathy in children [633, 634], for influenza vaccine and onset 
or exacerbation of arthropathy [635], or for hepatitis B vaccine and onset or exacerbation of 
arthritis [636, 637]. The IOM also concluded that there was no mechanistic evidence for an 




Do Vaccines Cause Asthma? 
 
Conclusion: Natural infection with influenza can contribute to asthma exacerbation. Thus, 
influenza vaccine prevents asthma exacerbation by protecting against natural infection. Influenza 
vaccines do not cause asthma or asthma exacerbation. Other vaccines currently routinely 
recommended to the general population in the U.S.* have not been shown to cause asthma or 
asthma exacerbation. 
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM) [222], now called 
the National Academy of Medicine (NAM), described a number of studies with sufficient validity 
and precision that all reported no association between inactivated influenza vaccination and asthma 
exacerbation [638-646]. The report described several studies with sufficient validity and precision 
that generally reported no association between live attenuated influenza vaccination (LAIV) and 
asthma exacerbation as well [275, 647-652]. However, a 2015 white paper on the safety of 
influenza vaccines concluded that LAIV was associated with an increase in wheezing in children 
ages 18 to 35 months who had a history of wheezing [653]. Two studies of the 2013-2014 and 
2014-2015 flu seasons in the United Kingdom study found that LAIV was well tolerated among 
those with well-controlled asthma or recurrent wheezing [654, 655]. A prospective observational 
cohort study found an increased risk of wheezing among California children 2-4 years of age 
during the 42-day risk interval after receiving quadrivalent LAIV during the 2013–2014 influenza 
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season [656]. One study published in 2015 suggests a possible protective effect of MMR 
vaccination against asthma [657]. 
 
Proposed biological mechanism: Influenza, along with other natural viral respiratory infections, 
can contribute to asthma exacerbation, as these viruses enter and replicate within airway epithelial 
cells, initiating an immune response. Natural influenza infection also causes greater morbidity in 
asthmatic subjects than in the general population, perhaps due to a difference in the antiviral 
response of asthmatics [658].  
 
The 2012 IOM report described cases of asthma exacerbation after both inactivated and live 
attenuated influenza vaccination [659]; however, even after considering knowledge about the 
aforementioned natural infection, the IOM concluded that this mechanistic evidence was weak 
[222].   
 
296 
Do Vaccines Cause Ataxia? 
 
Conclusion: Natural mumps and varicella infections are associated with acute cerebellar ataxia. 
Thus, mumps and varicella vaccines prevent ataxia by protecting against natural infection. 
Vaccines currently routinely recommended to the general population in the U.S. 15F* have not been 
shown to cause ataxia.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing an association between ataxia and measles, mumps, rubella, varicella, diphtheria, tetanus 
or pertussis vaccines, since the only applicable studies available either had serious methodological 
limitations or used passive surveillance systems and therefore lacked an unvaccinated comparison 
group [222].  
 
A Vaccine Safety Datalink study published since the 2012 IOM report found a lowered risk of 
ataxia in the interval shortly after both MMR and MMRV (ProQuad®) vaccination versus the 
comparison interval of 57 to 180 days after vaccination [660]. Per the 2007 ACIP 
recommendations, acute cerebellar ataxia has been previously described as potentially associated 
with single-antigen varicella vaccine (Varivax®); however, available data are insufficient to 
determine a causal association [319]. 
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Proposed biological mechanism: Wild-type mumps and varicella infections are associated with 
cerebellar ataxia, and wild-type measles virus is known to invade the central nervous system [222]. 
MMR and varicella vaccines are live attenuated viral vaccines, and are therefore able to replicate 
in the body. Although it is biologically possible for these live vaccines to cause ataxia, the available 
evidence has not demonstrated an increased risk. For more information, see the Measles, Mumps 
and Rubella and Varicella summaries.  
 
The 2012 IOM report described one case of ataxia after measles vaccination [661]; however, even 
after considering knowledge about natural measles, mumps and varicella infections, the IOM 
concluded that this mechanistic evidence was weak. The IOM also concluded that there was no 
mechanistic evidence for an association between ataxia and rubella, diphtheria, tetanus or pertussis 
vaccines, as the publications reviewed provided no evidence beyond a temporal association [222].   
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Do Vaccines Cause Autism? 
 
Conclusion: Childhood vaccines do not cause autism.  Maternal vaccines have not been shown 
to cause autism.  
 
The Institute of Medicine (IOM), now called the National Academy of Medicine (NAM), 
concluded that the body of evidence favors rejection of a causal relationship between autism and 
MMR vaccine and thimerosal-containing vaccines [114, 222]. MMR vaccine also prevents rubella 
disease, thus preventing congenital rubella syndrome and its associated cases of autism. 
 
Why this is an issue:  Andrew Wakefield, a gastroenterologist at the Royal Free Hospital in 
England, published a case series in the medical journal The Lancet in 1998. In this article he 
described 12 children with pervasive developmental disorder associated with gastrointestinal 
symptoms, 8 of whom had behavioral issues temporally associated with MMR vaccination via 
retrospective accounts by their parents or physicians [96]. Despite study authors acknowledging 
that this did not prove an association between the vaccine and autism, the lead author went far 
beyond the paper’s conclusions in a press release and ongoing interactions with the media [97, 98]. 
Public concern on the topic grew quickly. In 2010, Dr. Wakefield’s license to practice medicine 
in the UK was revoked by the British General Medical Council and his study was retracted by The 
Lancet as evidence of serious professional misconduct mounted. Among other infractions, 
Wakefield was found to have ordered unnecessary invasive procedures on children without 
approval of the hospital ethics committee and received undeclared financial considerations from 
the Legal Aid Board, a group pursuing multiparty legal action for allegedly vaccine-damaged 
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children [99-104]. In addition, he had applied for patents for vaccines to rival MMR vaccine. It 
was also revealed that, for most of the children in the original study, their symptoms either started 
well before or long after MMR vaccination. Despite the complete refutation of Wakefield’s 
fraudulent findings by the scientific community, concern still exists among some parents.  
 
Vaccines of interest:  While the initial vaccine targeted by Dr. Wakefield was MMR, the target 
has shifted over time, especially as epidemiological evidence accumulated that the MMR vaccine 
was not associated with autism spectrum disorder (ASD). Other targets have included the 
preservative thimerosal as well as simultaneous vaccination with multiple vaccines. See the Do 
Vaccine Ingredients Cause Adverse Events? and the Do Combination Vaccines or Simultaneous 
Vaccination Increase the Risk of Adverse Events? summaries for more details. 
 
Epidemiological evidence:  There have been 15 methodologically sound, controlled 
epidemiological studies exploring an association between ASD and receipt of MMR vaccine [105-
112], thimerosal in vaccines [112, 508-512], and simultaneous vaccination with multiple vaccines 
[513, 514], in addition to the relevant systematic reviews [113-117] and one meta-analysis [118]. 
Together, these studies included more than 1.8 million children. Notwithstanding 11 studies from 
another pair of authors [515-525], all of which had substantial methodological flaws [114-116, 
526], the epidemiological evidence consistently shows no association between MMR vaccine, 
thimerosal in vaccines, or simultaneous vaccination and ASD.  
 
One recent study suggested a possible increased risk of ASD among children whose mothers 
received an influenza vaccination during their first trimester of pregnancy, although this 
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association was not statistically significant after a post hoc analysis adjusting for multiple 
comparisons, and there was no association between ASD and influenza vaccination received 
during any trimester [527]. Another recent study showed that receiving Tdap vaccine during 
pregnancy is not associated with increased risk of ASD in the child [528].  
 
Proposed biological mechanism: The overlapping times of childhood vaccine administration and 
usual onset of ASD symptoms have led to speculations about a possible causal pathway; however, 
the proposed links have been unsubstantiated [529]. Several different theories were proposed to 
attribute the cause of ASD to vaccines. Wakefield suggested that a dysregulated immune response 
to measles antigen in the MMR vaccine led to persistent intestinal infection, allowing “toxins” to 
enter the blood stream and enter the central nervous system leading to developmental regression 
in children. He claimed support for this because of his alleged detection of measles virus RNA in 
bowel specimens of several children with ASD [96]. However, his referenced study was found to 
be fraudulent, and no evidence of persistent infection has been shown in studies that used 
appropriate methods [530-532]. Another proposed trigger for ASD was thimerosal, an 
ethylmercury-containing preservative that used to be present in some vaccines, although not in the 
MMR vaccine. This theory was based on observed similarities in some features of ASD and 
mercury poisoning [119]; however, the degree of these similarities and the plausibility of this 
suspected association was refuted by neurologists [121]. The IOM found no valid mechanistic 




Do Vaccines Cause Bell’s Palsy? 
 
Conclusion: Natural infections with varicella, tetanus and diphtheria have each been associated 
with Bell’s Palsy. Thus, varicella, tetanus and diphtheria vaccines prevent Bell’s Palsy by 
protecting against these natural infections. Vaccines currently routinely recommended to the 
general population in the U.S.16F* have not been shown to cause Bell’s Palsy.  
 
Epidemiological evidence: The only vaccine ever confirmed to cause Bell’s Palsy was Berna 
Biotech’s Nasalflu®, an inactivated intranasal influenza vaccine adjuvanted with E. coli heat-labile 
toxin which is no longer being produced. This vaccine was licensed for the 2000-2001 flu season 
in Switzerland and then permanently withdrawn from the market upon detection of the Bell’s Palsy 
caused by the vaccine [662]. It was never used in the United States. 
 
The 2012 report by the Institute of Medicine (IOM) [222], now called the National Academy of 
Medicine (NAM), described two studies with sufficient validity and precision that both reported 
no association between inactivated influenza vaccine and Bell’s Palsy [663, 664]. The report also 
described one study assessing an association between acellular pertussis vaccination and Bell’s 
Palsy [665]; however, this study did not provide convincing evidence due to a lack of validity and 
precision [222]. Most studies published since the 2012 IOM report have also reported no 
association between vaccination and Bell’s Palsy [666-668]; however, one study did find a 
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temporal association between receipt of meningococcal conjugate vaccine concomitantly with 
other vaccines and Bell’s Palsy [669].  
 
Proposed biological mechanism: Known causes of Bell’s Palsy include infections due to Borrelia 
burgdorferi, the agent of Lyme disease, and zoster virus in Ramsay-Hunt syndrome. Infections 
with Clostridium tetani or Corynebacterium diphtheria have been associated with facial nerve 
palsy as well, albeit very rarely [222]. Although other viral infections such as herpes simplex virus 
(HSV) and varicella zoster virus (VZV) have also been associated with Bell’s Palsy [670-673], the 
pathogenesis of Bell’s Palsy remains poorly understood. Hypotheses include reactivation of latent 
viral infections in facial nerve ganglia [674] or an autoimmune mechanism possibly with 
segmental demyelination [675]. Regarding the association of Bell’s Palsy with Nasalflu®, an 
influenza vaccine adjuvanted with E. coli heat-labile toxin, the most likely hypothesis is that the 
E. coli enterotoxin resulted in inflammation and entrapment of the facial nerve in the facial canal 
[653, 676].  
 
The IOM concluded that the only mechanistic evidence for an association between Bell’s Palsy 
and tetanus or diphtheria vaccines was knowledge about the natural infection, and that there was 





Do Vaccines Cause Brachial Neuritis? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S.17F* 
have not been shown to cause brachial neuritis.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing an association between vaccination and brachial neuritis [222]. No relevant studies of 
quality have been published since this report.  
 
Proposed biological mechanism: Although the etiology of brachial neuritis is still uncertain, it is 
generally considered to be an immune-mediated inflammatory reaction against nerve fibers in the 
brachial plexus. One possible mechanism is activation of the complement system, in which a 
cascade of proteolysis and successive release of cytokines functions to amplify the immune 
response but can damage host cells if not properly regulated. Other mechanisms for such a reaction 
include anti-peripheral nerve myelin antibodies or T cells [677].  
 
The IOM concluded that there was no mechanistic evidence for an association between vaccination 
and brachial neuritis, as the publications reviewed provided no evidence beyond a temporal 
association [222]. 
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Do Vaccines Cause Chronic Inflammatory Disseminated Polyneuropathy? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 18F* 
have not been shown to cause chronic inflammatory disseminated polyneuropathy (CIDP).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing CIDP and MMR, diphtheria, tetanus, pertussis, influenza, hepatitis A, hepatitis B, or 
meningococcal conjugate vaccines [222]. No relevant studies of quality have been published since 
this report. 
 
Proposed biological mechanism: One potential mechanism that could contribute to CIDP is 
molecular mimicry [222], which refers to the possibility that similar epitopes shared between self-
peptides and foreign peptides (introduced via infection or immunization) inadvertently cause the 
activation of autoreactive T or B cells, leading to autoimmunity. 
 
The 2012 IOM report described three reports of CIDP after influenza vaccine, in two of which 
development of CIDP occurred in the patients after vaccine administration in two separate years 
[678]. However, the publication provided no evidence beyond a temporal association and the IOM 
concluded that this mechanistic evidence was weak. The IOM also concluded that there was no 
mechanistic evidence for an association between CIDP and MMR, diphtheria, tetanus, pertussis, 
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hepatitis A, hepatitis B, HPV or meningococcal conjugate vaccines, as the publications reviewed 




Do Vaccines Cause Complex Regional Pain Syndrome? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 19F* 
have not been shown to cause complex regional pain syndrome (CRPS).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing CRPS and vaccination [222]. A combined analysis of seven phase III clinical trials of 9-
valent HPV vaccine published since this report found no association between the vaccine and 
CRPS [679]. 
 
Proposed biological mechanism: Previous controlled studies have shown an association between 
pain and injection of norepinephrine and phenylephrine [680, 681]. About half of patients with 
CRPS have documented trauma to the affected area prior to injection [222]. 
 
The 2012 IOM report described one case of CRPS after hepatitis B vaccination showing a 
reoccurrence of symptoms after vaccine re-challenge [682]. However, the rest of the publications 
reviewed provided little evidence beyond a temporal association [222].  
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Do Vaccines Cause Deltoid Bursitis? 
 
Conclusion: Vaccines can cause deltoid bursitis when administered incorrectly.  
 
Resources pertaining to correct administration of vaccines, including a printable infographic, are 
provided by the Centers for Disease Control and Prevention (CDC) at the following link: 
https://www.cdc.gov/vaccines/hcp/infographics/call-the-shots.html.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), described one study assessing an association between the 
injection of a vaccine and deltoid bursitis [683]; however, this study did not provide convincing 
evidence due to a lack of validity and precision [222].  
 
Proposed biological mechanism: A vaccine that is unintentionally injected into the synovial 
tissue structures underlying the deltoid muscle can induce a prolonged immune-mediated 
inflammatory response [684-686]. Such an error in vaccine administration could occur due to 
inappropriate needle length or improper injection technique involving administration in the upper 
one-third of the muscle [687-691]. The 2012 IOM report described several cases providing strong 
clinical evidence that vaccine injection was a contributing cause of the rapid development of 




Do Vaccines Cause Diabetes? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 20F* do 
not cause diabetes. 
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM) [222], now called 
the National Academy of Medicine (NAM), described a number of studies with sufficient validity 
and precision that all reported a lack of an association between MMR, DTaP or Tdap vaccines and 
type 1 diabetes [693-698]. Studies published since this report also reported a null, or in some cases 
even protective, association between vaccination and type 1 diabetes [576, 699-704]. This includes 
a meta-analysis of 23 observational studies investigating 16 different vaccines [705]. Studies 
examining inactivated seasonal influenza and Tdap vaccinations in pregnancy reported either no 
association with, or even a possible protective effect against, gestational diabetes [366, 394, 706, 
707]. National Health and Nutrition Examination Survey (NHANES) data from 2005-2010 
suggested a possible protective effect of hepatitis B vaccination against diabetes as well [708]. A 
retrospective observational study of California infants found no cases of type 1 diabetes during the 
30-day risk interval after 46,486 doses of DTaP-IPV/Hib vaccine administered [709].  
 
Persons with chronic illnesses such as type 1 or type 2 diabetes have high morbidity and mortality 
associated with common infectious diseases such as influenza, hepatitis b, and pneumococcal 
disease. Thus, routine vaccination per current ACIP recommendations is also strongly 
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recommended for all persons with diabetes by the American Diabetes Association [710, 711]. In 
addition, the ACIP recommends the administration of hepatitis b vaccine to all unvaccinated adults 
with diabetes mellitus aged 19 through 59 [712].  
 
Proposed biological mechanism: Mechanisms that may induce type 1 diabetes include activation 
of the complement system, in which a cascade of proteolysis and successive release of cytokines 
functions to amplify the immune response but can damage host cells if not properly regulated, as 
well as molecular mimicry, which refers to the possibility that similar epitopes shared between 
self-peptides and foreign peptides (introduced via infection or immunization) inadvertently cause 
the activation of autoreactive T or B cells, leading to autoimmunity. However, the IOM concluded 
that there was no mechanistic evidence for an association between vaccination and type 1 diabetes, 




Do Vaccines Cause Disseminated Varicella Infection? 
 
Conclusion: Disseminated varicella infection is a serious potential complication of natural 
infection with varicella virus, particularly among immunodeficient persons. Thus, varicella 
vaccine prevents disseminated varicella infection by protecting against natural infection. However, 
varicella vaccines can rarely cause disseminated varicella infection in patients with severe 
immune deficiency, for whom the vaccine is contraindicated. Other vaccines currently routinely 
recommended to the general population in the U.S.21F* do not cause disseminated varicella infection.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), described one study assessing varicella vaccination with 
disseminated varicella infection [713]; however, it did not provide convincing evidence due to a 
lack of validity and precision [222].  
 
Proposed biological mechanism: Varicella vaccines are live attenuated viral vaccines, and are 
therefore able to replicate in the body. Generalized rash is reported in 4-6% of recipients. Systemic 
reactions are uncommon but possible. Mild zoster illness (shingles) resulting from a latent 
infection with varicella vaccine virus has been reported. Immunodeficiency is a contraindication 
for most live vaccines, including varicella vaccine. For more information, see the Varicella 
summary.  
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The 2012 IOM report described cases of disseminated varicella infection after varicella 
vaccination [714-733], and concluded that these cases together presented strong mechanistic 
evidence supporting an association [222]. In immunodeficient persons, disseminated varicella 
infection can also result in pneumonia [714-716, 725-727], meningitis [718], or hepatitis [714-
716, 720, 722].  
 
There have been several deaths due to disseminated varicella in children who had undiagnosed 
severe combined immunodeficiency (SCID) at the time of vaccination. However, it is extremely 




Do Vaccines Cause Erythema Nodosum?  
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 22F* 
have not been shown to cause erythema nodosum (EN).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing EN and hepatitis B vaccine [222]. No relevant studies of quality have been published 
since this report. 
 
Proposed biological mechanism: The most common cause of EN is infection [738]. Although 
the pathogenesis of EN is not fully understood, it is thought to be caused by an influx of immune 
complexes into the subcutaneous fat [739]. Another possible mechanism is activation of the 
complement system, in which a cascade of proteolysis and successive release of cytokines 
functions to amplify the immune response but can damage host cells if not properly regulated. 
Other mechanisms that could contribute to the development of EN include autoantibodies or T 
cells [222].  
 
The 2012 IOM report described one case of EN after hepatitis B vaccination [740]; however, the 
IOM concluded that this mechanistic evidence was weak. 
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Do Vaccines Cause Fibromyalgia or Chronic Fatigue Syndrome?  
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 23F* 
have not been shown to cause fibromyalgia or chronic fatigue syndrome (CFS).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing an association between fibromyalgia and MMR, influenza, hepatitis B or DTaP vaccines, 
or between CFS and MMR vaccine [222]. One self-controlled case series published since this 
report found no association between CFS and bivalent HPV vaccine (Cervarix®) [741]. Two 
Norwegian register-based studies found no increased risk of CFS following pH1N1 vaccination 
[742] or HPV vaccination [743], respectively. 
 
Proposed biological mechanism: The etiological causes and underlying pathogenic mechanisms 
of fibromyalgia and CFS are still unclear and the subject of much debate [744-746]. Theories that 
attempt to explain the mechanisms behind the development of these two disorders generally focus 
on sympathetic nervous system dysfunction, the inflammatory and oxidative stress pathways and 
the neuroendocrine system. Symptoms such as pain and fatigue have been associated with chronic 
inflammation, raised levels of oxidative stress and mitochondrial dysfunction. It has also been 
suggested that the hypothalamic-pituitary-adrenal axis and cortisol also have a role in the 
pathogenesis of fibromyalgia and CFS; however, it is still unclear whether these pathways are 
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causes or just byproducts of these syndromes [747, 748]. Environmental stimuli such as stress or 
viral infection are thought to be able to trigger the pathogenesis of these disorders in genetically 
predisposed individuals [745, 749]. 
 
The IOM concluded that there was no mechanistic evidence for an association between 





Do Vaccines Cause Guillain-Barré Syndrome? 
 
Conclusion: Influenza vaccines reduce the risk of influenza infection, which causes Guillain-
Barré syndrome (GBS). Thus, influenza vaccines prevent GBS by protecting against natural 
influenza infection. However, influenza vaccines can very rarely cause GBS within 6 weeks of 
vaccination in adults, at an estimated rate of 1-3 cases per million vaccinations. Influenza vaccines 
have not been shown to cause GBS in children. Older formulations of rabies vaccine did cause 
GBS, but newer formulations of rabies vaccine have not been shown to cause GBS, and rabies 
vaccine is not routinely recommended to the general population in the United States. Other 
vaccines that are currently routinely recommended to the general population in the U.S. 24F* have not 
been shown to cause GBS. 
 
In most years when influenza vaccine strains are a good match for the circulating wild type viruses, 
influenza vaccines prevent much more GBS than the vaccines cause [286, 653]. Therefore, the 
very small risk of GBS from influenza vaccines pales in comparison to the benefits of the 
vaccine.  
 
Why this is an issue: In 1976, a new strain of influenza emerged that bore similarities to the strain 
that caused the deadly 1918 flu pandemic. A vaccine consisting of the inactivated strain was 
prepared and administered to mitigate the impact of a pandemic if it were to occur. Fortunately, 
the feared pandemic never occurred. However, safety surveillance installed and expanded as part 
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of this program picked up clusters of GBS in the recently vaccinated. Although this adverse event 
was quite rare, it was shown to be significantly associated with this particular vaccine, and the 
program was terminated in late 1976 amid much public criticism. Enhanced surveillance for GBS 
after influenza vaccination has been conducted since this time [286, 750].  
 
Epidemiological evidence: The incidence of GBS due to all causes has been estimated as 0.4–4.0 
cases per 100,000 person-years [286]. Clinical trials do not approach the size necessary to examine 
a potential causal association between vaccines and a rare adverse event like GBS [751]. A 
systematic literature review identified 24 relevant controlled studies with unduplicated data, 
including 9 cohort [663, 750, 752-758], 3 case-control [759-761] and 12 self-controlled studies 
[287, 762-772].  
 
Adults who received the 1976-77 swine flu vaccine were 9.5 (95% Confidence Interval: 8.2-10.3) 
times more likely to develop GBS compared to those who did not receive the vaccine [750]. This 
increased risk was primarily in the six weeks following vaccination, translating into about one 
excess cases per 100,000 vaccinations. Without the widespread pandemic of swine influenza 
anticipated in 1976, this risk of GBS led to the cessation of the 1976-77 flu vaccine campaign.  
 
Since the 1976-77 influenza season, safety surveillance has monitored GBS after influenza 
vaccination closely. The level of risk seen in 1976-77 has been ruled out in these studies. A meta-
analysis of 6 active surveillance systems in the U.S. in the 2009-10 influenza season showed a 
small statistically significant increased risk of GBS in the 42 days after pandemic H1N1 influenza 
vaccination (incident rate ratio 2.35; 95% CI 1.53-3.68) [287]. An international collaboration in 
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the 2009-10 influenza season combining data from Australia, Canada, China, Denmark, Finland, 
the Netherlands, Singapore, Spain, the UK, and the U.S. found a similarly small but significant 
increase in risk during the 42 days post pandemic H1N1 vaccination (relative incidence 2.42; 95% 
CI 1.58-3.72) [767]. A 2015 meta-analysis also found a small but significant increase in risk of 
GBS following influenza vaccination (relative risk 1.41; 95% CI 1.20-1.66), although the risk was 
higher for pandemic vaccines (RR 1.84; 95% CI 1.36-2.50) than for seasonal vaccines (RR 1.22; 
95% CI 1.01-1.48) [773]. These three meta-analyses indicate an approximate doubling of risk of 
GBS in the six weeks following pandemic H1N1 influenza vaccination. This is also consistent 
with estimates of risk of GBS in many studies of seasonal influenza vaccine, many of which were 
underpowered to show such a small increase in risk with statistical significance [287, 663, 750, 
752-772, 774]. This doubling of risk translates into only 1-3 excess cases of GBS per million 
persons vaccinated, with a higher attributable risk among older populations due to a higher 
background rate of GBS among older populations. The evidence for post-influenza vaccine GBS 
among children is inadequate to draw definitive conclusions. The risk for GBS post-influenza 
vaccine is much less than the estimated risk after wild-type influenza infection, providing further 
evidence that the benefits of influenza vaccination greatly outweigh the risks [286].  
 
Other than influenza vaccines, vaccines routinely used in the U.S. have not been shown to cause 
GBS.  A retrospective observational study of California infants found no cases of GBS during the 
30-day risk interval after 46,486 doses of DTaP-IPV/Hib vaccine administered [709]. A review of 
quadrivalent HPV vaccine safety data published between 2006 and 2015 found no increase in 
incidence of GBS compared to background rates [775]. Most studies published since this 2006-
2015 review have also found no increased risk of GBS following HPV vaccine [776-778], with 
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the exception of one large cohort study in France [779], which found a positive association between 
HPV vaccine and GBS (adjusted hazard ratio 3.78; 95% CI 1.79-7.98), resulting in an attributable 
risk of 1-2 GBS cases per 100,000 girls vaccinated against HPV. One rabies vaccine that contained 
sheep brain tissue was associated with GBS, but this vaccine is no longer used in the U.S. [780].  
 
Proposed biological mechanism: Most GBS cases are preceded by a recent respiratory or 
gastrointestinal infection. Campylobacter jejuni, which causes gastrointestinal infections, is the 
most common specific infectious agent identified through molecular mimicry. [781]. 
Campylobacter jejuni induces antibodies that react against GM1 gangliosides in human neurons 
due to shared antigenic and epitopic features with lipo-oligosaccharide moieties on the cell wall of 
the Campylobacter bacterium [782, 783]. The mechanism for other infectious agents associated 




Do Vaccines Cause Hearing Loss? 
 
Conclusion: Natural infections with viruses such as measles and mumps have been associated 
with both transient and permanent hearing loss. Thus, measles and mumps vaccines prevent such 
hearing loss by protecting against natural infection. Vaccines currently routinely recommended to 
the general population in the U.S.25F* have not been shown to cause hearing loss.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing hearing loss and MMR vaccine, since the only applicable study available used a passive 
surveillance system and therefore lacked an unvaccinated comparison group [222]. A large case-
centered analysis published since the IOM report found no association between hearing loss and 
vaccination [785]. 
 
Proposed biological mechanism: Natural infection with wild-type mumps virus has been 
associated with transient high-frequency deafness in 4.4% of cases among members of the military, 
as well as with permanent unilateral deafness approximately once every 20,000 cases [222]. Prior 
to the use of mumps vaccine, mumps was the most common cause of acquired hearing loss in 
children in the United States and other countries [786-788]. Direct viral infection has been 
implicated as the mechanism in such cases of hearing loss. Measles infection can also cause 
hearing loss, most likely as a result of encephalitis [222, 789]. 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 




The 2012 IOM report described several cases [790-792] and some experimental evidence [793, 
794] of hearing loss after measles or mumps vaccines. The IOM concluded that there was no 
mechanistic evidence for an association between hearing loss and rubella vaccine [222]. Although 
spontaneous hearing loss does rarely occur after these vaccinations, the causes are unknown, and 




Do Vaccines Cause Hepatitis? 
 
Conclusion: Natural infection with hepatitis viruses is known to cause hepatitis disease. Natural 
infection with measles, mumps, rubella and varicella viruses have also been associated with 
hepatitis, albeit rarely. Thus, measles, mumps, rubella and varicella vaccines, and especially 
hepatitis A and hepatitis B vaccines, prevent hepatitis disease by protecting against natural 
infection. Vaccines currently routinely recommended to the general population in the U.S. 26F* do not 
cause hepatitis when administered to immunocompetent persons. 
 
Varicella is a live virus vaccine that is contraindicated for most patients with underlying immune 
deficiencies. If the vaccine is mistakenly administered to severely immune deficient individuals, 
it can cause hepatitis as well as other complications. For more information, see the Varicella, the 
Do Vaccines Cause Disseminated Varicella Infection? and the Do Vaccines Cause Herpes Zoster? 
summaries. 
 
Patients with chronic hepatic diseases such as chronic hepatitis B or hepatitis C infection can and 
should receive all routine vaccinations as recommended by the ACIP. Hepatitis A and hepatitis B 
vaccines are specifically recommended for such individuals to protect them from these natural 
infections leading to more severe disease [795].  
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing an association between hepatitis and either MMR or Hepatitis A vaccines [222]. No 
relevant studies of quality have been published since this report. 
 
Proposed biological mechanism: Infection with wild-type hepatitis viruses can cause both acute 
and chronic hepatitis disease. However, hepatitis A vaccine is formalin-inactivated and hepatitis 
B vaccine is a yeast-derived recombinant vaccine; neither are live vaccines [40]. For more 
information, please see the Hepatitis A and Hepatitis B summaries.  
 
Infection with wild-type measles, mumps, rubella and varicella viruses have on rare occasions 
been associated with hepatitis. Potential mechanisms in which general viral infection could 
contribute to symptoms of hepatitis include activation of the complement system, in which a 
cascade of proteolysis and successive release of cytokines functions to amplify the immune 
response but can damage host cells if not properly regulated, as well as autoantibodies or T cells 
[222]. MMR and varicella vaccines are live attenuated viral vaccines, and are therefore able to 
replicate in the body. For more information, see the Measles, Mumps and Rubella and Varicella 
summaries.  
 
The IOM found only weak mechanistic evidence for an association between hepatitis and either 
MMR or Hepatitis A vaccines, even when considering knowledge about the natural infection, as 







Do Vaccines Cause Herpes Zoster? 
 
Conclusion: Varicella vaccines can rarely cause herpes zoster due to vaccine-strain viral 
reactivation. Other vaccines currently routinely recommended to the general population in the 
U.S.44F* do not cause vaccine-strain viral reactivation.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), described one study assessing varicella vaccination with 
vaccine-strain viral reactivation [796]; however, it did not provide convincing evidence due to a 
lack of validity and precision [222]. One large randomized controlled trial published since the 
2012 IOM report and conducted in ten European countries found one unconfirmed case of herpes 
zoster infection and one papular rash out of 4976 recipients of either the MMR vaccine Priorix® 
and the varicella vaccine Varilrix® or the combination MMRV vaccine Priorix-Tetra®, all vaccines 
not used in the U.S. Both of these serious adverse events45F1 were reported as recovered or resolved 
[797].  
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
 
1 A serious adverse event is defined by the Food and Drug Administration (FDA) as resulting “in any of the 
following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-
threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.” This definition is found in Title 21, §312.32 of the Electronic Code of Federal 
Regulations, which can be accessed at the following link:  http://www.ecfr.gov/cgi-bin/text-idx?SID= 
6b68426ec6d55c78a6799d161ba 6754c&mc=true&node=se21.5.312_132&rgn=div8  
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Proposed biological mechanism: Varicella vaccines are live attenuated viral vaccines, and are 
therefore able to replicate in the body. Generalized rash is reported in 4-6% of recipients. Systemic 
reactions are uncommon but possible. Mild zoster illness (shingles) resulting from a latent 
infection with varicella vaccine virus has been reported. Some cases of herpes zoster after 
vaccination are due to reactivation of wild type varicella virus from a prior (usually unrecognized) 
primary varicella infection [714]. Immunodeficiency is a contraindication for most live vaccines, 
including varicella vaccine. For more information, see the Varicella summary.  
 
The 2012 IOM report described cases of vaccine-strain viral reactivation after varicella vaccination 
[714-733], and concluded that these cases together presented strong mechanistic evidence 
supporting an association [222]. A laboratory-documented case of herpes zoster caused by the 
vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine was 
reported in 2014 [798]. In immunodeficient persons, vaccine-strain viral reactivation can result in 




Do Vaccines Cause Hypersensitivity Reactions (e.g. anaphylaxis, hives)? 
 
Conclusion: Vaccines can very rarely cause immediate hypersensitivity reactions (i.e. 
anaphylaxis, angioedema, and/or hives) usually within minutes, but up to several hours of 
vaccination in persons with allergy to a vaccine component. Also, vaccines can cause large local 
swelling reactions or nodules at the injection site due to delayed-type hypersensitivity reactions. 
 
International consensus for evaluation and management of allergic reactions to vaccines can be 
found at the following link: https://waojournal.biomedcentral.com/articles/10.1186/s40413-
016-0120-5 [272]. 
 
Epidemiological evidence: Allergic reactions to vaccines (including immediate hypersensitivity 
reactions) have been estimated to occur approximately once per 50,000-1,000,000 doses. 
Anaphylaxis, the most concerning type of such reactions, has been estimated to occur 
approximately once per 100,000-1,000,000 doses for most commonly administered vaccines 
[272]. Rates of anaphylaxis can differ depending on the vaccine, age of the recipient, and gender; 
for example, adult females are at a relatively higher risk of hypersensitivity reactions including 
anaphylaxis than males. However, anaphylaxis is very rare [541]. Hives occurs more commonly, 
but no precise rate is available. 
 
The 2012 report by the Institute of Medicine (IOM), now called the National Academy of Medicine 
(NAM), described one study assessing influenza vaccination and anaphylaxis [663]; however, this 
study did not provide convincing evidence of an association due to a lack of validity and precision. 
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The IOM found no relevant studies of quality in the literature assessing any other vaccines and 
anaphylaxis, since the only applicable studies available used passive surveillance systems and 
therefore lacked an unvaccinated comparison group [222]. However, numerous case studies have 
provided strong mechanistic evidence, as described in the Proposed Biological Mechanism section 
below.  
 
Most studies published since the 2012 IOM report have not found a statistically significant 
association between vaccination and anaphylaxis [551, 758, 772, 775], but this is unsurprising 
considering the rarity of this adverse event and possibility of misclassification; prospective cohort 
studies are usually too small to detect the small increased risk of anaphylaxis following vaccines 
[541]. A recent Vaccine Safety Datalink study identified 33 confirmed vaccine-triggered 
anaphylaxis cases among 25,173,965 vaccine doses, which corresponds to a rate of 1.3 cases of 
anaphylaxis per million vaccine doses [799]. Two studies of the 2013-2014 and 2014-2015 flu 
seasons in the United Kingdom study found no occurrences of systemic allergic reactions 
following LAIV in young people with egg allergy, even among those who had previously 
experienced anaphylaxis to eggs [654, 655]. A prospective observational cohort study of California 
children and adults 2-49 years of age found no significantly increased risk of hypersensitivity 
during the 3-day risk interval for 62,040 quadrivalent LAIV recipients during the 2013–2014 
influenza season overall; although when restricting the analysis to recipients 5-8 years of age, a 
significantly higher risk of hypersensitivity was observed [656]. 
 
The IOM found no relevant studies of quality in the literature assessing chronic urticaria and 
diphtheria, tetanus or pertussis vaccines [222]. Since the publication of the 2012 IOM report, 
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randomized controlled trials in Hong Kong and Korea found no increased risk of urticaria in 
recipients of the AS04-adjuvanted HPV-16/18 vaccine (Cervarix®) [610, 612]. A randomized 
controlled trial in the U.S. found no association between localized or systemic urticaria and the 
inactivated influenza vaccine Fluzone® [269]. A randomized controlled trial in the U.S. and South 
America found no association between quadrivalent meningococcal conjugate vaccine and 
urticaria in young infants in the year following vaccination [800]. A retrospective observational 
study of California infants had 3 cases of urticaria considered related to vaccine receipt out of 
46,486 doses of DTaP-IPV/Hib vaccine administered [709].  
 
A few studies have reported an association between vaccines containing aluminum adjuvants and 
persistent nodules at the injection site, at an estimated rate of 0.03-0.83% [533-536]. Extensive 
swelling reactions in the injected limb after vaccination with DTaP has also been reported [801-
803]. 
 
Proposed biological mechanism: Vaccines have been shown to incite immediate hypersensitivity 
reactions, including anaphylaxis, usually mediated through IgE antibody. These reactions are more 
likely due to potential allergens among the vaccine constituents rather than to the active 
ingredients, but often the direct cause of the reaction is not discovered [804]. Chronic urticaria 
involves different pathogenic mechanisms [272]. A full list of potential allergens within vaccines 





The 2012 IOM report provides case reports of anaphylaxis after MMR [805-816], varicella [715, 
716, 817-822], influenza [817, 823-829], hepatitis B [817], meningococcal conjugate [830] and 
tetanus toxoid vaccines [831-834], which together present strong mechanistic evidence for a rare 
causal association with these vaccines. The report also provides several reports for HPV [835, 836] 
and hepatitis A vaccines [828], for which the mechanistic evidence is less conclusive [222].  
 
Development of acute urticaria is associated with natural infections, including viral hepatitis and 
many different bacteria [837-839]. One mechanism that could contribute to the development of 
chronic urticaria is IgE hypersensitivity. Other possible mechanisms include activation of the 
complement system, in which a cascade of proteolysis and successive release of cytokines 
functions to amplify the immune response but can damage host cells if not properly regulated. 
However, the IOM concluded that there was no mechanistic evidence for an association between 





Do Vaccines Cause Immune Thrombocytopenic Purpura? 
 
Conclusion: Natural viral infections such as influenza, varicella, measles, mumps and rubella are 
associated with immune thrombocytopenic purpura (ITP). Thus, influenza, varicella, measles, 
mumps and rubella vaccines prevent ITP by protecting against natural infection. Measles-
containing vaccines can very rarely cause ITP within 6 weeks of vaccination in children. 
However, these vaccines prevent many more cases of ITP than they cause. Influenza vaccines 
do not cause ITP. Other vaccines currently routinely recommended to the general population in 
the U.S.27F* have not been shown to cause ITP.  
 
Epidemiological evidence: Rates of ITP after MMR vaccination have been estimated at 1-3 cases 
per 100,000 doses [40, 840, 841]. However, this is significantly lower than rates of ITP after 
natural infection otherwise prevented by the vaccine; the incidence of ITP after natural rubella 
infection is an estimated 1 per 3,000, and incidence after natural measles infection is estimated to 
be even higher [841]. 
 
The 2012 report by the Institute of Medicine (IOM), now called the National Academy of Medicine 
(NAM), found no relevant studies of quality in the literature assessing an association between ITP 
and diphtheria, tetanus, pertussis and varicella vaccines, since the only applicable studies available 
used passive surveillance systems and therefore lacked an unvaccinated comparison group [222].  
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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Studies published since this report have consistently shown an increased risk of thrombocytopenic 
purpura in children within 6 weeks of measles-containing vaccination [840-843]. However, several 
studies published since this report have found no association between influenza vaccines and ITP 
[768, 844, 845], and early childhood vaccines other than MMR or MMRV (ProQuad®) have not 
been shown to cause ITP [840, 841]. One study examining the safety of trivalent inactivated 
seasonal influenza vaccination in pregnant women reported a null association with 
thrombocytopenia [846]. A VSD study of 438,487 live births between 2007 and 2013 found 
slightly decreased rates of venous thromboembolic events and thrombocytopenia among pregnant 
women receiving Tdap vaccination [394]. A retrospective observational study of California infants 
found no cases of ITP during the 30-day risk interval after 46,486 doses of DTaP-IPV/Hib vaccine 
administered [709]. 
 
Proposed biological mechanism: ITP has been associated with natural viral infections such as 
influenza, varicella, measles, mumps and rubella [841, 847]. Patients with ITP have antibodies to 
platelets. Measles virus has an affinity for platelets and measles vaccine results in a transient 
decrease in platelet counts in the first few days following vaccination. ITP occurs later, within the 
first 6 weeks following vaccination. The most likely pathogenesis for ITP involves altered immune 
processing of the measles virus-platelet aggregations and induction of anti-platelet antibodies 
[848]. The IOM found only weak mechanistic evidence for an association between ITP and 
varicella vaccine, even when considering knowledge about the natural infection, as the only post-
vaccination case documented provided little evidence beyond recurrence of symptoms after 
vaccine re-challenge [716]. The IOM also concluded that there was no mechanistic evidence for 






Do Vaccines Cause Meningitis or Encephalitis/Encephalopathy? 
 
Conclusion: Varicella vaccine in routine use in the United States28F* can very rarely cause viral 
meningitis. Measles-containing vaccines can very rarely cause measles inclusion body 
encephalitis (MIBE). Mumps vaccines used in other countries have caused meningitis and 
encephalitis. However, the mumps vaccine in routine use in the United States* is made from a 
different strain of vaccine virus and has not been shown to cause meningitis or encephalitis. The 
benefit of vaccination in preventing neurologic diseases such as meningitis and encephalitis 
greatly outweighs the minimal risk of vaccine complications. 
 
Natural infections with measles, mumps, rubella and varicella viruses can cause encephalitis and 
meningitis. Thus, measles, mumps, rubella and varicella vaccines protect against encephalitis and 
meningitis caused by these agents. These vaccines are made from attenuated versions of the wild-
type viruses, and do not cause central nervous system infections in normal hosts. However, these 
attenuated vaccine viruses can cause disease in persons with certain immune deficiencies, and are 
therefore contraindicated in these populations. For instance, varicella vaccine virus can persist and 
cause reactivation zoster, which has been very rarely associated with viral meningitis, although 
affected patients without immune deficiencies recover fully without any lasting effects. In 
addition, very rare cases of measles inclusion body encephalitis (MIBE) have occurred following 
administration of measles-containing vaccines.  
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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Natural infections with Neisseria meningitidis (meningococcus), Streptococcus pneumoniae 
(pneumococcus) and Haemophilus influenzae type b (Hib) can cause severe bacterial meningitis. 
Pneumococcal, Hib, and meningococcal vaccines protect against meningitis caused by these 
agents. The vaccines that protect against these infections do not cause meningitis; the vaccines are 
made from only the outer capsule and/or bacterial proteins so they cannot cause infections like the 
naturally occurring bacteria [40, 849-854].  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM) [222], now called 
the National Academy of Medicine (NAM), described three studies with sufficient validity and 
precision that reported null associations between MMR vaccine and meningitis [110, 855, 856]. 
The report also described several studies assessing meningitis, encephalitis or encephalopathy and 
MMR [110, 857, 858], DTaP [665, 859] or meningococcal [858] vaccines, but these studies did 
not provide convincing evidence due to a lack of validity and precision. The IOM found no relevant 
studies of quality in the literature assessing encephalitis or encephalopathy and varicella, influenza 
or hepatitis B vaccines, since the only applicable studies available either had serious 
methodological limitations or used passive surveillance systems and therefore lacked an 
unvaccinated comparison group [222].  
 
Since the publication of the 2012 IOM report, one large post-licensure study found no association 
between herpes zoster vaccination and meningitis, encephalitis or encephalopathy [860]. A case-
centered analysis of 110 childhood encephalitis cases from California found no association 
between vaccination and encephalitis [861]. Large Vaccine Safety Datalink studies found no 
association between meningitis/encephalitis and either 2012-2013 influenza vaccines [758], the 
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DTaP-IPV combination vaccine (Kinrix®) [551], or MMR, MMRV (ProQuad®) and varicella 
vaccine (Varivax®) [660]. A retrospective observational study of California infants found no cases 
of encephalitis or meningitis during the 30-day risk interval after 46,486 doses of DTaP-IPV/Hib 
vaccine administered [709]. A 2017 Norwegian registry study found no increased risk of 
encephalitis following pH1N1 vaccine [862].  
The IOM found no relevant epidemiologic studies of quality in the literature assessing an 
association between vaccination and MIBE [222].  
 
Proposed biological mechanism: An estimated 1-10% of persons naturally infected with wild-
type mumps virus develop meningitis. Natural infection with wild-type measles, mumps or rubella 
viruses occasionally leads to development of encephalitis, at estimated rates of one case per 1000-
2000 patients infected with measles, 400-6000 patients infected with mumps, or 5000 patients 
infected with rubella, respectively [222]. Measles can also cause a persistent infection of the brain 
resulting in subacute sclerosing panencephalitis (SSPE), which occurs at a rate of approximately 
22 cases of SSPE per 100,000 reported cases of measles [863]. Natural infection with wild-type 
influenza has also been associated with encephalitis, albeit rarely [222, 864-866].  
 
In early-onset encephalitis after infection with mumps virus, neuronal damage is suspected to 
result from direct viral invasion. Natural viral infection can cause meningitis or encephalitis via 
either direct viral invasion or a viral-induced autoimmune reaction. Mechanisms proposed for the 
development of meningitis or encephalitis after viral vaccination include direct viral infection, 
autoimmune mechanisms resulting in post-infectious encephalitis (such as ADEM), varicella 
vaccine-strain viral reactivation, and persistent viral infection [222]. For more information, see the 
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Do Vaccines Cause Acute Disseminated Encephalomyelitis (ADEM)? and the Do Vaccines Cause 
Herpes Zoster? summaries. 
 
Encephalitis and encephalopathy have even been reported as complications of some bacterial 
infections such as diphtheria and pertussis. There is also some evidence that pertussis-specific 
antigens can traverse the blood-brain barrier and thereby directly affect the central nervous system 
[222]. Historically, the whole cell pertussis vaccine (no longer used in the US) was associated with 
encephalopathy within 7 days of vaccination by the IOM in 1994. However, subsequent studies 
have failed to show such an association [857, 867], and a landmark study from 2006 showed that 
11 of 14 children with alleged vaccine encephalopathy actually had a specific de novo mutation 
explaining their encephalopathy (SCN1A encephalopathy, also known as Dravet Syndrome) [868].  
 
The IOM also concluded that there was no mechanistic evidence of quality showing an association 
between encephalitis or encephalopathy and varicella, hepatitis b and meningococcal vaccines, nor 
for an association between meningitis and measles or rubella vaccines, as the publications 
reviewed provided no evidence beyond a temporal association [222]. The 2012 IOM report 
described several cases of encephalitis or encephalopathy after MMR [869-871], influenza [872] 
and DTaP [873] vaccines, and four cases of meningitis after mumps vaccine [869, 874, 875], but 
when considering knowledge about the natural infection the IOM concluded this mechanistic 
evidence was weak [222]. However, there is one well documented case of measles vaccine virus 
isolated from the cerebrospinal fluid of a patient with encephalitis in Canada [876], as well as 
documented cases of meningitis following reactivation of vaccine-type varicella zoster virus [731, 




MMR and varicella vaccines are live attenuated viral vaccines which replicate in the body. Severe 
immunosuppression is a contraindication for MMR, MMRV, and varicella vaccine [40]. For more 
information, see the Measles, Mumps and Rubella and Varicella summaries.  
 
In immunodeficient persons, persistent infection with live vaccine viruses is possible. Measles 
vaccine virus can lead to central nervous system infection and MIBE [222]. The 2012 IOM report 
described several cases of MIBE after measles vaccination in immunodeficient persons [876, 879, 
880], and concluded that these cases together presented strong mechanistic evidence supporting 




Do Vaccines Cause Multiple Sclerosis? 
 
Conclusion: Influenza vaccines do not cause multiple sclerosis (MS). Other vaccines currently 
routinely recommended to the general population in the U.S.29F* have not been shown to cause MS.  
 
Epidemiological evidence: Most studies described in the 2012 report by the Institute of Medicine 
(IOM), now called the National Academy of Medicine (NAM), found no association between 
vaccination and MS, whether assessing onset [881-885] or relapse [886, 887] in adults, or onset 
[881, 888] or relapse [889] in children; however, these studies did not provide convincing evidence 
due to a lack of validity and precision [222]. Studies published since the 2012 IOM report focusing 
on the pandemic H1N1 influenza vaccine Pandremix [575, 614, 890], quadrivalent HPV vaccine 
(Gardasil®) [576-578, 775] and hepatitis B vaccine [577] have also found no association with MS. 
A white paper on influenza vaccine safety published in 2015 concluded that while each individual 
study had relatively low power, as a group they provide consistent evidence against a causal 
association between influenza vaccine in adults and MS onset or relapse; although the data are 
more limited in children, there is no signal to indicate concern [653]. A recent systematic review 
found no increase in risk of development of MS after vaccination against hepatitis B, HPV, 
influenza, MMR, tetanus, diphtheria, polio, smallpox, or BCG vaccines [891]. Another recent 
literature review also found no increase in risk of onset or relapse of MS after vaccination [892]. 
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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Proposed biological mechanism: Hypersensitivity reactions triggered by autoimmunity, genetics 
or environmental factors such as viral infection are often incriminated in the destruction of the 
host’s myelin basic protein (MBP) and other antigens [893]. Similarities in features of MS and 
other demyelinating disorders have been described and some subjects with the diagnosis of Acute 
Disseminated Encephalomyelitis (ADEM) have had recurrences and progressed to MS [585, 894]. 
One possible mechanism is molecular mimicry, which refers to the possibility that similar epitopes 
shared between self-peptides and foreign peptides (introduced via infection or immunization) 
inadvertently cause the activation of autoreactive T or B cells, leading to autoimmunity. Of the 
many vaccines assessed for a possible association with MS, the hepatitis B vaccine has captured 
the most interest, because molecular mimicry has been demonstrated in rabbits between hepatitis 
B viral polymerase and the part of the MBP that leads to encephalitis [895]. This suggests that 
infection with a virus showing similarities with MBP regions associated with the development of 
encephalitis could induce MS through molecular mimicry. However, the IOM concluded that there 
was no mechanistic evidence for an association between vaccination and MS, as the publications 




Do Vaccines Cause Myocardial Infarction or Stroke? 
 
Conclusion: Myocardial infarction (MI) has been associated with natural influenza infection, and 
stroke has been associated with natural varicella infection, albeit both very rarely. Thus, influenza 
vaccine prevents MI and varicella vaccine prevents stroke by protecting against natural infection. 
Vaccines currently routinely recommended to the general population in the U.S. 30F* have not been 
shown to cause myocardial infarction or stroke. Influenza vaccine has been associated with a 
reduced risk of stroke.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), described one study with sufficient validity and precision 
that reported a decreased risk of both MI and stroke within the first month after influenza vaccine 
[896]. The report also described one study assessing stroke and varicella vaccine (Varivax®) 
[796], but this study did not provide convincing evidence due to a lack of validity and precision 
[222].  
 
A matched case-control study of 78,706 persons published since the 2012 IOM report found that 
receipt of seasonal influenza vaccine within the previous year was significantly associated with 
lower odds of MI (adjusted odds ratio: 0.81; 95% confidence interval: 0.77-0.85) and receipt of 
pneumococcal vaccine was not associated with a change in odds of MI in adults [897]. Another 
matched case-control study of 94,022 persons found that receipt of seasonal influenza vaccine 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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within-season was significantly associated with lower odds of stroke (aOR: 0.76; 95% CI: 0.72-
0.80) and receipt of pneumococcal vaccine was not associated with a change in odds of stroke 
[898]. A self-controlled case-series study of 17,853 persons found a reduction in incidence of 
stroke after receipt of influenza vaccine [899]. In all three of these studies, early seasonal influenza 
vaccination (before mid-November) was much more beneficial than later seasonal influenza 
vaccination. A 2017 meta-analysis also concluded that influenza vaccine was associated with a 
reduced risk of stroke (OR: 0.82; 95% CI: 0.75-0.91) [900]. A self-controlled case series found a 
decreased incidence of MI up to 60 days after seasonal influenza vaccination, ranging from a 32% 
reduction within the first 14 days (incidence rate ratio: 0.68; 95% CI: 0.60-0.78) to a 18% reduction 
within 29-59 days (IRR: 0.82; 95% CI: 0.75-0.90) [901]. A case-control study of 559 Australian 
patients also found decreased odds of MI after influenza vaccination (aOR: 0.55; 95% CI 0.35-
0.85) [902]. Pooled data from several studies examining adults with recent ischemic stroke found 
no association between influenza vaccination and MI or stroke [903]. Two case-control studies 
and one population study of Taiwanese patients over 65 years of age found decreased odds of 
cardiovascular events such as MI and stroke after influenza vaccination [904-906]. Prospective 
cohorts of older adults found that receipt of pneumococcal polysaccharide vaccine was either not 
associated with MI or stroke [907, 908] or associated with a decreased risk of acute coronary 
syndrome events in general [909, 910]. A prospective cohort of 27,204 Spanish individuals 
initially found a decreased risk of stroke in individuals receiving 23-valent pneumococcal 
polysaccharide vaccine [911]; however, this association was later refuted by the authors [912]. 
This study did show that influenza vaccine was associated with reduced risk of death from stroke 
[913], and that pneumococcal vaccine was not associated with MI [914]. A study in 193,083 adults 
over 50 years of age found no association between varicella zoster vaccine and MI using both case-
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centered and self-controlled case series analyses [860]. Two large Vaccine Safety Datalink studies 
found no association between stroke and receipt of quadrivalent HPV vaccine (Gardasil®) in 
females age 9 to 26 [915] or receipt of the DTaP-IPV combination vaccine (Kinrix®) in children 
age 4 to 6 [551], respectively. A review of quadrivalent HPV vaccine safety data published 
between 2006 and 2015 found no increase in incidence of stroke compared to background rates 
[775]. Herpes zoster vaccine was not associated with an increased risk of stroke or cardiovascular 
events in numerous safety studies [916]. A 2015 international case-control study concluded that 
routine vaccinations in childhood appear to be protective against stroke [917]. A 2015 Cochrane 
review determined that influenza vaccination may reduce cardiovascular mortality and combined 
cardiovascular events among patients with cardiovascular disease, although not enough evidence 
was available to establish whether influenza vaccination prevented primary cardiovascular disease 
[918]. 
 
Proposed biological mechanism: Potential mechanisms for MI include viral infection and 
alterations in the coagulation cascade [222]. MI has been associated with natural influenza 
infection, albeit very rarely [919]. Potential mechanisms for stroke include direct viral infection, 
viral reactivation, and alterations in the coagulation cascade [222]. Stroke has been associated with 
natural varicella infection, at an incidence of about 1 in 15,000 cases [920]. 
 
The IOM concluded that the only mechanistic evidence for an association between MI and live 
attenuated influenza vaccine or between stroke and varicella vaccine was knowledge about the 
natural infections. The IOM also concluded that there was no mechanistic evidence for an 
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association between stroke and influenza vaccine or between MI and inactivated influenza vaccine, 




Do Vaccines Cause Myocarditis or Myocardopathy/Cardiomyopathy? 
 
Conclusion: Myocarditis can be induced by either viral or bacterial infection, most notably 
developing in up to two thirds of persons infected with diphtheria. Thus, diphtheria vaccine 
prevents myocarditis by protecting against natural infection. Smallpox vaccine does very rarely 
cause myocarditis and myocardopathy/cardiomyopathy, but is not routinely recommended to the 
general population in the United States. Other vaccines that are currently routinely recommended 
to the general population in the U.S. 31F* have not been shown to cause myocarditis or 
myocardopathy/cardiomyopathy.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing myocarditis and diphtheria, tetanus or pertussis vaccines [222].  
 
One study published since this report of 193,083 adults over 50 years of age found no association 
between zoster vaccine and myocarditis using both case-centered and self-controlled case series 
analyses [860]. A VSD study of 438,487 live births between 2007 and 2013 found no increased 
risk of cardiac events such as cardiomyopathy, myocarditis, pericarditis, or heart failure among 
pregnant women receiving Tdap vaccination [394]. 
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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U.S. military personnel administered smallpox vaccine had almost 7.5 times higher incidence of 
myopericarditis in the 30 days post vaccination than non-vaccinated active duty military personnel 
(16.11 per 100,000 vaccinees versus 2.16 per 100,000 non-vaccinees) [921]. A 2015 prospective 
cohort study also found an increased risk of myocarditis/pericarditis after smallpox vaccine, but 
no cases of myocarditis after receipt of trivalent inactivated influenza vaccine [922].  
 
Proposed biological mechanism: Myocarditis often results from a prolonged immune response 
induced by viral infection [923]. In particular, myocardopathy/cardiomyopathy develops in up to 
two thirds of persons infected with Corynebacterium diphtheria, due to the effects of the exotoxin 
released by the bacteria. However, the diphtheria vaccine does not contain active toxin. Other 
mechanisms that could contribute to myocarditis include autoantibodies or T cells [222].  
 
The IOM concluded that there was no mechanistic evidence for an association between 




Do Vaccines Cause Narcolepsy? 
 
Conclusion: The AS03-adjuvanted 2009 pandemic H1N1 influenza vaccine (trade name: 
PandemrixTM) was associated with an increased risk of narcolepsy in several northern European 
countries. In other countries where there is a lower prevalence of genetic factors associated with 
narcolepsy, studies did not find an increase in risk with this vaccine or other influenza vaccines. 
The vaccine in question (PandemrixTM) was not licensed in the United States, and vaccines in 
routine use in the United States32F* have not been shown to cause narcolepsy.  
 
Why this is an issue: A sharp increase in the number of narcolepsy diagnoses in children was 
noticed shortly after immunization campaigns for the pandemic 2009 H1N1 vaccines in Finland 
and Sweden. Subsequent analysis confirmed an association between the European AS03-
adjuvanted pandemic 2009 H1N1 vaccine (PandemrixTM) and narcolepsy onset in several northern 
European countries. Immunization with this vaccine is thus no longer recommended in children 
[924-926]. This vaccine was not used in the United States, and no increase in narcolepsy has been 
found with any vaccine routinely used in the United States.  
 
Epidemiological evidence: Multiple studies have consistently documented an increased risk of 
narcolepsy associated with AS03-adjuvanted influenza vaccines, primarily in the childhood 
populations of northern European countries [575, 924-936]. The estimated rate was 1 case per 
16,000 persons vaccinated between 4 and 19 years of age in Finland [924]. The strength of this 
                                                          
* These conclusions do not consider vaccines recommended only for special populations in the United States such as 
Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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association varied depending on the country studied, with an intermediate association in the rest 
of Europe and a possible association in Canada [930, 937]. This could be explained by differences 
in population genetics [938]. Studies have not shown any association between narcolepsy and other 
influenza vaccines, either MF59-adjuvanted or without an adjuvant [656, 772, 939-941]. A cohort 
study of almost one million adolescent girls in Denmark and Sweden found no association between 
quadrivalent HPV vaccine and narcolepsy [942]. A 2018 meta-analysis found that during the first 
year after vaccination with PandemrixTM the relative risk of narcolepsy increased 5 to 14-fold in 
children and adolescents and 2 to 7-fold in adults, and the vaccine attributable risk in children and 
adolescents was approximately 1 per 18,400 doses of vaccine [943]. 
 
Proposed biological mechanism: The 1918 pandemic of influenza infection was associated with 
an illness consistent with narcolepsy. The 2009-10 pandemic influenza may have been associated 
with an increase in narcolepsy in China, but no increase was observed in many other countries 
[944]. Almost all patients with narcolepsy have HLA DQB1*0602, a genetic marker for 
predisposition to the disorder [945, 946]. Recent studies have provided further evidence that 
infections may serve as a potential trigger for the pathogenesis of narcolepsy [947]. A number of 
mechanisms have been postulated to explain the association with the ASO3-adjuvanted vaccine in 
several European countries, but many of these hypotheses have been found to be lacking. One 
recent hypothesis includes the possibility that a combination of infection with the 2009 pandemic 
H1N1 influenza virus followed by the ASO3-adjuvanted vaccine could have resulted in narcolepsy 




Do Vaccines Cause Oculorespiratory Syndrome? 
 
Conclusion: The Fluviral S/F® and Vaxigrip® vaccines used in Canada between 2000 and 2003 
(but never used in the United States) did commonly cause oculorespiratory syndrome (ORS) 
within 24 hours of vaccination, at an estimated rate of up to 2.9 cases per 100 vaccinations. 
Changes have been made in the formulation of these vaccines that have resulted in a dramatic 
decrease in the risk of ORS. 
 
There have been reports of ORS-like symptoms after receipt of inactivated influenza vaccines 
(IIV) in routine use in the United States. However, these reports are rare, and symptoms are 
generally mild and transient. 
 
Why this is an issue: ORS is an adverse event associated with influenza vaccine that was first 
described in Canada during the 2000-2001 influenza season. It is characterized by conjunctivitis, 
facial swelling, and upper respiratory symptoms that develop within 24 hours of vaccination. ORS 
is generally mild, resolving within 48 to 72 hours [31]. 
 
Epidemiological evidence: 96% of the ORS cases reported in Canada during the 2000–2001 
influenza season occurred after vaccination with Fluviral S/F® [949]. The attributable risk of ORS 
for the 2001-2002 formulation of Fluviral S/F® was estimated to be 2.9 cases per 100 vaccinees 
[950]. The 2012 report by the Institute of Medicine (IOM) [222], now called the National Academy 
of Medicine (NAM), described three studies with sufficient validity and precision that 




Most studies have not demonstrated a causal relationship between ORS and influenza vaccines 
used in the U.S. [641]. However, according to the 2012 IOM report, this could be due to 
underreporting of the typically mild symptoms of ORS as well as the annual variance in influenza 
vaccine formulation [222]. The ACIP recommendations for influenza vaccines in 2013-2014 noted 
several investigations that identified persons with symptoms meeting an ORS case definition in 
safety monitoring systems and trials that had been conducted before 2000 in Canada, the United 
States, and Europe [953]. 
 
Proposed biological mechanism: The clinical presentation of ORS indicates that its pathogenesis 
is most likely immune-based [31]. One mechanism suggested for the development of ORS after 
influenza vaccination is activation of the complement system, in which a cascade of proteolysis 
and successive release of cytokines functions to amplify the immune response but can damage host 
cells if not properly regulated [222]. Possible mechanisms of complement activation by influenza 
viruses include direct binding of the matrix (M1) protein [954] and immune complex formation 
with preformed nonprotective antibodies leading to tissue pathology [955]. Host factors involving 
cytokine production may also predispose some individuals to develop ORS after influenza 
vaccination [956].  
 
The presence of numerous microaggregates of unsplit viruses in the 2000-2001 Canadian 
formulation has been proposed as an important factor behind that season’s high rates of ORS, and 




The 2012 IOM report described both experimental and clinical evidence [951, 952, 957-960] 




Do Vaccines Cause Opsoclonus Myoclonus Syndrome? 
 
Conclusion: Opsoclonus myoclonus syndrome (OMS) is a very rare neurological condition that 
generally begins at one to two years of age and is characterized by uncontrolled, irregular and rapid 
movements of the muscles and eyes [54].  
 
Vaccines currently routinely recommended to the general population in the U.S. 34F* have not been 
shown to cause OMS. 
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing OMS and measles, mumps, rubella, diphtheria, tetanus or pertussis vaccines [222]. No 
relevant studies of quality have been published since this report. 
 
Proposed biological mechanism: OMS is generally caused by either a tumor or a viral infection 
[961-964]. Potential mechanisms for OMS include activation of the complement system, in which 
a cascade of proteolysis and successive release of cytokines functions to amplify the immune 
response but can damage host cells if not properly regulated, as well as molecular mimicry, which 
refers to the possibility that similar epitopes shared between self-peptides and foreign peptides 
(introduced via infection or immunization) inadvertently cause the activation of autoreactive T or 
B cells, leading to autoimmunity.  
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 




The IOM concluded that there was no mechanistic evidence for an association between OMS and 
measles, mumps, rubella, diphtheria, tetanus or pertussis vaccines, as the publications reviewed 




Do Vaccines Cause Optic Neuritis or Neuromyelitis Optica? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 35F* 
have not been shown to cause optic neuritis or neuromyelitis optica (NMO).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM) [222], now called 
the National Academy of Medicine (NAM), described two studies assessing optic neuritis and 
MMR, influenza, hepatitis B, diphtheria and tetanus vaccines [883, 965], but these studies did not 
provide convincing evidence due to a lack of validity and precision. The IOM found no relevant 
studies of quality in the literature assessing optic neuritis and pertussis vaccine or NMO and MMR, 
influenza, hepatitis B or HPV vaccines [222].  
 
Studies published since the 2012 IOM report have not found evidence of an association between 
vaccination and optic neuritis. A prospective cohort study of 189,629 females receiving 
quadrivalent HPV vaccine (Gardasil®) in California did not find a statistically significant 
association with optic neuritis [576]. A Vaccine Safety Datalink study found no cases of optic 
neuritis in over 200,000 pregnant women within 42 days after receiving trivalent inactivated 
influenza vaccine [846]. A claims-based retrospective matched cohort analysis of females 9-26 
years of age did not find an association between HPV vaccine and optic neuritis [966]. A cohort 
study of 3,983,824 females 10-44 years of age in Denmark and Sweden found no association 
between quadrivalent HPV vaccine and demyelinating diseases including optic neuritis and 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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neuromyelitis optica [578]. A case-centered analysis in a large integrated Californian health plan 
population did not find an association between vaccines and optic neuritis [967]. A recent literature 
review found no increase in risk of optic neuritis after vaccination [892]. 
 
Proposed biological mechanism: Anti-phosphatidylcholine antibodies have been suggested as a 
potential cause of optic neuritis [968]. A highly specific immunoglobulin G autoantibody that 
targets aquaporin-4 is present in up to 80% of patients with NMO [969, 970]. One possible 
mechanism for this is molecular mimicry, which refers to the possibility that similar epitopes 
shared between self-peptides and foreign peptides (introduced via infection or immunization) 
inadvertently cause the activation of autoreactive T or B cells, leading to autoimmunity. Another 
possible mechanism is activation of the complement system, in which a cascade of proteolysis and 
successive release of cytokines functions to amplify the immune response but can damage host 
cells if not properly regulated. Other mechanisms that could contribute to optic neuritis or NMO 
include formation of immune complexes, as well as direct or persistent viral infection. Natural 
infection with wild-type measles, mumps or rubella viruses has been associated with optic neuritis, 
albeit very rarely [222].  
 
The 2012 IOM report described two cases of optic neuritis after MMR [971, 972], two cases of 
optic neuritis after influenza vaccine showing a reoccurrence of symptoms after vaccine 
rechallenge [678, 973], and one case of NMO after rubella vaccine [974]; however, even when 
considering knowledge about the aforementioned natural infections, the IOM concluded that this 
mechanistic evidence was weak. The IOM also concluded that there was no mechanistic evidence 
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for an association between optic neuritis and hepatitis B, diphtheria, tetanus or pertussis vaccines, 




Do Vaccines Cause Primary Ovarian Insufficiency?  
 
Conclusion: Vaccines in routine use in the United States36F* have not been shown to cause primary 
ovarian insufficiency (POI, formerly called primary ovarian failure), and the available evidence 
does not support a causal relationship.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), did not assess POI as a potential outcome of vaccination 
[222]. A recent VSD retrospective cohort study of nearly 200,000 young women in Oregon and 
Washington found no association between HPV, Tdap, or MenACWY vaccines and POI [249]. 
Publications of case series include a combined six total case reports of POI that may have had 
onset at varying times after HPV vaccination [975-977]. Other publications are mostly limited to 
commentaries about the reports, and preliminary analyses from passive surveillance or ecological 
data.  
 
Proposed biological mechanism: The cause of POI is not known for most affected patients and 
only a very small proportion of cases are due to autoimmunity [978]. Mechanisms proposed by 
authors of case reports for HPV to be involved with the pathogenesis involve either toxic effects 
or autoimmune responses to the vaccine [979, 980]. However, questions have been raised 
regarding the validity of the arguments put forth in these publications in several letters to the editor 
[981, 982] and a special editorial [983]. Major problems with the proposed associations include 
                                                          
* These conclusions do not consider vaccines recommended only for special populations in the United States such as 
Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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the inconsistent time intervals between vaccination and onset, the plausibility of the proposed 
mechanism, the lack of population-level or passive surveillance changes in rates, and potential 
conflicts of interest of several of the authors. A systematic review and critical appraisal of the 





Do Vaccines Cause Seizures?  
 
Conclusion: Fever is a common symptom of many natural infections, including bacteria such as 
diphtheria, pertussis, meningococcus and pneumococcus, and viruses such as hepatitis A, hepatitis 
B, influenza, measles mumps, rubella, polio, rotavirus and varicella. Fever is associated with 
febrile seizures in infants. Thus, many vaccines prevent fever and febrile seizures by protecting 
against natural infections.  
 
However, all vaccines that cause fever in young children also have a small inherent risk of causing 
febrile seizures. The first dose of measles-containing vaccines can rarely cause febrile seizures 
in infants and young children 7-10 days after vaccination, at an estimated rate of 26.4 per 1000 
person-years after MMR and 84.6 per 1,000 person-years after MMRV (ProQuad®). Influenza 
and pneumococcal conjugate vaccines when administered separately can very rarely cause febrile 
seizures in infants and young children in the 24 hours after vaccination, at an estimated rate of 5 
events per 100,000 doses in the U.S. The risk of febrile seizures is increased when influenza and 
pneumococcal conjugate vaccines are given simultaneously, to an estimated rate of 17.5 per 
100,000 doses. The DTaP-IPV-Hib combination vaccine in use in Denmark can very rarely cause 
febrile seizures in infants and young children, at an estimated rate of less than 4 per 100,000 doses. 
Whole-cell DTP vaccine did cause febrile seizures, but is no longer used in the United States. 
Vaccines currently routinely recommended to the general population in the U.S. 37F* have not been 
shown to cause persistent epilepsy or infantile spasms. 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 




Febrile seizures are a common and typically benign childhood condition, occurring in 2-5% of 
children at some point during their first five years of life. Febrile seizures have an estimated 
background incidence of 240–480 per 100,000 person-years in children under five years, although 
this varies considerably by age, genetics, co-morbidities and environmental risk factors. There are 
no long-term effects of simple febrile seizures, with the possible exception of an increased risk of 
recurrence [293-296].  
 
Considering the benign nature of simple febrile seizures, the rarity of vaccine-induced febrile 
seizures and the relative frequency of fever related to natural infection particularly among young 
children, the benefits of vaccination greatly outweigh the minimal risk of vaccine 
complications. 
 
Epidemiological evidence: Between 5% and 15% of children receiving the first dose of measles-
containing vaccines develop a transient fever ≥ 103°F, 7-12 days after the first dose. Nine 
methodologically sound, controlled epidemiological studies have all found an increased risk of 
seizures 7-14 days after MMR vaccination [858, 985-992]. A 2016 summary of 23 post-licensure 
clinical trials and a 2015 meta-analysis both confirmed these findings [993, 994]. The MMRV 
combination vaccine (ProQuad®) has a higher risk of febrile convulsions than simultaneous yet 
separate administration of MMR and varicella vaccine (Varivax®) [297, 543-547]. Febrile seizures 
occurred at a rate of 26.4 per 1000 person-years after MMR and 84.6 per 1,000 person-years after 
MMRV in the 7-10 days after vaccination [297]. There is no increased risk of fever or febrile 
seizures in children receiving their second dose of measles-containing vaccine at 4 to 6 years of 
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age, whether given MMR or MMRV [40, 220, 995]. Delaying MMR or MMRV vaccines past 15 
months of age results in a higher risk of seizures than vaccinating according to the recommended 
schedule [548, 549].  
 
Febrile seizures were estimated to occur at a rate of 17.5 per 100,000 doses in children aged 6-59 
months after receiving concomitant trivalent inactivated influenza vaccine (TIV) and 13-valent 
pneumococcal conjugate vaccine (abbreviation: PCV13; trade name: Prevnar13®); lower rates of 
4.9 per 100,000 doses and 5.3 per 100,000 doses were estimated in children who received TIV 
without concomitant PCV13 and in children who received PCV13 without concomitant TIV, 
respectively. However, these risk differences varied substantially with age due to the age-
dependent background rates of febrile seizures, with the highest estimates at 16 months and the 
lowest at 59 months [296]. 
 
Aside from the CSL Biotherapies trivalent vaccine licensed in Australia in 2010 [996-998], 
influenza vaccines have generally not been associated with seizures. Six methodologically sound, 
controlled epidemiological studies found no statistically significant association between seizures 
and influenza vaccination [640, 641, 999-1002]. However, a large Vaccine Safety Datalink (VSD) 
study of children under 5 years of age did find a small increased risk of seizures after TIV 
(incidence rate ratio 2.4; 95% CI 1.2-4.7), as well as a similar increased risk after PCV13 (IRR 
2.5; 95% CI 1.3-4.7) and an even further increased risk after receiving both vaccines 
simultaneously (IRR 5.9; 95% CI 3.1-11.3) [296]. Another VSD study found an increased risk of 
febrile seizures following concomitant administration of TIV and PCV13 (relative risk 5.3; 95% 
CI 1.87-14.75) [1003]. A self-controlled risk interval analysis found that although TIV 
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administered by itself had no increased risk of febrile seizures, risk of febrile seizures on the two 
days following vaccination increased when TIV was administered simultaneously with either PCV 
(IRR 3.50; 95% CI 1.13-10.85) or DTaP-containing vaccines (IRR 3.50; 95% CI 1.52-8.07). This 
concomitant administration led to a small absolute risk of 30 excess febrile seizures per 100,000 
persons vaccinated [1004]. In addition, a study of 226,889 Norwegian children found a twofold 
increased risk of febrile seizures in the 1-3 days after pH1N1 vaccination [1005]. However, the 
same study also found a tenfold increased risk of febrile seizures in the 1-3 days after diagnosis of 
pH1N1 infection. 
 
The 2012 report by the Institute of Medicine (IOM) [222], now called the National Academy of 
Medicine (NAM), did not find convincing evidence of an association between seizures and 
varicella, DTaP or hepatitis B vaccines [665, 713, 990, 1006, 1007]. A large cohort study published 
since this report found a small increased risk of febrile seizure after the first two doses of the DTaP-
IPV-Hib combination vaccine in Denmark, with an absolute risk of less than 4 per 100,000 
vaccinations [550]. Two large VSD studies published since the 2012 IOM report found no 
association between seizures and the DTaP-IPV combination vaccine (Kinrix®) [551] or 
quadrivalent HPV vaccine (Gardasil®) [915]. A retrospective observational study of California 
infants had 5 cases of seizures considered related to vaccine receipt out of 46,486 doses of DTaP-
IPV/Hib vaccine administered [709]. A large VSD study found that vaccination in children 3-5 
months of age was associated with increased risk of febrile seizures (incidence rate ratio: 23; 95% 
CI 5.13-100.8) on the day of and the day after vaccination, leading to a small attributable risk of 




A case-control study reviewed in the 2012 IOM report did not find convincing evidence of an 
association between infantile spasms and the tetanus and diphtheria toxoid vaccines [1009], and 
the report found no relevant studies of quality in the literature assessing an association between 
infantile spasms and pertussis vaccine [222]. No relevant studies of quality examining infantile 
spasms and vaccination have been published since this report. 
 
Proposed biological mechanism: Immunization may induce fever through the release of 
cytokines from inflammatory cells, and fever is associated with febrile seizures [222]. Although 
an interaction of genetics, brain maturity, and fever is hypothesized, the pathophysiology of febrile 
seizures is largely unknown [295]. The pathogenesis may be explained by alteration of brain ion 
channel function due to change in temperature [1010, 1011], modification of neuronal excitability 
[1012] or fever-induced respiratory alkalosis [1013]. Studies have shown that genetic 
susceptibility plays an important role in the pathogenesis of febrile seizures, and various loci have 
been mapped on different chromosomes in individuals with febrile seizures [1014-1027]. For well-
studied vaccines such as influenza vaccines, increases in reactogenicity have been shown to be 




Do Vaccines Cause Serum Sickness? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 38F* 
have not been shown to cause serum sickness. 
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing serum sickness and diphtheria, tetanus or pertussis vaccines [222]. No relevant studies 
of quality have been published since this report. 
 
Proposed biological mechanism: Formation of immune complexes is a known mechanism in the 
development of serum sickness. Another mechanism that could potentially contribute to 
development of serum sickness is activation of the complement system, in which a cascade of 
proteolysis and successive release of cytokines functions to amplify the immune response but can 
damage host cells if not properly regulated [222].  
 
The 2012 IOM report described one case of serum sickness after a diphtheria and tetanus vaccine 
[1031]; however, the IOM concluded that this mechanistic evidence was weak. The IOM also 
concluded that there was no mechanistic evidence for an association between serum sickness and 
pertussis vaccine [222]. Since publication of the 2012 IOM report, a case of serum sickness after 
H1N1 pandemic influenza vaccine was also described in the literature [1032].  
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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Do Vaccines Cause Small Fiber Neuropathy? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 39F* 
have not been shown to cause small fiber neuropathy (SFN).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing SFN and varicella or influenza vaccines [222]. No relevant studies of quality have been 
published since this report. 
 
Proposed biological mechanism: SFN encompasses the heterogeneous group of disorders that 
damage the small subsets of sensory and autonomic nerve fibers with little to no large fiber 
involvement [1033]. One mechanism that could contribute to SFN is molecular mimicry, which 
refers to the possibility that similar epitopes shared between self-peptides and foreign peptides 
(introduced via infection or immunization) inadvertently cause the activation of autoreactive T or 
B cells, leading to autoimmunity. However, the IOM concluded that there was no mechanistic 
evidence for an association between SFN and varicella or influenza vaccines, as the publication 
reviewed provided no evidence beyond a temporal association [222]. 
  
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
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Do Vaccines Cause Spontaneous Abortion? 
 
Conclusion: Vaccines currently routinely recommended for pregnant women in the U.S. have not 
been shown to cause spontaneous abortion (SAb). Although one study has suggested a possible 
increase in risk of SAb early in pregnancy following inactivated influenza vaccine (IIV), other 
studies have not found an association and the results are not conclusive.  
 
Why this is an issue: The Advisory Committee on Immunization Practices (ACIP) recommends 
that “all women who are pregnant or who might be pregnant in the influenza season receive 
influenza vaccine. Any licensed, recommended, and age-appropriate influenza vaccine may be 
used. Influenza vaccine can be administered at any time during pregnancy, before and during the 
influenza season.” Live attenuated influenza vaccine (LAIV) has never been recommended for use 
in pregnancy in the U.S. [262]. 
 
The recommendation for IIV in pregnancy was based upon the benefits of the vaccine for 
prevention of influenza in the mother and infants born to women immunized in pregnancy, and the 
overall excellent safety profile of IIV among children and adults [325]. SAb is defined in the 
United States as the loss of a fetus before 20 weeks of gestation (before 24 weeks in some other 
countries), and occurs in roughly 15-20% of clinically recognized pregnancies [1034].  
 
Donahue et al. recently reported results from a case-control study examining the risk of SAb 
following receipt of inactivated influenza vaccines containing A/H1N1pdm2009 antigen in the 
2010-11 and 2011-12 seasons [372]. The odds of vaccine receipt in the 28-day exposure window 
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were double among women who had an SAb compared with the control women who had live 
births or stillbirths (adjusted odds ratio: 2.0; 95% Confidence Interval: 1.1–3.6). This association 
was mostly seen in the 2010-11 season (aOR: 3.7; 95%CI: 1.4-9.4) rather than the 2011-12 season 
(aOR: 1.4; 95%CI: 0.6–3.3). In a post-hoc analysis, the study found the risk was almost entirely 
attributed to women who had received vaccines containing pandemic H1N1 (pH1N1) antigen in 
the previous year (aOR: 7.7; 95%CI: 2.2–27.3) compared to women unvaccinated in the previous 
year (aOR: 1.3; 95%CI: 0.7–2.7) [372].  
 
As pointed out by Chambers et al. in an accompanying commentary, SAb is one of the most 
challenging birth outcomes to study using observational studies. Many clinically unrecognized 
pregnancies occur and retrospective studies have a difficult time capturing these pregnancies and 
SAbs [373]. Limitations of the Donahue et al. study include ascertainment of SAb date, the 
potential that healthcare seeking for SAb care was associated with vaccination, preferential 
vaccination among women with comorbidities or other risk factors for SAb, the potential that cases 
had greater opportunity for vaccination because they sought care for symptoms foreshadowing 
SAb diagnosis, and others discussed in the paper and commentary [372, 373]. 
 
Epidemiological evidence:  The Donahue et al. findings need to be interpreted in the context of 
other epidemiological data. Studies of IIV conducted in pregnant women prior to this 
recommendation had not revealed an increase in risk of SAb, but most did not assess the risk in 
the first trimester or were underpowered to detect a small increased risk. One recent randomized 
trial recruiting women at 17-34 weeks gestation [374], thirteen other observational studies [375-
387], two systematic reviews [364, 388], and one meta-analysis [355] have assessed the potential 
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association between influenza vaccine and SAb or a related outcome, and none have found an 
association.  
 
Steinhoff et al. enrolled 3,693 women in a randomized, placebo-controlled trial of influenza 
immunization during pregnancy in Nepal. Three participants in the placebo group (0.2%) and 5 in 
the vaccine group (0.3%) experienced miscarriage (risk ratio: 1.67; 95%CI: 0.40-6.98). 31 
participants in the placebo group (1.7%) and 33 in the vaccine group (1.8%) experienced stillbirth 
(RR: 1.07; 95%CI: 0.66-1.73) [374]. SAb was uncommon in this study given the age of study 
enrollment (17-34 weeks). 
 
Chambers et al. followed 1,032 American and Canadian women between 2009 and 2012 in a 
prospective cohort study. 841 of these women received a pH1N1-containing vaccine during 
pregnancy. No increased risk of SAb was found (adjusted hazard ratio: 0.92; 95%CI: 0.31-2.72). 
184 women vaccinated during the first trimester were included in an analysis that showed no 
increased risk of SAb (aHR: 0.84; 95%CI: 0.27–2.64) [375].  
 
Chambers et al. also recruited 1,730 American and Canadian women between 2010 to 2014 as part 
of the cohort arm of the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS). 
1,263 of these women were exposed to an influenza vaccine during pregnancy. There was no 
overall increase in risk of spontaneous abortion in first trimester exposure compared to the 
unexposed (aHR: 1.12; 95%CI: 0.47-2.65). Additionally, women who were vaccinated in the first 
trimester or any trimester were more likely than unvaccinated women to deliver a live born child 




Chavant et al. included 2,415 pregnant women vaccinated between November 2009 and March 
2010 in France in a prospective cohort study. 97.6% of these women received a vaccine without 
adjuvant and 2.4% received an adjuvanted vaccine. They found that exposure to pH1N1-
containing vaccines during pregnancy did not increase the risk of adverse pregnancy outcomes. 12 
of the 2,246 pregnancies with known outcomes ended in spontaneous abortion. This 0.5% rate is 
below the base rate in the general population, observed at 10-15%; however, this is probably 
because only 3.9% of women in this study were vaccinated during their first trimester. Of the 92 
women who were vaccinated during their first trimester, 5 experienced SAb [377].  
 
Ma et al. included 226 pregnant women in China in a prospective cohort study. 122 of these women 
were immunized with pH1N1 vaccine. They found no difference in rates of spontaneous abortion 
between the vaccinated and unvaccinated group (0.8% vs 1.9%, respectively; P=0.470). However, 
the trimester of vaccination is not reported [380]. 
 
Oppermann et al. included 1,652 pregnant women in Germany in a prospective cohort study. 323 
of these women were immunized with pH1N1 vaccine between September 2009 and March 2010. 
No increased risk of SAb was found (HR: 0.89; 95%CI: 0.36–2.19), although this was reported for 
all trimesters instead of just first trimester due to the limited number of first trimester vaccinations 
(n=55) and inability to adjust fully for confounders. The study also showed a higher rate of live 




Pasternak et al. studied SAb among 35,408 Danish women using a national register based cohort 
study. 2,736 of these women were immunized with pH1N1 vaccine. No increased risk of SAb was 
found (HR: 1.11; 95%CI: 0.71-1.73). The risk of SAb specific to first trimester vaccinations was 
not reported. No increased risk of fetal death (either spontaneous abortion or stillbirth) was found 
among all vaccinated (HR: 0.79; 95%CI: 0.53-1.16) or first-trimester vaccinated women (HR: 
0.96; 95%CI: 0.63-1.47) [382]. 
 
Tavares et al. included 267 pregnant women vaccinated in Britain during the 2009 flu season in a 
prospective cohort study. Of the 41 (15.4%) women vaccinated during the first trimester with 
known pregnancy outcomes, 3 ended in SAbs. They reported that this and all adverse events were 
consistent with the expected rates in their population [383].  
 
De Vries et al. recruited 295 pregnant women who received pH1N1 vaccine for a cohort study in 
the Netherlands, of which 23 were vaccinated in their first trimester, and reported no increased 
risk of spontaneous abortions compared with the background rate [387].  
 
Eaton et al. surveyed 5,365 pregnant women in Northern California by telephone, 40.7% of whom 
were vaccinated in the first trimester, and found no difference in SAb between pH1N1 and seasonal 
influenza vaccines. The risk of SAb specific to first trimester vaccinations was not reported [1035]. 
 
Irving et al. found in a 2005-2006 case-control study in the U.S. no association with SAb during 
the 28 days after receipt of IIV (adjusted matched odds ratio: 1.23; 95%CI: 0.53-2.89). The study 
included 243 women with SAbs and 243 matched control women. 16 (7%) women with SAb and 
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15 (6%) matched control group women received influenza vaccine within the 28-day exposure 
window, all women included in the study were vaccinated before conception or in the first trimester 
[384].  
 
Sammon et al. found in a retrospective cohort study in the U.K. a reduced risk of SAb and fetal 
death among pregnant women vaccinated against pandemic influenza. However, this may have 
been due to residual confounding that was unable to be measured, as suggested by sensitivity 
analyses [385].  
 
Heikkinen et al. analyzed 4,508 pregnancy outcomes in a mixed prospective and retrospective 
cohort study in Argentina, Italy, and the Netherlands. Of the cohort, 2,295 (50.9%) women were 
vaccinated, 92 (4%) in their first trimester. They found no spontaneous abortions among women 
vaccinated against pandemic influenza, although this was attributed to the high average gestational 
age at enrollment [386].  
 
Bratton et al. conducted a systematic review and meta-analysis. Their pooled estimate for SAb was 
not significant (relative risk: 0.91; 95%CI: 0.68-1.22). They did find that women who received 
influenza vaccine had a lower likelihood of stillbirth (RR: 0.73; 95%CI: 0.55-.96); even when 
restricted to pH1N1 vaccine (RR, 0.69; 95% CI, 0.53-0.90) [355].  
 
The only study that investigated the effect of previous season vaccination history was Donahue et 
al. The epidemiological evidence of a possible association between SAb and a second dose of 
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inactivated influenza vaccine between 5-20 gestational weeks is inconclusive and requires 
additional study.  
 
Studies of HPV [775, 1036-1045] and rubella [1046-1048] vaccines inadvertently given during 
pregnancy have not found an association with SAb or miscarriage. A systematic review of hepatitis 
B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy [1049] 
and a meta-analysis of smallpox vaccination in pregnancy [1050] also found no association with 
SAb. Studies examining a potential association with SAb among other vaccines are lacking. 
 
Proposed biological mechanism: Infection with wild-type influenza virus during pregnancy can 
cause life-threatening illness in pregnant women and increases the risk of SAb, as demonstrated 
during the 2009 influenza pandemic [1051, 1052].  
 
No clear biological mechanism explains the observations in the Donahue et al. study. The authors 
hypothesized that an increased inflammatory response following a second (or booster) dose of 
pandemic influenza vaccine may increase the risk of SAb in early pregnancy [372]. They point out 
that studies have demonstrated a relationship between vaccination and inflammation, and between 
inflammation and pregnancy loss [1053-1055]. It has been shown that influenza vaccine can 
trigger a brief inflammatory response in pregnant women that is similar to that seen in non-
pregnant women [1056, 1057]. Other studies found that infection with or vaccination against 
pandemic influenza virus induced an expansion of T helper type 1 (Th1) cells, which are thought 
to be pro-inflammatory [1058, 1059]. Significant associations between an increased Th1 response 
and miscarriage have been reported [1053, 1054]. The observation of the increase in SAb in those 
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who had been vaccinated the previous year (especially during the 2010-2011 season) is perplexing 
and is not explainable by just inflammation. No studies have demonstrated an increase in 
inflammation in those with previous vaccination. In fact, repeat vaccination has been shown to 
result in lower antibody response [1060-1062]. It may be that the observation noted by Donahue 
is unique to the 2010-2011 season due to the pandemic of 2009, that it was attributable to one of 
the aforementioned limitations of the study, or that the finding was due to chance. Ongoing studies 




Do Vaccines Cause Sudden Infant Death Syndrome (SIDS)? 
 
Conclusion: DTP and hepatitis B vaccines do not cause sudden infant death syndrome (SIDS). 
Other vaccines currently routinely recommended to the general population in the U.S. 40F* have not 
been shown to cause SIDS.  
 
Epidemiological evidence: In a 2003 report entitled Immunization Safety Review: Vaccinations 
and Sudden Unexpected Death in Infancy, the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), concluded that the evidence favored rejection of a causal 
relationship between DTP vaccine or exposure to multiple vaccines and SIDS [223]. The 2012 
IOM report found no new relevant studies of quality in the literature assessing SIDS and DTaP 
vaccination [222]. Two large randomized controlled trials found no association between SIDS and 
pentavalent rotavirus vaccine [1063, 1064]. No increase in the risk of SIDS after immunization 
with the DTP vaccine was found among a cohort of 129,834 U.S. children born between 1974 and 
1984 [1065]. A Vaccine Safety Datalink study of more than 350,000 live births between 1993 and 
1998 found no association between hepatitis B birth immunization and neonatal death [1066]. A 
meta-analysis found that immunizations are actually associated with a reduced risk of SIDS; 
however, this may be attributable to the healthy vaccinee effect [1067]. A reanalysis of three case-
control studies included in this meta-analysis using the self-controlled case series method found 
neither an increased nor reduced risk of SIDS during the period after vaccination [1068]. A 
retrospective observational study of California infants found no cases of SIDS that were considered 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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to be related to the administration of 46,486 doses of DTaP-IPV/Hib vaccine [709]. Case-control 
and self-controlled case series analyses of the Taiwanese death registration databases found no 
association between SIDS and DTaP vaccine [1069].  
 
Proposed biological mechanism: The IOM concluded that there was no mechanistic evidence for 
an association between SIDS and diphtheria, tetanus or pertussis vaccination, as the publications 




Do Vaccines Cause Syncope? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 41F* 
can rarely cause syncope up to an hour after vaccination, most frequently among adolescents, and 
especially among females 11-18 years of age.  
 
Potential injury from syncope after vaccination can be prevented by careful monitoring of vaccine 
recipients and having them sit or lay down if symptoms develop [246]. The ACIP recommends 
that recipients always receive the vaccine while sitting and that providers observe adolescent and 
adult patients for 15 minutes after vaccination [244, 245]. To avoid a hysterical reaction among 
peers to a post-vaccination syncope case, it is also recommended that adolescents are vaccinated 
out of sight of others awaiting vaccination [247]. 
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing an association between vaccination and syncope, since the only applicable studies 
available either had limited power or serious methodological limitations, or used passive 
surveillance systems and therefore lacked an unvaccinated comparison group [222]. However, 
numerous case studies have provided strong mechanistic evidence, as described in the proposed 
biological mechanism section below.  
 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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A study by the U.S. Armed Forces published since the 2012 IOM report estimated annual rates of 
syncope associated with immunization to be between 4.4 and 14.1 events per 100,000 
immunizations [1070].  
 
Proposed biological mechanism: Syncope is usually caused by a vasovagal reaction in which 
sympathetic nervous system stimulation brings a sudden onset of hypotension. Potential stimuli 
for a vasovagal reaction include invasive medical procedures such as venipuncture, as well as 
simply the sight of blood in some persons [246].  
 
The 2012 IOM report described a number of cases of syncope after vaccination [246, 678, 836, 
1071-1078]. Due to the consistency of the prodromal symptoms, such as dizziness and pallor, and 
that most cases had a latency of 15 minutes or less between vaccine injection and the development 
of vasovagal syncope, the IOM concluded that this mechanistic evidence was strong and presented 
definitive clinical evidence [222]. Syncope following vaccination has also occasionally been 




Do Vaccines Cause Systemic Lupus Erythematosus? 
 
Conclusion: Vaccines currently routinely recommended to the general population in the U.S. 42F* 
have not been shown to cause systemic lupus erythematosus (SLE).  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM) [222], now called 
the National Academy of Medicine (NAM), described four studies assessing exacerbation of SLE 
and influenza vaccine [1079-1082] and one study assessing onset of SLE and hepatitis B vaccine 
[1083]; however, these studies did not provide convincing evidence due to a lack of validity and 
precision. The IOM found no relevant studies of quality in the literature assessing either 
exacerbation of SLE and hepatitis B vaccine or onset of SLE and influenza vaccine [222].  
 
Two cohort studies published since the 2012 IOM report, a retrospective cohort of people over 60 
years of age who received the herpes zoster vaccine (Zostavax®) [1084] and a prospective cohort 
of women receiving quadrivalent HPV vaccine (Gardasil®) [576], found no association between 
vaccination and SLE. A controlled trial in Brazil randomized 54 SLE patients to receive either 
varicella vaccine or placebo and vaccinated 28 healthy matched controls, and found no difference 
in adverse event frequency between groups [1085]. A 2017 clinical trial found that quadrivalent 
HPV vaccine was safe and well tolerated in patients with SLE [1086]. Two 2016 meta-analyses 
found no difference in adverse event rates after influenza vaccination between SLE patients and 
healthy controls [1087, 1088]. A 2015 systematic review did not find an increased risk of SLE 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 
States such as Yellow Fever vaccine (international travelers) or Smallpox vaccine (military personnel).  
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exacerbation following HPV vaccination [1089]. A 2016 meta-analysis found that influenza and 
pneumococcal vaccines had no impact on SLE disease activity [1090].  
 
Proposed biological mechanism: There is evidence that natural infection may exacerbate 
symptoms in SLE patients [1091]. Inflammation is present both during SLE exacerbations and 
during immune responses to infection or vaccination. One possible mechanism is activation of the 
complement system, in which a cascade of proteolysis and successive release of cytokines 
functions to amplify the immune response but can damage host cells if not properly regulated. 
Other mechanisms that could contribute to onset or exacerbation of SLE include autoantibodies or 
T cells, and formation of immune complexes.  
 
The 2012 IOM report described some experimental evidence and one case of SLE after hepatitis 
B vaccination [1092]; however, the IOM concluded that this mechanistic evidence was weak. The 
IOM also concluded that there was no mechanistic evidence for an association between SLE and 





Do Vaccines Cause Transverse Myelitis? 
 
Conclusion: Natural viral infections with influenza, hepatitis A, measles, mumps and rubella and 
varicella have all been associated with transverse myelitis, albeit rarely. Thus, these viral vaccines 
may prevent transverse myelitis by protecting against natural infection. Vaccines currently 
routinely recommended to the general population in the U.S. 43F* have not been shown to cause 
transverse myelitis.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM), now called the 
National Academy of Medicine (NAM), found no relevant studies of quality in the literature 
assessing an association between transverse myelitis and MMR, varicella, influenza, hepatitis A, 
hepatitis B, HPV, meningococcal conjugate, diphtheria, tetanus or pertussis vaccines, since the 
only applicable studies available either had serious methodological limitations or used passive 
surveillance systems and therefore lacked an unvaccinated comparison group [222].  
 
Two Vaccine Safety Datalink studies published since the 2012 IOM report found no cases of 
transverse myelitis in over 200,000 pregnant women within 42 days after receiving trivalent 
inactivated influenza vaccine [846] and in over 9,000 pregnant women within 42 days after 
receiving 2009 H1N1 pandemic influenza vaccine [1093]. A cohort study of 3,983,824 females 
10-44 years of age in Denmark and Sweden found no association between quadrivalent HPV 
vaccine and demyelinating diseases, including transverse myelitis [578]. 
                                                          
* These conclusions do not necessarily consider vaccines recommended only for special populations in the United 




Proposed biological mechanism: Natural infection with wild-type influenza, hepatitis A, 
measles, mumps and rubella viruses, as well as herpes zoster and reactivation of latent wild-type 
varicella virus, have all been associated with transverse myelitis, albeit rarely. Mechanisms that 
could contribute to transverse myelitis include viral reactivation [222], as well as molecular 
mimicry, which refers to the possibility that similar epitopes shared between self-peptides and 
foreign peptides (introduced via infection or immunization) inadvertently cause the activation of 
autoreactive T or B cells, leading to autoimmunity.  
 
The 2012 IOM report described a few cases of transverse myelitis after MMR [1094-1096], 
varicella [1097], and hepatitis B vaccines [1098], but even when also considering knowledge about 
the aforementioned natural infections the IOM concluded this mechanistic evidence was weak. 
The IOM also concluded that there was no mechanistic evidence for an association between 





Do Vaccines Cause Vasculitis or Polyarteritis Nodosa? 
 
Conclusion: Polyarteritis nodosa (PAN) has been reported as a rare complication of natural 
infection with hepatitis B virus. Thus, hepatitis B vaccine prevents PAN by protecting against 
natural infection. Vaccines currently routinely recommended to the general population in the U.S. 46F* 
have not been shown to cause vasculitis or PAN.  
 
Epidemiological evidence: The 2012 report by the Institute of Medicine (IOM) [222], now called 
the National Academy of Medicine (NAM), described two studies assessing exacerbation of 
vasculitis and influenza vaccine [1099, 1100], but these studies did not provide convincing 
evidence due to a lack of validity and precision. The IOM found no relevant studies of quality in 
the literature assessing onset of vasculitis or PAN and influenza or hepatitis B vaccines, or 
exacerbation of vasculitis and hepatitis B vaccine [222].  
 
Since the IOM report, a randomized trial found that influenza vaccine was safe for patients in 
remission with anti-neutrophil cytoplasmic antibody-associated vasculitis [1101], and a 
prospective observational study found that vaccinations had no significant clinical impact on 
patients with systemic necrotising vasculitis [1102]. An Italian case-control study found an 
increased risk of Henoch-Schonlein purpura, a common childhood vasculitis, within 12 weeks of 
MMR vaccination (odds ratio 3.4; 95% CI 1.2-10.0) [1103]. A large VSD study found that 
vaccination was associated with a decrease in incidence of the vascular disorder known as 
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Kawasaki disease [1104], and a 2017 systematic review concluded that evidence is lacking for a 
causal relationship between immunization and Kawasaki disease [1105].  
 
Proposed biological mechanism: PAN has been reported as a rare complication of natural 
infection with hepatitis B virus. Formation of immune complexes has been suggested as a potential 
mechanism for vasculitis or PAN after hepatitis B vaccine. Another possible mechanism is 
activation of the complement system, in which a cascade of proteolysis and successive release of 
cytokines functions to amplify the immune response but can damage host cells if not properly 
regulated. Other mechanisms that could contribute to vasculitis include autoantibodies or T cells 
[222].  
 
The 2012 IOM report described two cases of exacerbation of vasculitis after influenza vaccine that 
showed recurrence of symptoms after vaccine re-challenge [678], and three cases of PAN after 
hepatitis B vaccine [1106-1109]; however, even when considering knowledge about the 
aforementioned natural infections, the IOM concluded that this mechanistic evidence was weak. 
The IOM also concluded that there was no mechanistic evidence for an association between PAN 
and influenza vaccine, between exacerbation of vasculitis and hepatitis B vaccine, or between 









1. Gellin, B.G., E.W. Maibach, and E.K. Marcuse, Do Parents Understand Immunizations? A National 
Telephone Survey. Pediatrics, 2000. 106(5): p. 1097-1102. 
2. Kennedy, A., et al., Confidence about vaccines in the United States: understanding parents' 
perceptions. Health Aff (Millwood), 2011. 30(6): p. 1151-9. 
3. Salmon, D.A., et al., Vaccine hesitancy: Causes, consequences, and a call to action. Vaccine, 
2015. 33 Suppl 4: p. D66-71. 
4. Mellerson, J.L., et al., Vaccination Coverage for Selected Vaccines and Exemption Rates Among 
Children in Kindergarten - United States, 2017-18 School Year. MMWR Morb Mortal Wkly Rep, 
2018. 67(40): p. 1115-1122. 
5. Omer, S.B., et al., Trends in Kindergarten Rates of Vaccine Exemption and State-Level Policy, 
2011-2016. Open Forum Infect Dis, 2018. 5(2): p. ofx244. 
6. Omer, S.B., et al., Nonmedical exemptions to school immunization requirements: secular trends 
and association of state policies with pertussis incidence. Jama, 2006. 296(14): p. 1757-63. 
7. Omer, S.B., et al., Vaccination policies and rates of exemption from immunization, 2005-2011. N 
Engl J Med, 2012. 367(12): p. 1170-1. 
8. Atwell, J.E., et al., Nonmedical vaccine exemptions and pertussis in California, 2010. Pediatrics, 
2013. 132(4): p. 624-30. 
9. Rosen, J.B., et al., Public Health Consequences of a 2013 Measles Outbreak in New York City. 
JAMA Pediatr, 2018. 
10. Gust, D.A., et al., Underimmunization among children: effects of vaccine safety concerns on 
immunization status. Pediatrics, 2004. 114(1): p. e16-22. 
11. Glanz, J.M., et al., Association between undervaccination with diphtheria, tetanus toxoids, and 
acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of 
age. JAMA Pediatr, 2013. 167(11): p. 1060-4. 
12. Kahn, K.E., et al., Influenza and Tdap Vaccination Coverage Among Pregnant Women - United 
States, April 2018. MMWR Morb Mortal Wkly Rep, 2018. 67(38): p. 1055-1059. 
13. Ten great public health achievements--United States, 2001-2010. MMWR Morb Mortal Wkly 
Rep, 2011. 60(19): p. 619-23. 
14. Hill, H.A., et al., Vaccination Coverage Among Children Aged 19-35 Months - United States, 2017. 
MMWR Morb Mortal Wkly Rep, 2018. 67(40): p. 1123-1128. 
15. McCauley, M.M., et al., Exploring the choice to refuse or delay vaccines: a national survey of 
parents of 6- through 23-month-olds. Acad Pediatr, 2012. 12(5): p. 375-83. 
16. Freed, G.L., et al., Sources and perceived credibility of vaccine-safety information for parents. 
Pediatrics, 2011. 127 Suppl 1: p. S107-12. 
17. Salmon, D.A., et al., Factors associated with refusal of childhood vaccines among parents of 
school-aged children: a case-control study. Arch Pediatr Adolesc Med, 2005. 159(5): p. 470-6. 
18. Vadaparampil, S.T., et al., Missing the Target for Routine Human Papillomavirus Vaccination: 
Consistent and Strong Physician Recommendations are Lacking for 11–12 Year Old Males. 
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for 
Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. 25(10): p. 
1435-1446. 
19. McRee, A.-L., M.B. Gilkey, and A.F. Dempsey, HPV vaccine hesitancy: Findings from a statewide 
survey of healthcare providers. Journal of pediatric health care : official publication of National 
Association of Pediatric Nurse Associates & Practitioners, 2014. 28(6): p. 541-549. 
 
384 
20. Power, M.L., et al., Obstetrician-gynecologists' practices and perceived knowledge regarding 
immunization. Am J Prev Med, 2009. 37(3): p. 231-4. 
21. Scherr, C.L., et al., Provider-reported acceptance and use of the Centers for Disease Control and 
Prevention messages and materials to support HPV vaccine recommendation for adolescent 
males. Vaccine, 2016. 34(35): p. 4229-4234. 
22. MacDougall, D.M. and S.A. Halperin, Improving rates of maternal immunization: Challenges and 
opportunities. Hum Vaccin Immunother, 2016. 12(4): p. 857-65. 
23. Kempe, A., et al., Prevalence of parental concerns about childhood vaccines: the experience of 
primary care physicians. Am J Prev Med, 2011. 40(5): p. 548-55. 
24. Salmon, D.A., et al., Vaccine hesitancy: Causes, consequences, and a call to action. Vaccine, 
2015. 33: p. D66-D71. 
25. Fortner, K.B., et al., Influenza and tetanus, diphtheria, and acellular pertussis vaccinations during 
pregnancy. Obstet Gynecol Surv, 2012. 67(4): p. 251-7. 
26. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular 
pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close 
contact with an infant aged <12 months --- Advisory Committee on Immunization Practices 
(ACIP), 2011. MMWR Morb Mortal Wkly Rep, 2011. 60(41): p. 1424-6. 
27. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices 
(ACIP), 2012. MMWR Morb Mortal Wkly Rep, 2013. 62(7): p. 131-5. 
28. Grohskopf, L.A., et al., Prevention and Control of Seasonal Influenza with Vaccines: 
Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-
18 Influenza Season. MMWR Recomm Rep, 2017. 66(2): p. 1-20. 
29. Tamma, P.D., M.C. Steinhoff, and S.B. Omer, Influenza infection and vaccination in pregnant 
women. Expert Rev Respir Med, 2010. 4(3): p. 321-8. 
30. Fowlkes, A., et al., Incidence of medically attended influenza during pandemic and post-
pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. Lancet Respir 
Med, 2015. 3(9): p. 709-718. 
31. Poehling, K.A., et al., The underrecognized burden of influenza in young children. N Engl J Med, 
2006. 355(1): p. 31-40. 
32. Siston, A.M., et al., Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in 
the United States. Jama, 2010. 303(15): p. 1517-25. 
33. Bhat, N., et al., Influenza-associated deaths among children in the United States, 2003-2004. N 
Engl J Med, 2005. 353(24): p. 2559-67. 
34. Neuzil, K.M., et al., Burden of interpandemic influenza in children younger than 5 years: a 25-
year prospective study. J Infect Dis, 2002. 185(2): p. 147-52. 
35. Paules, C. and K. Subbarao, Influenza. Lancet, 2017. 390(10095): p. 697-708. 
36. Neuzil, K.M., et al., Impact of influenza on acute cardiopulmonary hospitalizations in pregnant 
women. Am J Epidemiol, 1998. 148(11): p. 1094-102. 
37. Izurieta, H.S., et al., Influenza and the rates of hospitalization for respiratory disease among 
infants and young children. N Engl J Med, 2000. 342(4): p. 232-9. 
38. Zhang, L., et al., Acellular vaccines for preventing whooping cough in children. Cochrane 
Database Syst Rev, 2014(9): p. Cd001478. 
39. Rasmussen, S.A., D.J. Jamieson, and T.M. Uyeki, Effects of influenza on pregnant women and 
infants. American journal of obstetrics and gynecology, 2012. 207(3): p. S3-S8. 
40. Epidemiology and Prevention of Vaccine-Preventable Diseases, K.A. Hamborsky J, Wolfe S Editor. 
2015, Centers for Disease Control and Prevention: Washington D.C. 
 
385 
41. Heininger, U., D. Weibel, and J.L. Richard, Prospective nationwide surveillance of hospitalizations 
due to pertussis in children, 2006-2010. Pediatr Infect Dis J, 2014. 33(2): p. 147-51. 
42. de Greeff, S.C., et al., Pertussis disease burden in the household: how to protect young infants. 
Clin Infect Dis, 2010. 50(10): p. 1339-45. 
43. Bosdure, E., et al., [Systematic family screening in case of infant pertussis]. Med Mal Infect, 
2008. 38(9): p. 477-82. 
44. Wendelboe, A.M., et al., Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis 
J, 2007. 26(4): p. 293-9. 
45. Nieves, D.J. and U. Heininger, Bordetella pertussis. Microbiol Spectr, 2016. 4(3). 
46. Forsyth, K., et al., Strategies to decrease pertussis transmission to infants. Pediatrics, 2015. 
135(6): p. e1475-82. 
47. Swamy, G.K. and S.M. Wheeler, Neonatal pertussis, cocooning and maternal immunization. 
Expert Rev Vaccines, 2014. 13(9): p. 1107-14. 
48. Moriarty, L.F. and S.B. Omer, Infants and the seasonal influenza vaccine. A global perspective on 
safety, effectiveness, and alternate forms of protection. Hum Vaccin Immunother, 2014. 10(9): p. 
2721-8. 
49. O'Leary, S.T., et al., Influenza and Pertussis Vaccination Among Pregnant Women and Their 
Infants' Close Contacts: Reported Practices and Attitudes. Pediatr Infect Dis J, 2015. 34(11): p. 
1244-9. 
50. Roush, S.W., T.V. Murphy, and a. Vaccine-Preventable Disease Table Working Group, Historical 
comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. 
JAMA, 2007. 298(18): p. 2155-2163. 
51. Anderson, R.M., The concept of herd immunity and the design of community-based 
immunization programmes. Vaccine, 1992. 10(13): p. 928-35. 
52. Anderson, R.M. and R.M. May, Infectious Diseases of Humans: Dynamics and Control. 1992, 
Oxford: Oxford University Press. 
53. Eames, K.T., Networks of influence and infection: parental choices and childhood disease. J R Soc 
Interface, 2009. 6(38): p. 811-4. 
54. May, T. and R.D. Silverman, 'Clustering of exemptions' as a collective action threat to herd 
immunity. Vaccine, 2003. 21(11-12): p. 1048-51. 
55. Salathe, M. and S. Bonhoeffer, The effect of opinion clustering on disease outbreaks. J R Soc 
Interface, 2008. 5(29): p. 1505-8. 
56. Omer, S.B., et al., Geographic clustering of nonmedical exemptions to school immunization 
requirements and associations with geographic clustering of pertussis. Am J Epidemiol, 2008. 
168(12): p. 1389-96. 
57. Atwell, J.E., et al., Nonmedical Vaccine Exemptions and Pertussis in California, 2010. Pediatrics, 
2013. 
58. Imdad, A., et al., Religious Exemptions for Immunization and Risk of Pertussis in New York State, 
2000–2011. Pediatrics, 2013. 132(1): p. 37-43. 
59. Phadke, V.K., et al., Association Between Vaccine Refusal and Vaccine-Preventable Diseases in 
the United States: A Review of Measles and Pertussis. Jama, 2016. 315(11): p. 1149-58. 
60. Meeting of the Strategic Advisory Group of Experts on immunization, October 2014 - conclusions 
and recommendations. Wkly Epidemiol Rec, 2014. 89(50): p. 561-76. 
61. Larson, H.J., et al., Understanding vaccine hesitancy around vaccines and vaccination from a 
global perspective: a systematic review of published literature, 2007-2012. Vaccine, 2014. 
32(19): p. 2150-9. 
62. Edwards, K.M. and J.M. Hackell, Countering Vaccine Hesitancy. Pediatrics, 2016. 138(3). 
 
386 
63. Larson, H.J., et al., Measuring vaccine hesitancy: The development of a survey tool. Vaccine, 
2015. 33(34): p. 4165-75. 
64. Domek, G.J., et al., Measuring vaccine hesitancy: Field testing the WHO SAGE Working Group on 
Vaccine Hesitancy survey tool in Guatemala. Vaccine, 2018. 36(35): p. 5273-5281. 
65. Lane, S., et al., Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint 
Reporting Form data-2015-2017. Vaccine, 2018. 36(26): p. 3861-3867. 
66. Shapiro, G.K., et al., The vaccine hesitancy scale: Psychometric properties and validation. 
Vaccine, 2018. 36(5): p. 660-667. 
67. Opel, D.J., et al., Development of a survey to identify vaccine-hesitant parents: the parent 
attitudes about childhood vaccines survey. Hum Vaccin, 2011. 7(4): p. 419-25. 
68. Opel, D.J., et al., Validity and reliability of a survey to identify vaccine-hesitant parents. Vaccine, 
2011. 29(38): p. 6598-605. 
69. Opel, D.J., et al., The relationship between parent attitudes about childhood vaccines survey 
scores and future child immunization status: a validation study. JAMA Pediatr, 2013. 167(11): p. 
1065-71. 
70. Oladejo, O., et al., Comparative analysis of the Parent Attitudes about Childhood Vaccines 
(PACV) short scale and the five categories of vaccine acceptance identified by Gust et al. Vaccine, 
2016. 34(41): p. 4964-8. 
71. Oladejo, O., et al., Comparative analysis of the Parent Attitudes about Childhood Vaccines 
(PACV) short scale and the five categories of vaccine acceptance identified by Gust et al. Vaccine, 
2016. 34(41): p. 4964-4968. 
72. Gilkey, M.B., et al., Validation of the Vaccination Confidence Scale: A Brief Measure to Identify 
Parents at Risk for Refusing Adolescent Vaccines. Acad Pediatr, 2016. 16(1): p. 42-9. 
73. Martin, L.R. and K.J. Petrie, Understanding the Dimensions of Anti-Vaccination Attitudes: the 
Vaccination Attitudes Examination (VAX) Scale. Ann Behav Med, 2017. 51(5): p. 652-660. 
74. Forster, A.S., et al., Development and validation of measures to evaluate adolescents' knowledge 
about human papillomavirus (HPV), involvement in HPV vaccine decision-making, self-efficacy to 
receive the vaccine and fear and anxiety. Public Health, 2017. 147: p. 77-83. 
75. Olive, J.K., et al., The state of the antivaccine movement in the United States: A focused 
examination of nonmedical exemptions in states and counties. PLoS Med, 2018. 15(6): p. 
e1002578. 
76. Olive, J.K., et al., Correction: The state of the antivaccine movement in the United States: A 
focused examination of nonmedical exemptions in states and counties. PLoS medicine, 2018. 
15(7): p. e1002616-e1002616. 
77. Wang, E., et al., Nonmedical exemptions from school immunization requirements: a systematic 
review. American journal of public health, 2014. 104(11): p. e62-e84. 
78. Safi, H., et al., Vaccine policy and Arkansas childhood immunization exemptions: a multi-year 
review. Am J Prev Med, 2012. 42(6): p. 602-5. 
79. Jones, M., et al., Mandatory Health Care Provider Counseling For Parents Led To A Decline In 
Vaccine Exemptions In California. Health Aff (Millwood), 2018. 37(9): p. 1494-1502. 
80. Buttenheim, A.M., et al., Conditional admission, religious exemption type, and nonmedical 
vaccine exemptions in California before and after a state policy change. Vaccine, 2018. 36(26): p. 
3789-3793. 
81. Omer, S.B., et al., Exemptions From Mandatory Immunization After Legally Mandated Parental 
Counseling. Pediatrics, 2018. 141(1). 
82. Gust, D.A., et al., Parents with doubts about vaccines: which vaccines and reasons why. 
Pediatrics, 2008. 122(4): p. 718-25. 
 
387 
83. Leask, J., et al., Communicating with parents about vaccination: a framework for health 
professionals. BMC Pediatr, 2012. 12: p. 154. 
84. Schwartz, J.L., New media, old messages: themes in the history of vaccine hesitancy and refusal. 
Virtual Mentor, 2012. 14(1): p. 50-5. 
85. Wolfe, R.M. and L.K. Sharp, Anti-vaccinationists past and present. Bmj, 2002. 325(7361): p. 430-
2. 
86. Hussain, A., et al., The Anti-vaccination Movement: A Regression in Modern Medicine. Cureus, 
2018. 10(7): p. e2919-e2919. 
87. Porter, D. and R. Porter, The politics of prevention: anti-vaccinationism and public health in 
nineteenth-century England. Med Hist, 1988. 32(3): p. 231-52. 
88. Scarpelli, G., "Nothing in nature that is not useful". The anti-vaccination crusade and the idea of 
'harmonia naturae' in Alfred Russel Wallace. Nuncius, 1992. 7(1): p. 109-30. 
89. Swales, J.D., The Leicester anti-vaccination movement. Lancet, 1992. 340(8826): p. 1019-21. 
90. Williamson, S., Anti-vaccination leagues. Arch Dis Child, 1984. 59(12): p. 1195-6. 
91. Nelson, M.C. and J. Rogers, The right to die? Anti-vaccination activity and the 1874 smallpox 
epidemic in Stockholm. Soc Hist Med, 1992. 5(3): p. 369-88. 
92. Kaufman, M., The American anti-vaccinationists and their arguments. Bull Hist Med, 1967. 41(5): 
p. 463-78. 
93. Omer, S.B., et al., Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable 
diseases. N Engl J Med, 2009. 360(19): p. 1981-8. 
94. Orenstein, W.A. and A.R. Hinman, The immunization system in the United States - the role of 
school immunization laws. Vaccine, 1999. 17 Suppl 3: p. S19-24. 
95. Jackson, C.L., State laws on compulsory immunization in the United States. Public Health Rep, 
1969. 84(9): p. 787-95. 
96. Wakefield, A.J., et al., Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive 
developmental disorder in children. Lancet, 1998. 351(9103): p. 637-41. 
97. Horton, R., A statement by the editors of The Lancet. Lancet, 2004. 363(9411): p. 820-1. 
98. Murch, S.H., et al., Retraction of an interpretation. Lancet, 2004. 363(9411): p. 750. 
99. Eggertson, L., Lancet retracts 12-year-old article linking autism to MMR vaccines. Cmaj, 2010. 
182(4): p. E199-200. 
100. Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental 
disorder in children. Lancet, 2010. 375(9713): p. 445. 
101. Deer, B., Wakefield's "autistic enterocolitis" under the microscope. Bmj, 2010. 340: p. c1127. 
102. Deer, B., How the case against the MMR vaccine was fixed. Bmj, 2011. 342: p. c5347. 
103. Deer, B., Secrets of the MMR scare . How the vaccine crisis was meant to make money. Bmj, 
2011. 342: p. c5258. 
104. Deer, B., Secrets of the MMR scare. The Lancet's two days to bury bad news. Bmj, 2011. 342: p. 
c7001. 
105. Taylor, B., et al., Autism and measles, mumps, and rubella vaccine: no epidemiological evidence 
for a causal association. Lancet, 1999. 353(9169): p. 2026-9. 
106. Taylor, B., et al., Measles, mumps, and rubella vaccination and bowel problems or 
developmental regression in children with autism: population study. Bmj, 2002. 324(7334): p. 
393-6. 
107. Farrington, C.P., E. Miller, and B. Taylor, MMR and autism: further evidence against a causal 
association. Vaccine, 2001. 19(27): p. 3632-5. 
108. Madsen, K.M., et al., A population-based study of measles, mumps, and rubella vaccination and 
autism. N Engl J Med, 2002. 347(19): p. 1477-82. 
 
388 
109. Smeeth, L., et al., MMR vaccination and pervasive developmental disorders: a case-control study. 
Lancet, 2004. 364(9438): p. 963-9. 
110. Makela, A., J.P. Nuorti, and H. Peltola, Neurologic disorders after measles-mumps-rubella 
vaccination. Pediatrics, 2002. 110(5): p. 957-63. 
111. Jain, A., et al., Autism occurrence by MMR vaccine status among US children with older siblings 
with and without autism. Jama, 2015. 313(15): p. 1534-40. 
112. Uno, Y., et al., Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-
containing vaccines and risk of autism spectrum disorder. Vaccine, 2015. 33(21): p. 2511-6. 
113. Institute of Medicine Immunization Safety Review, C., in Immunization Safety Review: Measles-
Mumps-Rubella Vaccine and Autism, K. Stratton, et al., Editors. 2001, National Academies Press 
(US): Washington (DC). 
114. Institute of Medicine Immunization Safety Review, C., The National Academies Collection: 
Reports funded by National Institutes of Health, in Immunization Safety Review: Vaccines and 
Autism. 2004, National Academies Press (US): Washington (DC). 
115. Parker, S.K., et al., Thimerosal-containing vaccines and autistic spectrum disorder: a critical 
review of published original data. Pediatrics, 2004. 114(3): p. 793-804. 
116. Schultz, S.T., Does thimerosal or other mercury exposure increase the risk for autism? A review of 
current literature. Acta Neurobiol Exp (Wars), 2010. 70(2): p. 187-95. 
117. Maglione, M.A., et al., Safety of vaccines used for routine immunization of U.S. children: a 
systematic review. Pediatrics, 2014. 134(2): p. 325-37. 
118. Taylor, L.E., A.L. Swerdfeger, and G.D. Eslick, Vaccines are not associated with autism: an 
evidence-based meta-analysis of case-control and cohort studies. Vaccine, 2014. 32(29): p. 3623-
9. 
119. Bernard, S., et al., Autism: a novel form of mercury poisoning. Med Hypotheses, 2001. 56(4): p. 
462-71. 
120. Ball, L.K., R. Ball, and R.D. Pratt, An assessment of thimerosal use in childhood vaccines. 
Pediatrics, 2001. 107(5): p. 1147-54. 
121. Nelson, K.B. and M.L. Bauman, Thimerosal and autism? Pediatrics, 2003. 111(3): p. 674-9. 
122. Chen, R.T. and B. Hibbs, Vaccine safety: current and future challenges. Pediatr Ann, 1998. 27(7): 
p. 445-55. 
123. Smith, P.J., et al., Association between health care providers' influence on parents who have 
concerns about vaccine safety and vaccination coverage. Pediatrics, 2006. 118(5): p. e1287-92. 
124. Lee, C., et al., Hurdles to herd immunity: Distrust of government and vaccine refusal in the US, 
2002-2003. Vaccine, 2016. 34(34): p. 3972-8. 
125. Gellin, B.G., E.W. Maibach, and E.K. Marcuse, Do parents understand immunizations? A national 
telephone survey. Pediatrics, 2000. 106(5): p. 1097-102. 
126. Allred, N.J., et al., Parental vaccine safety concerns: results from the National Immunization 
Survey, 2001-2002. Am J Prev Med, 2005. 28(2): p. 221-4. 
127. Cacciatore, M.A., G.J. Nowak, and N.J. Evans, It's Complicated: The 2014-2015 U.S. Measles 
Outbreak and Parents' Vaccination Beliefs, Confidence, and Intentions. Risk Anal, 2018. 
128. Nowak, G.J. and M.A. Cacciatore, Parents' confidence in recommended childhood vaccinations: 
Extending the assessment, expanding the context. Hum Vaccin Immunother, 2017. 13(3): p. 687-
700. 
129. Chung, Y., et al., Influences on Immunization Decision-Making among US Parents of Young 
Children. Matern Child Health J, 2017. 21(12): p. 2178-2187. 
130. Frew, P.M., et al., Changes in childhood immunization decisions in the United States: Results 
from 2012 & 2014 National Parental Surveys. Vaccine, 2016. 34(46): p. 5689-5696. 
 
389 
131. Darden, P.M., et al., Reasons for not vaccinating adolescents: National Immunization Survey of 
Teens, 2008-2010. Pediatrics, 2013. 131(4): p. 645-51. 
132. Dempsey, A.F., et al., Alternative vaccination schedule preferences among parents of young 
children. Pediatrics, 2011. 128(5): p. 848-56. 
133. Freed, G.L., et al., Parental vaccine safety concerns in 2009. Pediatrics, 2010. 125(4): p. 654-9. 
134. Gust, D., et al., Immunization attitudes and beliefs among parents: beyond a dichotomous 
perspective. Am J Health Behav, 2005. 29(1): p. 81-92. 
135. Hofstetter, A.M., et al., Parental Vaccine Hesitancy and Declination of Influenza Vaccination 
Among Hospitalized Children. Hosp Pediatr, 2018. 
136. Lavail, K.H. and A.M. Kennedy, The role of attitudes about vaccine safety, efficacy, and value in 
explaining parents' reported vaccination behavior. Health Educ Behav, 2013. 40(5): p. 544-51. 
137. Parrella, A., et al., Parental perspectives of vaccine safety and experience of adverse events 
following immunisation. Vaccine, 2013. 31(16): p. 2067-74. 
138. Zikmund-Fisher, B.J., E. Wittenberg, and T.A. Lieu, Parental weighting of seizure risks vs. fever 
risks in vaccination tradeoff decisions. Vaccine, 2016. 34(50): p. 6123-6125. 
139. Dube, E., et al., Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine 
acceptance among mothers of infants in Quebec, Canada. Hum Vaccin Immunother, 2018: p. 1-
8. 
140. Dube, E., et al., Measuring vaccine acceptance among Canadian parents: A survey of the 
Canadian Immunization Research Network. Vaccine, 2018. 36(4): p. 545-552. 
141. Dube, E., et al., Parental Vaccine Hesitancy in Quebec (Canada). PLoS Curr, 2016. 8. 
142. Perinet, S., et al., Delayed measles vaccination of toddlers in Canada: Associated socio-
demographic factors and parental knowledge, attitudes and beliefs. Hum Vaccin Immunother, 
2018. 14(4): p. 868-874. 
143. Berenson, A.B., et al., Relationship between maternal experiences and adolescent HPV 
vaccination. Hum Vaccin Immunother, 2017. 13(9): p. 2150-2154. 
144. Cheruvu, V.K., M.P. Bhatta, and L.N. Drinkard, Factors associated with parental reasons for "no-
intent" to vaccinate female adolescents with human papillomavirus vaccine: National 
Immunization Survey - Teen 2008-2012. BMC Pediatr, 2017. 17(1): p. 52. 
145. Clark, S.J., et al., Parent HPV vaccine perspectives and the likelihood of HPV vaccination of 
adolescent males. Hum Vaccin Immunother, 2016. 12(1): p. 47-51. 
146. DiAnna Kinder, F., Parental Refusal of the Human Papillomavirus Vaccine. J Pediatr Health Care, 
2016. 30(6): p. 551-557. 
147. Donahue, K.L., et al., Human Papillomavirus Vaccine Initiation among 9-13-Year-Olds in the 
United States. Prev Med Rep, 2015. 2: p. 892-898. 
148. Fuchs, E.L., M. Rahman, and A.B. Berenson, Examining maternal beliefs and human 
papillomavirus vaccine uptake among male and female children in low-income families. 
Papillomavirus Res, 2016. 2: p. 38-40. 
149. Gilkey, M.B., et al., Parents who refuse or delay HPV vaccine: Differences in vaccination behavior, 
beliefs, and clinical communication preferences. Hum Vaccin Immunother, 2017. 13(3): p. 680-
686. 
150. Hanson, K.E., et al., National Trends in Parental Human Papillomavirus Vaccination Intentions 
and Reasons for Hesitancy, 2010-2015. Clin Infect Dis, 2018. 67(7): p. 1018-1026. 
151. Mohammed, K.A., et al., Factors Associated With Parents' Intent to Vaccinate Adolescents for 
Human Papillomavirus: Findings From the 2014 National Immunization Survey-Teen. Prev 
Chronic Dis, 2017. 14: p. E45. 
152. Nickel, B., et al., Factors associated with the human papillomavirus (HPV) vaccination across 
three countries following vaccination introduction. Prev Med Rep, 2017. 8: p. 169-176. 
 
390 
153. O'Leary, S.T., et al., Exploring Facilitators and Barriers to Initiation and Completion of the Human 
Papillomavirus (HPV) Vaccine Series among Parents of Girls in a Safety Net System. Int J Environ 
Res Public Health, 2018. 15(2). 
154. Pellman, H. and B. Brown, Parental Reasons for Acceptance or Refusal of Human Papillomavirus 
Vaccine in a Southern California Pediatric Practice. Pediatr Infect Dis J, 2016. 35(1): p. 119-20. 
155. Perez, S., et al., Untangling the psychosocial predictors of HPV vaccination decision-making 
among parents of boys. Vaccine, 2017. 35(36): p. 4713-4721. 
156. Thompson, E.L., et al., Human Papillomavirus Vaccination: What Are the Reasons for 
Nonvaccination Among U.S. Adolescents? J Adolesc Health, 2017. 61(3): p. 288-293. 
157. Underwood, N.L., et al., Influence of Sources of Information and Parental Attitudes on Human 
Papillomavirus Vaccine Uptake among Adolescents. J Pediatr Adolesc Gynecol, 2016. 29(6): p. 
617-622. 
158. VanWormer, J.J., et al., Association between parent attitudes and receipt of human 
papillomavirus vaccine in adolescents. BMC Public Health, 2017. 17(1): p. 766. 
159. Fu, L.Y., et al., Associations of trust and healthcare provider advice with HPV vaccine acceptance 
among African American parents. Vaccine, 2017. 35(5): p. 802-807. 
160. Gilbert, N.L., et al., Estimates and determinants of HPV non-vaccination and vaccine refusal in 
girls 12 to 14 y of age in Canada: Results from the Childhood National Immunization Coverage 
Survey, 2013. Hum Vaccin Immunother, 2016. 12(6): p. 1484-90. 
161. Beavis, A., et al., Reasons for Lack of HPV Vaccine Initiation in NIS-Teen Over Time: Shifting the 
Focus From Gender and Sexuality to Necessity and Safety. Journal of Adolescent Health, 2018. 
63(5): p. 652-656. 
162. Barnard, M., et al., Human papillomavirus (HPV) vaccine knowledge, attitudes, and uptake in 
college students: Implications from the Precaution Adoption Process Model. PLoS One, 2017. 
12(8): p. e0182266. 
163. Cooper, D.L., et al., HPV vaccine awareness and the association of trust in cancer information 
from physicians among males. Vaccine, 2017. 35(20): p. 2661-2667. 
164. LaJoie, A.S., et al., Influencers and preference predictors of HPV vaccine uptake among US male 
and female young adult college students. Papillomavirus Res, 2018. 5: p. 114-121. 
165. Scherer, A.M., et al., Cross-sectional associations between psychological traits, and HPV vaccine 
uptake and intentions in young adults from the United States. PLoS One, 2018. 13(2): p. 
e0193363. 
166. Stephens, D.P., H. Tamir, and T.L. Thomas, Factors Motivating HPV Vaccine Uptake Among 
Vaccinated and Nonvaccinated Hispanic Young Adult Women. Hisp Health Care Int, 2016. 14(4): 
p. 184-191. 
167. Suryadevara, M., et al., Student HPV vaccine attitudes and vaccine completion by education 
level. Hum Vaccin Immunother, 2016. 12(6): p. 1491-7. 
168. Thompson, E.L., et al., Relationship status impacts primary reasons for interest in the HPV 
vaccine among young adult women. Vaccine, 2016. 34(27): p. 3119-3124. 
169. Thompson, V.L., et al., Factors Associated with Human Papillomavirus Vaccination Status at U.S. 
Colleges and Universities. Health Soc Work, 2017. 42(1): p. e1-e7. 
170. Fernandes, R., B.K. Potter, and J. Little, Attitudes of undergraduate university women towards 
HPV vaccination: a cross-sectional study in Ottawa, Canada. BMC Womens Health, 2018. 18(1): 
p. 134. 
171. Tatar, O., et al., Psychosocial correlates of HPV vaccine acceptability in college males: A cross-
sectional exploratory study. Papillomavirus Res, 2017. 4: p. 99-107. 
172. Moss, J.L., P.L. Reiter, and N.T. Brewer, HPV vaccine for teen boys: Dyadic analysis of parents' 
and sons' beliefs and willingness. Prev Med, 2015. 78: p. 65-71. 
 
391 
173. Adjei Boakye, E., et al., Approaching a decade since HPV vaccine licensure: Racial and gender 
disparities in knowledge and awareness of HPV and HPV vaccine. Hum Vaccin Immunother, 
2017. 13(11): p. 2713-2722. 
174. Brown, T., et al., Understanding Black Patients' Refusal of Pneumococcal Vaccination. J Racial 
Ethn Health Disparities, 2017. 4(1): p. 1-8. 
175. Crouse Quinn, S., et al., Determinants of influenza vaccination among high-risk Black and White 
adults. Vaccine, 2017. 35(51): p. 7154-7159. 
176. Cunningham-Erves, J., et al., Black mother's intention to vaccinate daughters against HPV: A 
mixed methods approach to identify opportunities for targeted communication. Gynecol Oncol, 
2018. 149(3): p. 506-512. 
177. De, P. and H. Budhwani, Human papillomavirus (HPV) vaccine initiation in minority Americans. 
Public Health, 2017. 144: p. 86-91. 
178. Freimuth, V.S., et al., Determinants of trust in the flu vaccine for African Americans and Whites. 
Soc Sci Med, 2017. 193: p. 70-79. 
179. Fry, C.A., E.P. Silverman, and S. Miller, Addressing Pneumococcal Vaccine Uptake Disparities 
among African-American Adults in the United States. Public Health Nurs, 2016. 33(4): p. 277-82. 
180. Healy, J., et al., Vaccination coverage among foreign-born and U.S.-born adolescents in the 
United States: Successes and gaps - National Immunization Survey-Teen, 2012-2014. Vaccine, 
2018. 36(13): p. 1743-1750. 
181. Henry, K.A., et al., Area-based socioeconomic factors and Human Papillomavirus (HPV) 
vaccination among teen boys in the United States. BMC Public Health, 2017. 18(1): p. 19. 
182. Maness, S.B., et al., HPV Awareness, Knowledge and Vaccination Attitudes among Church-going 
African-American Women. Am J Health Behav, 2016. 40(6): p. 771-778. 
183. Moran, M.B., et al., Individual, Cultural and Structural Predictors of Vaccine Safety Confidence 
and Influenza Vaccination Among Hispanic Female Subgroups. J Immigr Minor Health, 2017. 
19(4): p. 790-800. 
184. Nonzee, N.J., et al., Disparities in parental human papillomavirus (HPV) vaccine awareness and 
uptake among adolescents. Vaccine, 2018. 36(10): p. 1243-1247. 
185. Nuno, V.L., et al., A Cross-Sectional Study of Human Papillomavirus Vaccine Utilization Among 
University Women: The Role of Ethnicity, Race, and Risk Factors. J Low Genit Tract Dis, 2016. 
20(2): p. 131-4. 
186. Ojeaga, A., et al., Racial Disparities in HPV-related Knowledge, Attitudes, and Beliefs Among 
African American and White Women in the USA. J Cancer Educ, 2017. 
187. Okafor, C., X. Hu, and R.L. Cook, Racial/Ethnic Disparities in HPV Vaccine Uptake Among a 
Sample of College Women. J Racial Ethn Health Disparities, 2015. 2(3): p. 311-6. 
188. Otanez, S. and B.M. Torr, Ethnic and Racial Disparities in HPV Vaccination Attitudes. J Immigr 
Minor Health, 2017. 
189. Quinn, S.C., African American adults and seasonal influenza vaccination: Changing our approach 
can move the needle. Hum Vaccin Immunother, 2018. 14(3): p. 719-723. 
190. Quinn, S.C., et al., Breaking down the monolith: Understanding flu vaccine uptake among African 
Americans. SSM Popul Health, 2018. 4: p. 25-36. 
191. Quinn, S.C., et al., Exploring racial influences on flu vaccine attitudes and behavior: Results of a 
national survey of White and African American adults. Vaccine, 2017. 35(8): p. 1167-1174. 
192. Santibanez, T.A. and E.D. Kennedy, Reasons given for not receiving an influenza vaccination, 
2011-12 influenza season, United States. Vaccine, 2016. 34(24): p. 2671-8. 
193. Warner, E.L., et al., White, affluent, educated parents are least likely to choose HPV vaccination 
for their children: a cross-sectional study of the National Immunization Study - teen. BMC 
Pediatr, 2017. 17(1): p. 200. 
 
392 
194. Ahluwalia, I.B., et al., Tetanus, diphtheria, pertussis vaccination coverage before, during, and 
after pregnancy - 16 States and New York City, 2011. MMWR Morb Mortal Wkly Rep, 2015. 
64(19): p. 522-6. 
195. Beel, E.R., et al., Knowledge and attitudes of postpartum women toward immunization during 
pregnancy and the peripartum period. Hum Vaccin Immunother, 2013. 9(9): p. 1926-31. 
196. Chamberlain, A.T., et al., Factors Associated with Intention to Receive Influenza and Tetanus, 
Diphtheria, and Acellular Pertussis (Tdap) Vaccines during Pregnancy: A Focus on Vaccine 
Hesitancy and Perceptions of Disease Severity and Vaccine Safety. PLoS Curr, 2015. 7. 
197. Cunningham, R.M., et al., Prevalence of Vaccine Hesitancy Among Expectant Mothers in 
Houston, Texas. Acad Pediatr, 2018. 18(2): p. 154-160. 
198. Dlugacz, Y., et al., 2009 H1N1 vaccination by pregnant women during the 2009-10 H1N1 
influenza pandemic. Am J Obstet Gynecol, 2012. 206(4): p. 339.e1-8. 
199. Eppes, C., et al., Barriers to influenza vaccination among pregnant women. Vaccine, 2013. 
31(27): p. 2874-8. 
200. Gorman, J.R., et al., Theory-based predictors of influenza vaccination among pregnant women. 
Vaccine, 2012. 31(1): p. 213-8. 
201. Gorman, J.R. and C.D. Chambers, Pregnant women's attitudes toward influenza vaccination 
while breastfeeding. Prev Med Rep, 2015. 2: p. 333-6. 
202. Healy, C.M., et al., Knowledge and attitiudes of pregnant women and their providers towards 
recommendations for immunization during pregnancy. Vaccine, 2015. 33(41): p. 5445-5451. 
203. Henninger, M., et al., Predictors of seasonal influenza vaccination during pregnancy. Obstet 
Gynecol, 2013. 121(4): p. 741-9. 
204. Henninger, M.L., et al., Factors associated with seasonal influenza vaccination in pregnant 
women. J Womens Health (Larchmt), 2015. 24(5): p. 394-402. 
205. O'Halloran, A.C., et al., Tetanus, diphtheria, and acellular pertussis vaccination among women of 
childbearing age-United States, 2013. Am J Infect Control, 2016. 44(7): p. 786-93. 
206. Payakachat, N., K.B. Hadden, and D. Ragland, Promoting Tdap immunization in pregnancy: 
Associations between maternal perceptions and vaccination rates. Vaccine, 2016. 34(1): p. 179-
86. 
207. Weiner, J.L., et al., Childhood immunizations: First-time expectant mothers' knowledge, beliefs, 
intentions, and behaviors. Vaccine, 2015. 33 Suppl 4: p. D92-8. 
208. MacDougall, D.M., et al., Knowledge, attitudes, beliefs, and behaviors of pregnant women 
approached to participate in a Tdap maternal immunization randomized, controlled trial. Hum 
Vaccin Immunother, 2016. 12(4): p. 879-85. 
209. Halperin, B.A., et al., Maintaining the momentum: key factors influencing acceptance of 
influenza vaccination among pregnant women following the H1N1 pandemic. Hum Vaccin 
Immunother, 2014. 10(12): p. 3629-41. 
210. Bettinger, J.A., D. Greyson, and D. Money, Attitudes and Beliefs of Pregnant Women and New 
Mothers Regarding Influenza Vaccination in British Columbia. J Obstet Gynaecol Can, 2016. 
38(11): p. 1045-1052. 
211. Vannice, K.S., et al., Attitudes and beliefs of parents concerned about vaccines: impact of timing 
of immunization information. Pediatrics, 2011. 127 Suppl 1: p. S120-6. 
212. Betsch, C., et al., How baby's first shot determines the development of maternal attitudes 
towards vaccination. Vaccine, 2018. 36(21): p. 3018-3026. 
213. Glanz, J.M., et al., A mixed methods study of parental vaccine decision making and parent-
provider trust. Acad Pediatr, 2013. 13(5): p. 481-8. 
214. O'Leary, S.T., et al., Timing of Information-Seeking about Infant Vaccines. J Pediatr, 2018. 
 
393 
215. Poland, G.A. and R.M. Jacobson, Understanding those who do not understand: a brief review of 
the anti-vaccine movement. Vaccine, 2001. 19(17-19): p. 2440-5. 
216. Benin, A.L., et al., Qualitative analysis of mothers' decision-making about vaccines for infants: 
the importance of trust. Pediatrics, 2006. 117(5): p. 1532-41. 
217. Smith, P.J., et al., Parental Delay or Refusal of Vaccine Doses, Childhood Vaccination Coverage at 
24 Months of Age, and the Health Belief Model. Public Health Reports, 2011. 126(Suppl 2): p. 
135-146. 
218. Weiss, C., D. Schropfer, and S. Merten, Parental attitudes towards measles vaccination in the 
canton of Aargau, Switzerland: a latent class analysis. BMC Infect Dis, 2016. 16(1): p. 400. 
219. Centers for Disease Control and Prevention. Vaccine Safety. August 14, 2017 [cited 2018; 
Available from: https://www.cdc.gov/vaccinesafety/index.html. 
220. Centers for Disease Control and Prevention. Vaccine Information Statements (VIS). August 7, 
2015 [cited 2015; Available from: http://www.cdc.gov/vaccines/hcp/vis/current-vis.html. 
221. Centers for Disease Control and Prevention. Vaccines Do Not Cause Autism. November 23, 2015 
[cited 2018; Available from: https://www.cdc.gov/vaccinesafety/concerns/autism.html. 
222. Institute of Medicine, in Adverse Effects of Vaccines: Evidence and Causality, K. Stratton, et al., 
Editors. 2012, National Academies Press (US): Washington (DC). 
223. Institute of Medicine Immunization Safety Review, C., in Immunization Safety Review: 
Vaccinations and Sudden Unexpected Death in Infancy, K. Stratton, et al., Editors. 2003, National 
Academies Press (US). Copyright 2003 by the National Academy of Sciences. All rights reserved.: 
Washington (DC). 
224. Institute of Medicine Immunization Safety Review, C., in Immunization Safety Review: Multiple 
Immunizations and Immune Dysfunction, K. Stratton, C.B. Wilson, and M.C. McCormick, Editors. 
2002, National Academies Press (US): Washington (DC). 
225. Institute of Medicine Vaccine Safety, C., The National Academies Collection: Reports funded by 
National Institutes of Health, in Adverse Events Associated with Childhood Vaccines: Evidence 
Bearing on Causality, K.R. Stratton, C.J. Howe, and R.B. Johnston, Jr., Editors. 1994, National 
Academies Press (US). Copyright 1994 by the National Academy of Sciences. All rights reserved.: 
Washington (DC). 
226. Institute of Medicine Committee on Review of Priorities in the National Vaccine Plan, Appendix C 
1986 National Childhood Vaccine Injury Act (Public Law 99-660), in Priorities for the National 
Vaccine Plan. 2010, National Academies Press (US). Copyright 2010 by the National Academy of 
Sciences. All rights reserved.: Washington (DC). 
227. Maglione MA, G.C., Das L, Raaen L, Smith A, Chari R, Newberry S, Hempel S, Shanman R, Perry T, 
Goetz MB, Safety of Vaccines Used for Routine Immunization in the United States. Evidence 
Report/Technology Assessment No. 215. 2014, Agency for Healthcare Research and Quality: 
Rockville, MD. 
228. Briere, E.C., Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary 
Haemophilus influenzae Type b (Hib) Vaccination Series. MMWR Morb Mortal Wkly Rep, 2016. 
65(16): p. 418-9. 
229. Briere, E.C., et al., Prevention and control of haemophilus influenzae type b disease: 
recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm 
Rep, 2014. 63(Rr-01): p. 1-14. 







231. Immunization Action Coalition. Merck discontinues production of Comvax vaccine (Hib-HepB). 
IAC Express 2014  [cited 2018 March]; Issue 1136:[Available from: 
http://www.immunize.org/express/issue1136.asp#IACX6. 
232. Fiore, A.E., A. Wasley, and B.P. Bell, Prevention of hepatitis A through active or passive 
immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR Recomm Rep, 2006. 55(Rr-7): p. 1-23. 
233. Centers for Disease Control and Prevention. Hepatitis A Vaccines. in Meeting of the Advisory 
Committee on Immunization Practices (ACIP). 2018. Atlanta, GA. 
234. Zuckerman, J.N., Protective efficacy, immunotherapeutic potential, and safety of hepatitis B 
vaccines. J Med Virol, 2006. 78(2): p. 169-77. 
235. Ocama, P., C.K. Opio, and W.M. Lee, Hepatitis B virus infection: current status. Am J Med, 2005. 
118(12): p. 1413. 
236. Schillie, S., et al., Recommendations of the Advisory Committee on Immunization Practices for 
Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR Morb Mortal Wkly Rep, 2018. 
67(15): p. 455-458. 
237. Mast, E.E., et al., A comprehensive immunization strategy to eliminate transmission of hepatitis 
B virus infection in the United States: recommendations of the Advisory Committee on 
Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. 
MMWR Recomm Rep, 2005. 54(Rr-16): p. 1-31. 
238. Mast, E.E., et al., A comprehensive immunization strategy to eliminate transmission of hepatitis 
B virus infection in the United States: recommendations of the Advisory Committee on 
Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep, 2006. 
55(Rr-16): p. 1-33; quiz CE1-4. 
239. Schillie, S., C. Vellozzi, and A. Reingold, Prevention of Hepatitis B Virus Infection in the United 
States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb 
Mortal Wkly Rep, 2018. 67(1): p. 1–31. 
240. Markowitz, L.E., et al., Human papillomavirus vaccination: recommendations of the Advisory 
Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2014. 63(Rr-05): p. 1-30. 
241. Meites, E., A. Kempe, and L.E. Markowitz, Use of a 2-Dose Schedule for Human Papillomavirus 
Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. 
MMWR Morb Mortal Wkly Rep, 2016. 65(49): p. 1405-1408. 
242. Walker, T.Y., et al., National, Regional, State, and Selected Local Area Vaccination Coverage 
Among Adolescents Aged 13-17 Years - United States, 2017. MMWR Morb Mortal Wkly Rep, 
2018. 67(33): p. 909-917. 
243. Petrosky, E., et al., Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV 
vaccination recommendations of the advisory committee on immunization practices. MMWR 
Morb Mortal Wkly Rep, 2015. 64(11): p. 300-4. 
244. Kroger, A.T., J. Duchin, and M. Vázquez. General Best Practice Guidelines for Immunization. Best 
Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2017  [cited 
2017 October]; Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-
recs/index.html. 
245. Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly 
Rep, 2008. 57(17): p. 457-60. 
246. Braun, M.M., P.A. Patriarca, and S.S. Ellenberg, Syncope after immunization. Arch Pediatr 
Adolesc Med, 1997. 151(3): p. 255-9. 
247. Bernard, D.M., et al., The domino effect: adolescent girls' response to human papillomavirus 
vaccination. Med J Aust, 2011. 194(6): p. 297-300. 
 
395 
248. Bednarczyk, R.A., et al., Sexual Activity–Related Outcomes After Human Papillomavirus 
Vaccination of 11- to 12-Year-Olds. Pediatrics, 2012. 
249. Naleway, A.L., et al., Primary Ovarian Insufficiency and Adolescent Vaccination. Pediatrics, 2018. 
250. Bouvier, N.M. and P. Palese, The biology of influenza viruses. Vaccine, 2008. 26 Suppl 4: p. D49-
53. 
251. Treanor, J., Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med, 2004. 
350(3): p. 218-20. 
252. Barker, W.H., Excess pneumonia and influenza associated hospitalization during influenza 
epidemics in the United States, 1970-78. Am J Public Health, 1986. 76(7): p. 761-5. 
253. Barker, W.H. and J.P. Mullooly, Impact of epidemic type A influenza in a defined adult 
population. Am J Epidemiol, 1980. 112(6): p. 798-811. 
254. Mullooly, J.P., et al., Influenza- and RSV-associated hospitalizations among adults. Vaccine, 
2007. 25(5): p. 846-55. 
255. Fry, A.M., et al., Efficacy of oseltamivir treatment started within 5 days of symptom onset to 
reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a 
randomised placebo-controlled trial. Lancet Infect Dis, 2014. 14(2): p. 109-18. 
256. Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR 
Morb Mortal Wkly Rep, 2010. 59(33): p. 1057-62. 
257. Thompson, W.W., et al., Influenza-associated hospitalizations in the United States. Jama, 2004. 
292(11): p. 1333-40. 
258. Kostova, D., et al., Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the 
United States, 2005-2011. PLoS One, 2013. 8(6): p. e66312. 
259. Shang, M., et al., Influenza-Associated Pediatric Deaths in the United States, 2010–2016. 
Pediatrics, 2018. 
260. Centers for Disease Control and Prevention. Influenza (Flu) - Past Weekly Surveillance Reports. 
2017  [cited 2017 December 11]; Available from: 
https://www.cdc.gov/flu/weekly/pastreports.htm. 
261. Grohskopf, L.A., et al., Update: ACIP Recommendations for the Use of Quadrivalent Live 
Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. MMWR Morb 
Mortal Wkly Rep, 2018. 67(22): p. 643-645. 
262. Grohskopf, L.A., et al., Prevention and Control of Seasonal Influenza with Vaccines: 
Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 
Influenza Season. MMWR Recomm Rep, 2018. 67(3): p. 1-20. 
263. Garten, R., et al., Update: Influenza Activity in the United States During the 2017-18 Season and 
Composition of the 2018-19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep, 2018. 67(22): p. 
634-642. 
264. Centers for Disease Control and Prevention. FluVaxView. 2018 October 25, 2018 [cited 2018 
November 7]; Available from: https://www.cdc.gov/flu/fluvaxview/index.htm. 
265. Loeb, M., et al., Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A 
Cluster Randomized Blinded Trial. Ann Intern Med, 2016. 165(9): p. 617-624. 
266. Loeb, M., et al., Effect of influenza vaccination of children on infection rates in Hutterite 
communities: a randomized trial. Jama, 2010. 303(10): p. 943-50. 
267. Reichert, T.A., et al., The Japanese experience with vaccinating schoolchildren against influenza. 
N Engl J Med, 2001. 344(12): p. 889-96. 
268. Plans-Rubio, P., The vaccination coverage required to establish herd immunity against influenza 
viruses. Prev Med, 2012. 55(1): p. 72-7. 
269. Greenhawt, M.J., et al., Safe administration of the seasonal trivalent influenza vaccine to 
children with severe egg allergy. Ann Allergy Asthma Immunol, 2012. 109(6): p. 426-30. 
 
396 
270. Greenhawt, M., P.J. Turner, and J.M. Kelso, Administration of influenza vaccines to egg allergic 
recipients: A practice parameter update 2017. Annals of Allergy, Asthma & Immunology. 120(1): 
p. 49-52. 
271. American Academy of Allergy Asthma and Immunology. Egg Allergy and the Flu Vaccine.  [cited 
2018 March]; Available from: https://www.aaaai.org/conditions-and-treatments/library/allergy-
library/egg-allergy-and-the-flu-vaccine. 
272. Dreskin, S.C., et al., International Consensus (ICON): allergic reactions to vaccines. World Allergy 
Organ J, 2016. 9(1): p. 32. 
273. Young, B., et al., Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-
analysis, and Meta-regression of Test-Negative Design Case-Control Studies. J Infect Dis, 2018. 
217(5): p. 731-741. 
274. Clements, M.L., et al., Resistance of adults to challenge with influenza A wild-type virus after 
receiving live or inactivated virus vaccine. J Clin Microbiol, 1986. 23(1): p. 73-6. 
275. Belshe, R.B., et al., Live attenuated versus inactivated influenza vaccine in infants and young 
children. N Engl J Med, 2007. 356(7): p. 685-96. 
276. Centers for Disease Control and Prevention. Vaccine Effectiveness - How Well Does the Flu 
Vaccine Work? 2017  [cited 2018 March]; Available from: 
https://www.cdc.gov/flu/about/qa/vaccineeffect.htm. 
277. Brady, R.C., et al., Randomized trial to compare the safety and immunogenicity of CSL Limited's 
2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. 
Vaccine, 2014. 32(52): p. 7141-7. 
278. Greenberg, D.P., et al., Safety and immunogenicity of an inactivated quadrivalent influenza 
vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J, 2014. 33(6): p. 630-6. 
279. Baxter, R., et al., A Phase III evaluation of immunogenicity and safety of two trivalent inactivated 
seasonal influenza vaccines in US children. Pediatr Infect Dis J, 2010. 29(10): p. 924-30. 
280. Nolan, T., et al., Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine 
in infants and children. Influenza Other Respir Viruses, 2009. 3(6): p. 315-25. 
281. Domachowske, J.B., et al., A randomized trial of candidate inactivated quadrivalent influenza 
vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis, 2013. 
207(12): p. 1878-87. 
282. Langley, J.M., et al., Immunogenicity and safety of an inactivated quadrivalent influenza vaccine 
candidate: a phase III randomized controlled trial in children. J Infect Dis, 2013. 208(4): p. 544-
53. 
283. Tregnaghi, M.W., et al., Immunogenicity, safety, and tolerability of two trivalent subunit 
inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter 
study. Viral Immunol, 2012. 25(3): p. 216-25. 
284. Beran, J., et al., Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza 
vaccine: a randomized, controlled trial in adults. BMC Infect Dis, 2013. 13: p. 224. 
285. Nicholson, K.G., et al., Immunogenicity and safety of a two-dose schedule of whole-virion and 
AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, 
head-to-head trial. Lancet Infect Dis, 2011. 11(2): p. 91-101. 
286. Vellozzi, C., S. Iqbal, and K. Broder, Guillain-Barre syndrome, influenza, and influenza 
vaccination: the epidemiologic evidence. Clin Infect Dis, 2014. 58(8): p. 1149-55. 
287. Salmon, D.A., et al., Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 




288. Centers for Disease Control and Prevention. Misconceptions about Seasonal Flu and Flu 
Vaccines. 2017  [cited 2018 March]; Available from: 
https://www.cdc.gov/flu/about/qa/misconceptions.htm. 
289. Centers for Disease Control and Prevention, Vaccine Information Statement - Live Attenuated 
Influenza Vaccine. 2015. 
290. McLean, H.Q., et al., Prevention of measles, rubella, congenital rubella syndrome, and mumps, 
2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR Recomm Rep, 2013. 62(RR-04): p. 1-34. 
291. Demicheli, V., et al., Vaccines for measles, mumps and rubella in children. Cochrane Database 
Syst Rev, 2012. 2: p. Cd004407. 
292. Cardemil, C.V., et al., Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak 
Control. N Engl J Med, 2017. 377(10): p. 947-956. 
293. (AAP), A.A.o.P., Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics, 
2011. 127(2): p. 389-94. 
294. (AAP), A.A.o.P., Febrile seizures: clinical practice guideline for the long-term management of the 
child with simple febrile seizures. Pediatrics, 2008. 121(6): p. 1281-6. 
295. Bonhoeffer, J., et al., Generalized convulsive seizure as an adverse event following immunization: 
case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004. 
22(5-6): p. 557-62. 
296. Tse, A., et al., Signal identification and evaluation for risk of febrile seizures in children following 
trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. 
Vaccine, 2012. 30(11): p. 2024-31. 
297. Klein, N.P., et al., Measles-mumps-rubella-varicella combination vaccine and the risk of febrile 
seizures. Pediatrics, 2010. 126(1): p. e1-8. 
298. MacNeil, J.R., et al., Use of Serogroup B Meningococcal Vaccines in Adolescents and Young 
Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR 
Morb Mortal Wkly Rep, 2015. 64(41): p. 1171-6. 
299. Patton, M.E., et al., Updated Recommendations for Use of MenB-FHbp Serogroup B 
Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb 
Mortal Wkly Rep, 2017. 66(19): p. 509-513. 
300. Organization, W.H., Pneumococcal vaccines WHO position paper--2012. Wkly Epidemiol Rec, 
2012. 87(14): p. 129-44. 
301. Kobayashi, M., et al., Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the 
Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep, 2015. 
64(34): p. 944-7. 
302. von Elten, K.A., et al., Systemic inflammatory reaction after pneumococcal vaccine: a case series. 
Hum Vaccin Immunother, 2014. 10(6): p. 1767-70. 
303. Huang, D.T., et al., Protracted fever with cellulitis-like reaction in pneumococcal polysaccharide-
vaccinated children. Pediatr Infect Dis J, 2008. 27(10): p. 937-9. 
304. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) 
regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep, 2009. 58(30): p. 829-
30. 
305. Cortese, M.M. and U.D. Parashar, Prevention of rotavirus gastroenteritis among infants and 
children: recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR Recomm Rep, 2009. 58(Rr-2): p. 1-25. 
306. Aliabadi, N., J.E. Tate, and U.D. Parashar, Potential safety issues and other factors that may 




307. Yih, W.K., et al., Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med, 
2014. 370(6): p. 503-12. 
308. Parashar, U.D., et al., Value of post-licensure data on benefits and risks of vaccination to inform 
vaccine policy: The example of rotavirus vaccines. Vaccine, 2015. 
309. Bogaert, D., et al., Persistent rotavirus diarrhea post-transplant in a novel JAK3-SCID patient 
after vaccination. Pediatr Allergy Immunol, 2016. 27(1): p. 93-6. 
310. Bakare, N., et al., Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to 
the Vaccine Adverse Events Reporting System (VAERS). Vaccine, 2010. 28(40): p. 6609-12. 
311. Gambhir, M., et al., A change in vaccine efficacy and duration of protection explains recent rises 
in pertussis incidence in the United States. PLoS Comput Biol, 2015. 11(4): p. e1004138. 
312. Centers for Disease Control and Prevention. 2016 Provisional Pertussis Surveillance Report 2017  
[cited 2017 December 11]; Available from: https://www.cdc.gov/pertussis/downloads/pertuss-
surv-report-2016-provisional.pdf. 
313. Zlamy, M., Rediscovering Pertussis. Front Pediatr, 2016. 4: p. 52. 
314. Warfel, J.M., L.I. Zimmerman, and T.J. Merkel, Acellular pertussis vaccines protect against 
disease but fail to prevent infection and transmission in a nonhuman primate model. 
Proceedings of the National Academy of Sciences of the United States of America, 2014. 111(2): 
p. 787-792. 
315. Gill, C., P. Rohani, and D.M. Thea, The relationship between mucosal immunity, nasopharyngeal 
carriage, asymptomatic transmission and the resurgence of Bordetella pertussis. F1000Research, 
2017. 6: p. 1568. 
316. Gold, M.S., Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for 
concern? Drug Saf, 2002. 25(2): p. 85-90. 
317. Fulton, T.R., et al., Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review 
and Meta-analysis. Clin Infect Dis, 2016. 62(9): p. 1100-10. 
318. Van Rie, A., A.M. Wendelboe, and J.A. Englund, Role of maternal pertussis antibodies in infants. 
Pediatr Infect Dis J, 2005. 24(5 Suppl): p. S62-5. 
319. Marin, M., et al., Prevention of varicella: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep, 2007. 56(Rr-4): p. 1-40. 
320. Seward, J.F., M. Marin, and M. Vazquez, Varicella vaccine effectiveness in the US vaccination 
program: a review. J Infect Dis, 2008. 197 Suppl 2: p. S82-9. 
321. Shapiro, E.D., et al., Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis, 2011. 
203(3): p. 312-5. 
322. Perella, D., et al., Varicella Vaccine Effectiveness in Preventing Community Transmission in the 2-
Dose Era. Pediatrics, 2016. 137(4). 
323. Dreyer, S., et al., Pediatric vaccine-strain herpes zoster: a case series. Pediatr Dermatol, 2017. 
324. ACOG Committee Opinion No. 566: Update on immunization and pregnancy: tetanus, diphtheria, 
and pertussis vaccination. Obstet Gynecol, 2013. 121(6): p. 1411-4. 
325. Committee opinion no. 608: influenza vaccination during pregnancy. Obstet Gynecol, 2014. 
124(3): p. 648-51. 
326. Singh, M. and K. Lingappan, Whooping cough: the current scene. Chest, 2006. 130(5): p. 1547-
53. 
327. Influenza vaccination coverage among pregnant women--United States, 2012-13 influenza 
season. MMWR Morb Mortal Wkly Rep, 2013. 62(38): p. 787-92. 
328. Influenza vaccination coverage among pregnant women: 2011-12 influenza season, United 
States. MMWR Morb Mortal Wkly Rep, 2012. 61: p. 758-63. 
329. Influenza vaccination coverage among pregnant women --- United States, 2010-11 influenza 
season. MMWR Morb Mortal Wkly Rep, 2011. 60(32): p. 1078-82. 
 
399 
330. Ding, H., et al., Influenza Vaccination Coverage Among Pregnant Women--United States, 2014-
15 Influenza Season. MMWR Morb Mortal Wkly Rep, 2015. 64(36): p. 1000-5. 
331. Ding, H., et al., Influenza vaccination coverage among pregnant women--United States, 2013-14 
influenza season. MMWR Morb Mortal Wkly Rep, 2014. 63(37): p. 816-21. 
332. Ding, H., et al., Influenza Vaccination Coverage Among Pregnant Women - United States, 2016-
17 Influenza Season. MMWR Morb Mortal Wkly Rep, 2017. 66(38): p. 1016-1022. 
333. Callaghan, W.M., A.A. Creanga, and D.J. Jamieson, Pregnancy-Related Mortality Resulting From 
Influenza in the United States During the 2009-2010 Pandemic. Obstet Gynecol, 2015. 126(3): p. 
486-90. 
334. He, J., et al., A Systematic Review and Meta-Analysis of Influenza A Virus Infection During 
Pregnancy Associated with an Increased Risk for Stillbirth and Low Birth Weight. Kidney Blood 
Press Res, 2017. 42(2): p. 232-243. 
335. Fell, D.B., et al., Maternal influenza and birth outcomes: systematic review of comparative 
studies. Bjog, 2017. 124(1): p. 48-59. 
336. Black, S.B., et al., Effectiveness of influenza vaccine during pregnancy in preventing 
hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. 
Am J Perinatol, 2004. 21(6): p. 333-9. 
337. Puck, J.M., et al., Protection of infants from infection with influenza A virus by transplacentally 
acquired antibody. J Infect Dis, 1980. 142(6): p. 844-9. 
338. Sumaya, C.V. and R.S. Gibbs, Immunization of pregnant women with influenza A/New Jersey/76 
virus vaccine: reactogenicity and immunogenicity in mother and infant. J Infect Dis, 1979. 140(2): 
p. 141-6. 
339. Englund, J.A., et al., Maternal immunization with influenza or tetanus toxoid vaccine for passive 
antibody protection in young infants. J Infect Dis, 1993. 168(3): p. 647-56. 
340. Reuman, P.D., E.M. Ayoub, and P.A. Small, Effect of passive maternal antibody on influenza 
illness in children: a prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J, 
1987. 6(4): p. 398-403. 
341. Eick, A.A., et al., Maternal influenza vaccination and effect on influenza virus infection in young 
infants. Arch Pediatr Adolesc Med, 2011. 165(2): p. 104-11. 
342. Steinhoff, M.C., et al., Influenza immunization in pregnancy--antibody responses in mothers and 
infants. N Engl J Med, 2010. 362(17): p. 1644-6. 
343. Zaman, K., et al., Effectiveness of maternal influenza immunization in mothers and infants. N 
Engl J Med, 2008. 359(15): p. 1555-64. 
344. Thompson, M.G., et al., Effectiveness of seasonal trivalent influenza vaccine for preventing 
influenza virus illness among pregnant women: a population-based case-control study during the 
2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis, 2014. 58(4): p. 449-57. 
345. Richards, J.L., et al., Neonatal outcomes after antenatal influenza immunization during the 2009 
H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age 
birth. Clin Infect Dis, 2013. 56(9): p. 1216-22. 
346. Hulka, J.F., EFFECTIVENESS OF POLYVALENT INFLUENZA VACCINE IN PREGNANCY. REPORT OF A 
CONTROLLED STUDY DURING AN OUTBREAK OF ASIAN INFLUENZA. Obstet Gynecol, 1964. 23: p. 
830-7. 
347. Haberg, S.E., et al., Risk of fetal death after pandemic influenza virus infection or vaccination. N 
Engl J Med, 2013. 368(4): p. 333-40. 
348. Munoz, F.M., et al., Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol, 
2005. 192(4): p. 1098-106. 
 
400 
349. France, E.K., et al., Impact of maternal influenza vaccination during pregnancy on the incidence 
of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med, 2006. 160(12): p. 
1277-83. 
350. Benowitz, I., et al., Influenza vaccine given to pregnant women reduces hospitalization due to 
influenza in their infants. Clin Infect Dis, 2010. 51(12): p. 1355-61. 
351. Manske, J.M., Efficacy and effectiveness of maternal influenza vaccination during pregnancy: a 
review of the evidence. Matern Child Health J, 2014. 18(7): p. 1599-609. 
352. Rasmussen, S.A., D.J. Jamieson, and T.M. Uyeki, Effects of influenza on pregnant women and 
infants. Am J Obstet Gynecol, 2012. 207(3 Suppl): p. S3-8. 
353. Phadke, V.K. and S.B. Omer, Maternal vaccination for the prevention of influenza: current status 
and hopes for the future. Expert Rev Vaccines, 2016. 15(10): p. 1255-80. 
354. Steinhoff, M.C., et al., Neonatal outcomes after influenza immunization during pregnancy: a 
randomized controlled trial. Cmaj, 2012. 184(6): p. 645-53. 
355. Bratton, K.N., et al., Maternal influenza immunization and birth outcomes of stillbirth and 
spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis, 2015. 60(5): p. 
e11-9. 
356. Regan, A.K., et al., Seasonal Trivalent Influenza Vaccination During Pregnancy and the Incidence 
of Stillbirth: Population-Based Retrospective Cohort Study. Clin Infect Dis, 2016. 62(10): p. 1221-
7. 
357. Fell, D.B., et al., Fetal death and preterm birth associated with maternal influenza vaccination: 
systematic review. BJOG: An International Journal of Obstetrics & Gynaecology, 2015. 122(1): p. 
17-26. 
358. Fell, D.B., et al., Report of the WHO technical consultation on the effect of maternal influenza 
and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 
2015. Vaccine, 2017. 35(18): p. 2279-2287. 
359. Savitz, D.A., et al., Does influenza vaccination improve pregnancy outcome? Methodological 
issues and research needs. Vaccine, 2015. 33(47): p. 6430-5. 
360. Tamma, P.D., et al., Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol, 
2009. 201(6): p. 547-52. 
361. Bednarczyk, R.A., D. Adjaye-Gbewonyo, and S.B. Omer, Safety of influenza immunization during 
pregnancy for the fetus and the neonate. Am J Obstet Gynecol, 2012. 207(3 Suppl): p. S38-46. 
362. Keller-Stanislawski, B., et al., Safety of immunization during pregnancy: a review of the evidence 
of selected inactivated and live attenuated vaccines. Vaccine, 2014. 32(52): p. 7057-64. 
363. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec, 2012. 
87(47): p. 461-76. 
364. McMillan, M., et al., Influenza vaccination during pregnancy: A systematic review of fetal death, 
spontaneous abortion, and congenital malformation safety outcomes. Vaccine, 2015. 33(18): p. 
2108-2117. 
365. Polyzos, K.A., et al., Maternal Influenza Vaccination and Risk for Congenital Malformations: A 
Systematic Review and Meta-analysis. Obstet Gynecol, 2015. 126(5): p. 1075-84. 
366. Kharbanda, E.O., et al., Inactivated influenza vaccine during pregnancy and risks for adverse 
obstetric events. Obstet Gynecol, 2013. 122(3): p. 659-67. 
367. Regan, A.K., et al., A prospective cohort study assessing the reactogenicity of pertussis and 
influenza vaccines administered during pregnancy. Vaccine, 2016. 34(20): p. 2299-304. 
368. Fell, D.B., et al., Fetal death and preterm birth associated with maternal influenza vaccination: 
systematic review. Bjog, 2015. 122(1): p. 17-26. 
 
401 
369. Naleway, A.L., et al., Safety of influenza vaccination during pregnancy: A review of subsequent 
maternal obstetric events and findings from two recent cohort studies. Vaccine, 2014. 32(26): p. 
3122-3127. 
370. Nitsch-Osuch, A., et al., Epidemiological and clinical reasons for vaccination against pertussis and 
influenza in pregnant women. Adv Exp Med Biol, 2015. 849: p. 11-21. 
371. Sukumaran, L., et al., Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular 
Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol, 2015. 126(5): p. 1069-74. 
372. Donahue, J.G., et al., Association of spontaneous abortion with receipt of inactivated influenza 
vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine, 2017. 35(40): p. 5314-5322. 
373. Chambers, C.D., R. Xu, and A.A. Mitchell, Commentary on: "Association of spontaneous abortion 
with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12". 
Vaccine, 2017. 35(40): p. 5323-5324. 
374. Steinhoff, M.C., et al., Year-round influenza immunisation during pregnancy in Nepal: a phase 4, 
randomised, placebo-controlled trial. Lancet Infect Dis, 2017. 17(9): p. 981-989. 
375. Chambers, C.D., et al., Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth 
defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine, 
2013. 31(44): p. 5026-32. 
376. Chambers, C.D., et al., Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal 
influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and 
small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine, 2016. 34(37): 
p. 4443-4449. 
377. Chavant, F., et al., The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal 
Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza. Drug Safety, 
2013. 36(6): p. 455-465. 
378. Huang, W.T., et al., Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during 
pregnancy: a population-based study in Taiwan. Vaccine, 2014. 32(48): p. 6463-8. 
379. Ludvigsson, J.F., et al., Maternal vaccination against H1N1 influenza and offspring mortality: 
population based cohort study and sibling design. Bmj, 2015. 351: p. h5585. 
380. Ma, F., et al., Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant 
Chinese women. Clin Vaccine Immunol, 2014. 21(9): p. 1282-7. 
381. Oppermann, M., et al., A(H1N1)v2009: A controlled observational prospective cohort study on 
vaccine safety in pregnancy. Vaccine, 2012. 30(30): p. 4445-4452. 
382. Pasternak, B., et al., Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk 
of fetal death: cohort study in Denmark. BMJ : British Medical Journal, 2012. 344. 
383. Tavares, F., et al., Pregnancy and safety outcomes in women vaccinated with an AS03-
adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: A prospective 
cohort study. Vaccine, 2011. 29(37): p. 6358-6365. 
384. Irving, S.A., et al., Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion. Obstetrics 
& Gynecology, 2013. 121(1): p. 159-165. 
385. Sammon, C.J., et al., Evaluating the hazard of foetal death following H1N1 influenza vaccination; 
a population based cohort study in the UK GPRD. PLoS One, 2012. 7(12): p. e51734. 
386. Heikkinen, T., et al., Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a 
comparative cohort study. Am J Obstet Gynecol, 2012. 207(3): p. 177.e1-8. 
387. de Vries, L., et al., Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: 
description of a prospective cohort and spontaneously reported pregnancy-related adverse 
reactions in the Netherlands. Birth Defects Res A Clin Mol Teratol, 2014. 100(10): p. 731-8. 
 
402 
388. Bednarczyk, R.A., D. Adjaye-Gbewonyo, and S.B. Omer, Safety of influenza immunization during 
pregnancy for the fetus and the neonate. American Journal of Obstetrics & Gynecology, 2012. 
207(3): p. S38-S46. 
389. Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and 
Pertussis Vaccination. Obstet Gynecol, 2017. 130(3): p. e153-e157. 
390. Healy, C.M., et al., Prevalence of pertussis antibodies in maternal delivery, cord, and infant 
serum. J Infect Dis, 2004. 190(2): p. 335-40. 
391. Gall, S.A., J. Myers, and M. Pichichero, Maternal immunization with tetanus-diphtheria-pertussis 
vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol, 2011. 
204(4): p. 334.e1-5. 
392. Amirthalingam, G., et al., Sustained Effectiveness of the Maternal Pertussis Immunization 
Program in England 3 Years Following Introduction. Clin Infect Dis, 2016. 63(suppl 4): p. S236-
s243. 
393. McMillan, M., et al., Safety of Tetanus, Diphtheria, and Pertussis Vaccination During Pregnancy: 
A Systematic Review. Obstet Gynecol, 2017. 129(3): p. 560-573. 
394. Kharbanda, E.O., et al., Maternal Tdap vaccination: Coverage and acute safety outcomes in the 
vaccine safety datalink, 2007-2013. Vaccine, 2016. 34(7): p. 968-73. 
395. Kharbanda, E.O., et al., Evaluation of the association of maternal pertussis vaccination with 
obstetric events and birth outcomes. Jama, 2014. 312(18): p. 1897-904. 
396. Sukumaran, L., et al., Association of Tdap Vaccination With Acute Events and Adverse Birth 
Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. Jama, 2015. 
314(15): p. 1581-7. 
397. Control, C.f.D. and Prevention, Influenza vaccination coverage among pregnant women: 2011-12 
influenza season, United States. MMWR. Morbidity and mortality weekly report, 2012. 61: p. 
758. 
398. Ahluwalia, I.B., et al., Seasonal influenza vaccine coverage among pregnant women: pregnancy 
risk assessment monitoring system. Journal of women's health, 2011. 20(5): p. 649-651. 
399. Ahluwalia, I.B., et al., Tetanus, Diphtheria, Pertussis Vaccination Coverage Before, During, and 
After Pregnancy—16 States and New York City, 2011. MMWR Morb Mortal Wkly Rep, 2015. 
64(19): p. 522-6. 
400. Bisgard, K.M., et al., Infant pertussis: who was the source? Pediatr Infect Dis J, 2004. 23(11): p. 
985-9. 
401. Healy, C.M., M.A. Rench, and C.J. Baker, Implementation of cocooning against pertussis in a 
high-risk population. Clin Infect Dis, 2011. 52(2): p. 157-62. 
402. Rosenblum, E., et al., Protecting newborns by immunizing family members in a hospital-based 
vaccine clinic: a successful Tdap cocooning program during the 2010 California pertussis 
epidemic. Public Health Rep, 2014. 129(3): p. 245-51. 
403. Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018. Pediatrics, 
2017. 
404. Lim, G.H., S.L. Deeks, and N.S. Crowcroft, A cocoon immunisation strategy against pertussis for 
infants: does it make sense for Ontario? Euro Surveill, 2014. 19(5). 
405. Meregaglia, M., et al., Parent "cocoon" immunization to prevent pertussis-related hospitalization 
in infants: the case of Piemonte in Italy. Vaccine, 2013. 31(8): p. 1135-7. 
406. Skowronski, D.M., et al., The number needed to vaccinate to prevent infant pertussis 




407. Carcione, D., et al., The impact of parental postpartum pertussis vaccination on infection in 
infants: A population-based study of cocooning in Western Australia. Vaccine, 2015. 33(42): p. 
5654-61. 
408. Healy, C.M., et al., Evaluation of the impact of a pertussis cocooning program on infant pertussis 
infection. Pediatr Infect Dis J, 2015. 34(1): p. 22-6. 
409. Maltezou, H.C., et al., Impact of postpartum influenza vaccination of mothers and household 
contacts in preventing febrile episodes, influenza-like illness, healthcare seeking, and 
administration of antibiotics in young infants during the 2012-2013 influenza season. Clin Infect 
Dis, 2013. 57(11): p. 1520-6. 
410. Althouse, B.M. and S.V. Scarpino, Asymptomatic transmission and the resurgence of Bordetella 
pertussis. BMC Med, 2015. 13: p. 146. 
411. Van Rie, A. and H.W. Hethcote, Adolescent and adult pertussis vaccination: computer 
simulations of five new strategies. Vaccine, 2004. 22(23-24): p. 3154-65. 
412. Coudeville, L., A. van Rie, and P. Andre, Adult pertussis vaccination strategies and their impact 
on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. 
Epidemiol Infect, 2008. 136(5): p. 604-20. 
413. Coudeville, L., et al., Adult vaccination strategies for the control of pertussis in the United States: 
an economic evaluation including the dynamic population effects. PLoS One, 2009. 4(7): p. 
e6284. 
414. Westra, T.A., et al., Cost-effectiveness analysis of various pertussis vaccination strategies 
primarily aimed at protecting infants in the Netherlands. Clin Ther, 2010. 32(8): p. 1479-95. 
415. Terranella, A., et al., Pregnancy dose Tdap and postpartum cocooning to prevent infant 
pertussis: a decision analysis. Pediatrics, 2013. 131(6): p. e1748-56. 
416. Fernandez-Cano, M.I., L. Armadans Gil, and M. Campins Marti, Cost-benefit of the introduction 
of new strategies for vaccination against pertussis in Spain: cocooning and pregnant vaccination 
strategies. Vaccine, 2015. 33(19): p. 2213-20. 
417. Rivero-Santana, A., et al., Effectiveness and cost-effectiveness of different immunization 
strategies against whooping cough to reduce child morbidity and mortality. Health Policy, 2014. 
115(1): p. 82-91. 
418. Quinn, H.E., et al., Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics, 
2014. 134(4): p. 713-20. 
419. Healy, C.M., et al., Pertussis immunization in a high-risk postpartum population. Vaccine, 2009. 
27(41): p. 5599-602. 
420. Walter, E.B., et al., Cocooning infants: Tdap immunization for new parents in the pediatric office. 
Acad Pediatr, 2009. 9(5): p. 344-7. 
421. Dylag, A.M. and S.I. Shah, Administration of tetanus, diphtheria, and acellular pertussis vaccine 
to parents of high-risk infants in the neonatal intensive care unit. Pediatrics, 2008. 122(3): p. 
e550-5. 
422. Forsyth, K., et al., Pertussis immunization in the global pertussis initiative international region: 
recommended strategies and implementation considerations. Pediatr Infect Dis J, 2005. 24(5 
Suppl): p. S93-7. 
423. Forsyth, K.D., et al., Prevention of pertussis: recommendations derived from the second Global 
Pertussis Initiative roundtable meeting. Vaccine, 2007. 25(14): p. 2634-42. 
424. Urwyler, P. and U. Heininger, Protecting newborns from pertussis - the challenge of complete 
cocooning. BMC Infect Dis, 2014. 14: p. 397. 
425. Blain, A.E., et al., An Assessment of the Cocooning Strategy for Preventing Infant Pertussis-United 
States, 2011. Clin Infect Dis, 2016. 63(suppl 4): p. S221-s226. 
 
404 
426. Suryadevara, M. and J.B. Domachowske, Prevention of pertussis through adult vaccination. Hum 
Vaccin Immunother, 2015. 11(7): p. 1744-7. 
427. Stinson, C.F., G. Hooper, and J.S. Oliver, An Evidence-Based Protocol for Protecting Newborns 
From Pertussis. Nurs Womens Health, 2015. 19(5): p. 402-9. 
428. Steiner, B., G.K. Swamy, and E.B. Walter, Engaging expectant parents to receive Tdap 
vaccination. Am J Perinatol, 2014. 31(5): p. 407-12. 
429. Rossmann Beel, E., et al., Acceptability of immunization in adult contacts of infants: possibility of 
expanding platforms to increase adult vaccine uptake. Vaccine, 2014. 32(22): p. 2540-5. 
430. Rowe, S.L., et al., Uptake of a government-funded pertussis-containing booster vaccination 
program for parents of new babies in Victoria, Australia. Vaccine, 2015. 33(15): p. 1791-6. 
431. Jakubecz, M.A., M.E. Temple-Cooper, and E.H. Philipson, Development of an outpatient clinic to 
provide pertussis vaccinations to maternity patients and family members. Am J Health Syst 
Pharm, 2016. 73(1): p. e54-8. 
432. Krishnaswamy, S., et al., Protecting newborns from pertussis: The role of partner vaccination in 
the era of maternal immunization. Eur J Obstet Gynecol Reprod Biol, 2017. 216: p. 159-163. 
433. Decrequy, A., et al., [Cocooning strategy: Effectiveness of a pertussis vaccination program for 
parents in the maternity unit of a university hospital]. Arch Pediatr, 2016. 23(8): p. 787-91. 
434. Maltezou, H.C., et al., Acceptance of a post-partum influenza vaccination (cocooning) strategy 
for neonates in Greece. Vaccine, 2012. 30(40): p. 5871-4. 
435. Guzman-Cottrill, J.A., et al., Free vaccine programs to cocoon high-risk infants and children 
against influenza and pertussis. Am J Infect Control, 2012. 40(9): p. 872-6. 
436. Mills, B., et al., Pharmacist-led Tdap vaccination of close contacts of neonates in a women's 
hospital. Vaccine, 2014. 32(4): p. 521-5. 
437. Cooper White, P., et al., Cocooning: influenza vaccine for parents and caregivers in an urban, 
pediatric medical home. Clin Pediatr (Phila), 2010. 49(12): p. 1123-8. 
438. Goad, J.A., et al., Vaccinations administered during off-clinic hours at a national community 
pharmacy: implications for increasing patient access and convenience. Ann Fam Med, 2013. 
11(5): p. 429-36. 
439. Buttenheim, A.M., et al., A behavioral economics intervention to increase pertussis vaccination 
among infant caregivers: A randomized feasibility trial. Vaccine, 2016. 34(6): p. 839-45. 
440. Halperin, B.A., et al., Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis 
vaccine in women of childbearing age and postpartum women. Clin Infect Dis, 2011. 53(9): p. 
885-92. 
441. Visser, O., et al., Intention to Accept Pertussis Vaccination for Cocooning: A Qualitative Study of 
the Determinants. PLoS One, 2016. 11(6): p. e0155861. 
442. Visser, O., et al., Assessing determinants of the intention to accept a pertussis cocooning 
vaccination: A survey among Dutch parents. Vaccine, 2016. 34(39): p. 4744-51. 
443. United States Community Preventive Services Task Force. Increasing Appropriate Vaccination. 
Guide to Community Preventive Services 2017  [cited 2017 September]; Available from: 
https://www.thecommunityguide.org/topic/vaccination. 
444. Elangovan, S., K.J. Kallail, and G. Vargo, Improving pneumococcal vaccination rates in an elderly 
population by patient education in an outpatient clinic. J Am Board Fam Pract, 1996. 9(6): p. 411-
3. 
445. Herman, C.J., T. Speroff, and R.D. Cebul, Improving compliance with immunization in the older 
adult: results of a randomized cohort study. J Am Geriatr Soc, 1994. 42(11): p. 1154-9. 
446. Jacobson, T.A., et al., Use of a low-literacy patient education tool to enhance pneumococcal 
vaccination rates. A randomized controlled trial. Jama, 1999. 282(7): p. 646-50. 
 
405 
447. Thomas, D.M., et al., Patient education strategies to improve pneumococcal vaccination rates: 
randomized trial. J Investig Med, 2003. 51(3): p. 141-8. 
448. Eubelen, C., et al., Effect of an audiovisual message for tetanus booster vaccination broadcast in 
the waiting room. BMC Fam Pract, 2011. 12: p. 104. 
449. Holzman, G.S., et al., A media campaign to promote pneumococcal vaccinations: is a telephone 
survey an effective evaluation strategy? J Public Health Manag Pract, 2005. 11(3): p. 228-34. 
450. Luthi, J.C., et al., Evaluation of a population-based prevention program against influenza among 
Swiss elderly people. Swiss Med Wkly, 2002. 132(41-42): p. 592-7. 
451. McPhee, S.J., et al., Successful promotion of hepatitis B vaccinations among Vietnamese-
American children ages 3 to 18: results of a controlled trial. Pediatrics, 2003. 111(6 Pt 1): p. 
1278-88. 
452. Paunio, M., et al., Increase of vaccination coverage by mass media and individual approach: 
intensified measles, mumps, and rubella prevention program in Finland. Am J Epidemiol, 1991. 
133(11): p. 1152-60. 
453. Shenson, D., et al., Pneumococcal immunizations at flu clinics: the impact of community-wide 
outreach. J Community Health, 2001. 26(3): p. 191-201. 
454. Wallace, C., et al., The role of television advertising in increasing pneumococcal vaccination 
coverage among the elderly, North Coast, New South Wales, 2006. Aust N Z J Public Health, 
2008. 32(5): p. 467-70. 
455. Yoo, B.K., et al., Effects of mass media coverage on timing and annual receipt of influenza 
vaccination among Medicare elderly. Health Serv Res, 2010. 45(5 Pt 1): p. 1287-309. 
456. Meharry, P.M., et al., Maternal influenza vaccination: evaluation of a patient-centered pamphlet 
designed to increase uptake in pregnancy. Matern Child Health J, 2014. 18(5): p. 1205-14. 
457. Williams, S.E., et al., A Randomized Trial to Increase Acceptance of Childhood Vaccines by 
Vaccine-Hesitant Parents: A Pilot Study. Academic pediatrics, 2013. 13(5): p. 475-480. 
458. Glanz, J.M., et al., Web-based Social Media Intervention to Increase Vaccine Acceptance: A 
Randomized Controlled Trial. Pediatrics, 2017. 140(6). 
459. Pluviano, S., C. Watt, and S. Della Sala, Misinformation lingers in memory: Failure of three pro-
vaccination strategies. PLoS One, 2017. 12(7): p. e0181640. 
460. Nyhan, B., et al., Effective messages in vaccine promotion: a randomized trial. Pediatrics, 2014. 
133(4): p. e835-42. 
461. Nyhan, B. and J. Reifler, Does correcting myths about the flu vaccine work? An experimental 
evaluation of the effects of corrective information. Vaccine, 2015. 33(3): p. 459-64. 
462. Cameron, K.A., et al., Patient knowledge and recall of health information following exposure to 
"facts and myths" message format variations. Patient Educ Couns, 2013. 92(3): p. 381-7. 
463. Gust, D.A., et al., Developing tailored immunization materials for concerned mothers. Health 
Educ Res, 2008. 23(3): p. 499-511. 
464. Dempsey, A.F., et al., Characteristics of users of a tailored, interactive website for parents and its 
impact on adolescent vaccination attitudes and uptake. BMC Res Notes, 2015. 8: p. 739. 
465. Atkinson, K.M., et al., Can mobile technologies improve on-time vaccination? A study piloting 
maternal use of ImmunizeCA, a Pan-Canadian immunization app. Hum Vaccin Immunother, 
2016. 12(10): p. 2654-2661. 
466. Fadda, M., et al., Effectiveness of a smartphone app to increase parents' knowledge and 
empowerment in the MMR vaccination decision: A randomized controlled trial. Hum Vaccin 
Immunother, 2017. 13(11): p. 2512-2521. 
467. Bednarczyk, R.A., et al., ReadyVax: A new mobile vaccine information app. Hum Vaccin 
Immunother, 2017. 13(5): p. 1149-1154. 
 
406 
468. Marteau, T.M., R.E. Ashcroft, and A. Oliver, Using financial incentives to achieve healthy 
behaviour. BMJ, 2009. 338. 
469. Sutherland, K., J.B. Christianson, and S. Leatherman, Impact of Targeted Financial Incentives on 
Personal Health Behavior. Medical Care Research and Review, 2008. 65(6_suppl): p. 36S-78S. 
470. Tan, L.L.J., A review of the key factors to improve adult immunization coverage rates: What can 
the clinician do? Vaccine, 2017. 
471. Oyo-Ita, A., et al., Interventions for improving coverage of childhood immunisation in low- and 
middle-income countries. Cochrane Database Syst Rev, 2016. 7: p. Cd008145. 
472. Bassani, D.G., et al., Financial incentives and coverage of child health interventions: a systematic 
review and meta-analysis. BMC Public Health, 2013. 13 Suppl 3: p. S30. 
473. Johri, M., et al., Strategies to increase the demand for childhood vaccination in low- and middle-
income countries: a systematic review and meta-analysis. Bull World Health Organ, 2015. 93(5): 
p. 339-346c. 
474. Gibson, D.G., et al., Mobile phone-delivered reminders and incentives to improve childhood 
immunisation coverage and timeliness in Kenya (M-SIMU): a cluster randomised controlled trial. 
Lancet Glob Health, 2017. 5(4): p. e428-e438. 
475. Achat, H., P. McIntyre, and M. Burgess, Health care incentives in immunisation. Aust N Z J Public 
Health, 1999. 23(3): p. 285-8. 
476. Stone, E.G., et al., Interventions that increase use of adult immunization and cancer screening 
services: a meta-analysis. Ann Intern Med, 2002. 136(9): p. 641-51. 
477. Wigham, S., et al., Parental financial incentives for increasing preschool vaccination uptake: 
systematic review. Pediatrics, 2014. 134(4): p. e1117-28. 
478. Stitzer, M.L., et al., Drug users' adherence to a 6-month vaccination protocol: effects of 
motivational incentives. Drug Alcohol Depend, 2010. 107(1): p. 76-9. 
479. Seal, K.H., et al., A randomized controlled trial of monetary incentives vs. outreach to enhance 
adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend, 
2003. 71(2): p. 127-31. 
480. Topp, L., et al., A randomised controlled trial of financial incentives to increase hepatitis B 
vaccination completion among people who inject drugs in Australia. Prev Med, 2013. 57(4): p. 
297-303. 
481. Rafia, R., et al., An economic evaluation of contingency management for completion of hepatitis 
B vaccination in those on treatment for opiate dependence. Addiction, 2016. 111(9): p. 1616-27. 
482. Day, C.A., et al., Development of immunity following financial incentives for hepatitis B 
vaccination among people who inject drugs: A randomized controlled trial. J Clin Virol, 2016. 74: 
p. 66-72. 
483. Weaver, T., et al., Use of contingency management incentives to improve completion of hepatitis 
B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. 
Lancet, 2014. 384(9938): p. 153-63. 
484. Nowalk, M.P., et al., Improving influenza vaccination rates in the workplace: a randomized trial. 
Am J Prev Med, 2010. 38(3): p. 237-46. 
485. Drees, M., et al., Carrots and sticks: achieving high healthcare personnel influenza vaccination 
rates without a mandate. Infect Control Hosp Epidemiol, 2015. 36(6): p. 717-24. 
486. Mantzari, E., F. Vogt, and T.M. Marteau, Financial incentives for increasing uptake of HPV 
vaccinations: a randomized controlled trial. Health Psychol, 2015. 34(2): p. 160-71. 
487. Lefevere, E., et al., The impact of non-financial and financial encouragements on participation in 
non school-based human papillomavirus vaccination: a retrospective cohort study. Eur J Health 
Econ, 2016. 17(3): p. 305-15. 
 
407 
488. Walsh, J.M.E. and S.J. McPhee, A Systems Model of Clinical Preventive Care: An Analysis of 
Factors Influencing Patient and Physician. Health Education Quarterly, 1992. 19(2): p. 157-175. 
489. Petty, R.E. and J.T. Cacioppo, Communication and persuasion: Central and peripheral routes to 
attitude change. 1986, New York: Springer-Verlag. 
490. Walgreen Co. Store Count by State. 2016  [cited 2017 September]; Available from: 
http://news.walgreens.com/fact-sheets/store-count-by-state.htm. 
491. Langreth, R. and D. McLaughlin, Walgreens Wins U.S. Approval for Rite Aid Deal on Fourth Try, in 
Bloomberg. 2017. 
492. Murphy, P.A., et al., Pharmacy provision of influenza vaccinations in medically underserved 
communities. J Am Pharm Assoc (2003), 2012. 52(1): p. 67-70. 
493. Deshpande, M., et al., Parents' perceptions of pharmacists as providers of influenza vaccine to 
children. J Am Pharm Assoc (2003), 2013. 53(5): p. 488-95. 
494. Kirkdale, C.L., et al., Implementation of flu vaccination in community pharmacies: Understanding 
the barriers and enablers. Ann Pharm Fr, 2017. 75(1): p. 9-16. 
495. Higginbotham, S., A. Stewart, and A. Pfalzgraf, Impact of a pharmacist immunizer on adult 
immunization rates. J Am Pharm Assoc (2003), 2012. 52(3): p. 367-71. 
496. Kirkdale, C.L., et al., Benefits of pharmacist-led flu vaccination services in community pharmacy. 
Ann Pharm Fr, 2017. 75(1): p. 3-8. 
497. Walgreen Co. Balance Rewards Program Details.  [cited 2017 September]; Available from: 
https://www.walgreens.com/topic/balancerewards/balance-program-details.jsp. 
498. Rosenstock, I.M., Historical Origins of the Health Belief Model. Health Education Monographs, 
1974. 2(4): p. 328-335. 
499. Carpenter, C.J., A meta-analysis of the effectiveness of health belief model variables in predicting 
behavior. Health Commun, 2010. 25(8): p. 661-9. 
500. Bandura, A., Social foundations of thought and action: A social cognitive theory. Prentice-Hall 
series in social learning theory. 1986, Englewood Cliffs, NJ, US: Prentice-Hall, Inc. xiii, 617. 
501. Sharts-Hopko, N.C., Issues in pediatric immunization. MCN Am J Matern Child Nurs, 2009. 34(2): 
p. 80-8; quiz 89-90. 
502. Ventola, C.L., Immunization in the United States: Recommendations, Barriers, and Measures to 
Improve Compliance: Part 1: Childhood Vaccinations. Pharmacy and Therapeutics, 2016. 41(7): 
p. 426-436. 
503. Kennedy, A., et al., Confidence About Vaccines In The United States: Understanding Parents’ 
Perceptions. Health Affairs, 2011. 30(6): p. 1151-1159. 
504. O'Leary, S.T., C.A. Suh, and M. Marin, Febrile seizures and measles-mumps-rubella-varicella 
(MMRV) vaccine: what do primary care physicians think? Vaccine, 2012. 30(48): p. 6731-3. 
505. O'Leary, S.T., et al., Adoption of rotavirus vaccine by U.S. physicians: progress and challenges. 
Am J Prev Med, 2013. 44(1): p. 56-62. 
506. Institute for Vaccine Safety. Potential Adverse Events Following Immunization. 2018; Available 
from: http://www.vaccinesafety.edu/vs-overview.htm. 
507. Dudley, M.Z., et al., The Clinician’s Vaccine Safety Resource Guide: Optimizing Prevention of 
Vaccine-Preventable Diseases Across the Lifespan. 1 ed. 2018: Springer International Publishing. 
508. Hviid, A., et al., Association between thimerosal-containing vaccine and autism. Jama, 2003. 
290(13): p. 1763-6. 
509. Verstraeten, T., et al., Safety of thimerosal-containing vaccines: a two-phased study of 
computerized health maintenance organization databases. Pediatrics, 2003. 112(5): p. 1039-48. 
510. Andrews, N., et al., Thimerosal exposure in infants and developmental disorders: a retrospective 
cohort study in the United kingdom does not support a causal association. Pediatrics, 2004. 
114(3): p. 584-91. 
 
408 
511. Croen, L.A., et al., Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and 
risk of autism spectrum disorders. Am J Obstet Gynecol, 2008. 199(3): p. 234.e1-6. 
512. Price, C.S., et al., Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins 
and risk of autism. Pediatrics, 2010. 126(4): p. 656-64. 
513. Uno, Y., et al., The combined measles, mumps, and rubella vaccines and the total number of 
vaccines are not associated with development of autism spectrum disorder: the first case-control 
study in Asia. Vaccine, 2012. 30(28): p. 4292-8. 
514. DeStefano, F., C.S. Price, and E.S. Weintraub, Increasing exposure to antibody-stimulating 
proteins and polysaccharides in vaccines is not associated with risk of autism. J Pediatr, 2013. 
163(2): p. 561-7. 
515. Geier, M.R. and D.A. Geier, Neurodevelopmental disorders after thimerosal-containing vaccines: 
a brief communication. Exp Biol Med (Maywood), 2003. 228(6): p. 660-4. 
516. Geier, D.A. and M.R. Geier, An assessment of the impact of thimerosal on childhood 
neurodevelopmental disorders. Pediatr Rehabil, 2003. 6(2): p. 97-102. 
517. Geier, D. and M.R. Geier, Neurodevelopmental disorders following thimerosal-containing 
childhood immunizations: a follow-up analysis. Int J Toxicol, 2004. 23(6): p. 369-76. 
518. Geier, D.A. and M.R. Geier, An evaluation of serious neurological disorders following 
immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines. Brain Dev, 
2004. 26(5): p. 296-300. 
519. Geier, D.A. and M.R. Geier, A comparative evaluation of the effects of MMR immunization and 
mercury doses from thimerosal-containing childhood vaccines on the population prevalence of 
autism. Med Sci Monit, 2004. 10(3): p. Pi33-9. 
520. Geier, D.A. and M.R. Geier, A two-phased population epidemiological study of the safety of 
thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit, 2005. 11(4): p. Cr160-70. 
521. Geier, D.A. and M.R. Geier, An evaluation of the effects of thimerosal on neurodevelopmental 
disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United 
States. J Toxicol Environ Health A, 2006. 69(15): p. 1481-95. 
522. Geier, D.A. and M.R. Geier, A meta-analysis epidemiological assessment of neurodevelopmental 
disorders following vaccines administered from 1994 through 2000 in the United States. Neuro 
Endocrinol Lett, 2006. 27(4): p. 401-13. 
523. Geier, D.A. and M.R. Geier, An assessment of downward trends in neurodevelopmental disorders 
in the United States following removal of Thimerosal from childhood vaccines. Med Sci Monit, 
2006. 12(6): p. Cr231-9. 
524. Young, H.A., D.A. Geier, and M.R. Geier, Thimerosal exposure in infants and neurodevelopmental 
disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J 
Neurol Sci, 2008. 271(1-2): p. 110-8. 
525. Kern, J.K., et al., Thimerosal exposure and the role of sulfation chemistry and thiol availability in 
autism. Int J Environ Res Public Health, 2013. 10(8): p. 3771-800. 
526. Deer, B., Autism research: What makes an expert? Bmj, 2007. 334(7595): p. 666-7. 
527. Zerbo, O., et al., Association Between Influenza Infection and Vaccination During Pregnancy and 
Risk of Autism Spectrum Disorder. JAMA Pediatr, 2017. 171(1): p. e163609. 
528. Becerra-Culqui, T.A., et al., Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and 
Autism Spectrum Disorder. Pediatrics, 2018. 
529. Halsey, N.A. and S.L. Hyman, Measles-mumps-rubella vaccine and autistic spectrum disorder: 
report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, 
Illinois, June 12-13, 2000. Pediatrics, 2001. 107(5): p. E84. 
530. Hornig, M., et al., Lack of association between measles virus vaccine and autism with 
enteropathy: a case-control study. PLoS One, 2008. 3(9): p. e3140. 
 
409 
531. Libbey, J.E., et al., Are there altered antibody responses to measles, mumps, or rubella viruses in 
autism? J Neurovirol, 2007. 13(3): p. 252-9. 
532. D'Souza, Y., E. Fombonne, and B.J. Ward, No evidence of persisting measles virus in peripheral 
blood mononuclear cells from children with autism spectrum disorder. Pediatrics, 2006. 118(4): 
p. 1664-75. 
533. Baylor, N.W., W. Egan, and P. Richman, Aluminum salts in vaccines--US perspective. Vaccine, 
2002. 20 Suppl 3: p. S18-23. 
534. Bergfors, E., et al., How common are long-lasting, intensely itching vaccination granulomas and 
contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort 
study. Eur J Pediatr, 2014. 173(10): p. 1297-307. 
535. Bergfors, E., B. Trollfors, and A. Inerot, Unexpectedly high incidence of persistent itching nodules 
and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a 
single manufacturer. Vaccine, 2003. 22(1): p. 64-9. 
536. Netterlid, E., et al., Persistent itching nodules after the fourth dose of diphtheria-tetanus toxoid 
vaccines without evidence of delayed hypersensitivity to aluminium. Vaccine, 2004. 22(27-28): p. 
3698-706. 
537. Keith, L.S., D.E. Jones, and C.H. Chou, Aluminum toxicokinetics regarding infant diet and 
vaccinations. Vaccine, 2002. 20 Suppl 3: p. S13-7. 
538. Mitkus, R.J., et al., Updated aluminum pharmacokinetics following infant exposures through diet 
and vaccination. Vaccine, 2011. 29(51): p. 9538-43. 
539. Ameratunga, R., et al., Evidence Refuting the Existence of Autoimmune/Autoinflammatory 
Syndrome Induced by Adjuvants (ASIA). J Allergy Clin Immunol Pract, 2017. 5(6): p. 1551-
1555.e1. 
540. Stassijns, J., et al., A systematic review and meta-analysis on the safety of newly adjuvanted 
vaccines among children. Vaccine, 2016. 34(6): p. 714-22. 
541. Halsey, N.A., et al., Immediate hypersensitivity reactions following monovalent 2009 pandemic 
influenza A (H1N1) vaccines: reports to VAERS. Vaccine, 2013. 31(51): p. 6107-12. 
542. Offit, P.A. and R.K. Jew, Addressing parents' concerns: do vaccines contain harmful preservatives, 
adjuvants, additives, or residuals? Pediatrics, 2003. 112(6 Pt 1): p. 1394-7. 
543. Jacobsen, S.J., et al., Observational safety study of febrile convulsion following first dose MMRV 
vaccination in a managed care setting. Vaccine, 2009. 27(34): p. 4656-61. 
544. Klopfer, S.O., et al., Analysis of safety data in children after receiving two doses of ProQuad(R) 
(MMRV). Vaccine, 2014. 32(52): p. 7154-60. 
545. Macartney, K.K., et al., Febrile seizures following measles and varicella vaccines in young children 
in Australia. Vaccine, 2015. 33(11): p. 1412-7. 
546. MacDonald, S.E., et al., Risk of febrile seizures after first dose of measles-mumps-rubella-
varicella vaccine: a population-based cohort study. Cmaj, 2014. 186(11): p. 824-9. 
547. Schink, T., et al., Risk of febrile convulsions after MMRV vaccination in comparison to MMR or 
MMR+V vaccination. Vaccine, 2014. 32(6): p. 645-50. 
548. Hambidge, S.J., et al., Timely versus delayed early childhood vaccination and seizures. Pediatrics, 
2014. 133(6): p. e1492-9. 
549. Rowhani-Rahbar, A., et al., Effect of age on the risk of Fever and seizures following immunization 
with measles-containing vaccines in children. JAMA Pediatr, 2013. 167(12): p. 1111-7. 
550. Sun, Y., et al., Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, 
acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. Jama, 2012. 
307(8): p. 823-31. 
551. Daley, M.F., et al., Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus 
(DTaP-IPV) vaccine. Vaccine, 2014. 32(25): p. 3019-24. 
 
410 
552. Institute of Medicine, in The Childhood Immunization Schedule and Safety: Stakeholder 
Concerns, Scientific Evidence, and Future Studies. 2013, National Academies Press (US): 
Washington (DC). 
553. Ofori-Anyinam, O., et al., Immunogenicity and safety of an inactivated quadrivalent influenza 
vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate 
administration, in adults >/=50years of age: Results from a phase III, randomized, non-inferiority 
trial. Vaccine, 2017. 35(46): p. 6321-6328. 
554. Gasparini, R., et al., Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate 
Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J, 2016. 
35(1): p. 81-93. 
555. Vesikari, T., et al., Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal 
Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis 
and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. J Pediatric Infect Dis Soc, 2016. 
5(2): p. 180-7. 
556. Sukumaran, L., et al., Infant Hospitalizations and Mortality After Maternal Vaccination. 
Pediatrics, 2018. 
557. Glanz, J.M., et al., Association between estimated cumulative vaccine antigen exposure through 
the first 23 months of life and non–vaccine-targeted infections from 24 through 47 months of 
age. JAMA, 2018. 319(9): p. 906-913. 
558. Gust, D.A., et al., Underimmunization Among Children: Effects of Vaccine Safety Concerns on 
Immunization Status. Pediatrics, 2004. 114(1): p. e16-e22. 
559. Moniz, M.H., et al., Improving influenza vaccination rates in pregnancy through text messaging: 
a randomized controlled trial. Obstet Gynecol, 2013. 121(4): p. 734-40. 
560. Eppes, C., et al., Does obstetrician knowledge regarding influenza increase HINI vaccine 
acceptance among their pregnant patients? Vaccine, 2012. 30(39): p. 5782-4. 
561. Martin, J.A., et al., Births: Final Data for 2016. Natl Vital Stat Rep, 2018. 67(1): p. 1-55. 
562. Cassell, J.A., et al., Is the cultural context of MMR rejection a key to an effective public health 
discourse? Public Health, 2006. 120(9): p. 783-94. 
563. Flynn, M. and J. Ogden, Predicting uptake of MMR vaccination: a prospective questionnaire 
study. Br J Gen Pract, 2004. 54(504): p. 526-30. 
564. Brunson, E.K., The impact of social networks on parents' vaccination decisions. Pediatrics, 2013. 
131(5): p. e1397-404. 
565. Wheeler, M. and A.M. Buttenheim, Parental vaccine concerns, information source, and choice of 
alternative immunization schedules. Hum Vaccin Immunother, 2013. 9(8): p. 1782-9. 
566. Feikin, D.R., et al., Individual and community risks of measles and pertussis associated with 
personal exemptions to immunization. Jama, 2000. 284(24): p. 3145-50. 
567. Salmon, D.A., et al., Health consequences of religious and philosophical exemptions from 
immunization laws: individual and societal risk of measles. Jama, 1999. 282(1): p. 47-53. 
568. Smith, P.J., et al., The association between intentional delay of vaccine administration and timely 
childhood vaccination coverage. Public Health Rep, 2010. 125(4): p. 534-41. 
569. Luman, E.T., et al., Timeliness of childhood vaccinations in the United States: days 
undervaccinated and number of vaccines delayed. Jama, 2005. 293(10): p. 1204-11. 
570. Invasive Haemophilus influenzae Type B disease in five young children--Minnesota, 2008. MMWR 
Morb Mortal Wkly Rep, 2009. 58(3): p. 58-60. 
571. Glanz, J.M., et al., Parental refusal of varicella vaccination and the associated risk of varicella 
infection in children. Arch Pediatr Adolesc Med, 2010. 164(1): p. 66-70. 
572. Glanz, J.M., et al., Parental decline of pneumococcal vaccination and risk of pneumococcal 
related disease in children. Vaccine, 2011. 29(5): p. 994-9. 
 
411 
573. Zipprich, J., et al., Measles outbreak--California, December 2014-February 2015. MMWR Morb 
Mortal Wkly Rep, 2015. 64(6): p. 153-4. 
574. Clemmons, N.S., et al., Measles - United States, January 4-April 2, 2015. MMWR Morb Mortal 
Wkly Rep, 2015. 64(14): p. 373-6. 
575. Persson, I., et al., Risks of neurological and immune-related diseases, including narcolepsy, after 
vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of 
follow-up. J Intern Med, 2014. 275(2): p. 172-90. 
576. Chao, C., et al., Surveillance of autoimmune conditions following routine use of quadrivalent 
human papillomavirus vaccine. J Intern Med, 2012. 271(2): p. 193-203. 
577. Langer-Gould, A., et al., Vaccines and the risk of multiple sclerosis and other central nervous 
system demyelinating diseases. JAMA Neurol, 2014. 71(12): p. 1506-13. 
578. Scheller, N.M., et al., Quadrivalent HPV vaccination and risk of multiple sclerosis and other 
demyelinating diseases of the central nervous system. Jama, 2015. 313(1): p. 54-61. 
579. Baxter, R., et al., Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin 
Infect Dis, 2016. 
580. Harter, D.H. and P.W. Choppin, Possible mechanisms in the pathogenesis of "postinfectious" 
encephalomyelitis. Res Publ Assoc Res Nerv Ment Dis, 1971. 49: p. 342-55. 
581. Miller, S.D., et al., Evolution of the T-cell repertoire during the course of experimental immune-
mediated demyelinating diseases. Immunol Rev, 1995. 144: p. 225-44. 
582. Evans, C.F., et al., Viral infection of transgenic mice expressing a viral protein in oligodendrocytes 
leads to chronic central nervous system autoimmune disease. J Exp Med, 1996. 184(6): p. 2371-
84. 
583. Paterson, P.Y., Joseph E. Smadel Memorial Lecture: neuroimmunologic diseases of animals and 
humans. Rev Infect Dis, 1979. 1(3): p. 469-82. 
584. Ohtaki, E., et al., Acute disseminated encephalomyelitis after Japanese B encephalitis 
vaccination. Pediatr Neurol, 1992. 8(2): p. 137-9. 
585. Sejvar, J.J., et al., Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case 
definitions and guidelines for collection, analysis, and presentation of immunization safety data. 
Vaccine, 2007. 25(31): p. 5771-92. 
586. Karussis, D. and P. Petrou, The spectrum of post-vaccination inflammatory CNS demyelinating 
syndromes. Autoimmun Rev, 2014. 13(3): p. 215-24. 
587. Hemachudha, T., et al., Myelin basic protein as an encephalitogen in encephalomyelitis and 
polyneuritis following rabies vaccination. N Engl J Med, 1987. 316(7): p. 369-74. 
588. Konstantinou, D., et al., Two episodes of leukoencephalitis associated with recombinant hepatitis 
B vaccination in a single patient. Clin Infect Dis, 2001. 33(10): p. 1772-3. 
589. Tourbah, A., et al., Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis 
or MS? Neurology, 1999. 53(2): p. 396-401. 
590. Lopez Pison, J., et al., [Episodic disseminated inflammation of the central nervous system. Case 
mix review over a 13 year period]. Rev Neurol, 2004. 38(5): p. 405-10. 
591. Mitchell, L.A., et al., HLA-DR class II associations with rubella vaccine-induced joint 
manifestations. J Infect Dis, 1998. 177(1): p. 5-12. 
592. Slater, P.E., et al., Absence of an association between rubella vaccination and arthritis in 
underimmune postpartum women. Vaccine, 1995. 13(16): p. 1529-32. 
593. Ray, P., et al., Risk of chronic arthropathy among women after rubella vaccination. Vaccine 
Safety Datalink Team. JAMA, 1997. 278(7): p. 551-6. 
594. Tingle, A.J., et al., Randomised double-blind placebo-controlled study on adverse effects of 
rubella immunisation in seronegative women. Lancet, 1997. 349(9061): p. 1277-81. 
 
412 
595. Benjamin, C.M., G.C. Chew, and A.J. Silman, Joint and limb symptoms in children after 
immunisation with measles, mumps, and rubella vaccine. BMJ, 1992. 304(6834): p. 1075-8. 
596. Davis, R.L., et al., MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of 
adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine 
Safety Datalink Team. Pediatrics, 1997. 100(5): p. 767-71. 
597. Dos Santos, B.A., et al., An evaluation of the adverse reaction potential of three measles-mumps-
rubella combination vaccines. Rev Panam Salud Publica, 2002. 12(4): p. 240-6. 
598. Heijstek, M.W., et al., Safety of measles, mumps and rubella vaccination in juvenile idiopathic 
arthritis. Ann Rheum Dis, 2007. 66(10): p. 1384-7. 
599. LeBaron, C.W., et al., Evaluation of potentially common adverse events associated with the first 
and second doses of measles-mumps-rubella vaccine. Pediatrics, 2006. 118(4): p. 1422-30. 
600. Peltola, H. and O.P. Heinonen, Frequency of true adverse reactions to measles-mumps-rubella 
vaccine. A double-blind placebo-controlled trial in twins. Lancet, 1986. 1(8487): p. 939-42. 
601. Virtanen, M., et al., Day-to-day reactogenicity and the healthy vaccinee effect of measles-
mumps-rubella vaccination. Pediatrics, 2000. 106(5): p. E62. 
602. Chen, R.T., et al., Adverse events following measles-mumps-rubella and measles vaccinations in 
college students. Vaccine, 1991. 9(5): p. 297-9. 
603. Pattison, E., et al., Environmental risk factors for the development of psoriatic arthritis: results 
from a case-control study. Ann Rheum Dis, 2008. 67(5): p. 672-6. 
604. Bhatla, N., et al., Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted 
cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res, 2010. 36(1): p. 123-32. 
605. Elkayam, O., M. Yaron, and D. Caspi, Safety and efficacy of vaccination against hepatitis B in 
patients with rheumatoid arthritis. Ann Rheum Dis, 2002. 61(7): p. 623-5. 
606. Bengtsson, C., et al., Common vaccinations among adults do not increase the risk of developing 
rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis, 2010. 69(10): p. 1831-
3. 
607. Frey, S., et al., Clinical efficacy of cell culture-derived and egg-derived inactivated subunit 
influenza vaccines in healthy adults. Clin Infect Dis, 2010. 51(9): p. 997-1004. 
608. Jackson, L.A., et al., Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in 
healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect 
Dis, 2010. 10: p. 71. 
609. Madhi, S.A., et al., Trivalent inactivated influenza vaccine in African adults infected with human 
immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and 
safety. Clin Infect Dis, 2011. 52(1): p. 128-37. 
610. Ngan, H.Y., et al., Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: 
immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J, 2010. 
16(3): p. 171-9. 
611. Barrett, P.N., et al., Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent 
influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 
2011. 377(9767): p. 751-9. 
612. Kim, S.C., et al., Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: 
immunogenicity and safety in 15-25 years old healthy Korean women. J Gynecol Oncol, 2011. 
22(2): p. 67-75. 
613. Eder, L., et al., Association between environmental factors and onset of psoriatic arthritis in 
patients with psoriasis. Arthritis Care Res (Hoboken), 2011. 63(8): p. 1091-7. 
614. Bardage, C., et al., Neurological and autoimmune disorders after vaccination against pandemic 
influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in 
Stockholm, Sweden. Bmj, 2011. 343: p. d5956. 
 
413 
615. Baxter, R., et al., A postmarketing evaluation of the safety of Ann Arbor strain live attenuated 
influenza vaccine in children 5 through 17 years of age. Vaccine, 2012. 30(19): p. 2989-98. 
616. Ray, P., et al., Risk of rheumatoid arthritis following vaccination with tetanus, influenza and 
hepatitis B vaccines among persons 15-59 years of age. Vaccine, 2011. 29(38): p. 6592-7. 
617. Aikawa, N.E., et al., Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A 
(H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol, 2012. 
39(1): p. 167-73. 
618. Gabay, C., et al., Impact of synthetic and biologic disease-modifying antirheumatic drugs on 
antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-
label, parallel-cohort, single-center study. Arthritis Rheum, 2011. 63(6): p. 1486-96. 
619. Muller, R.B., et al., Efficient boosting of the antiviral T cell response in B cell-depleted patients 
with autoimmune rheumatic diseases following influenza vaccination. Clin Exp Rheumatol, 2013. 
31(5): p. 723-30. 
620. Oren, S., et al., Vaccination against influenza in patients with rheumatoid arthritis: the effect of 
rituximab on the humoral response. Ann Rheum Dis, 2008. 67(7): p. 937-41. 
621. Saad, C.G., et al., Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 
vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis, 2011. 70(6): p. 
1068-73. 
622. Shinoki, T., et al., Safety and response to influenza vaccine in patients with systemic-onset 
juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol, 2012. 22(6): p. 871-6. 
623. Toplak, N., et al., Safety and efficacy of influenza vaccination in a prospective longitudinal study 
of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol, 2012. 30(3): p. 436-44. 
624. Angeles-Han, S. and S. Prahalad, The genetics of juvenile idiopathic arthritis: what is new in 
2010? Curr Rheumatol Rep, 2010. 12(2): p. 87-93. 
625. Berkun, Y. and S. Padeh, Environmental factors and the geoepidemiology of juvenile idiopathic 
arthritis. Autoimmun Rev, 2010. 9(5): p. A319-24. 
626. Aslan, M., et al., Do infections trigger juvenile idiopathic arthritis? Rheumatol Int, 2011. 31(2): p. 
215-20. 
627. Frenkel, L.M., et al., A search for persistent rubella virus infection in persons with chronic 
symptoms after rubella and rubella immunization and in patients with juvenile rheumatoid 
arthritis. Clin Infect Dis, 1996. 22(2): p. 287-94. 
628. Best, J.M., J.E. Banatvala, and J.M. Bowen, New Japanese rubella vaccine: comparative trials. Br 
Med J, 1974. 3(5925): p. 221-4. 
629. Tingle, A.J., et al., Prospective immunological assessment of arthritis induced by rubella vaccine. 
Infect Immun, 1983. 40(1): p. 22-8. 
630. Mitchell, L.A., et al., Rubella virus vaccine associated arthropathy in postpartum immunized 
women: influence of preimmunization serologic status on development of joint manifestations. J 
Rheumatol, 2000. 27(2): p. 418-23. 
631. Mitchell, L.A., et al., Chronic rubella vaccine-associated arthropathy. Arch Intern Med, 1993. 
153(19): p. 2268-74. 
632. Tingle, A.J., et al., Postpartum rubella immunization: association with development of prolonged 
arthritis, neurological sequelae, and chronic rubella viremia. J Infect Dis, 1985. 152(3): p. 606-12. 
633. Geiger, R., et al., Persistent rubella infection after erroneous vaccination in an 
immunocompromised patient with acute lymphoblastic leukemia in remission. J Med Virol, 1995. 
47(4): p. 442-4. 
634. Peters, M.E. and S. Horowitz, Bone changes after rubella vaccination. AJR Am J Roentgenol, 
1984. 143(1): p. 27-8. 
 
414 
635. Thurairajan, G., et al., Polyarthropathy, orbital myositis and posterior scleritis: an unusual 
adverse reaction to influenza vaccine. Br J Rheumatol, 1997. 36(1): p. 120-3. 
636. Biasi, D., et al., A new case of reactive arthritis after hepatitis B vaccination. Clin Exp Rheumatol, 
1993. 11(2): p. 215. 
637. Maillefert, J.F., et al., Rheumatic disorders developed after hepatitis B vaccination. 
Rheumatology (Oxford), 1999. 38(10): p. 978-83. 
638. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med, 
2001. 345(21): p. 1529-36. 
639. Bueving, H.J., et al., Does influenza vaccination exacerbate asthma in children? Vaccine, 2004. 
23(1): p. 91-6. 
640. France, E.K., et al., Safety of the trivalent inactivated influenza vaccine among children: a 
population-based study. Arch Pediatr Adolesc Med, 2004. 158(11): p. 1031-6. 
641. Hambidge, S.J., et al., Safety of trivalent inactivated influenza vaccine in children 6 to 23 months 
old. Jama, 2006. 296(16): p. 1990-7. 
642. Kmiecik, T., et al., Influenza vaccination in adults with asthma: safety of an inactivated trivalent 
influenza vaccine. J Asthma, 2007. 44(10): p. 817-22. 
643. Nicholson, K.G., et al., Randomised placebo-controlled crossover trial on effect of inactivated 
influenza vaccine on pulmonary function in asthma. Lancet, 1998. 351(9099): p. 326-31. 
644. Pedroza, A., et al., The safety and immunogenicity of influenza vaccine in children with asthma in 
Mexico. Int J Infect Dis, 2009. 13(4): p. 469-75. 
645. Stenius-Aarniala, B., et al., Lack of clinical exacerbations in adults with chronic asthma after 
immunization with killed influenza virus. Chest, 1986. 89(6): p. 786-9. 
646. Tata, L.J., et al., Does influenza vaccination increase consultations, corticosteroid prescriptions, 
or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax, 
2003. 58(10): p. 835-9. 
647. Ashkenazi, S., et al., Superior relative efficacy of live attenuated influenza vaccine compared with 
inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr 
Infect Dis J, 2006. 25(10): p. 870-9. 
648. Belshe, R.B., et al., Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza 
vaccine in an indicated population aged 5-49 years. Clin Infect Dis, 2004. 39(7): p. 920-7. 
649. Bergen, R., et al., Safety of cold-adapted live attenuated influenza vaccine in a large cohort of 
children and adolescents. Pediatr Infect Dis J, 2004. 23(2): p. 138-44. 
650. Gaglani, M.J., et al., Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in 
children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J, 2008. 27(5): 
p. 444-52. 
651. Piedra, P.A., et al., Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 
months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, 
nonrandomized, open-label trial. Pediatrics, 2005. 116(3): p. e397-407. 
652. Fleming, D.M., et al., Comparison of the efficacy and safety of live attenuated cold-adapted 
influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and 
adolescents with asthma. Pediatr Infect Dis J, 2006. 25(10): p. 860-9. 
653. Halsey, N.A., et al., The safety of influenza vaccines in children: An Institute for Vaccine Safety 
white paper. Vaccine, 2015. 33: p. F1-F67. 
654. Turner, P.J., et al., Safety of live attenuated influenza vaccine in young people with egg allergy: 
multicentre prospective cohort study. Bmj, 2015. 351: p. h6291. 
655. Turner, P.J., et al., Safety of live attenuated influenza vaccine in atopic children with egg allergy. 
J Allergy Clin Immunol, 2015. 136(2): p. 376-81. 
 
415 
656. Baxter, R., et al., Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-
49years. Vaccine, 2017. 35(9): p. 1254-1258. 
657. Timmermann, C.A., et al., Asthma and allergy in children with and without prior measles, 
mumps, and rubella vaccination. Pediatr Allergy Immunol, 2015. 26(8): p. 742-9. 
658. Jackson, D.J. and S.L. Johnston, The role of viruses in acute exacerbations of asthma. J Allergy 
Clin Immunol, 2010. 125(6): p. 1178-87; quiz 1188-9. 
659. de Jongste, J.C., et al., Bronchial responsiveness and leucocyte reactivity after influenza vaccine 
in asthmatic patients. Eur J Respir Dis, 1984. 65(3): p. 196-200. 
660. Klein, N.P., et al., Safety of measles-containing vaccines in 1-year-old children. Pediatrics, 2015. 
135(2): p. e321-9. 
661. Landrigan, P.J. and J.J. Witte, Neurologic disorders following live measles-virus vaccination. 
JAMA, 1973. 223(13): p. 1459-62. 
662. Mutsch, M., et al., Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy 
in Switzerland. N Engl J Med, 2004. 350(9): p. 896-903. 
663. Greene, S.K., et al., Near real-time surveillance for influenza vaccine safety: Proof-of-concept in 
the vaccine safety datalink project. American Journal of Epidemiology, 2010. 171(2): p. 177-188. 
664. Stowe, J., et al., Bell's palsy and parenteral inactivated influenza vaccine. Hum Vaccin, 2006. 
2(3): p. 110-2. 
665. Yih, W.K., et al., An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular 
pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety 
Datalink. Vaccine, 2009. 27(32): p. 4257-62. 
666. Lee, G.M., et al., H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink 
project. Am J Prev Med, 2011. 41(2): p. 121-8. 
667. Rowhani-Rahbar, A., et al., Immunization and Bell's palsy in children: a case-centered analysis. 
Am J Epidemiol, 2012. 175(9): p. 878-85. 
668. Wijnans, L., et al., Bell's palsy and influenza(H1N1)pdm09 containing vaccines: A self-controlled 
case series. PLoS One, 2017. 12(5): p. e0175539. 
669. Tseng, H.F., et al., Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-
Olds. Pediatrics, 2017. 139(1). 
670. Ravin, L.C., Facial paralysis as a complication of chickenpox. Am J Ophthalmol, 1961. 52: p. 723-
4. 
671. Peitersen, E. and A.E. Caunt, The incidence of herpes zoster antibodies in patients with peripheral 
facial palsy. J Laryngol Otol, 1970. 84(1): p. 65-70. 
672. Tomita, H. and W. Hayakawa, Varicella-Zoster virus in idiopathic facial palsy. Arch Otolaryngol, 
1972. 95(4): p. 364-8. 
673. McCormick, D.P., Herpes-simplex virus as a cause of Bell's palsy. Lancet, 1972. 1(7757): p. 937-9. 
674. Murakami, S., et al., Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial 
fluid and muscle. Ann Intern Med, 1996. 124(1 Pt 1): p. 27-30. 
675. Manos-Pujol, M., et al., Etiopathogenesis of Bell's palsy: an immune-mediated theory. Eur Arch 
Otorhinolaryngol, 1994: p. S445-6. 
676. Lewis, D.J., et al., Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a 
genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One, 2009. 4(9): p. e6999. 
677. Shaikh, M.F., T.J. Baqai, and H. Tahir, Acute brachial neuritis following influenza vaccination. BMJ 
Case Rep, 2012. 2012. 
678. Vellozzi, C., et al., Safety of trivalent inactivated influenza vaccines in adults: background for 
pandemic influenza vaccine safety monitoring. Vaccine, 2009. 27(15): p. 2114-20. 
679. Moreira, E.D., Jr., et al., Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 
Phase III Clinical Trials. Pediatrics, 2016. 138(2). 
 
416 
680. Ali, Z., et al., Intradermal injection of norepinephrine evokes pain in patients with 
sympathetically maintained pain. Pain, 2000. 88(2): p. 161-8. 
681. Mailis-Gagnon, A. and G.J. Bennett, Abnormal contralateral pain responses from an intradermal 
injection of phenylephrine in a subset of patients with complex regional pain syndrome (CRPS). 
Pain, 2004. 111(3): p. 378-84. 
682. Jastaniah, W.A., et al., Complex regional pain syndrome after hepatitis B vaccine. J Pediatr, 2003. 
143(6): p. 802-4. 
683. Black, S., et al., A post-licensure evaluation of the safety of inactivated hepatitis A vaccine 
(VAQTA, Merck) in children and adults. Vaccine, 2004. 22(5-6): p. 766-72. 
684. Cooke, T.D., et al., The pathogenesis of chronic inflammation in experimental antigen-induced 
arthritis. II. Preferential localization of antigen-antibody complexes to collagenous tissues. J Exp 
Med, 1972. 135(2): p. 323-38. 
685. Cooke, T.D. and H.E. Jasin, The pathogenesis of chronic inflammation in experimental antigen-
induced arthritis. I. The role of antigen on the local immune response. Arthritis Rheum, 1972. 
15(4): p. 327-37. 
686. Dumonde, D.C. and L.E. Glynn, The production of arthritis in rabbits by an immunological 
reaction to fibrin. Br J Exp Pathol, 1962. 43: p. 373-83. 
687. Bodor, M. and E. Montalvo, Vaccination-related shoulder dysfunction. Vaccine, 2007. 25(4): p. 
585-7. 
688. Cook, I.F., M. Williamson, and D. Pond, Definition of needle length required for intramuscular 
deltoid injection in elderly adults: an ultrasonographic study. Vaccine, 2006. 24(7): p. 937-40. 
689. Koster, M.P., et al., Needle length for immunization of early adolescents as determined by 
ultrasound. Pediatrics, 2009. 124(2): p. 667-72. 
690. Lippert, W.C. and E.J. Wall, Optimal intramuscular needle-penetration depth. Pediatrics, 2008. 
122(3): p. e556-63. 
691. Poland, G.A., et al., Determination of deltoid fat pad thickness. Implications for needle length in 
adult immunization. JAMA, 1997. 277(21): p. 1709-11. 
692. Atanasoff, S., et al., Shoulder injury related to vaccine administration (SIRVA). Vaccine, 2010. 
28(51): p. 8049-52. 
693. DeStefano, F., et al., Childhood vaccinations, vaccination timing, and risk of type 1 diabetes 
mellitus. Pediatrics, 2001. 108(6): p. E112. 
694. Klein, N.P., et al., Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria 
toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a 
United States health maintenance organization. Pediatr Infect Dis J, 2010. 29(7): p. 613-7. 
695. Altobelli, E., et al., Infections and risk of type I diabetes in childhood: a population-based case-
control study. Eur J Epidemiol, 2003. 18(5): p. 425-30. 
696. Blom, L., L. Nystrom, and G. Dahlquist, The Swedish childhood diabetes study. Vaccinations and 
infections as risk determinants for diabetes in childhood. Diabetologia, 1991. 34(3): p. 176-81. 
697. Hviid, A., et al., Childhood vaccination and type 1 diabetes. N Engl J Med, 2004. 350(14): p. 1398-
404. 
698. Patterson, C.C., Infections and vaccinations as risk factors for childhood type I (insulin-
dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 
Study Group. Diabetologia, 2000. 43(1): p. 47-53. 
699. Duderstadt, S.K., et al., Vaccination and risk of type 1 diabetes mellitus in active component U.S. 
Military, 2002-2008. Vaccine, 2012. 30(4): p. 813-9. 
700. Hummel, M., et al., No major association of breast-feeding, vaccinations, and childhood viral 
diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care, 2000. 
23(7): p. 969-74. 
 
417 
701. Black, S.B., et al., Lack of association between receipt of conjugate haemophilus influenzae type 
B vaccine (HbOC) in infancy and risk of type 1 (juvenile onset) diabetes: long term follow-up of 
the HbOC efficacy trial cohort. Pediatr Infect Dis J, 2002. 21(6): p. 568-9. 
702. Karvonen, M., Z. Cepaitis, and J. Tuomilehto, Association between type 1 diabetes and 
Haemophilus influenzae type b vaccination: birth cohort study. BMJ, 1999. 318(7192): p. 1169-
72. 
703. Elding Larsson, H., et al., Pandemrix(R) vaccination is not associated with increased risk of islet 
autoimmunity or type 1 diabetes in the TEDDY study children. Diabetologia, 2018. 61(1): p. 193-
202. 
704. Vaarala, O., et al., Rotavirus Vaccination and the Risk of Celiac Disease or Type 1 Diabetes in 
Finnish Children at Early Life. Pediatr Infect Dis J, 2017. 36(7): p. 674-675. 
705. Morgan, E., et al., Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of 
observational studies. Diabetologia, 2016. 59(2): p. 237-43. 
706. Naleway, A.L., et al., Safety of influenza vaccination during pregnancy: a review of subsequent 
maternal obstetric events and findings from two recent cohort studies. Vaccine, 2014. 32(26): p. 
3122-7. 
707. Fabiani, M., et al., A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse 
maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine, 2015. 
33(19): p. 2240-2247. 
708. Karnchanasorn, R., et al., Viral Hepatitis and Diabetes: Clinical Implications of Diabetes 
Prevention Through Hepatitis Vaccination. Curr Diab Rep, 2016. 16(10): p. 101. 
709. Hansen, J., et al., Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. 
Vaccine, 2016. 34(35): p. 4172-4179. 
710. Vaccination Practices for Hepatitis B, Influenza, and Pneumococcal Disease for People With 
Diabetes. The Diabetes Educator, 2014. 40(1): p. 122-124. 
711. Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes, 
2016. 34(1): p. 3-21. 
712. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the 
Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep, 2011. 
60(50): p. 1709-11. 
713. Black, S., et al., Postmarketing evaluation of the safety and effectiveness of varicella vaccine. 
Pediatr Infect Dis J, 1999. 18(12): p. 1041-6. 
714. Galea, S.A., et al., The safety profile of varicella vaccine: a 10-year review. J Infect Dis, 2008. 197 
Suppl 2: p. S165-9. 
715. Sharrar, R.G., et al., The postmarketing safety profile of varicella vaccine. Vaccine, 2000. 19(7-8): 
p. 916-23. 
716. Wise, R.P., et al., Postlicensure safety surveillance for varicella vaccine. Jama, 2000. 284(10): p. 
1271-9. 
717. Angelini, P., et al., Aplastic anemia following varicella vaccine. Pediatr Infect Dis J, 2009. 28(8): p. 
746-8. 
718. Bryan, C.J., et al., Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with 
neuroblastoma. Pediatr Infect Dis J, 2008. 27(10): p. 946-8. 
719. Chaves, S.S., et al., Safety of varicella vaccine after licensure in the United States: experience 
from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis, 2008. 197 
Suppl 2: p. S170-7. 
720. Ghaffar, F., et al., Disseminated infection with varicella-zoster virus vaccine strain presenting as 




721. Goulleret, N., et al., Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of 
the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine, 2010. 28(36): p. 
5878-82. 
722. Ihara, T., et al., Viremic phase in a leukemic child after live varicella vaccination. Pediatrics, 1992. 
89(1): p. 147-9. 
723. Jean-Philippe, P., et al., Severe varicella caused by varicella-vaccine strain in a child with 
significant T-cell dysfunction. Pediatrics, 2007. 120(5): p. e1345-9. 
724. Kraft, J.N. and J.C. Shaw, Varicella infection caused by Oka strain vaccine in a heart transplant 
recipient. Arch Dermatol, 2006. 142(7): p. 943-5. 
725. Kramer, J.M., et al., Disseminated vaccine strain varicella as the acquired immunodeficiency 
syndrome-defining illness in a previously undiagnosed child. Pediatrics, 2001. 108(2): p. E39. 
726. Levy, O., et al., Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, 
in a patient with a novel deficiency in natural killer T cells. J Infect Dis, 2003. 188(7): p. 948-53. 
727. Waters, V., K.S. Peterson, and P. LaRussa, Live viral vaccines in a DiGeorge syndrome patient. 
Arch Dis Child, 2007. 92(6): p. 519-20. 
728. Chan, Y., et al., Herpes zoster due to Oka vaccine strain of varicella zoster virus in an 
immunosuppressed child post cord blood transplant. J Paediatr Child Health, 2007. 43(10): p. 
713-5. 
729. Ota, K., et al., Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an 
immunocompetent 2-year-old. Pediatr Infect Dis J, 2008. 27(9): p. 847-8. 
730. Chouliaras, G., et al., Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] 
and encephalitis in an immunocompetent child. Pediatrics, 2010. 125(4): p. e969-72. 
731. Iyer, S., M.K. Mittal, and R.L. Hodinka, Herpes zoster and meningitis resulting from reactivation 
of varicella vaccine virus in an immunocompetent child. Ann Emerg Med, 2009. 53(6): p. 792-5. 
732. Levin, M.J., et al., Development of resistance to acyclovir during chronic infection with the Oka 
vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis, 2003. 188(7): 
p. 954-9. 
733. Levin, M.J., et al., Herpes zoster with skin lesions and meningitis caused by 2 different genotypes 
of the Oka varicella-zoster virus vaccine. J Infect Dis, 2008. 198(10): p. 1444-7. 
734. Leung, J., et al., Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin 
Immunother, 2014. 10(1): p. 146-9. 
735. Schrauder, A., et al., Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet, 
2007. 369(9568): p. 1232. 
736. Woo, E.J., Letter to the editor: Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum 
Vaccin Immunother, 2015. 11(3): p. 679. 
737. Dutmer, C.M., et al., Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-
Strain VZV Infection. J Clin Immunol, 2015. 35(8): p. 754-60. 
738. Chowaniec, M., A. Starba, and P. Wiland, Erythema nodosum - review of the literature. 
Reumatologia, 2016. 54(2): p. 79-82. 
739. Blake, T., M. Manahan, and K. Rodins, Erythema nodosum - a review of an uncommon 
panniculitis. Dermatol Online J, 2014. 20(4): p. 22376. 
740. Goolsby, P.L., Erythema nodosum after Recombivax HB hepatitis B vaccine. N Engl J Med, 1989. 
321(17): p. 1198-9. 
741. Donegan, K., et al., Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in 
girls in the UK. Vaccine, 2013. 31(43): p. 4961-7. 
742. Magnus, P., et al., Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated 
with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. 
Vaccine, 2015. 33(46): p. 6173-7. 
 
419 
743. Feiring, B., et al., HPV vaccination and risk of chronic fatigue syndrome/myalgic 
encephalomyelitis: A nationwide register-based study from Norway. Vaccine, 2017. 35(33): p. 
4203-4212. 
744. Bazzichi, L., et al., Fibromyalgia: a critical digest of the recent literature. Clin Exp Rheumatol, 
2011. 29(6 Suppl 69): p. S1-11. 
745. Moss-Morris, R., V. Deary, and B. Castell, Chronic fatigue syndrome. Handb Clin Neurol, 2013. 
110: p. 303-14. 
746. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue, S., P. 
Board on the Health of Select, and M. Institute of, The National Academies Collection: Reports 
funded by National Institutes of Health, in Beyond Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome: Redefining an Illness. 2015, National Academies Press (US) 
Copyright 2015 by the National Academy of Sciences. All rights reserved.: Washington (DC). 
747. Romano, G.F., et al., Fibromyalgia and chronic fatigue: the underlying biology and related 
theoretical issues. Adv Psychosom Med, 2015. 34: p. 61-77. 
748. Martinez-Martinez, L.A., et al., Sympathetic nervous system dysfunction in fibromyalgia, chronic 
fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control 
studies. J Clin Rheumatol, 2014. 20(3): p. 146-50. 
749. Buskila, D., F. Atzeni, and P. Sarzi-Puttini, Etiology of fibromyalgia: the possible role of infection 
and vaccination. Autoimmun Rev, 2008. 8(1): p. 41-3. 
750. Schonberger, L.B., et al., Guillain-Barre syndrome following vaccination in the National Influenza 
Immunization Program, United States, 1976--1977. Am J Epidemiol, 1979. 110(2): p. 105-23. 
751. Ellenberg, S.S. and M.M. Braun, Monitoring the safety of vaccines: assessing the risks. Drug Saf, 
2002. 25(3): p. 145-52. 
752. Johnson, D.E., Guillain-Barre syndrome in the US Army. Arch Neurol, 1982. 39(1): p. 21-4. 
753. Hurwitz, E.S., et al., Guillain-Barre syndrome and the 1978-1979 influenza vaccine. New England 
Journal of Medicine, 1981. 304(26): p. 1557-1561. 
754. Kaplan, J.E., et al., Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. 
Journal of the American Medical Association, 1982. 248(6): p. 698-700. 
755. Roscelli, J.D., J.W. Bass, and L. Pang, Guillain-Barre syndrome and influenza vaccination in the US 
Army, 1980-1988. American Journal of Epidemiology, 1991. 133(9): p. 952-955. 
756. Lasky, T., et al., The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza 
vaccines. New England Journal of Medicine, 1998. 339(25): p. 1797-1802. 
757. Ho, T.Y., et al., The Impact of Influenza Vaccinations on the Adverse Effects and Hospitalization 
Rate in the Elderly: A National Based Study in an Asian Country. PLoS ONE, 2012. 7(11). 
758. Kawai, A.T., et al., Absence of associations between influenza vaccines and increased risks of 
seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. 
Pharmacoepidemiology and Drug Safety, 2014. 23(5): p. 548-553. 
759. Grimaldi-Bensouda, L., et al., Guillain-barre syndrome, influenzalike illnesses, and influenza 
vaccination during seasons with and without circulating A/H1N1 viruses. American Journal of 
Epidemiology, 2011. 174(3): p. 326-335. 
760. Galeotti, F., et al., Risk of Guillain-Barre syndrome after 2010-2011 influenza vaccination. 
European Journal of Epidemiology, 2013. 28(5): p. 433-444. 
761. Dieleman, J., et al., Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 
vaccine: Multinational case-control study in Europe. BMJ, 2011. 343(7815). 
762. Stowe, J., et al., Investigation of the temporal association of Guillain-Barre syndrome with 
influenza vaccine and influenzalike illness using the United Kingdom general practice research 
database. American Journal of Epidemiology, 2009. 169(3): p. 382-388. 
 
420 
763. Juurlink, D.N., et al., Guillain-Barre syndrome after influenza vaccination in adults: A population-
based study. Archives of Internal Medicine, 2006. 166(20): p. 2217-2221. 
764. Hughes, R.A., et al., No association between immunization and Guillain-Barre syndrome in the 
United Kingdom, 1992 to 2000. Archives of Internal Medicine, 2006. 166(12): p. 1301-1304. 
765. Baxter, R., et al., Lack of association of Guillain-Barre syndrome with vaccinations. Clinical 
Infectious Diseases, 2013. 57(2): p. 197-204. 
766. Burwen, D.R., et al., Evaluation of Guillain-Barre syndrome among recipients of influenza vaccine 
in 2000 and 2001. American Journal of Preventive Medicine, 2010. 39(4): p. 296-304. 
767. Dodd, C.N., et al., International collaboration to assess the risk of Guillain Barre Syndrome 
following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 2013. 31(40): p. 4448-4458. 
768. Huang, W.T., et al., Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-
Controlled Case Series Study. PLoS ONE, 2013. 8(3). 
769. Prestel, J., et al., Risk of Guillain-Barre syndrome following pandemic influenza A(H1N1) 2009 
vaccination in Germany. Pharmacoepidemiol Drug Saf, 2014. 
770. Greene, S.K., et al., Guillain-Barre Syndrome, Influenza Vaccination, and Antecedent Respiratory 
and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-
2011. PLoS ONE, 2013. 8(6). 
771. Kwong, J.C., et al., Risk of Guillain-Barre syndrome after seasonal influenza vaccination and 
influenza health-care encounters: A self-controlled study. The Lancet Infectious Diseases, 2013. 
13(9): p. 769-776. 
772. McCarthy, N.L., et al., Evaluating the safety of influenza vaccine using a claims-based health 
system. Vaccine, 2013. 31(50): p. 5975-82. 
773. Martin Arias, L.H., et al., Guillain-Barre syndrome and influenza vaccines: A meta-analysis. 
Vaccine, 2015. 33(31): p. 3773-8. 
774. Sandhu, S.K., et al., Near real-time surveillance for Guillain-Barre syndrome after influenza 
vaccination among the Medicare population, 2010/11 to 2013/14. Vaccine, 2017. 35(22): p. 
2986-2992. 
775. Vichnin, M., et al., An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 
2015. Pediatr Infect Dis J, 2015. 34(9): p. 983-91. 
776. Andrews, N., J. Stowe, and E. Miller, No increased risk of Guillain-Barre syndrome after human 
papilloma virus vaccine: A self-controlled case-series study in England. Vaccine, 2017. 35(13): p. 
1729-1732. 
777. Gee, J., L. Sukumaran, and E. Weintraub, Risk of Guillain-Barre Syndrome following quadrivalent 
human papillomavirus vaccine in the Vaccine Safety Datalink. Vaccine, 2017. 35(43): p. 5756-
5758. 
778. Grimaldi-Bensouda, L., et al., Risk of autoimmune diseases and human papilloma virus (HPV) 
vaccines: Six years of case-referent surveillance. J Autoimmun, 2017. 79: p. 84-90. 
779. Miranda, S., et al., Human papillomavirus vaccination and risk of autoimmune diseases: A large 
cohort study of over 2million young girls in France. Vaccine, 2017. 35(36): p. 4761-4768. 
780. Haber, P., et al., Vaccines and Guillain-Barre syndrome. Drug Saf, 2009. 32(4): p. 309-23. 
781. Yuki, N. and H.P. Hartung, Guillain-Barre syndrome. N Engl J Med, 2012. 366(24): p. 2294-304. 
782. Mizoguchi, K., Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher 
syndrome. Neurol Res, 1998. 20(7): p. 617-24. 
783. Rees, J.H., et al., Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med, 
1995. 333(21): p. 1374-9. 
784. Tam, C.C., et al., Guillain-Barre syndrome and preceding infection with campylobacter, influenza 
and Epstein-Barr virus in the general practice research database. PLoS One, 2007. 2(4): p. e344. 
 
421 
785. Baxter, R., et al., Sudden-Onset Sensorineural Hearing Loss after Immunization: A Case-Centered 
Analysis. Otolaryngol Head Neck Surg, 2016. 155(1): p. 81-6. 
786. Brookhouser, P.E., D.W. Worthington, and W.J. Kelly, Unilateral hearing loss in children. 
Laryngoscope, 1991. 101(12 Pt 1): p. 1264-72. 
787. Mizushima, N. and Y. Murakami, Deafness following mumps: the possible pathogenesis and 
incidence of deafness. Auris Nasus Larynx, 1986. 13 Suppl 1: p. S55-7. 
788. Unal, M., et al., Sudden total bilateral deafness due to asymptomatic mumps infection. Int J 
Pediatr Otorhinolaryngol, 1998. 45(2): p. 167-9. 
789. Cohen, B.E., A. Durstenfeld, and P.C. Roehm, Viral Causes of Hearing Loss: A Review for Hearing 
Health Professionals. Trends in Hearing, 2014. 18: p. 2331216514541361. 
790. Asatryan, A., et al., Live attenuated measles and mumps viral strain-containing vaccines and 
hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003. 
Vaccine, 2008. 26(9): p. 1166-72. 
791. Brodsky, L. and J. Stanievich, Sensorineural hearing loss following live measles virus vaccination. 
Int J Pediatr Otorhinolaryngol, 1985. 10(2): p. 159-63. 
792. Hulbert, T.V., et al., Bilateral hearing loss after measles and rubella vaccination in an adult. N 
Engl J Med, 1991. 325(2): p. 134. 
793. Fukuda, S., et al., An anti-mumps IgM antibody level in the serum of idiopathic sudden 
sensorineural hearing loss. Auris Nasus Larynx, 2001. 28 Suppl: p. S3-5. 
794. Fukuda, S., K. Ishikawa, and Y. Inuyama, Acute measles infection in the hamster cochlea. Acta 
Otolaryngol Suppl, 1994. 514: p. 111-6. 
795. Alter, M.J., Vaccinating Patients with Chronic Liver Disease. Gastroenterology & Hepatology, 
2012. 8(2): p. 120-122. 
796. Donahue, J.G., et al., Varicella vaccination and ischemic stroke in children: is there an 
association? Pediatrics, 2009. 123(2): p. e228-34. 
797. Prymula, R., et al., Protection against varicella with two doses of combined measles-mumps-
rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, 
observer-blind, randomised, controlled trial. Lancet, 2014. 383(9925): p. 1313-24. 
798. Tseng, H.F., et al., Herpes zoster caused by vaccine-strain varicella zoster virus in an 
immunocompetent recipient of zoster vaccine. Clin Infect Dis, 2014. 58(8): p. 1125-8. 
799. McNeil, M.M., et al., Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin 
Immunol, 2016. 137(3): p. 868-78. 
800. Klein, N.P., et al., Safety and immunogenicity of a novel quadrivalent meningococcal CRM-
conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J, 
2012. 31(1): p. 64-71. 
801. Rennels, M.B., et al., Safety of a fifth dose of diphtheria and tetanus toxoid and acellular 
pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr 
Infect Dis J, 2008. 27(5): p. 464-5. 
802. Rennels, M.B., et al., Extensive swelling after booster doses of acellular pertussis-tetanus-
diphtheria vaccines. Pediatrics, 2000. 105(1): p. e12. 
803. Sekaran, N.K. and K.M. Edwards, Extensive swelling reaction associated with diphtheria and 
tetanus toxoids and acellular pertussis vaccine. Pediatr Infect Dis J, 2006. 25(4): p. 374-5. 
804. Wood, R.A., Allergic reactions to vaccines. Pediatr Allergy Immunol, 2013. 24(6): p. 521-6. 
805. Aukrust, L., et al., Severe hypersensitivity or intolerance reactions to measles vaccine in six 
children. Clinical and immunological studies. Allergy, 1980. 35(7): p. 581-7. 
806. Baxter, D.N., Measles immunization in children with a history of egg allergy. Vaccine, 1996. 
14(2): p. 131-4. 
 
422 
807. Bohlke, K., et al., Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics, 
2003. 112(4): p. 815-20. 
808. Erlewyn-Lajeunesse, M., et al., Anaphylaxis following single component measles and rubella 
immunisation. Arch Dis Child, 2008. 93(11): p. 974-5. 
809. Fasano, M.B., et al., Egg hypersensitivity and adverse reactions to measles, mumps, and rubella 
vaccine. J Pediatr, 1992. 120(6): p. 878-81. 
810. Giampietro, P.G., et al., Adverse reaction to measles immunization. Eur J Pediatr, 1993. 152(1): 
p. 80. 
811. Herman, J.J., R. Radin, and R. Schneiderman, Allergic reactions to measles (rubeola) vaccine in 
patients hypersensitive to egg protein. J Pediatr, 1983. 102(2): p. 196-9. 
812. Kelso, J.M., R.T. Jones, and J.W. Yunginger, Anaphylaxis to measles, mumps, and rubella vaccine 
mediated by IgE to gelatin. J Allergy Clin Immunol, 1993. 91(4): p. 867-72. 
813. Patja, A., et al., Serious adverse events after measles-mumps-rubella vaccination during a 
fourteen-year prospective follow-up. Pediatr Infect Dis J, 2000. 19(12): p. 1127-34. 
814. Patja, A., et al., Allergic reactions to measles-mumps-rubella vaccination. Pediatrics, 2001. 
107(2): p. E27. 
815. Pool, V., et al., Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after 
measles-mumps rubella vaccine in the United States. Pediatrics, 2002. 110(6): p. e71. 
816. Puvvada, L., et al., Systemic reactions to measles-mumps-rubella vaccine skin testing. Pediatrics, 
1993. 91(4): p. 835-6. 
817. DiMiceli, L., et al., Vaccination of yeast sensitive individuals: review of safety data in the US 
vaccine adverse event reporting system (VAERS). Vaccine, 2006. 24(6): p. 703-7. 
818. Kumagai, T., et al., Gelatin-specific humoral and cellular immune responses in children with 
immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella 
vaccines. J Allergy Clin Immunol, 1997. 100(1): p. 130-4. 
819. Ozaki, T., et al., Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological 
and serological studies in Japan. Vaccine, 2005. 23(10): p. 1205-8. 
820. Sakaguchi, M., H. Miyazawa, and S. Inouye, Sensitization to gelatin in children with systemic non-
immediate-type reactions to varicella vaccines. Ann Allergy Asthma Immunol, 2000. 84(3): p. 
341-4. 
821. Sakaguchi, M., et al., Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines 
including gelatin. Vaccine, 2000. 19(4-5): p. 431-6. 
822. Sakaguchi, M., et al., IgE-mediated systemic reactions to gelatin included in the varicella vaccine. 
J Allergy Clin Immunol, 1997. 99(2): p. 263-4. 
823. Chung, E.Y., L. Huang, and L. Schneider, Safety of influenza vaccine administration in egg-allergic 
patients. Pediatrics, 2010. 125(5): p. e1024-30. 
824. Coop, C.A., et al., Anaphylaxis from the influenza virus vaccine. Int Arch Allergy Immunol, 2008. 
146(1): p. 85-8. 
825. Izurieta, H.S., et al., Adverse events reported following live, cold-adapted, intranasal influenza 
vaccine. JAMA, 2005. 294(21): p. 2720-5. 
826. James, J.M., et al., Safe administration of influenza vaccine to patients with egg allergy. J 
Pediatr, 1998. 133(5): p. 624-8. 
827. Muhammad, R.D., et al., Adverse Events Following Trivalent Inactivated Influenza Vaccination in 
Children: Analysis of the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J, 2010. 
828. Peng, M.M. and H. Jick, A population-based study of the incidence, cause, and severity of 
anaphylaxis in the United Kingdom. Arch Intern Med, 2004. 164(3): p. 317-9. 
829. Zheng, W. and S.C. Dreskin, Thimerosal in influenza vaccine: an immediate hypersensitivity 
reaction. Ann Allergy Asthma Immunol, 2007. 99(6): p. 574-5. 
 
423 
830. Yergeau, A., et al., Adverse events temporally associated with meningococcal vaccines. CMAJ, 
1996. 154(4): p. 503-7. 
831. Bilyk, M.A. and G. Dubchik, [Anaphylactic reaction following subcutaneous administration of 
tetanus anatoxin]. Klin Med (Mosk), 1978. 56(9): p. 137-8. 
832. Mandal, G.S., M. Mukhopadhyay, and A.R. Bhattacharya, Adverse reactions following tetanus 
toxoid injection. J Indian Med Assoc, 1980. 74(2): p. 35-7. 
833. Mansfield, L.E., et al., Systemic reactions during cutaneous testing for tetanus toxoid 
hypersensitivity. Ann Allergy, 1986. 57(2): p. 135-7. 
834. Zaloga, G.P. and B. Chernow, Life-threatening anaphylactic reaction to tetanus toxoid. Ann 
Allergy, 1982. 49(2): p. 107-8. 
835. Brotherton, J.M., et al., Anaphylaxis following quadrivalent human papillomavirus vaccination. 
CMAJ, 2008. 179(6): p. 525-33. 
836. Slade, B.A., et al., Postlicensure safety surveillance for quadrivalent human papillomavirus 
recombinant vaccine. JAMA, 2009. 302(7): p. 750-7. 
837. Cribier, B., Urticaria and hepatitis. Clin Rev Allergy Immunol, 2006. 30(1): p. 25-9. 
838. Darlenski, R., et al., Chronic urticaria as a systemic disease. Clin Dermatol, 2014. 32(3): p. 420-3. 
839. Minciullo, P.L., et al., Urticaria and bacterial infections. Allergy Asthma Proc, 2014. 35(4): p. 295-
302. 
840. O'Leary, S.T., et al., The risk of immune thrombocytopenic purpura after vaccination in children 
and adolescents. Pediatrics, 2012. 129(2): p. 248-55. 
841. Cecinati, V., et al., Vaccine administration and the development of immune thrombocytopenic 
purpura in children. Hum Vaccin Immunother, 2013. 9(5): p. 1158-62. 
842. Andrews, N., et al., A collaborative approach to investigating the risk of thrombocytopenic 
purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine, 2012. 
30(19): p. 3042-6. 
843. Bertuola, F., et al., Association between drug and vaccine use and acute immune 
thrombocytopenia in childhood: a case-control study in Italy. Drug Saf, 2010. 33(1): p. 65-72. 
844. Grimaldi-Bensouda, L., et al., A case-control study to assess the risk of immune 
thrombocytopenia associated with vaccines. Blood, 2012. 120(25): p. 4938-44. 
845. Villa, M., et al., Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a 
comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in 
northern Italy. Am J Epidemiol, 2013. 178(7): p. 1139-45. 
846. Nordin, J.D., et al., Maternal safety of trivalent inactivated influenza vaccine in pregnant women. 
Obstet Gynecol, 2013. 121(3): p. 519-25. 
847. Yenicesu, I., et al., Virus-associated immune thrombocytopenic purpura in childhood. Pediatr 
Hematol Oncol, 2002. 19(6): p. 433-7. 
848. Oski, F.A. and J.L. Naiman, Effect of live measles vaccine on the platelet count. N Engl J Med, 
1966. 275(7): p. 352-6. 
849. Buchanan, R. and D.J. Bonthius, Measles Virus and Associated Central Nervous System Sequelae. 
Seminars in Pediatric Neurology, 2012. 19(3): p. 107-114. 
850. Studahl, M., et al., Acute viral infections of the central nervous system in immunocompetent 
adults: diagnosis and management. Drugs, 2013. 73(2): p. 131-58. 
851. Gilden, D., M.A. Nagel, and R.J. Cohrs, Chapter 12 - Varicella-zoster, in Handbook of Clinical 
Neurology, C.T. Alex and B. John, Editors. 2014, Elsevier. p. 265-283. 
852. Griffin, D.E., Chapter 27 - Measles virus and the nervous system, in Handbook of Clinical 
Neurology, C.T. Alex and B. John, Editors. 2014, Elsevier. p. 577-590. 
853. Tyor, W. and T. Harrison, Chapter 28 - Mumps and rubella, in Handbook of Clinical Neurology, 
C.T. Alex and B. John, Editors. 2014, Elsevier. p. 591-600. 
 
424 
854. Rubin, S., et al., Molecular biology, pathogenesis and pathology of mumps virus. J Pathol, 2015. 
235(2): p. 242-52. 
855. Ki, M., et al., Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in 
Korean children by using a case-crossover design. Am J Epidemiol, 2003. 157(2): p. 158-65. 
856. Black, S., et al., Risk of hospitalization because of aseptic meningitis after measles-mumps-
rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink 
(VSD) Project. Pediatr Infect Dis J, 1997. 16(5): p. 500-3. 
857. Ray, P., et al., Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence 
for a causal association in a retrospective case-control study. Pediatr Infect Dis J, 2006. 25(9): p. 
768-73. 
858. Ward, K.N., et al., Risk of serious neurologic disease after immunization of young children in 
Britain and Ireland. Pediatrics, 2007. 120(2): p. 314-21. 
859. Greco, D., Case-control study on encephalopathy associated with diphtheria-tetanus 
immunization in Campania, Italy. Bull World Health Organ, 1985. 63(5): p. 919-25. 
860. Tseng, H.F., et al., Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine 
Safety Datalink study. J Intern Med, 2012. 271(5): p. 510-20. 
861. Pahud, B.A., et al., Lack of association between childhood immunizations and encephalitis in 
California, 1998-2008. Vaccine, 2012. 30(2): p. 247-53. 
862. Ghaderi, S., et al., Encephalitis after influenza and vaccination: a nationwide population-based 
registry study from Norway. Int J Epidemiol, 2017. 46(5): p. 1618-1626. 
863. Bellini, W.J., et al., Subacute sclerosing panencephalitis: more cases of this fatal disease are 
prevented by measles immunization than was previously recognized. J Infect Dis, 2005. 192(10): 
p. 1686-93. 
864. Goenka, A., et al., Neurological manifestations of influenza infection in children and adults: 
results of a National British Surveillance Study. Clin Infect Dis, 2014. 58(6): p. 775-84. 
865. Britton, P.N., et al., Influenza-associated Encephalitis/Encephalopathy Identified by the 
Australian Childhood Encephalitis Study 2013-2015. Pediatr Infect Dis J, 2017. 36(11): p. 1021-
1026. 
866. Hoshino, A., et al., Epidemiology of acute encephalopathy in Japan, with emphasis on the 
association of viruses and syndromes. Brain Dev, 2012. 34(5): p. 337-43. 
867. Moore, D.L., et al., Lack of evidence of encephalopathy related to pertussis vaccine: active 
surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J, 2004. 23(6): p. 568-71. 
868. Berkovic, S.F., et al., De-novo mutations of the sodium channel gene SCN1A in alleged vaccine 
encephalopathy: a retrospective study. Lancet Neurol, 2006. 5(6): p. 488-92. 
869. Bakshi, N., et al., Fatal mumps meningoencephalitis in a child with severe combined 
immunodeficiency after bone marrow transplantation. J Child Neurol, 1996. 11(2): p. 159-62. 
870. Lacroix, C., et al., Acute necrotizing measles encephalitis in a child with AIDS. J Neurol, 1995. 
242(4): p. 249-51. 
871. Valmari, P., et al., Measles virus in the cerebrospinal fluid in postvaccination immunosuppressive 
measles encephalopathy. Pediatr Infect Dis J, 1987. 6(1): p. 59-63. 
872. Froissart, M., J.P. Mizon, and J.L. Leroux, [Acute meningoencephalitis immediately after an 
influenza vaccination]. Lille Med, 1978. 23(8): p. 548-51. 
873. Schwarz, G., G. Lanzer, and W.F. List, Acute midbrain syndrome as an adverse reaction to tetanus 
immunization. Intensive Care Med, 1988. 15(1): p. 53-4. 
874. Ehrengut, W. and K. Zastrow, [Complications after preventive mumps vaccination in West 




875. Fescharek, R., et al., Measles-mumps vaccination in the FRG: an empirical analysis after 14 years 
of use. II. Tolerability and analysis of spontaneously reported side effects. Vaccine, 1990. 8(5): p. 
446-56. 
876. Bitnun, A., et al., Measles inclusion-body encephalitis caused by the vaccine strain of measles 
virus. Clin Infect Dis, 1999. 29(4): p. 855-61. 
877. Han, J.Y., D.C. Hanson, and S.S. Way, Herpes zoster and meningitis due to reactivation of 
varicella vaccine virus in an immunocompetent child. Pediatr Infect Dis J, 2011. 30(3): p. 266-8. 
878. Gershon, A.A., et al., Varicella zoster virus infection. Nat Rev Dis Primers, 2015. 1: p. 15016. 
879. Baram, T.Z., et al., Subacute sclerosing panencephalitis in an infant: diagnostic role of viral 
genome analysis. Ann Neurol, 1994. 36(1): p. 103-8. 
880. Poon, T.P., V. Tchertkoff, and H. Win, Subacute measles encephalitis with AIDS diagnosed by fine 
needle aspiration biopsy. A case report. Acta Cytol, 1998. 42(3): p. 729-33. 
881. Ahlgren, C., et al., A population-based case-control study on viral infections and vaccinations and 
subsequent multiple sclerosis risk. Eur J Epidemiol, 2009. 24(9): p. 541-52. 
882. Ascherio, A., et al., Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med, 2001. 
344(5): p. 327-32. 
883. DeStefano, F., et al., Vaccinations and risk of central nervous system demyelinating diseases in 
adults. Arch Neurol, 2003. 60(4): p. 504-9. 
884. Hernan, M.A., et al., Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a 
prospective study. Neurology, 2004. 63(5): p. 838-42. 
885. Hocine, M.N., et al., Hepatitis B vaccination and first central nervous system demyelinating 
events: reanalysis of a case-control study using the self-controlled case series method. Vaccine, 
2007. 25(31): p. 5938-43. 
886. Confavreux, C., et al., Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in 
Multiple Sclerosis Study Group. N Engl J Med, 2001. 344(5): p. 319-26. 
887. Miller, A.E., et al., A multicenter, randomized, double-blind, placebo-controlled trial of influenza 
immunization in multiple sclerosis. Neurology, 1997. 48(2): p. 312-4. 
888. Mikaeloff, Y., et al., Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. 
Arch Pediatr Adolesc Med, 2007. 161(12): p. 1176-82. 
889. Mikaeloff, Y., et al., Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS 
inflammatory demyelination. Brain, 2007. 130(Pt 4): p. 1105-10. 
890. Farez, M.F., et al., H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-
controlled case-series study. Mult Scler, 2012. 18(2): p. 254-6. 
891. Mailand, M.T. and J.L. Frederiksen, Vaccines and multiple sclerosis: a systematic review. Journal 
of Neurology, 2016: p. 1-16. 
892. Frederiksen, J.L. and M. Topsoe Mailand, Vaccines and multiple sclerosis. Acta Neurol Scand, 
2017. 136 Suppl 201: p. 49-51. 
893. Pena, J.A. and T.E. Lotze, Pediatric multiple sclerosis: current concepts and consensus definitions. 
Autoimmune Dis, 2013. 2013: p. 673947. 
894. Krupp, L.B., et al., International Pediatric Multiple Sclerosis Study Group criteria for pediatric 
multiple sclerosis and immune-mediated central nervous system demyelinating disorders: 
revisions to the 2007 definitions. Mult Scler, 2013. 19(10): p. 1261-7. 
895. Fujinami, R.S. and M.B. Oldstone, Amino acid homology between the encephalitogenic site of 
myelin basic protein and virus: mechanism for autoimmunity. Science, 1985. 230(4729): p. 1043-
5. 
896. Smeeth, L., et al., Risk of myocardial infarction and stroke after acute infection or vaccination. N 
Engl J Med, 2004. 351(25): p. 2611-8. 
 
426 
897. Siriwardena, A.N., S.M. Gwini, and C.A. Coupland, Influenza vaccination, pneumococcal 
vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ, 2010. 
182(15): p. 1617-23. 
898. Siriwardena, A.N., Z. Asghar, and C.C. Coupland, Influenza and pneumococcal vaccination and 
risk of stroke or transient ischaemic attack-matched case control study. Vaccine, 2014. 32(12): p. 
1354-61. 
899. Asghar, Z., C. Coupland, and N. Siriwardena, Influenza vaccination and risk of stroke: Self-
controlled case-series study. Vaccine, 2015. 33(41): p. 5458-5463. 
900. Lee, K.R., et al., Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-
Analysis. Neuroepidemiology, 2017. 48(3-4): p. 103-110. 
901. Gwini, S.M., C.A. Coupland, and A.N. Siriwardena, The effect of influenza vaccination on risk of 
acute myocardial infarction: self-controlled case-series study. Vaccine, 2011. 29(6): p. 1145-9. 
902. Macintyre, C.R., et al., Ischaemic heart disease, influenza and influenza vaccination: a 
prospective case control study. Heart, 2013. 99(24): p. 1843-8. 
903. Lavallee, P.C., et al., Influenza vaccination and cardiovascular risk in patients with recent TIA and 
stroke. Neurology, 2014. 82(21): p. 1905-13. 
904. Lin, H.C., et al., Association of influenza vaccination and reduced risk of stroke hospitalization 
among the elderly: a population-based case-control study. Int J Environ Res Public Health, 2014. 
11(4): p. 3639-49. 
905. Chiang, M.H., et al., Association between influenza vaccination and reduced risks of major 
adverse cardiovascular events in elderly patients. Am Heart J, 2017. 193: p. 1-7. 
906. Hsu, S.Y., et al., A Matched Influenza Vaccine Strain Was Effective in Reducing the Risk of Acute 
Myocardial Infarction in Elderly Persons: A Population-Based Study. Medicine (Baltimore), 2016. 
95(10): p. e2869. 
907. Tseng, H.F., et al., Pneumococcal vaccination and risk of acute myocardial infarction and stroke 
in men. JAMA, 2010. 303(17): p. 1699-706. 
908. Hedlund, J., et al., Effects of a large-scale intervention with influenza and 23-valent 
pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine, 2003. 21(25-26): p. 3906-
11. 
909. Eurich, D.T., et al., Pneumococcal vaccination and risk of acute coronary syndromes in patients 
with pneumonia: population-based cohort study. Heart, 2012. 98(14): p. 1072-7. 
910. Vlachopoulos, C.V., et al., Association between pneumococcal vaccination and cardiovascular 
outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol, 2015. 
22(9): p. 1185-99. 
911. Vila-Corcoles, A., et al., Clinical effectiveness of pneumococcal vaccination against acute 
myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-
up. BMC Public Health, 2012. 12: p. 222. 
912. Vila-Corcoles, A., et al., Ineffectiveness of pneumococcal vaccination in cardiovascular 
prevention: the CAPAMIS study. JAMA Intern Med, 2013. 173(20): p. 1918-20. 
913. Vila-Corcoles, A., et al., Evaluating clinical effectiveness of pneumococcal vaccination in 
preventing stroke: the CAPAMIS Study, 3-year follow-up. J Stroke Cerebrovasc Dis, 2014. 23(6): p. 
1577-84. 
914. Ochoa-Gondar, O., et al., Evaluating the clinical effectiveness of pneumococcal vaccination in 
preventing myocardial infarction: The CAPAMIS study, three-year follow-up. Vaccine, 2014. 
32(2): p. 252-7. 
915. Gee, J., et al., Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from 
the Vaccine Safety Datalink. Vaccine, 2011. 29(46): p. 8279-84. 
 
427 
916. Keating, G.M., Shingles (herpes zoster) vaccine (zostavax((R))): a review of its use in the 
prevention of herpes zoster and postherpetic neuralgia in adults aged >/=50 years. Drugs, 2013. 
73(11): p. 1227-44. 
917. Fullerton, H.J., et al., Infection, vaccination, and childhood arterial ischemic stroke: Results of the 
VIPS study. Neurology, 2015. 85(17): p. 1459-66. 
918. Clar, C., et al., Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst 
Rev, 2015(5): p. Cd005050. 
919. Estabragh, Z.R. and M.A. Mamas, The cardiovascular manifestations of influenza: a systematic 
review. Int J Cardiol, 2013. 167(6): p. 2397-403. 
920. Nagel, M.A., et al., Virus vasculopathy and stroke: an under-recognized cause and treatment 
target. Infect Disord Drug Targets, 2010. 10(2): p. 105-11. 
921. Poland, G.A., J.D. Grabenstein, and J.M. Neff, The US smallpox vaccination program: a review of 
a large modern era smallpox vaccination implementation program. Vaccine, 2005. 23(17-18): p. 
2078-81. 
922. Engler, R.J., et al., A prospective study of the incidence of myocarditis/pericarditis and new onset 
cardiac symptoms following smallpox and influenza vaccination. PLoS One, 2015. 10(3): p. 
e0118283. 
923. Biesbroek, P.S., et al., Diagnosis of myocarditis: Current state and future perspectives. Int J 
Cardiol, 2015. 191: p. 211-219. 
924. Nohynek, H., et al., AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the 
incidence of childhood narcolepsy in Finland. PLoS One, 2012. 7(3): p. e33536. 
925. Partinen, M., et al., Increased incidence and clinical picture of childhood narcolepsy following the 
2009 H1N1 pandemic vaccination campaign in Finland. PLoS One, 2012. 7(3): p. e33723. 
926. Szakacs, A., N. Darin, and T. Hallbook, Increased childhood incidence of narcolepsy in western 
Sweden after H1N1 influenza vaccination. Neurology, 2013. 80(14): p. 1315-21. 
927. Johansen, K., The roles of influenza virus antigens and the AS03 adjuvant in the 2009 pandemic 
vaccine associated with narcolepsy needs further investigation. Dev Med Child Neurol, 2014. 
56(11): p. 1041-2. 
928. Dauvilliers, Y., et al., Increased risk of narcolepsy in children and adults after pandemic H1N1 
vaccination in France. Brain, 2013. 136(Pt 8): p. 2486-96. 
929. Wijnans, L., et al., The incidence of narcolepsy in Europe: before, during, and after the influenza 
A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine, 2013. 31(8): p. 1246-54. 
930. European Centre for Disease Prevention and Control, Narcolepsy in association with pandemic 
influenza vaccination (a multi-country European epidemiological investigation). ECDC: 
Stockholm. 
931. Miller, E., et al., Risk of narcolepsy in children and young people receiving AS03 adjuvanted 
pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. Bmj, 2013. 346: p. f794. 
932. O'Flanagan, D., et al., Investigation of an association between onset of narcolepsy and 
vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill, 
2014. 19(17): p. 15-25. 
933. Stowe, J., et al., Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza 
Vaccine in Adults: A Case-Coverage Study in England. Sleep, 2016. 39(5): p. 1051-7. 
934. Heier, M.S., et al., Incidence of narcolepsy in Norwegian children and adolescents after 
vaccination against H1N1 influenza A. Sleep Med, 2013. 14(9): p. 867-71. 
935. Oberle, D., et al., Retrospective multicenter matched case-control study on the risk factors for 
narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and 
infections in Germany. Sleep Med, 2017. 34: p. 71-83. 
 
428 
936. Feltelius, N., et al., A coordinated cross-disciplinary research initiative to address an increased 
incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden. J 
Intern Med, 2015. 278(4): p. 335-53. 
937. Montplaisir, J., et al., Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 
(2009) pandemic influenza vaccine in Quebec. PLoS One, 2014. 9(9): p. e108489. 
938. Partinen, M., et al., Narcolepsy as an autoimmune disease: the role of H1N1 infection and 
vaccination. Lancet Neurol, 2014. 13(6): p. 600-13. 
939. Tsai, T.F., et al., Explorations of clinical trials and pharmacovigilance databases of MF59(R)-
adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis, 2011. 43(9): 
p. 702-6. 
940. Ahmed, S.S., et al., Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza 
vaccinations: what is known and unknown about the neurological disorder, the role for 
autoimmunity, and vaccine adjuvants. J Autoimmun, 2014. 50: p. 1-11. 
941. Duffy, J., et al., Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United 
States. Neurology, 2014. 83(20): p. 1823-30. 
942. Arnheim-Dahlström, L., et al., Autoimmune, neurological, and venous thromboembolic adverse 
events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in 
Denmark and Sweden: cohort study. BMJ : British Medical Journal, 2013. 347. 
943. Sarkanen, T.O., et al., Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic 
review and meta-analysis. Sleep Med Rev, 2018. 38: p. 177-186. 
944. Han, F., et al., Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in 
China. Ann Neurol, 2011. 70(3): p. 410-7. 
945. Matsuki, K., et al., DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet, 1992. 
339(8800): p. 1052. 
946. Kadotani, H., J. Faraco, and E. Mignot, Genetic studies in the sleep disorder narcolepsy. Genome 
Res, 1998. 8(5): p. 427-34. 
947. Dye, T.J., N. Gurbani, and N. Simakajornboon, Epidemiology and Pathophysiology of Childhood 
Narcolepsy. Paediatr Respir Rev, 2016. 
948. Johansen, K., et al., Where are we in our understanding of the association between narcolepsy 
and one of the 2009 adjuvanted influenza A (H1N1) vaccines? Biologicals, 2016. 44(4): p. 276-
280. 
949. Squires, S.G., et al., Influenza in Canada--1999-2000 season. Can Commun Dis Rep, 2001. 27(1): 
p. 1-9. 
950. Scheifele, D.W., et al., Ocular and respiratory symptoms attributable to inactivated split 
influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis, 2003. 36(7): p. 
850-7. 
951. De Serres, G., et al., Recurrence risk of oculorespiratory syndrome after influenza vaccination: 
randomized controlled trial of previously affected persons. Arch Intern Med, 2004. 164(20): p. 
2266-72. 
952. Skowronski, D.M., et al., Randomized, double-blind, placebo-controlled trial to assess the rate of 
recurrence of oculorespiratory syndrome following influenza vaccination among persons 
previously affected. Clin Infect Dis, 2003. 37(8): p. 1059-66. 
953. Grohskopf, L.A., et al., Prevention and control of seasonal influenza with vaccines. 
Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-
2014. MMWR Recomm Rep, 2013. 62(Rr-07): p. 1-43. 
954. Zhang, J., et al., Influenza A virus M1 blocks the classical complement pathway through 
interacting with C1qA. J Gen Virol, 2009. 90(Pt 11): p. 2751-8. 
 
429 
955. Monsalvo, A.C., et al., Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune 
complexes. Nat Med, 2011. 17(2): p. 195-9. 
956. Al-Dabbagh, M., et al., Elevated inflammatory mediators in adults with oculorespiratory 
syndrome following influenza immunization: a public health agency of Canada/Canadian 
Institutes of Health Research Influenza Research Network Study. Clin Vaccine Immunol, 2013. 
20(8): p. 1108-14. 
957. De Serres, G., et al., Oculo-respiratory syndrome after influenza vaccination: trends over four 
influenza seasons. Vaccine, 2005. 23(28): p. 3726-32. 
958. Fredette, M.J., G. De Serres, and M. Malenfant, Ophthalmological and biological features of the 
oculorespiratory syndrome after influenza vaccination. Clin Infect Dis, 2003. 37(8): p. 1136-8. 
959. Skowronski, D.M., et al., Oculorespiratory syndrome after influenza immunization in children. 
Pediatr Infect Dis J, 2005. 24(1): p. 63-9. 
960. Skowronski, D.M., et al., Low risk of recurrence of oculorespiratory syndrome following influenza 
revaccination. CMAJ, 2002. 167(8): p. 853-8. 
961. Gorman, M.P., Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia 
syndrome. Curr Opin Pediatr, 2010. 22(6): p. 745-50. 
962. Hero, B. and G. Schleiermacher, Update on pediatric opsoclonus myoclonus syndrome. 
Neuropediatrics, 2013. 44(6): p. 324-9. 
963. Pike, M., Opsoclonus-myoclonus syndrome. Handb Clin Neurol, 2013. 112: p. 1209-11. 
964. Pranzatelli, M.R. and E.D. Tate, Trends and tenets in relapsing and progressive opsoclonus-
myoclonus syndrome. Brain Dev, 2016. 38(5): p. 439-48. 
965. Payne, D.C., et al., Anthrax vaccination and risk of optic neuritis in the United States military, 
1998-2003. Arch Neurol, 2006. 63(6): p. 871-5. 
966. Sridhar, G., et al., Evaluation of optic neuritis following human papillomavirus vaccination. Hum 
Vaccin Immunother, 2017. 13(7): p. 1705-1713. 
967. Baxter, R., et al., Case-centered Analysis of Optic Neuritis After Vaccines. Clin Infect Dis, 2016. 
63(1): p. 79-81. 
968. Korematsu, S., et al., Elevated serum anti-phosphatidylcholine IgG antibodies in patients with 
influenza vaccination-associated optic neuritis. Vaccine, 2014. 32(48): p. 6345-8. 
969. Jarius, S., B. Wildemann, and F. Paul, Neuromyelitis optica: clinical features, 
immunopathogenesis and treatment. Clin Exp Immunol, 2014. 176(2): p. 149-64. 
970. Wingerchuk, D.M. and B.G. Weinshenker, Neuromyelitis optica (Devic's syndrome). Handb Clin 
Neurol, 2014. 122: p. 581-99. 
971. Riikonen, R.S., Retinal vasculitis caused by rubella. Neuropediatrics, 1995. 26(3): p. 174-6. 
972. Stevenson, V.L., et al., Optic neuritis following measles/rubella vaccination in two 13-year-old 
children. Br J Ophthalmol, 1996. 80(12): p. 1110-1. 
973. Hull, T.P. and J.H. Bates, Optic neuritis after influenza vaccination. Am J Ophthalmol, 1997. 
124(5): p. 703-4. 
974. Kline, L.B., S.L. Margulies, and S.J. Oh, Optic neuritis and myelitis following rubella vaccination. 
Arch Neurol, 1982. 39(7): p. 443-4. 
975. Colafrancesco, S., et al., Human papilloma virus vaccine and primary ovarian failure: another 
facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol, 
2013. 70(4): p. 309-16. 
976. Little, D.T. and H.R. Ward, Adolescent Premature Ovarian Insufficiency Following Human 
Papillomavirus Vaccination: A Case Series Seen in General Practice. J Investig Med High Impact 
Case Rep, 2014. 2(4): p. 2324709614556129. 
977. Little, D.T. and H.R. Ward, Premature ovarian failure 3 years after menarche in a 16-year-old girl 
following human papillomavirus vaccination. BMJ Case Rep, 2012. 2012. 
 
430 
978. Gordon, C.M., T. Kanaoka, and L.M. Nelson, Update on primary ovarian insufficiency in 
adolescents. Curr Opin Pediatr, 2015. 27(4): p. 511-9. 
979. Gruber, N. and Y. Shoenfeld, A link between human papilloma virus vaccination and primary 
ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol, 2015. 27(4): p. 265-70. 
980. Shoenfeld, Y. and N. Agmon-Levin, 'ASIA' - autoimmune/inflammatory syndrome induced by 
adjuvants. J Autoimmun, 2011. 36(1): p. 4-8. 
981. Pellegrino, P., et al., On the association between human papillomavirus vaccine and primary 
ovarian failure. Am J Reprod Immunol, 2014. 71(4): p. 293-4. 
982. Wiznitzer, M., RE: Human papillomavirus vaccine and primary ovarian failure paper. Am J 
Reprod Immunol, 2014. 72(3): p. 259. 
983. Hawkes, D. and J.P. Buttery, Human papillomavirus vaccination and primary ovarian 
insufficiency: an association based on ideology rather than evidence. Curr Opin Obstet Gynecol, 
2016. 28(1): p. 70-2. 
984. Hawkes, D., et al., Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune 
Syndrome Induced by Adjuvants (ASIA). J Autoimmun, 2015. 59: p. 77-84. 
985. Barlow, W.E., et al., The risk of seizures after receipt of whole-cell pertussis or measles, mumps, 
and rubella vaccine. N Engl J Med, 2001. 345(9): p. 656-61. 
986. Farrington, P., et al., A new method for active surveillance of adverse events from 
diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet, 1995. 345(8949): p. 
567-9. 
987. Chen, R.T., et al., Vaccine Safety Datalink project: a new tool for improving vaccine safety 
monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics, 1997. 99(6): p. 
765-73. 
988. Griffin, M.R., et al., Risk of seizures after measles-mumps-rubella immunization. Pediatrics, 1991. 
88(5): p. 881-5. 
989. Vestergaard, M., et al., MMR vaccination and febrile seizures: evaluation of susceptible 
subgroups and long-term prognosis. Jama, 2004. 292(3): p. 351-7. 
990. Andrews, N., et al., Post-licensure safety of the meningococcal group C conjugate vaccine. Hum 
Vaccin, 2007. 3(2): p. 59-63. 
991. Miller, E., et al., Risks of convulsion and aseptic meningitis following measles-mumps-rubella 
vaccination in the United Kingdom. Am J Epidemiol, 2007. 165(6): p. 704-9. 
992. Gold, M., et al., Use of the Australian Childhood Immunisation Register for vaccine safety data 
linkage. Vaccine, 2010. 28(26): p. 4308-11. 
993. Kuter, B.J., et al., Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella 
Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009. Pediatr Infect 
Dis J, 2016. 35(9): p. 1011-20. 
994. Ma, S.J., et al., Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: A 
systematic review and meta-analysis. Vaccine, 2015. 33(31): p. 3636-49. 
995. Macartney, K., et al., Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine 
Introduction in Australia. JAMA Pediatr, 2017. 171(10): p. 992-998. 
996. Armstrong, P.K., et al., Epidemiological study of severe febrile reactions in young children in 
Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open, 2011. 
1(1): p. e000016. 
997. Kelly, H.A., et al., Adverse events associated with 2010 CSL and other inactivated influenza 
vaccines. Med J Aust, 2011. 195(6): p. 318-20. 
998. Li-Kim-Moy, J., et al., Systematic review of fever, febrile convulsions and serious adverse events 




999. Goodman, M.J., et al., The safety of trivalent influenza vaccine among healthy children 6 to 24 
months of age. Pediatrics, 2006. 117(5): p. e821-6. 
1000. Greene, S.K., et al., Near real-time surveillance for influenza vaccine safety: proof-of-concept in 
the Vaccine Safety Datalink Project. Am J Epidemiol, 2010. 171(2): p. 177-88. 
1001. Stowe, J., et al., Risk of convulsions in children after monovalent H1N1 (2009) and trivalent 
influenza vaccines: a database study. Vaccine, 2011. 29(51): p. 9467-72. 
1002. Kawai, A.T., et al., Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine. 
Pediatrics, 2015. 136(4): p. e848-55. 
1003. Li, R., et al., Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 
2013-2014 and 2014-2015 seasons. Pharmacoepidemiol Drug Saf, 2016. 25(8): p. 928-34. 
1004. Duffy, J., et al., Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics, 
2016. 138(1). 
1005. Bakken, I.J., et al., Febrile seizures after 2009 influenza A (H1N1) vaccination and infection: a 
nationwide registry-based study. BMC Infect Dis, 2015. 15: p. 506. 
1006. Lewis, E., et al., Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J, 2001. 
20(11): p. 1049-54. 
1007. Huang, W.T., et al., Lack of association between acellular pertussis vaccine and seizures in early 
childhood. Pediatrics, 2010. 126(2): p. 263-9. 
1008. Duffy, J., et al., Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. 
Pediatr Neurol, 2017. 76: p. 72-78. 
1009. Goodman, M., S.H. Lamm, and M.H. Bellman, Temporal relationship modeling: DTP or DT 
immunizations and infantile spasms. Vaccine, 1998. 16(2-3): p. 225-31. 
1010. Shibasaki, K., et al., Effects of body temperature on neural activity in the hippocampus: 
regulation of resting membrane potentials by transient receptor potential vanilloid 4. J Neurosci, 
2007. 27(7): p. 1566-75. 
1011. Thomas, E.A., et al., Heat opens axon initial segment sodium channels: a febrile seizure 
mechanism? Ann Neurol, 2009. 66(2): p. 219-26. 
1012. Balosso, S., et al., A novel non-transcriptional pathway mediates the proconvulsive effects of 
interleukin-1beta. Brain, 2008. 131(Pt 12): p. 3256-65. 
1013. Schuchmann, S., et al., Experimental febrile seizures are precipitated by a hyperthermia-induced 
respiratory alkalosis. Nat Med, 2006. 12(7): p. 817-23. 
1014. Wallace, R.H., et al., Suggestion of a major gene for familial febrile convulsions mapping to 8q13-
21. J Med Genet, 1996. 33(4): p. 308-12. 
1015. Johnson, E.W., et al., Evidence for a novel gene for familial febrile convulsions, FEB2, linked to 
chromosome 19p in an extended family from the Midwest. Hum Mol Genet, 1998. 7(1): p. 63-7. 
1016. Peiffer, A., et al., A locus for febrile seizures (FEB3) maps to chromosome 2q23-24. Ann Neurol, 
1999. 46(4): p. 671-8. 
1017. Nakayama, J., et al., Significant evidence for linkage of febrile seizures to chromosome 5q14-q15. 
Hum Mol Genet, 2000. 9(1): p. 87-91. 
1018. Nakayama, J., et al., A nonsense mutation of the MASS1 gene in a family with febrile and afebrile 
seizures. Ann Neurol, 2002. 52(5): p. 654-7. 
1019. Nabbout, R., et al., A locus for simple pure febrile seizures maps to chromosome 6q22-q24. Brain, 
2002. 125(Pt 12): p. 2668-80. 
1020. Nakayama, J., et al., Linkage and association of febrile seizures to the IMPA2 gene on human 
chromosome 18. Neurology, 2004. 63(10): p. 1803-7. 
1021. Hedera, P., et al., Identification of a novel locus for febrile seizures and epilepsy on chromosome 
21q22. Epilepsia, 2006. 47(10): p. 1622-8. 
 
432 
1022. Audenaert, D., C. Van Broeckhoven, and P. De Jonghe, Genes and loci involved in febrile seizures 
and related epilepsy syndromes. Hum Mutat, 2006. 27(5): p. 391-401. 
1023. Poduri, A., et al., Novel susceptibility locus at chromosome 6q16.3-22.31 in a family with GEFS+. 
Neurology, 2009. 73(16): p. 1264-72. 
1024. Schlachter, K., et al., A splice site variant in the sodium channel gene SCN1A confers risk of febrile 
seizures. Neurology, 2009. 72(11): p. 974-8. 
1025. Saghazadeh, A., M. Mastrangelo, and N. Rezaei, Genetic background of febrile seizures. Rev 
Neurosci, 2014. 25(1): p. 129-61. 
1026. Feenstra, B., et al., Common variants associated with general and MMR vaccine-related febrile 
seizures. Nat Genet, 2014. 46(12): p. 1274-82. 
1027. Verbeek, N.E., et al., Etiologies for seizures around the time of vaccination. Pediatrics, 2014. 
134(4): p. 658-66. 
1028. Blyth, C.C., et al., Trivalent influenza vaccine and febrile adverse events in Australia, 2010: 
clinical features and potential mechanisms. Vaccine, 2011. 29(32): p. 5107-13. 
1029. Rockman, S., et al., Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that 
the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is 
associated with adverse events. Vaccine, 2014. 32(30): p. 3861-8. 
1030. Rockman, S., et al., Role of viral RNA and lipid in the adverse events associated with the 2010 
Southern Hemisphere trivalent influenza vaccine. Vaccine, 2014. 32(30): p. 3869-76. 
1031. Daschbach, R.J., Serum sickness and tetanus immunization. JAMA, 1972. 220(12): p. 1619. 
1032. Bonds, R.S. and B.C. Kelly, Severe serum sickness after H1N1 influenza vaccination. Am J Med Sci, 
2013. 345(5): p. 412-3. 
1033. Gibbons, C.H., Small fiber neuropathies. Continuum (Minneap Minn), 2014. 20(5 Peripheral 
Nervous System Disorders): p. 1398-412. 
1034. Farquharson, R.G., E. Jauniaux, and N. Exalto, Updated and revised nomenclature for description 
of early pregnancy events. Human Reproduction, 2005. 20(11): p. 3008-3011. 
1035. Eaton, A., et al., Birth outcomes following immunization of pregnant women with pandemic 
H1N1 influenza vaccine 2009-2010. Vaccine, 2017. 
1036. Angelo, M.G., et al., Pooled analysis of large and long-term safety data from the human 
papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol 
Drug Saf, 2014. 23(5): p. 466-79. 
1037. Baril, L., et al., Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old 
women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United 
Kingdom. Vaccine, 2015. 33(48): p. 6884-91. 
1038. Bonde, U., et al., Is HPV vaccination in pregnancy safe? Hum Vaccin Immunother, 2016. 12(8): p. 
1960-1964. 
1039. Dana, A., et al., Pregnancy outcomes from the pregnancy registry of a human papillomavirus 
type 6/11/16/18 vaccine. Obstet Gynecol, 2009. 114(6): p. 1170-8. 
1040. Forinash, A.B., et al., Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy. 
Ann Pharmacother, 2011. 45(2): p. 258-62. 
1041. Garland, S.M., et al., Pregnancy and infant outcomes in the clinical trials of a human 
papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled 
trials. Obstet Gynecol, 2009. 114(6): p. 1179-88. 
1042. Goss, M.A., et al., Final report on exposure during pregnancy from a pregnancy registry for 
quadrivalent human papillomavirus vaccine. Vaccine, 2015. 33(29): p. 3422-8. 
1043. Panagiotou, O.A., et al., Effect of bivalent human papillomavirus vaccination on pregnancy 
outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. Bmj, 2015. 
351: p. h4358. 
 
433 
1044. Scheller, N.M., et al., Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy 
Outcomes. N Engl J Med, 2017. 376(13): p. 1223-1233. 
1045. Wacholder, S., et al., Risk of miscarriage with bivalent vaccine against human papillomavirus 
(HPV) types 16 and 18: pooled analysis of two randomised controlled trials. Bmj, 2010. 340: p. 
c712. 
1046. Badilla, X., et al., Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect 
Dis J, 2007. 26(9): p. 830-5. 
1047. Sato, H.K., et al., Rubella vaccination of unknowingly pregnant women: the Sao Paulo 
experience, 2001. J Infect Dis, 2011. 204 Suppl 2: p. S737-44. 
1048. Tookey, P.A., et al., Rubella vaccination in pregnancy. CDR (Lond Engl Rev), 1991. 1(8): p. R86-8. 
1049. Makris, M.C., et al., Safety of hepatitis B, pneumococcal polysaccharide and meningococcal 
polysaccharide vaccines in pregnancy: a systematic review. Drug Saf, 2012. 35(1): p. 1-14. 
1050. Badell, M.L., et al., Risks Associated With Smallpox Vaccination in Pregnancy: A Systematic 
Review and Meta-analysis. Obstet Gynecol, 2015. 125(6): p. 1439-51. 
1051. Mosby, L.G., S.A. Rasmussen, and D.J. Jamieson, 2009 pandemic influenza A (H1N1) in 
pregnancy: a systematic review of the literature. American Journal of Obstetrics and 
Gynecology, 2011. 205(1): p. 10-18. 
1052. Rasmussen, S.A., D.J. Jamieson, and T.M. Uyeki, Effects of influenza on pregnant women and 
infants. American Journal of Obstetrics and Gynecology, 2012. 207(3, Supplement): p. S3-S8. 
1053. Calleja-Agius, J., et al., Pro- and antiinflammatory cytokines in threatened miscarriages. 
American Journal of Obstetrics and Gynecology, 2011. 205(1): p. 83.e8-83.e16. 
1054. Lissauer, D., et al., Profile of maternal CD4 T-cell effector function during normal pregnancy and 
in women with a history of recurrent miscarriage. Clinical Science, 2014. 126(5): p. 347-354. 
1055. Christiansen, O.B., H.S. Nielsen, and A.M. Kolte, Inflammation and miscarriage. Seminars in Fetal 
and Neonatal Medicine, 2006. 11(5): p. 302-308. 
1056. Christian, L.M., et al., Inflammatory responses to trivalent influenza virus vaccine among 
pregnant women. Vaccine, 2011. 29(48): p. 8982-7. 
1057. Christian, L.M., et al., Proinflammatory cytokine responses correspond with subjective side 
effects after influenza virus vaccination. Vaccine, 2015. 33(29): p. 3360-6. 
1058. Yang, J., et al., CD4+ T cells recognize unique and conserved 2009 H1N1 influenza hemagglutinin 
epitopes after natural infection and vaccination. International Immunology, 2013. 25(8): p. 447-
457. 
1059. Schmidt, T., et al., CD4+T-cell immunity after pandemic influenza vaccination cross-reacts with 
seasonal antigens and functionally differs from active influenza infection. European Journal of 
Immunology, 2012. 42(7): p. 1755-1766. 
1060. Belongia, E.A., et al., Repeated annual influenza vaccination and vaccine effectiveness: review of 
evidence. Expert Rev Vaccines, 2017. 16(7): p. 1-14. 
1061. Feng, J., et al., Antibody quantity versus quality after influenza vaccination. Vaccine, 2009. 
27(45): p. 6358-62. 
1062. Sasaki, S., et al., Influence of prior influenza vaccination on antibody and B-cell responses. PLoS 
One, 2008. 3(8): p. e2975. 
1063. Armah, G.E., et al., Efficacy of pentavalent rotavirus vaccine against severe rotavirus 
gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-
blind, placebo-controlled trial. Lancet, 2010. 376(9741): p. 606-14. 
1064. Goveia, M.G., et al., Safety and efficacy of the pentavalent human-bovine (WC3) reassortant 
rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J, 2007. 26(12): p. 1099-104. 
1065. Griffin, M.R., et al., Risk of sudden infant death syndrome after immunization with the 
diphtheria-tetanus-pertussis vaccine. N Engl J Med, 1988. 319(10): p. 618-23. 
 
434 
1066. Eriksen, E.M., et al., Lack of association between hepatitis B birth immunization and neonatal 
death: a population-based study from the vaccine safety datalink project. Pediatr Infect Dis J, 
2004. 23(7): p. 656-62. 
1067. Vennemann, M.M., et al., Do immunisations reduce the risk for SIDS? A meta-analysis. Vaccine, 
2007. 25(26): p. 4875-9. 
1068. Kuhnert, R., et al., Reanalyses of case-control studies examining the temporal association 
between sudden infant death syndrome and vaccination. Vaccine, 2012. 30(13): p. 2349-56. 
1069. Huang, W.T., et al., Vaccination and unexplained sudden death risk in Taiwanese infants. 
Pharmacoepidemiol Drug Saf, 2017. 26(1): p. 17-25. 
1070. Armed Forces Health Surveillance Center, Syncope, active and reserve components, U.S. Armed 
Forces, 1998-2012. MSMR, 2013. 20(11): p. 5-9. 
1071. Buttery, J.P., et al., Mass psychogenic response to human papillomavirus vaccination. Med J 
Aust, 2008. 189(5): p. 261-2. 
1072. D'Souza, R.M., et al., Adverse events following immunisation associated with the 1998 Australian 
Measles Control Campaign. Commun Dis Intell, 2000. 24(2): p. 27-33. 
1073. Keyserling, H., et al., Safety, immunogenicity, and immune memory of a novel meningococcal 
(groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in 
healthy adolescents. Arch Pediatr Adolesc Med, 2005. 159(10): p. 907-13. 
1074. Laribiere, A., et al., Surveillance of adverse effects during a vaccination campaign against 
meningitis C. Eur J Clin Pharmacol, 2005. 61(12): p. 907-11. 
1075. Meyer, K., et al., Neurocardiogenic syncope in a 10-year-old boy. Pediatr Cardiol, 2001. 22(5): p. 
415-6. 
1076. Miller, E.R. and E.J. Woo, Time to prevent injuries from postimmunization syncope. Nursing, 
2006. 36(12 Pt.1): p. 20. 
1077. Wiersbitzky, S., R. Bruns, and U. Schmidt, [Cerebral seizures and/or encephalitis after MMR, oral 
polio, HiB or DPT vaccination?]. Kinderarztl Prax, 1993. 61(6): p. 232-4. 
1078. Zimmerman, R.K., et al., Randomized trial of an alternate human papillomavirus vaccine 
administration schedule in college-aged women. J Womens Health (Larchmt), 2010. 19(8): p. 
1441-7. 
1079. Abu-Shakra, M., et al., Influenza virus vaccination of patients with systemic lupus erythematosus: 
effects on disease activity. J Rheumatol, 2000. 27(7): p. 1681-5. 
1080. Del Porto, F., et al., Influenza vaccine administration in patients with systemic lupus 
erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine, 2006. 24(16): p. 
3217-23. 
1081. Stojanovich, L., Influenza vaccination of patients with systemic lupus erythematosus (SLE) and 
rheumatoid arthritis (RA). Clin Dev Immunol, 2006. 13(2-4): p. 373-5. 
1082. Williams, G.W., et al., Influenza immunization in systemic lupus eruthematosus. A double-blind 
trial. Ann Intern Med, 1978. 88(6): p. 729-34. 
1083. Cooper, G.S., et al., Risk factors for development of systemic lupus erythematosus: allergies, 
infections, and family history. J Clin Epidemiol, 2002. 55(10): p. 982-9. 
1084. Baxter, R., et al., Safety of Zostavax--a cohort study in a managed care organization. Vaccine, 
2012. 30(47): p. 6636-41. 
1085. Barbosa, C.M., et al., Immune response and tolerability of varicella vaccine in children and 
adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin 
Exp Rheumatol, 2012. 30(5): p. 791-8. 
1086. Dhar, J.P., et al., The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic 
lupus erythematosus. Vaccine, 2017. 35(20): p. 2642-2646. 
 
435 
1087. Huang, Y., et al., Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity 
and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis. Medicine 
(Baltimore), 2016. 95(19): p. e3637. 
1088. Liao, Z., et al., Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus 
Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis. PLoS One, 2016. 
11(2): p. e0147856. 
1089. Pellegrino, P., S. Radice, and E. Clementi, Immunogenicity and safety of the human 
papillomavirus vaccine in patients with autoimmune diseases: A systematic review. Vaccine, 
2015. 33(30): p. 3444-9. 
1090. Puges, M., et al., Immunogenicity and impact on disease activity of influenza and pneumococcal 
vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. 
Rheumatology (Oxford), 2016. 55(9): p. 1664-72. 
1091. Doria, A., et al., Infections as triggers and complications of systemic lupus erythematosus. 
Autoimmun Rev, 2008. 8(1): p. 24-8. 
1092. Poirriez, J., A preliminary experiment of absorption of antinuclear antibodies by the hepatitis B 
vaccine components, in a case of neurolupus. Vaccine, 2004. 22(23-24): p. 3166-8. 
1093. Nordin, J.D., et al., Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute 
adverse events. Vaccine, 2014. 32(39): p. 4985-92. 
1094. Holt, S., et al., Diffuse myelitis associated with rubella vaccination. Br Med J, 1976. 2(6043): p. 
1037-8. 
1095. Joyce, K.A. and J.E. Rees, Transverse myelitis after measles, mumps, and rubella vaccine. BMJ, 
1995. 311(7002): p. 422. 
1096. Lim, S., et al., Transverse myelitis after measles and rubella vaccination. J Paediatr Child Health, 
2004. 40(9-10): p. 583-4. 
1097. LaRovere, K.L., G.P. Raju, and M.P. Gorman, Postvaricella acute transverse myelitis in a 
previously vaccinated child. Pediatr Neurol, 2008. 38(5): p. 370-2. 
1098. Tartaglino, L.M., et al., MR imaging in a case of postvaccination myelitis. AJNR Am J Neuroradiol, 
1995. 16(3): p. 581-2. 
1099. Stassen, P.M., et al., Influenza vaccination does not result in an increase in relapses in patients 
with ANCA-associated vasculitis. Nephrol Dial Transplant, 2008. 23(2): p. 654-8. 
1100. Holvast, A., et al., Wegener's granulomatosis patients show an adequate antibody response to 
influenza vaccination. Ann Rheum Dis, 2009. 68(6): p. 873-8. 
1101. Jeffs, L.S., et al., Randomized trial investigating the safety and efficacy of influenza vaccination in 
patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton), 
2015. 20(5): p. 343-51. 
1102. Kerneis, S., et al., Do vaccinations affect the clinical course of systemic necrotising vasculitis? A 
prospective observational web-based study. Clin Exp Rheumatol, 2016. 34(3 Suppl 97): p. S89-92. 
1103. Da Dalt, L., et al., Henoch-Schonlein purpura and drug and vaccine use in childhood: a case-
control study. Ital J Pediatr, 2016. 42(1): p. 60. 
1104. Abrams, J.Y., et al., Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-
2006. Vaccine, 2015. 33(2): p. 382-7. 
1105. Phuong, L.K., et al., Kawasaki disease and immunisation: A systematic review. Vaccine, 2017. 
35(14): p. 1770-1779. 
1106. Begier, E.M., et al., Polyarteritis nodosa reports to the vaccine adverse event reporting system 
(VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol, 
2004. 31(11): p. 2181-8. 
1107. Bourgeais, A.M., et al., [Cutaneous polyarteritis nodosa following hepatitis B vaccination]. Ann 
Dermatol Venereol, 2003. 130(2 Pt 1): p. 205-7. 
 
436 
1108. De Keyser, F., et al., Immune-mediated pathology following hepatitis B vaccination. Two cases of 
polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol, 
2000. 18(1): p. 81-5. 
1109. Ventura, F., et al., Cutaneous polyarteritis nodosa in a child following hepatitis B vaccination. Eur 






Matthew Z. Dudley 
 
Date revised: January 1, 2019 
 
 
PERSONAL DATA  
Birth  
Born February 11, 1987 in Concord, New Hampshire, USA 
 Business address Home address 
Johns Hopkins School of Public 
Health 615 N. Wolfe St. 
Baltimore, MD 21205  
E: mattdudley@jhu.edu 
1309 N. Calvert St. #4 




EDUCATION AND TRAINING  
Degree Year Institution Field 
PhD 2018 
Johns Hopkins 
Bloomberg School of 
Public Health 
International Health 
- Concentration in Global Disease 
Epidemiology and Control 
- GPA: 4.0 
 
Dissertation: How Pregnant Women in the 
United States Perceive Vaccines for 





Bloomberg School of 
Public Health 
International Health 
- Concentration in Global Disease 
Epidemiology and Control 
- Certificate in Vaccine Science and Policy 
- GPA: 4.0  
 
 
MSPH Essay: The effects of separating HIV 
and TB patients in April 2001 on outbreaks of 
spoligotyped drug resistant TB strains in 
Lima, Peru's Hospital Dos de Mayo 
BA 2009 Emory University 
- Concentration in Chemistry 





PROFESSIONAL EXPERIENCE  
Position Dates Institution 
Epidemiologist   8/14 – present 
Institute for Vaccine Safety, 
Johns Hopkins Bloomberg 
School of Public Health 
 
Research Associate   8/14 – 8/15 
Johns Hopkins Bloomberg 
School of Public Health 
Project Coordinator, 
Norovirus 
8/13 – 5/14 
Asociación Benefica 
PRISMA, Lima Peru 
AmeriCorps Health Educator 9/11 – 7/12 
Erie Family Health Center, 
Amundsen High School, 
Chicago IL 
Registration Specialist 8/10 – 2/11 
Piedmont Heart Institute, 
Atlanta GA 
Teaching Assistant 9/09 - 5/10 
Ecoles élémentaires 
Michelet, La Forêt, Juliot 
Curie, and Maxime 






• World Health Organization, Geneva, Switzerland. August-December 2014 
 
HONORS AND AWARDS 
 
Honors 
• Member of Delta Omega Public Health Honor Society - Alpha Chapter 







1. Dudley MZ, Sheen P, Gilman RH, et al. Detecting Mutations in the 
Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection 
Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus 
Coinfection. Am J Trop Med Hyg. 2016 Dec 7;95(6):1239-1246. Epub 2016 Oct 
24. PubMed PMID: 27928075; PubMed Central PMCID: PMC5154434. 
2. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: Causes, 
consequences, and a call to action. Vaccine. 2015 Nov 27;33 Suppl 4:D66-71. doi: 
 
439 
10.1016/j.vaccine.2015.09.035. PubMed PMID: 26615171. 
3. Halsey NA, Talaat KR, Greenbaum A, Mensah E, Dudley MZ, Proveaux T, 
Salmon DA. The safety of influenza vaccines in children: An Institute for Vaccine 
Safety white paper. Vaccine. 2015 Dec 30;33 Suppl 5:F1-F67. doi: 
10.1016/j.vaccine.2015.10.080. Review. PubMed PMID: 26822822. 
4. Frew PM, Randall LA, Malik F, Limaye RJ, Wilson A, O'Leary ST, Salmon D, 
Donnelly M, Ault K, Dudley MZ, Fenimore VL, Omer SB. Clinician perspectives 
on strategies to improve patient maternal immunization acceptability in obstetrics 
and gynecology practice settings. Hum Vaccin Immunother. 2018 Jul 
3;14(7):1548-1557. doi: 10.1080/21645515.2018.1425116. Epub 2018 Feb 15. 
PubMed PMID: 29313458; PubMed Central PMCID: PMC6067872.  
5. Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O'Leary ST, Omer SB. 
Enhancing uptake of influenza maternal vaccine. Expert Rev Vaccines. 2018 Dec 
27. doi: 10.1080/14760584.2019.1562907. PubMed PMID: 30587042. 
 
